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The older population, often defined as people aged ≥ 65 years is growing. With older 
age, the risk of multimorbidity (commonly defined as the presence of ≥ 2 chronic 
conditions) increases together with the use of a high number of daily medicines or 
polypharmacy (≥ 5 daily medicines). These are two risk factors of poor health 
outcomes in older people, putting them at greater risk of experiencing potentially 
inappropriate prescribing (PIP), adverse drug events (ADEs) and poor quality of life 
(QoL). To reduce polypharmacy and the associated risk, the number of medications 
used per patient needs to be reduced by means of carefully considered deprescribing 
when appropriate. Deprescribing is the process of discontinuing inappropriate 
medications with the goal of optimising pharmacotherapy and improving health 
outcomes. Existing research is limited to support the effective and practical 
implementation of deprescribing. Pharmacists are trained to evaluate PIP and their 
knowledge and skills may benefit the process of deprescribing. As the majority of 
prescribing takes place in primary care, it is logical that GPs would liaise with 
community pharmacists in a collaborative intervention/practice to deprescribe. 
Therefore, the aim of this thesis was to identify the challenges and potential benefits 
of deprescribing, and to explore the potential involvement of the community 
pharmacist in deprescribing. 
 
Methods 
A study design comprising both quantitative and qualitative designs was used. Firstly, 
a narrative literature review summarised the existing qualitative and quantitative 
literature on healthcare professionals’ views on deprescribing (Chapter 2). Secondly, 
a systematic literature review and meta-analysis was conducted according to the 
PRISMA guidelines, to determine the effectiveness of existing deprescribing 
interventions (Chapter 3). Thirdly, to determine if PIP is predominantly a 
phenomenon of later life or whether it has its origins in early old age, a secondary 
xvi 
 
data analysis of a population-based primary care cohort of patients aged 60-74 years 
was done over a continuous five-year period (Chapter 4). Fourthly, total net 
ingredient cost (NIC) was estimated for the PIMs identified in the same population-
based primary care cohort studied in Chapter 4 in the period from 2016 to 2018, and 
a potential cost reduction of the routine application of the STOPP criteria was 
determined (Chapter 5). Fifthly, the views of community pharmacists on their role in 
medication optimisation and reducing PIP was examined in a qualitative interview 
study (Chapter 6). Finally, the views of general practitioners (GPs) and community 
pharmacists, on their collaboration and the potential role of the pharmacist in 
deprescribing, were explored in a qualitative study (Chapter 7).  
 
Results  
The narrative review (Chapter 2) included 23 studies. The content analysis identified 
five broad themes describing the barriers and facilitators of deprescribing in older 
patients with multimorbidity: (i) interprofessional relationships, (ii) medication 
review, (iii) information, (iv) the patient and (v) environmental needs. The systematic 
literature review (Chapter 3) summarised findings of 31 studies of which 30 studies 
were included in the behaviour change component (BCT) analysis and 21 were 
included in the meta-analysis. The meta-analysis showed that deprescribing 
interventions are effective in reducing the number of drugs and inappropriate 
prescribing in older people, although the evidence is mixed. BCT clusters more 
frequently present in studies reporting intervention effectiveness compared to 
studies reporting no effectiveness were:  goals and planning; shaping knowledge; 
natural consequences; comparison of behaviour; comparison of outcomes; 
regulation; antecedents; and identity. A total of 974 participants aged 60-74 years 
were included in the secondary analysis in Chapter 4 and data from baseline to year 
5 of follow-up was studied. The odds of being exposed to potential prescribing 
omissions (PPOs) and potentially inappropriate medications (PIMs) increased 
significantly during years of follow-up (OR 1.08, 95% CI 1.07 1.09 and OR 1.04 95% CI 
1.03, 1.06, respectively). A higher number of medicines and new diagnoses were 
associated with the increasing trend in both PPO and PIM prevalence. The cost-
xvii 
 
analysis in Chapter 5 was based on the same population studied in Chapter 4 (n=974) 
but in the period from 2016 to 2018 (year 6 to year 8 of follow-up). The study showed 
a high prevalence of PIMs (46%-52%) during the study period. The total net 
ingredient cost of PIMs identified ranged from €87,152.04 at year 6 and €86,112.48 
at year 8 of follow-up. The mean cost of PIM per participant per year was between 
€178.68 - €179.64 during the three years of follow-up. The qualitative interviews 
(Chapter 6) included a total 18 community pharmacists. Seven domains from 
theoretical domains framework (TDF) were identified as relevant to PIP reduction 
and pharmacist involvement: (i) beliefs about capabilities, (ii) environmental context 
and resources, (iii) knowledge, (iv) social influences, (v) social professional role and 
identity, (vi) memory, attention and decision processes, and (vii) reinforcement. In 
Chapter 7, a total of 26 interviews were conducted with GPs and community 
pharmacists. The thematic content analysis identified five themes relevant to the role 
of the community pharmacist in deprescribing: (i) the GP’s role in deprescribing – is 
there room for a pharmacist?, (ii) working relationship, (iii) the role of the pharmacist 
in deprescribing, (iv) patients’ interaction with the healthcare system, and (v) 
environmental factors.   
 
Conclusions 
The findings presented in this thesis provide a detailed understanding of the 
potential role of the community pharmacist in deprescribing. The prospective 
benefits of and the barriers and facilitators to pharmacists involved in this role of 
deprescribing have also been elucidated. This thesis contributes to the existing 
literature, through the provision of novel research that demonstrates the need for 
the community pharmacist support within the context of deprescribing. The 
community pharmacist is in a favourable position to bring pharmaceutical care closer 
to the patient through patient counselling and close collaboration with the patient’s 
GP. To integrate the role of the pharmacist with that of the GP in practice, there is a 
need to consider the mode of pharmaceutical service delivery and to expand the 
collaboration between community pharmacists and GPs by building on existing 
xviii 
 
positive experiences of collaboration and clearly define the role and responsibilities 
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1 Thesis introduction  
 
1.1 The ageing population 
“Old age isn’t so bad, when you consider the alternative”; this quotation was 
attributed to Maurice Chevalier, which is relevant to the present time when people 
are living longer and as a result, the older population is growing. This demographic 
change is evident nationally and internationally in reports by the Department of 
Health in the Republic of Ireland [1], the Organisation for Economic Co-operation and 
Development (OECD) [2] and the World Health Organization (WHO) [3].  Across the 
OECD countries, including Ireland, the population aged 65 years or older comprised 
less than 9% of the population in 1960, 17% in 2015 and is expected to comprise up 
to 28% of the population in 2050 [2]. Looking at the growth characteristics of the 
population at a more advanced old age (≥80 years), on average nearly 5% of the 
population was 80 years or older in 2015 across the OECD countries, and is expected 
to reach 10% or more by 2050 [2]. The two main drivers for the ageing population 
are increasing life expectancy and decreasing fertility rates [2, 3]. Improved survival 
of people at younger ages but also at older ages yields the observed longer life 
expectancy. This is largely the result of the global socioeconomic development that 
has taken place over the last 50 years with greater access to healthcare, more focus 
on healthier lifestyles and improved living conditions before and after people enter 
old age [3].  
Longer life expectancy among the older population does not necessarily mean 
that these extra years are lived in good health [2]. In  Europe, the average number of 
healthy life years in those aged 65 or more, is 9.3 years for men and 9.4 years for 
women [2]. In Ireland, women aged 65 years or more, have a life expectancy of 21.1 
years and men of a similar age have a life expectancy of 18.4 years [1]. Of these extra 
years, Irish women and men at age 65 have an expected 12.3 / 11.4 healthy life years 
ahead, respectively [1]. It should be noted that the level of pressure on any 
healthcare system, attributable to advancing age, will be highly dependent upon the 
state of health of persons in old age. If people experience these extra healthy life 
years, they will feel better and enjoy life more, and  their contribution to society may 
2 
 
be greater, whether it be within their family, within their local community or society 
at large [3]. Conversely, decline in health, whether in the form of loss of physical or 
mental capacity, brings greater challenges and increased need for health and 
personal care services which adds to the existing pressures on healthcare system 
resources [3]. Additionally, rising income among the general population increases 
expectations of higher quality of life in old age, which creates upward pressure on 
healthcare systems [2].  
 
1.2 Multimorbidity 
With advancing age, people are at greater risk of experiencing chronic conditions, 
and the proportion of people with multiple chronic conditions is expected to increase 
substantially over the coming decades [4-6]. Multimorbidity is the coexistence of 
multiple chronic conditions in an individual. The threshold for number of coexisting 
chronic conditions to constitute multimorbidity varies according to the definition 





Table 1-1 Terms and definitions 
Term Definition and description of the term 
Multimorbidity Multimorbidity is the coexistence of multiple chronic conditions in 
an individual. The threshold for number of coexisting chronic 
conditions to constitute multimorbidity varies according to the 
definition used, from ≥2  condition [7-9] to ≥3 conditions [7]. The 
most commonly used definition defines a threshold of ≥2 chronic 
conditions [7-9]. Variations in definitions used and populations 
studied have provided prevalence estimates of multimorbidity 
ranging from 12.5% in people aged ≥18 years to 95% in older people 
aged ≥65 years [7, 10, 11]. 
Polypharmacy Polypharmacy has been defined as the concomitant use of several 
different drugs by an individual [12-15]. Currently, no formally 
accepted numerical threshold for polypharmacy exist. 
Polypharmacy is sometimes referred to as the concurrent use of four 
or more regular medicines [15, 16] but more often the use of five or 
more regular medicines  [12-14, 17-19]. The use of 10 or more 
regular medicines is often referred to as “excessive polypharmacy” 
or ‘hyper-polypharmacy’ or ‘major polypharmacy’ [12, 18, 19]. An 
alternative definition of polypharmacy is the use of more 
medications than are medically necessary [20], and the term 
polypharmacy often has a dual meaning in that it can mean the use 
of multiple medicines or the use of too many medicines. 
 
Multimorbidity is associated with increased healthcare utilisation, greater levels of 
functional decline, reduced quality of life (QoL) and higher treatment burden [4, 11, 
21, 22]. Treatment of chronic conditions comprises eight of the top eleven causes of 
hospital admissions in the United Kingdom (UK) and is a large burden to the UK 
healthcare system [23]. In Europe, 70%-80% of healthcare expenditure is related to 
managing chronic conditions [23]. In Ireland, the mean number of primary care 
consultations and hospital out-patient visits increase significantly with increasing 
numbers of chronic conditions [11] and multimorbidity comprises a significant 
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amount of the total healthcare costs for primary and secondary care among Irish 
patients aged ≥50 years [11].  
 When people become ill, one of the mainstays of management and treatment 
is medication, and thus the selection of appropriate pharmacotherapy in the older 
population is crucial [24, 25]. The coexistence of numerous chronic conditions in a 
single multimorbid patient challenges the traditional approach taken to treating 
individual conditions separately [9]. Having multiple chronic conditions and seeing 
multiple providers often results in a large number of medications and several 
different dosage regimens. This may be inconvenient and/ or difficult for the patient 
to manage [25, 26]. A higher number of medicines may further result in a higher risk 
of unsafe, or suboptimal, drug combinations, drug interactions and adverse drug 
events (ADEs) [26, 27]. Ironically, once an ADE has occurred, the response from the 
physician may be to prescribe another medication to ameliorate the ADE, a situation 
that is generally referred to as a “prescribing cascade” i.e. the prescribing of an 
additional medicine to offset an adverse effect of another [26]. A daily use of multiple 




With the increasing number of multimorbid older people, the prevalence of 
polypharmacy (see definition in Table 1-1) among older people is also growing as well 
as the incident ratio over time [13, 14, 28]. Prevalence estimates of polypharmacy 
(≥5 daily medicines), and hyper-polypharmacy (≥10 daily medicines), have been 




Table 1-2 Prevalence of polypharmacy across countries (literature search in PubMed using search 





(% of study population) 
Hyper-polypharmacy 
≥10 medicines 
 (% of population) 
Sweden [12] ≥65 years 44% 12% 
Spain [13] ≥65 years 22% 0.6% 
Switzerland [17] 40-81 years 11% 1.4% 
England [18] ≥50 years 35% 11% 
Australia [29] ≥65 years - 39% 
The Netherlands 
[30] 
≥20 years 27% - 
Canada [28] 45-69 years 32% - 












§Polypharmacy was defined as 6-10 daily medicines and excessive polypharmacy was defined as ≥11 
daily medicines.  
In Ireland, several estimates of polypharmacy prevalence have been published, some 
of which are reported in Table 1-2. A report based on Irish national data has 
summarised that more than one in four (28%) people aged 52 years or older take five 
or more daily medicines with a higher prevalence among the older patient groups as 
illustrated in Figure 1.1. This prevalence of polypharmacy in Ireland has been 
significantly increasing from 22% in 2010 to 28% in 2013 [1]. Other studies reporting 
on Irish data have shown similar high prevalence estimates of polypharmacy, 
particularly in the older patient cohort (aged ≥65 years): the study by Moriarty et al. 
[34] showed that over the 15 year-period from 1997 to 2012, the percentage of 
people aged 65 years and older using polypharmacy (≥5 medicines) increased from 
18% to 60% [34]. The study also reported a similar trend for excessive polypharmacy 
(≥10 medicines) increasing from 2% to 22% for the same time period and age group. 
Furthermore, this study showed that polypharmacy is not just the burden of the older 
population but is also present in the age group 45-64 years as well with similar 
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increasing trends from 1997 to 2012. In 1997, 8% of people aged 45-64 years took ≥5 
medicines daily. In 2012, this number had increased to 30% [34]. 
  
 
Figure 1.1 Percentage of men and women aged 52 years or older who are taking five or more 
medications in Ireland in 2012. The figure reports on data from The Irish Longitudinal Study on 
Ageing (TILDA) Wave 2 in 2012. TILDA participants were 52+ years in Wave 2 [1] 
Groups of patients more likely to be exposed to polypharmacy are people 
with dementia and those with severe/profound intellectual disability (ID): the study 
by Walsh et al. [35] reported a prevalence of polypharmacy (≥5 medicines)  in 84% in 
people with dementia compared to 77% in those without dementia [35]. The study 
by O’Dwyer et al. [32] reported that 47% of those aged 41 to 90 years with 
polypharmacy (5-9 medications) had severe/profound ID and 29% of those with 
severe/profound ID reported excessive polypharmacy (10 or more medicines). In 
contrast, less than 5% of those living independently were exposed to excessive 
polypharmacy [32]. 
 
1.3.2 Factors associated with polypharmacy 
Several different parameters have been associated with the increase in 


















Table 1-3 Factors shown to be positively associated with increasing prevalence of polypharmacy 
Factor associated with increasing prevalence of 
polypharmacy 
Description 
– Chronic conditions and number of 
medicines 
A higher number of chronic diseases 
and older age are both strongly, and 
positively, correlated with a higher 
number of daily medicines [12, 17, 
18].  One study has shown that for 
each additional chronic disease there 
is  on average a 0.95 increase in the 
number of daily drugs (95% CI 0.94-
0.96) [12].  
– Gender Some studies have associated female 
gender with increasing prevalence of 
polypharmacy [12, 13, 17-19, 34]. 
– Obesity Obesity and/or having a higher body 
mass index (BMI) have been shown to 
be positively associated with an 
increasing prevalence of 
polypharmacy [13, 17, 18]. 
– Smoking. 
– Being alone (divorced, separated or 
widowed.) 
– Having poorer self-rated health. 
– Having lower wealth and/or living in 
deprived areas. 
Prevalence of polypharmacy has been 
positively associated with: smoking 
[17]; being alone (divorced, 
separated or widowed) [18]; having 
poorer self-rated health [18]; having 
lower wealth and/or living in 
deprived areas [18, 19]. 
 
1.3.3 Potential consequences of polypharmacy 
Polypharmacy has been associated with numerous negative outcomes such as: drug-
drug interactions, adverse drug reactions (ADRs), risk of falls, hospitalisation, poor 
8 
 
functional status, medication non-adherence, morbidity and mortality [12, 17, 20, 
36]. The increased risk of ADEs in older adults with polypharmacy is the result of a 
number of factors, principally:  
 
1. Higher number of medicines comes with a higher risk of drug-drug 
interactions. 
2. Age-related physiological changes make older people more prone to ADEs as 
described in Table 1-4.  
3. High prevalence of multimorbidity, described previously, associated with 
older age, increases the risk of drug-disease interactions [12].  
 
In addition, polypharmacy is  believed to cause unnecessary health expense to both 
the patient and the healthcare system, due to extensive drug sales and higher levels 
of adverse outcomes with a need for further drug treatment and healthcare 
utilisation [14, 20]. Polypharmacy has been shown to increase the overall medical 
care costs by up to 30% [20].  
Previously, polypharmacy implied potentially inappropriate prescribing (PIP), but 
this is not necessarily true if the prescribed drugs have an appropriate clinical 
indication [36]. The use of multiple drugs in an individual can be both rational and 
safe and polypharmacy is also believed to provide major health benefits for older 
patients with multimorbidity [14]. However, healthcare providers must be aware of 
the fact that polypharmacy is a strong determinant of PIP  in older people [37]. 
Ensuring appropriate polypharmacy is of considerable importance to ensure patient 





Table 1-4 Age-related physiological changes pertaining to pharmacokinetic and pharmacodynamic 
function.  
Pharmacokinetic changes 
Absorption i. Decreased acidity and function of 
mucosal cells in the stomach is believed 
to potentially affect the absorption of 
some drugs that require an acidic 
environment [26]. 
ii. Altered motility of the gastrointestinal 
(GI) tract may negatively affect the 
absorption of oral medications, but the 
effects are proposed to be minimal due 
to the large surface area of the GI tract 
[26].  
Distribution i. Reduction in total body water resulting 
in a smaller distribution volume and thus 
a higher and potentially toxic 
concentration of some drugs. 
ii. Increase in the body fat percentage, 
which may prolong the effects of 
lipophilic drugs while prolonging the 
elimination half-life.  
iii. Reduction in serum albumin resulting in 
less drug binding to serum proteins and 
more drug circulating in the serum with 
increasing risk of toxicity [26, 39].  
Metabolism i. Hepatic blood flow and liver mass 
decreases with age and results in 
decreased first pass metabolism, 
resulting in more drug available in the 
bloodstream [39]. 
Elimination i. Renal function decreases with age 
resulting in prolonged half-life, and 




metabolites. As most drugs are 
eliminated through the renal system, 
renal function should be a primary 
consideration when prescribing for older 
people [26, 39]. 
Pharmacodynamic changes 
Sensitivity i. Physiological changes to the organ 
systems of an older person are generally 
considered to increase sensitivity to 
drugs, and therefore, reduced doses are 
generally recommended when 




1.4 Potentially Inappropriate Prescribing (PIP) 
 
1.4.1 Definition 
Potentially inappropriate prescribing (PIP) comprises potentially inappropriate 
medicines (PIMs) and potential prescribing omissions (PPOs) and encompasses a 





Table 1-5 Suboptimal prescribing practices described by the terms potentially inappropriate 
medicines (PIMs) and potential prescribing omissions (PPOs) 
PIP Suboptimal prescribing practices 
PIMs (i) Prescribing of a medicine in which the risk outweighs the 
benefit when there is a safer and/or more effective 
alternative available to treat the same condition [29, 40-
42]. 
(ii) Prescribing of a medicine without a clear evidence-based 
indication [37]. 
(iii) Prescribing of a medicine that is not cost-effective [37]. 
(iv) Prescribing of medicine for longer periods than clinically 
indicated [29].Prescribing of medicine for longer periods 
than clinically indicated [29]. 
(v) Use of medicines that are likely to cause drug-drug 
interactions or drug-disease interactions [29].Use of 
medicines that are likely to cause drug-drug interactions or 
drug-disease interactions [29]. 
PPOs (i) Omissions of clinically indicated medications [41]. 
Omissions of clinically indicated medications [41].  
 
1.4.2 Prevalence 
Prevalence estimates of PIP vary greatly across countries, healthcare settings and 
studies with reported ranges of 2.9% to 38.5% [43], 11.5% to 62.5% [44], and 14.0% 
to 23.5% [45]. In Ireland, the PIM prevalence has been estimated to be 36% in the 
acute hospital setting [37] and 64.8% in the community setting [46] whilst the PPO 
prevalence has been reported to be 56.6% among the community-dwelling older Irish 
population [46]. This puts Ireland in a comparable situation to Northern Ireland [38] 
and Italy [47] with regards to PIP prevalence.  
 
1.4.3 Adverse outcomes 
Exposure to PIP puts older people at greater risk of drug-related morbidity and 
mortality and PIP has been linked to poorer health outcomes for the patients [37]. 
12 
 
PIP has been associated with increased risk of ADEs among older people [48]. In 
Ireland, the likelihood of experiencing an ADE has been shown to increase 
significantly with PIP prevalence among older people, with 94% of people exposed to 
PIMs experiencing an ADE compared to 71% for those unexposed to PIMs [49].  
Healthcare services utilisation is another important consequence of PIP 
prevalence among older people. In Ireland, Cahir et al. [49] reported a two-fold 
increased risk in the rate of visits to the hospital emergency department (IRR 1.85, 
95% CI 1.32, 2.58) for those exposed to ≥2 PIPs [49]. Similarly, the study by Lau et al. 
[50] showed that older people prescribed PIM, have a 30% higher risk of being 
hospitalised, and a 21% higher risk of mortality, compared to those who are not [50].  
Reducing polypharmacy and PIP in primary care may thus help lower the burden 
of ADEs, improve patient health outcomes and QoL whilst reducing healthcare 
utilisation and associated costs to the healthcare system, such as reduced prescribing 
budgets [49]. However, new strategies are needed. 
 
1.4.4 Strategies to reduce PIP - the pharmacist 
Pharmacist-led interventions have been suggested as an effective way of reducing 
PIP [51-53]. In 2012, a Cochrane review [54] concluded that medication reviews of 
patients conducted in close collaboration between pharmacists and physicians 
resulted in reductions in inappropriate prescribing either through substitution with 
appropriate medicines or discontinuation of PIMs [54, 55]. The Pharmacist-led 
Information technology Intervention (PINCER) trial [56] conducted in general practice 
in the UK, demonstrated these positive outcomes of a pharmacist support 
intervention. Participants in the intervention arm were at significantly lower risk of 
hazardous prescribing and inadequate blood-test monitoring of medicines compared 
to the control patients. In the PINCER trial, the intervention patients received a 
pharmacist-led information technology intervention (PINCER) composed of 
feedback, educational outreach and pharmacist support. The general practice 
received computer-generated prescribing feedback, and the pharmacist then met 
with the general practice team to discuss the feedback. The pharmacist was also 
available to support the practice team after the meeting [56].  Similarly, in Ireland, 
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the Optimizing Prescribing for Older People in Primary Care (OPTI-SCRIPT trial) [40] 
demonstrated that a multi-faceted pharmacist-led intervention in general practice 
reduces PIP. In this trial, pharmacists used academic detailing to coach GPs to review 
medicines together with their patients. The GPs were also given pharmaceutical 
treatment algorithms to further support the medicines reviews by suggesting 
alternative therapies to a PIP drug. At the end of the study, the percentage of patients 
with PIP was lower for the intervention group (52%) compared to the control group 
(77%), and the mean number of PIP drugs was also lower in the intervention group 
(0.7) than the control group (1.18) [40].  
Integrating pharmacists into multi-disciplinary teams has been suggested as 
an effective method to reduce the Medication Appropriateness Index (MAI) scores in 
both the primary and secondary care settings [52, 53]. In the General-Practitioner-
Pharmacist-Collaboration (GPPC) study [57] from New Zealand carried out in people 
aged ≥65 years, community pharmacists conducted a clinical medication review and 
met with the patient’s GP to discuss recommended medication changes. Even though 
only 40% of pharmacist recommendations were implemented, the study showed 
that the mean MAI scores had improved significantly at 6 months of follow-up in the 
intervention group compared to the control group, and the difference in MAI-scores 
between the two groups was significantly different. In the intervention group the 
mean number of changes per patient was 3.1 at 6 months compared to 1.6 in the 
control group. The majority of changes in the intervention group comprised the 
discontinuation of a medicine (32%) whereas initiation of a medicine was the primary 
change in the control group (39%). This also resulted in a significantly higher number 
of initiated medicines in the control group compared to the intervention group [57]. 
The PINCER, OPTI-SCRIPT and GPPC trials all demonstrated that collaboration 
between general practitioners and pharmacists is a potential means of reducing 
hazardous and inappropriate prescribing..  
 With the increasing complexity of medicines management in the multimorbid 
older patient, the role of the pharmacist is more important than ever. In turn, greater 
emphasis is being placed on the integration of pharmacists to enhance patient access 
to healthcare services, minimise ADEs and help prevent drug-related hospital 
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admissions. The increasing demands for healthcare have created an opportunity for 
pharmacists to attain a more central role in medicines management [58, 59]. Today, 
pharmacists have gained a larger role in the provision of medicines management 
worldwide with the Home Medicine Review (HMR) in Australia [60], the Medication 
Therapy Management (MTM) services in USA [61] and the Medicines Use Reviews 
(MURs) in the UK [62], Italy [63]and New Zealand [64]. However, these reviews are 
not meant to be clinical reviews and prescribing appropriateness is not generally 
considered in these reviews, as pharmacists do not have clinical information available 
to them.  
The role of the community pharmacist in Ireland is currently a role of 
managing the safe supply and rational use of medicines within the community 
setting. Community pharmacists are trained and expected to screen for potential 
interactions with other medicines (i.e. prescription, over-the-counter, herbal 
supplements etc.), to identify and help prevent adverse effects and to ensure that 
patients know how to take their medication correctly [65]. 
In recent years, the community pharmacy profession in Ireland has 
undergone a significant change. The Pharmacy Act 2007 introduced a new modern 
system for the profession underpinned by the Code of Conduct and the Core 
Competency Framework outlining the competencies expected of a practising 
pharmacist [65]. Following this Pharmacy Act in 2007 was the provision for new 
services to be directly available to patients from their community pharmacists. These 
services include; administering seasonal influenza vaccinations and emergency 
hormonal contraception. A new legislation from 2015 expanded the vaccination 
programme and allowed community pharmacists to administer emergency 
medicines to patients in life-threatening situations (including epinephrine 
(adrenaline), salbutamol, glyceryl trinitrate, glucagon and naloxone). Since 2010, all 
community pharmacies have a designated patient consultation room, which has 
enabled a more direct patient care in the pharmacy and has created a space for 
patients to discuss their medication with their pharmacist. Other innovations  to 
community pharmacy practice in Ireland includes anticoagulation services in 
collaboration with the hospital haematologist [65]. Monitoring of disease 
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progression is a key part of chronic disease management, and these anticoagulation 
clinics in community pharmacies have been successful in Ireland, although on a 
smaller scale compared to New Zealand [66, 67]. These clinics have proven useful in 
moving services from the hospital setting to the primary care setting to increase 
patient access and reduce costs to the healthcare service [66, 67].  
Today, in Ireland, changes to a prescription must be made by the medical 
practitioner, dentist or registered nurse prescriber. Legislation supporting 
pharmacist prescribing has been implemented in the UK, Canada and New Zealand 
with the aim to improve patient access to care, enhance safe and rational use of 
medicines and to utilise the source of the pharmacists [68]. A new legislation in 
Ireland from 2015 allowing trained pharmacists to supply and administer certain 
prescription only medicines to patients in the event of an emergency highlights the 
role that the pharmacist can play in directly treating the patients in the community 
in Ireland as well. These new responsibilities of the pharmacist role demonstrate that 
while pharmacists  may have been over qualified and underutilised, the Government 
has realised their potential to support safer use of medicines and patient care [65]. 
Despite these services being available, further evidence is needed on clinical 
outcomes and the acceptability of these services to all stakeholders. In the UK, the 
MUR service has been available since 2005, but the value and acceptance of this 
service to the public has not yet been established [69]. In addition to patient barriers, 
the successful uptake of MURs is challenged by a lack of awareness among GPs of 
this service but also a lack of evidence supporting the effectiveness of MURs [69].  
Overall, there is evidence to suggest that the involvement of pharmacists in reducing 
PIP is of benefit to patient care but barriers still persist to the successful integration 
of this pharmacist support [54, 70].  
1.5 Deprescribing 
 
1.5.1 Deprescribing - a new term 
Since polypharmacy and PIP is a result of a large number of daily medicines taken by 
a patient, the solution to overcome this inappropriate use of medicines appears 
simple: reduce the number of medications a person takes through ‘deprescribing’ 
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[71]. Deprescribing is a relatively new term that focuses the attention on stopping 
medications to improve outcomes and reduce risks of adversity relating to 
medication use [55]. Deprescribing is defined as ‘the process of withdrawal of 
inappropriate medication by a healthcare professional with the goal of managing 
polypharmacy and improving outcomes’ [71]. The process aims to avoid denying safe 
and effective treatment to people whilst simultaneously eliminating the risks of 
people receiving unnecessary treatment which is unlikely to benefit them or may 
increase the risk of harm [72]. This definition describes the true meaning of 
deprescribing, namely to undo the prescribing of a medication by discontinuing it. 
However, this may be a reductive definition. It could be said that reducing the dosage 
or frequency of a medication or switching to a safer medication are actions 
undertaken with the specific purpose of eliminating the risks of people receiving 
unnecessary treatment and thus belongs to the deprescribing process as well. 
Deprescribing is a complex process of eliminating inappropriate medication 
usage by weighing up the risks and benefits of a medication in an individual patient 
but it is equally a process that may benefit from taking into account patients’ 
individual care goals, functional status and life expectancy [73].  
In practice, the process has been described as follows:  
(1) consider all medications currently taken by a person and the indication for 
each medication, 
(2) identify and prioritise the medication(s) to be targeted for deprescribing. This 
step should be guided by patient characteristics (e.g. age-related changes and 
multimorbidity) and the medication used (pharmacokinetic and 
pharmacodynamic characteristics) [74],  
(3) discontinue the medication, which should include planning the process and 
communicating with the patient and liaising with other healthcare providers, and  
(4) monitor the patient for beneficial and harmful effects of stopping the 




1.5.2 The need to deprescribe 
There are many reasons why medications should be deprescribed, including but not 
limited to: (i) lack of efficacy, (ii) increased risk of medication-related problems, and 
(iii) low levels of medication adherence [72, 74]. In particular, the older patient 
population is an important group for consideration of deprescribing. As older people 
often have multiple comorbidities with a concomitantly high number of daily 
medicines, there is an increased concern for this patient group about the heightened 
risk of medication-related adversity, and deprescribing medications in this 
population seems a reasonable first step [75].  
1.5.3 Safety and effectiveness of deprescribing 
A literature search on deprescribing (search terms ‘deprescriptions’ [MeSH term] and 
‘deprescribing’) identified studies aiming to deprescribe in specific therapeutic areas. 
Proton pump inhibitors (PPIs) is a drug class receiving attention in deprescribing. 
Guidelines in dyspepsia management recommend that patients treated with PPIs 
should have their doses reduced to the lowest effective dose or return to self-care 
[76]. Similarly, the Screening Tool of Older People’s Prescriptions (STOPP) 
recommends stopping or reducing the dose of PPIs at full therapeutic dosage for 
more than 8 weeks in older people (aged ≥65 years) if used for uncomplicated peptic 
ulcer disease or erosive peptic oesophagitis [77]. Despite these recommendations, 
PPIs are continued in the long term in patients, which may result in unnecessary side 
effects, pill burden or unnecessary high costs [76]. An interventional study from the 
UK examined the effects of a nurse-led educational support programme and rescue 
therapy for rebound symptoms offered to patients prescribed PPIs [76]. At 12 
months post-intervention, 75% (6249) of patients reduced dosage or dosing 
frequency or discontinued PPIs. The study also showed that PPI prescriptions had 
gone from nearly 90,000 to 46,000, however, simultaneously, the number of 
prescriptions for alginate had gone up from 2,400 to 6,700. The study demonstrated 
that PPIs can be safely withdrawn from patients or in some cases, substituted to a 
safer drug, i.e. alginate [76]. 
Another study tested the effectiveness of a clinical pharmacist-led 
programme that included tapering instructions, patient education and follow-up 
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[78]. Patients included in this study were taking a PPI long term for gastroesophageal 
reflux disease without esophagitis or without a clear indication. Clinical pharmacists 
then identified candidates for PPI deprescribing. Only 126 patients were assessed for 
eligibility in the study and of these, only 22 patients agreed to participate and 
attempt to have their PPIs discontinued or dose reduced. The study showed a high 
success rate of 86% (19 patients) having their PPI completely discontinued post-
intervention and only 5% (1 patient) being unable to reduce dose or discontinue the 
PPI [78]. Hence, this study showed that PPIs can be deprescribed successfully, but 
the study was limited due to its small number of participants and short duration of 
follow-up.  
 Other studies have targeted deprescribing of benzodiazepines [79]. The use 
of benzodiazepines in the older patient is of particular concern due to their age-
related physiological changes and the significant side-effect profile of 
benzodiazepines. Consequently, benzodiazepines are commonly described as 
potentially inappropriate medicines (PIMs) and both benzodiazepines and hypnotic 
‘Z’-drugs are recommended to stop in people aged ≥65 years in the STOPP tool due 
to their sedative effects [77]. Despite this, benzodiazepines are frequently prescribed 
to older people for the treatment of insomnia, anxiety and delirium. It has been 
estimated that between 5% and 33% of older people are taking benzodiazepines to 
treat sleep disorders. Known side-effects of benzodiazepines are cognitive 
impairment, delirium, dizziness, insomnia and increased falls risk [79]. One study 
conducted in hospitalised patients attempted to deprescribe benzodiazepines by 
applying an intervention consisting of a structured medication review, patient 
educational material, patient counselling and post-discharge communication of the 
deprescribing intervention to the patient’s primary care physician. Only 12 patients 
were included in this study of whom 11 had deprescribing initiated. At study 
completion (3 months after enrolment), benzodiazepines were successfully 
deprescribed for six patients and a 50% dosage reduction was achieved in the 
remaining five patients. During the withdrawal process, seven patients experienced 
worsening of anxiety symptoms, withdrawal symptoms or a fall. Four patients 
required substitution of the benzodiazepine with an antidepressant and one patient 
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required substitution to an antipsychotic whilst one patient required a return to 
original dose of the benzodiazepine. This study highlighted the difficulties of 
deprescribing benzodiazepines, and that consideration must be given within the 
withdrawal process to the option of substituting the benzodiazepine to a more 
appropriate medication, such as antidepressants as done in the study. Despite the 
fact that this study did not show a reduction in the total number of medications per 
patient, it did show an improvement in prescribing by substitutions to safer 
medications, which, as suggested by the study itself, could be of equal value to the 
patients [79].  
 Another study also looked at the feasibility of deprescribing benzodiazepines 
and hypnotic ‘Z’-drugs in patients taking these inappropriately for a longer duration 
than the prescribed period. A clinical pharmacist conducted a comprehensive 
medical review and identified potentially inappropriate benzodiazepines or ‘Z’-drugs 
used for more than 4 weeks. Shared decision making of deprescribing with the 
patient and the department psychiatrist was then done. Based on this and the 
deprescribing algorithm for benzodiazepines published by Pottie et al. [80], a 
withdrawal plan was developed  and initiated. Patients were then monitored for 
withdrawal symptoms or returning of symptoms. The study was conducted in in- and 
outpatients of the Department of Psychiatry in a hospital in India. A total of 109 
patients were included in the study. Of these 109 patients, the use of 
benzodiazepines was deemed inappropriate in 99 patients. Of these 99 patients, 33 
patients were started on dose reduction and seven patients were prescribed their 
benzodiazepine on an emergency basis. Amongst the 33 patients who were started 
on dose tapering, 27 were completely discontinued and six were advised to continue 
the tapered dose. Two people experienced withdrawal symptoms. The study showed 
that benzodiazepines and hypnotic ‘Z’-drugs can be deprescribed however the 
evidence is weak considering the small number of participants and the lack of follow-
up in the study [81].  
The studies mentioned above have shown that deprescribing interventions 
can be used to successfully discontinue inappropriate use of certain medication such 
as PPIs and benzodiazepines. However, it is important to consider the risk of 
20 
 
recurrence of the medical condition or withdrawal effects when stopping a 
medication as this may require restarting of the medication or prescribing of another 
medication to relieve the symptoms. This in turn may affect the true effect of a 
deprescribing intervention on the total number of medicines a patient is taken. 
Furthermore, the durations of follow-up in some of the studies may have been too 
short to detect medications later restarted, which again, may have impacted the true 
effect of deprescribing on the number of drugs prescribed to a patient. Additionally, 
studies were limited by small sample sizes which may have compromised the 
generalisability of the findings. Small sample sizes may limit inferences depending on 
how representative the study population is of the target population.  
In addition to deprescribing interventions targeting specific drugs or drug 
classes, deprescribing interventions across settings and drug classes have been 
shown to be effective in reducing the total number of medications and reduce 
inappropriate medication use. A systematic review by Page et al. [71] summarised 
the results of 116 studies on the effectiveness of deprescribing interventions 
targeting single and multiple medications. The included studies comprised a mix of 
RCTs and comparative studies and reported results for a total of 34,143 participants. 
The review identified that deprescribing reduced both the total number of 
medications and number of PIMs in the intervention groups, and deprescribing was 
not associated with a significant increase in adverse drug withdrawal events. This 
highlights that deprescribing is safe and effective in reducing the number of 
inappropriate medicines. Looking at clinical outcomes, deprescribing did not 
significantly affect mortality across studies. However, a subgroup analysis did show 
that mortality was significantly reduced in patient-specific interventions compared 
to educational interventions. Deprescribing interventions however did not result in 
significant changes of the incidence of ADEs, cognitive function, quality of life nor risk 
of falls. Hence, this review summarized the growing body of research on 
deprescribing but also highlighted that deprescribing interventions have not proven 
themselves effective in improving clinical outcomes [71].  
Another systematic review by Johansson et al. [82] included 25 studies (RCTs, 
cluster RCTs and nonrandomised controlled trials) including a total of 10,980 
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participants. Only three of the included studies demonstrated a substantial change 
in the number of drugs taken. The analyses of all-cause mortality and hospitalisations 
showed that the interventions to reduce polypharmacy had no effect on either, all-
cause mortality or, hospitalisation rates. Based on these findings, the authors of the 
review concluded that the overall evidence of the effectiveness of interventions to 
reduce polypharmacy is very limited [82].  
A Cochrane review [16] including 12 studies with a total of 22,438 older 
patients further adds to the findings of the previous aforementioned literature 
reviews [71, 82].  Interventions included in the Cochrane review demonstrated a 
reduction of inappropriate prescribing and improvements in the appropriateness of 
polypharmacy similar to the other two literature reviews. The difference in 
hospitalisations observed varied from (i) no difference, to (ii) a non-significant 
difference and (iii) a significant difference between the included studies depending 
on the methods of assessment. No difference in health-related quality of life (HRQoL) 
was seen in the studies. The findings of this Cochrane review highlighted that 
evidence exists that deprescribing intervention are effective in reducing 
inappropriate prescribing but that it remains unclear if these interventions improve 
hospitalisations and quality of life [16].  
 The findings of these systematic literature reviews highlight that when one 
seeks to determine the effect of deprescribing on improved clinical outcomes, the 
evidence is mixed. Heterogeneous study designs of deprescribing interventions have 
hampered direct comparisons of the effectiveness of such interventions but as it 
shows, no RCT has confirmed a significant reduction in mortality among participants 
receiving a deprescribing intervention and most deprescribing interventions have 
failed to show a statistically significant reduction of hospitalisations, ADEs or falls. 
More evidence is needed from high-quality RCTs to determine the clinical outcomes 
of deprescribing in multimorbid older populations. However, such trials will require 
thousands of participants, and conducting these trials in practice will be challenging. 
Instead, the clinical benefits of deprescribing are expected to arise from reducing 
doses or discontinuing PIMs and minimising the use of polypharmacy – outcomes for 
which deprescribing has proven effective. Reducing the total number of medications 
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and inappropriate prescribing in a patient, should be considered as stand-alone 
outcomes worth achieving in that the patient’s treatment burden and unnecessary 
costs are reduced, which makes deprescribing an area worthwhile to investigate 
further. 
 Recently, attempts at creating an evidence-base for deprescribing, such as 
with the European Union funded trials SENATOR [83] and OPERAM [84] have begun 
in earnest. These two trials have investigated the effect of the routine application of 
the STOPP criteria and the Screening Tool to Alert to Right Treatment (START) to the 
medication lists of hospitalised, older people (aged ≥65 years) using computerised 
decision support systems. The results of these trials, when published, may thus add 
useful data to the effectiveness and safety of the deprescribing process. [83, 84]. 
 
1.5.4 Guiding deprescribing  
There are few evidence-based guidelines on deprescribing as part of medicines 
management in multimorbid older people [55]. In contrast to prescribing, which is 
guided by robust evidence from RCTs, deprescribing is often guided empirically due 
to the common exclusion of this process in clinical trials [74]. In addition, clinical 
guidelines are usually developed based on evidence from trials that tend to list older 
people with multiple comorbidities as exclusion criteria, which limits their 
transferability to this population [72, 74]. Furthermore, current clinical guidelines 
often have a single-disease focus and rarely take [55, 74]  into consideration the 
complexity of treatment in multimorbid patients [26, 85, 86]. GPs have reported 
feeling obliged to adhere to clinical guidelines in medicines management, and a high 
number of medications can thus easily be reached when guidelines to treat individual 
conditions are followed unquestioningly by physicians prescribing for patients with 
multiple comorbidities [26, 72].  
As part of the process to meet the needs for deprescribing guidelines, a 
number of tools and criteria have been developed, but only some have been 
validated to date. Of these, some of the most widely referenced and used are the 
Beers criteria [87-91], the STOPP tool [77], PROMPT criteria [92], the Medication 
Appropriateness Index (MAI), STOPPFrail tool [93] and the CEASE deprescribing 
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framework [94]. These tools and criteria have their limitations when used to assess 
medication appropriateness in individual patients. These tools, to different extents, 
fail to consider the multiple factors affecting the appropriateness of a medication in 
an individual patient, such as severity of the disease, advanced age and life-
expectancy, multi-morbidity, physical and mental capacity, care goals and personal 
preferences. This highlights the complexity of deprescribing due to this individualised 
context that requires a nuanced approach exceeding that of the current tools and 
guidelines. However, guidelines  provide a more systematic framework for assessing 
appropriateness of medicines and guiding steps towards successful discontinuation 
[95].  
 A Canadian group has developed evidence-based deprescribing guidelines for 
a number of specific drug classes including proton pump inhibitors (PPIs), 
benzodiazepines, antipsychotics, antihyperglycemics, cholinesterase inhibitors and 
memantine [80, 96-99]. These guidelines are supported by algorithms to guide 
healthcare providers through the process of discontinuing one of the 
abovementioned drug classes in patients. In clinical practice, the use of these 
deprescribing guidelines seems beneficial but data from RCTs are needed to confirm 
their applicability to practice [100].  
 
1.5.5 Patient-involvement in deprescribing 
While the abovementioned guidelines on deprescribing provide guidance on the 
identification of medication to be deprescribed and the management, they are 
mainly targeted at the healthcare professional, and to some extent excluding the 
patient perspective. Suggested by Barnett et al. [101] deprescribing would benefit 
from the addition of a more patient-centered approach and they have published a 
guide to support patient-involvement in practice. This guide divides the process into 
seven steps and provides explanation of the purpose of each step, things to consider, 
actions to take and questions to ask the patients in order to undertake deprescribing 
safely [101]. This patient-centered deprescribing is in line with the published 
evidence. Tannebaum et al. [102] tested the effectiveness of a direct patient 
education about drug harms on benzodiazepine therapy discontinuation among 
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older people (aged ≥65 years) receiving long-term benzodiazepine therapy. The study 
showed that a benzodiazepine discontinuation rate of 27% was found in the 
intervention group compared to only 5% in the control group, at 6 months after the 
intervention [102]. In the study by Krol et al. [103] a simple information leaflet was 
developed to provide information on dyspepsia medication and to suggest stopping 
or reducing long-term PPI use with the help of the GP. Suggestions were made to the 
patient to seek help from the GP for stopping the PPI or reduce its use. At 20 weeks 
after the intervention, 15% of patients had stopped taking PPIs or were taking a lower 
dose compared to baseline [103]. Patient-involvement in deprescribing thus seems 
to be an enabler to successful deprescribing, and the patient has been suggested as 
a barrier and facilitator of deprescribing [104]. Summarized in studies by Reeve et al. 
[104, 105] greater involvement of patients in the deprescribing process is associated 
with greater patient willingness to have a medication stopped. The majority of older 
people (88%) and their caregivers (84%) are willing to have a medication stopped if 
deemed possible by the prescribing doctor [105]. However, a number of barriers and 
facilitators affect this willingness. Hope for future benefits and experiencing 
improvement when taking a medication are reasons reported for not wanting to have 
a medication deprescribed. For some patients, taking the medication gives them a 
feeling that they are doing something for their health and gives a sense of comfort 
[104]. Patients have also reported feeling pressured by their family, caregivers or 
healthcare professionals to taking a medication and believe that if a prescription is 
reissued by the prescriber, that this is done with an express for the patient to 
continue taking the medication. Previous negative experiences of stopping a 
medication and fear of recurrence of previous conditions also make patients less 
open to deprescribing. However, reported enablers to deprescribing are the 
inconvenience of taking a high number of medications and the cost of same [104]. 
 A main patient barrier to deprescribing is the lack of time and support from 
the primary care physician both during the initiating conversation about 
deprescribing, instructions on the process and follow-up after the medication has 
stopped. The study concluded that interventions designed to overcome patient 
barriers should include a plan for the actual cessation, educating the patient on what 
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they should do if they experience return of symptoms or withdrawal side-effects. 
More support of the patient is needed, preferably from their primary care physician. 
However, with the existing workload on primary care physicians, the study suggested 
that future interventions should consider a multidisciplinary approach to 
deprescribing, with primary care physicians being supported by other healthcare 
professionals [104]. Support from other healthcare professionals to successful 
patient-centred deprescribing may thus create an opportunity for the community 
pharmacist to be more involved in patient care.  
 
1.5.6 Strategies for deprescribing - a new role for the pharmacist 
Despite increasing efforts, challenges still exist to design deprescribing interventions 
that will improve important clinical outcomes. Hence, attention should be drawn to 
the careful selection of the intervention design and to how deprescribing can be 
successfully implemented within routine clinical practice [72, 100, 106]. This should 
be informed by an understanding of the components underlying an effective 
intervention as well as the barriers to the implementation of such intervention.  
 As the majority of prescribing takes place in primary care, it makes sense that 
GPs would liaise with community pharmacists as part of a collaborative strategy on 
deprescribing. Discontinuing medicines requires careful consideration of 
pharmacology and patient characteristics, and pharmacists have the knowledge, 
training and several competencies to assess appropriateness of medicine use versus 
potential risks and benefits of discontinuation [55, 72, 75]. Community pharmacists 
represent an important support resource for prescribers and can provide information 
on appropriate medicine use, drug-drug interactions and ADRs [107]. In addition, 
community pharmacists are an accessible source of healthcare in the community and 
are in a key position to take more responsibility for medicines management and 
patient care which may be of benefit to patient-centred deprescribing [74]. The focus 
of the community pharmacist is currently changing from a drug-focus to a patient 
care-focus with a suggested beneficial role in reducing PIP [52, 53, 58, 59].Therefore, 
there is a potential to evaluate the role of the community pharmacist in supporting 
the deprescribing process. As described, community pharmacists in Ireland do not 
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have prescribing authority for either supplementary or independent prescribing. This 
raises the question if community pharmacists should deprescribe in the true meaning 
of the term? Ultimately, the responsibility of deprescribing lies with the person 
responsible for prescribing, in Irish community practice, the GP. However, supporting 
the GP by providing pharmacological input, identifying potential inappropriate 
medicines to be stopped and monitoring the cessation of a medication may allow 
new responsibilities to be managed by community pharmacists with the purpose of 
enhancing safe and successful deprescribing in the primary care setting in Ireland. 
There is a need to investigate the potential for a clearly defined role for a community 
pharmacist to input into the deprescribing process.   
 
1.6 Aims and objectives 
The concept of deprescribing is relatively new, and the role of the pharmacist in 
medicines management is evolving but requires a stronger research evidence base. 
In this thesis, the potential role of the community pharmacist to give input into 
deprescribing will be explored, along with the barriers and facilitators to the 
integration of the pharmacist’s supportive role in deprescribing. The work conducted 
in this thesis is expected to provide a framework from which to make 
recommendations for pharmacists and policymakers to help facilitate the integration 
of pharmacists into the deprescribing process. Additionally, the findings of this thesis 
are expected to generate a series of key implications for interprofessional 
collaboration and education for pharmacists and GPs to promote the delivery of safe 
and effective deprescribing. Finally, the combined work in this thesis could help 
inform the design and implementation of future deprescribing interventions and 
contribute to the growing discussion about deprescribing and the role of the 
pharmacist.  
 
The overall aim of this thesis was to identify the challenges and potential benefits of 




The thesis objectives were: 
i. To identify the barriers and facilitators to deprescribing as viewed by 
healthcare professionals. 
ii. To examine the effectiveness of deprescribing interventions. 
iii. To determine the long-term prevalence of inappropriate prescribing in early 
old aged people. 
iv. To assess the potential cost-avoidance of using explicit criteria to reduce 
potentially inappropriate prescribing in primary care. 
v. To explore the views of the community pharmacist and the GP on pharmacist 





2 Challenges of deprescribing in older patients with 
multimorbidity, from healthcare professionals’ perspectives - 
a narrative review 
 
2.1 Chapter description 
It was decided to synthesise the current literature on deprescribing, and the 
challenges to deprescribing as viewed by healthcare professionals. This was done 
with the aim to identify knowledge gaps to be explored in depth. This review helped 
informed the research questions for the next research chapters. I conducted the 
literature search, screened the retrieved literature for eligibility, summarised the 
study findings in a narrative synthesis and wrote the chapter and submitted it for 
publication. The other authors of this chapter and publication reviewed the chapter 
and gave their input and advice during the study.  
  
2.2 Publication 
The work of this chapter has been published as Raae-Hansen C, Byrne S, O’Mahony 
D, Kearney P, Sahm L, Cullinan S. Challenges of deprescribing in the multimorbid 
patient. European Journal of Hospital Pharmacy. 2017; 24:43-46. Doi: 




Multimorbidity and associated polypharmacy are among the biggest risk factors for 
inappropriate medication use, ADRs, ADEs and morbidity leading to hospitalisations 
[108, 109]. Discontinuation of medication is one of the most common 
recommendations following medication review in older people despite having a low 
probability of being implemented in practice [110, 111]. Strategies are urgently 
needed to facilitate the implementation of deprescribing among patients with 
multimorbidity. The deprescribing process includes some or all of the following 
elements; a review of  current medications, identification of medications to be 
discontinued, a discontinuation regimen, involvement of patients, and a review with 
follow up [112].  
Among the solutions proposed to reduce the number of medications per 
patient, are various screening tools that support prescribers in their decision-making, 
such as Beer’s Criteria [87] and Screening Tool of Older People’s Prescriptions 
(STOPP) and Screening Tool to Alert to Right Treatment (START criteria) for 
potentially inappropriate prescribing (PIP) [77]. Despite the evidence that these PIP 
screening tools reduce potentially inappropriate medication use, little is known 
about  their specific utility in patients with multimorbidity and limited life expectancy 
[113].  
  Deprescribing can be a difficult task for practitioners in many categories of 
patients but is further complicated in older persons due to the need to consider age-
related changes in pharmacokinetics and pharmacodynamics [114]. Therefore, 
despite existing guidelines on safe withdrawal of most drugs, healthcare 
professionals must also take account of the patient’s age and multimorbidity in the 
deprescribing process. There is a need to tailor the deprescribing process to the 
needs of the multimorbid, older patient based on sound clinical recommendations. 
The aim of this narrative review was to explore the viewpoints of healthcare 
professionals on the challenges and practicalities of deprescribing in older patients, 






2.4.1 Literature search 
The PubMed, CINAHL and Academic Search Complete databases were searched for 
primary, original literature in English published between January 2006 and February 
2019. In all three databases, the word ‘deprescribing’ was used to search for relevant 
literature. The deprescribing process was perceived as being a component of 
polypharmacy management, and an additional literature search in the same three 
databases was performed with the medical subject headings (MeSH) term 
‘polypharmacy’ combined with ‘elderly’ and the truncations of ‘physician’ and 
‘practitioner’ using the Boolean operators. A ‘snowballing’ approach was used to 
identify additional literature through the screening of the reference lists of the 
primary literature and the reference lists of these as well. In addition, the reference 
lists of literature reviews relevant to deprescribing and polypharmacy management 
were hand-searched [106, 115-117].  
 
2.4.2 Study selection 
The retrieved literature was screened for eligibility according to pre-specified 
inclusion- and exclusion criteria based on the citation titles followed by a review of 
their abstracts. The inclusion and exclusion criteria for this review are outlined in 
Table 2-1. Full manuscripts of the articles that appeared eligible for inclusion were 






Table 2-1 Inclusion- and exclusion criteria used to identify eligible literature for inclusion in this 
narrative review 
Inclusion criteria Exclusion criteria 
(i) Original primary research; 
(ii) Articles published in English; 
(iii) Articles published in 2006-
2019; 
(iv) Articles that contain data on 
healthcare professionals’ 
views on deprescribing and 
polypharmacy management 
in older patients. 
(i) Articles about specific drugs, drug 
classes, treatments and conditions; 
(ii) Articles not specific to the topic of 
healthcare professionals’ views on 
deprescribing and polypharmacy 
management in older patients; 
(iii) Reviews; 
(iv) Case studies, framework; 
(v) Comments, posters, editorials, brief 
reports. 
 
2.4.3 Study appraisal and synthesis 
The purpose of this narrative review is to summarise in a narrative format the 
findings of the literature on healthcare professionals’ views on deprescribing. The 
findings of each study included were not pooled or combined as in systematic 
reviews or meta-analyses, and it was not deemed necessary to formally assess the 
study quality. Instead, data were extracted and categorised according to country, 
study design, data collection method, type and number of participants, and the focus 
i.e. whether this was specified as deprescribing or more generally on polypharmacy 
management in older patients. The findings of the included studies were grouped 




2.5.1 Search results 
From the literature searches in the three databases, a total of 1,569 citations were 
retrieved after the removal of duplicates. Based upon the title and abstract screening 
of the citations, 1,522 articles were excluded. Another 27 articles were excluded after 
reading the full-texts. Reasons for exclusion of the articles are presented in Table 2-2. 
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The remaining 20 articles were eligible for inclusion in this review, and from the 
reference lists of these another three eligible articles were identified. The flow chart 
of literature acquisition is outlined in Figure 2.1. 
 
Table 2-2 Reasons for the exclusion of articles from this narrative review and the number of articles 
excluded. 
Reason Articles excluded (n) 
Topics specific to drugs, drug classes, treatment and conditions 252 
Reviews 119 
Case studies and framework 33 
Commentaries, letter to the Editor, editorials, brief reports and 
perspectives 
123 
Not specific to deprescribing or polypharmacy management in 
older patients 
181 
Not about healthcare professionals’ views on deprescribing or 







Figure 2.1 Flow diagram of the acquisition of literature for inclusion in this narrative review. 
2.5.2 Study characteristics 
A total of 23 articles were included in this review; 17 reported on deprescribing, and 
the remaining six reported on medicines management, i.e., deprescribing was not 
the main focus in these latter studies. All the included studies focussed on the older 
patient population. The characteristics of the included studies are presented in Table 
2-3. 
Literature search: 
Deprescribing and Polypharmacy 
Pubmed, CINAHL, Academic Search Complete 
Filters: 2006-2019 and English language 
N = 2119 
 
Duplicates removed,  
n = 550 
Citations after removal of 
duplicates, n = 1,569 
Citations excluded based 
on title screening,  
n = 1,315 
Citations after title screening, 
n = 254 
Citations after abstract 
screening, n = 47 
Citations eligible for inclusion, 
n = 20 
Citations excluded based 
on abstract screening,  
n = 207 
Citations excluded based 
on full text screening,  
n = 27 
Literature identified from 
references lists inclusion, 
 n = 3 
Articles included in the review,  
n = 23 
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Table 2-3 Characteristics of the included studies in the narrative literature review 
Study, year Country Study design Data collection Participants, (n) Focus 
Ailabouni et al. [119], 2016 New 
Zealand 
Qualitative Semi-structured interviews General Practitioners (GPs), 
(n=10) 
Deprescribing 
AlRasheed et al. [120], 
2018 
Saudi Arabia Qualitative Focus groups Family medicine physicians 
(n=15) 
Deprescribing 
Anderson et al. [121], 2017 Australia Qualitative Focus groups GPs (n=32) and consultant 
pharmacists (n=15) 
Deprescribing 
Anthierens et al. [122], 2010 Belgium Qualitative Semi-structured interviews General practitioners, (n=65) Polypharmacy 
management 
Djatche et al.[123], 2017 Italy Quantitative Survey Primary care physicians (n=160) Deprescribing 






Expert panel discussion and 
three surveys (inclusive of 
free-text responses) 
Pharmacists (55-68%), family 
physicians (11-17%), geriatricians 
(9-12%), nurse practitioners /13-
16%). (n=64, n=53, n=47)§ 
Deprescribing 







Focus groups Physicians (90%), nurse 
practitioners (5%), Physician 




Hansen et al. [126], 2019 Ireland Qualitative Semi-structured interviews Community pharmacists (n=18) Deprescribing 
Harriman et al. [127], 2014 Canada Quantitative 
 
Survey Family physicians, (n=30) Deprescribing 
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Study, year Country Study design Data collection Participants, (n) Focus 
Jubraj et al. 





Survey incl. free-text  
Responses 
Foundation Year 1 (FY1) doctors, 
(n=20) 
Deprescribing 
Laursen et al. [129], 2018 Denmark Qualitative In-depth, semi-structured 
interviews 
GPs (n=14) Polypharmacy 
management 




Focus groups General practitioners, (n=31) Polypharmacy  
management 
Nadarajan et al. [131], 2017 Singapore Quantitative Survey Senior hospital doctors (n=34), 
junior hospital doctors (n=56) 
Deprescribing 
Ní Chrónín et al. [132], 2015   Australia,  
New 
Zealand 
Quantitative  Survey  Geriatricians† (84%), trainees† 
(16% ), (n=134) 
Deprescribing 
Nixon et al. [133], 2016 Denmark Qualitative Semi-structured interviews GPs (n= 24) Deprescribing 
Palagyi et al. 
[134], 2016 
Australia Qualitative Focus groups 
Semi-structured interviews 
Nine focus groups with residents* 
(n = 25), relatives (n = 16) and 
staff members* (n = 19). One 
focus group with GPs** (n = 8). 
Pharmacists (n = 4)  
Deprescribing 
Pype et al. [135], 2018 Belgium Qualitative Semi-structured interviews GPs (n=11) Deprescribing 




Focus groups Experienced general practitioners 
(GPs)‡,(n=29) 
Deprescribing 
Shemeili et al. [136], 2015 Abu Dhabi Qualitative In-depth semi-structured  
Interviews 
Physicians (26%), pharmacists 





Study, year Country Study design Data collection Participants, (n) Focus 
Sinnige et al. [137], 2016 Netherlands Qualitative Focus groups GPs (n=12) Polypharmacy 
management 
Sweta et al. [138], 2019 India Quantitative Survey and interviewsa  Medical practitioners (n=422) Deprescribing 
Turner et al. [139], 2016 Australia Qualitative Focus groups GPs (n=19), nurses (n=12), 
pharmacists (n=14), residents 
(n=11) 
Deprescribing 
Wallis et al. [140], 2017 New 
Zealand 
Qualitative Semi-structured interviews Primary care physicians (n=24) Deprescribing 
†Geriatricians and geriatrician trainees refer to specialist physicians/trainees caring for older patients. ‡Experienced defined as a minimum of five years’ experience. 
§The number of participants varied in the three consecutive surveys, survey 1, 2, and 3, respectively. *Residents (i.e. patients) and staff members belonged to long-
term care facilities in New South Wales, Australia. **The GPs included in the study all provided regular medical care to residents of long-term care facilities in New 
South Wales, Australia. aInterviews were based on the tool “Perceptions, Attitudes and Challenges of Physicians towards Deprescribing" which asks the interviewee 






The included studies displayed similar themes on the factors influencing 
deprescribing. Additional factors associated with management of polypharmacy 
were identified, e.g. drug selection, drug initiation. However, for this literature 
review I focussed solely on the factors influencing the discontinuation/deprescribing 
of medications as part of the management.  
 
2.5.3 Study findings 
From the content analysis approach to the study findings, five broad themes were 
identified as challenges to deprescribing in older patients with multimorbidity: (i) 
interprofessional relationships, (ii) medication review, (iii) information, (iv) the 
patient and (v) environmental needs. The main findings within each theme are 
described in Table 2-4. 
Table 2-4 Summary of the main findings of the thematic analysis 
Theme Main finding(s) 
Interprofessional 
relationship 
Too many prescribers in the treatment of multimorbid older 
patients adds to the complexity of deprescribing. Poor 
communication between healthcare professionals, lack of 
experience with deprescribing and a reluctance to interfere 
with the decisions made by other healthcare professionals 
are challenging the decision-making process of 
deprescribing. With GPs as the responsible profession for 
overall medicines management including deprescribing, 
pharmacists were a welcomed support. 
Medication 
reviews 
Not having a comprehensive medication review and not 
understanding the motives of a prescriber to change a 
patient’s medication are barriers to the decision-making 
process of deprescribing.  
Information Current prescribing guidelines are too disease-specific to 
treat multimorbidity, they are lacking the evidence-base to 




Theme Main finding(s) 
guidance on deprescribing. These limitations, together with 
limited access to guidelines are barriers described to the 
deprescribing process. 
Patient Successful deprescribing is challenged by i) patients 
withholding of important information to make an informed 
deprescribing decision, ii) their willingness to stop a 
medication, iii) their acceptance of the GP’s role and iv) the 
difficulties experienced by the prescriber when engaging in 
a conversation with the patient about deprescribing.  
Environmental 
needs 
Lack of time, financial resources, education and decision 
support systems are needed to overcome the deprescribing 
barriers pertaining to the working environment.  
 
 Interprofessional relationship 
In the treatment of multimorbid older patients, the involvement of several 
healthcare professionals is common; this was highlighted as an important factor in 
12 of the studies reviewed [70, 119, 122, 124, 127, 130-132, 134-136, 138]. The 
involvement of multiple prescribers was reported by three studies [70, 119, 129] to 
result in individual prescribers following his/her specialty treatment guideline(s), and 
to dominate the patient’s treatment with their own particular focus. Similarly, 
Shemeili et al. [136] and Pype et al. [135] described how some physicians believed 
that they were solely responsible for the medicines management within their 
specialty, and that the overall management was the responsibility of others.  
 In principal, the primary care physicians welcomed the help of pharmacists to 
support them in polypharmacy management, and most pharmacists were in favour 
of the suggested clinical role for them in treating multimorbidity [119, 120, 129, 131, 
136, 138]. However, the perceived value of a pharmacist’s recommendations varied 
between the GPs in the study by Palagyi et al. [134], and was determined by the 
perceived relationship between the medical and the pharmacy profession. The junior 




professionals responsible for deprescribing, followed by senior house officers (SHOs), 
pre-registration junior doctors and pharmacists. In the studies by Anthierens et al. 
[122] and Palagyi et al. [134], GPs felt that the responsibility to review the patient’s 
overall health status and quality of life lay within the remit of their profession. Hence, 
they believed that they have a coordinating role in reviewing the patient’s medical 
treatment, including lowering the doses, quantifying the medication use and 
reducing the number of inappropriate drugs. However, the GPs in both studies also 
described the challenges of these tasks which included a heavy workload on top of 
their regular work commitments [122, 134] as illustrated below: 
 
 “It’s a great idea to reduce medication if you can do it in a safe manner that’s 
not going to make us have to go out to the nursing homes 55 more times:” [134] 
 
The fear of damaging the professional relationship with the original prescriber [119, 
120, 123, 129, 131, 134, 135, 137, 138] and a lack of knowledge about and/or 
experience with deprescribing [119-121, 129, 131, 135, 140] were other concepts 
identified within this theme. Level of confidence and a fear of the potential outcomes 
of discontinuing medication influenced the extent to which prescribers and 
pharmacists would deprescribe/advice deprescribing [119, 121, 123, 126, 131, 135, 
138].  Having experience with deprescribing contributed to higher confidence whilst 
negative experiences enhanced a tendency to continue with the treatment as 
prescribed without interfering [121, 135]. The primary concern among the GPs for 
pharmacist-support in deprescribing was that pharmacists working in the community 
do not have access to patient information which may limit the clinical importance of 
their recommendations [119].  
 
Reported challenges to the interdisciplinary management of deprescribing were;  
i) difficulties in the determination of ongoing benefit versus harm of a medication 




ii) lack of knowledge and experience when deprescribing another doctor’s 
recommended medication [119, 120, 129-131, 136, 140], and 
iii) poor communication between levels of care resulting in inappropriate prescribing 
and/or several prescribers treating the same indication [119, 122, 129, 134, 136].  
 
 Medication reviews 
Multiple prescribers for the same patient usually result in the lack of a clear overview 
of the patient’s medical treatment [70, 122, 136, 140]. This was further compounded 
by low levels of interprofessional communication, in particular poor documentation 
of changes made to a treatment, e.g., initiation, amendments and discontinuation. 
In turn, this poor documentation was a barrier to deprescribing; as it hindered the 
understanding of other doctors’ motivations for the initiation or continuation of 
particular treatments [70, 120-122, 134, 136].  
  Apart from the poor documentation from prescribers involved, the difficulty 
of gaining a complete and updated list of the patients’ medications was a barrier to 
deprescribing. Shemeili et al. [136] reported that the main difficulty with medication 
review was the need to consult several information sources, e.g., pharmacy, patient, 
family and GP, to complete the list, coupled with uncertainty as to which source 
provides the optimal list of drugs taken by the patient. Not knowing which 
medications should be included on the list, like “as required” (PRN) analgesics or 
topical medicines was another challenge mentioned [136]. The study by Moen et al. 
[130] described how incomplete information was perceived as a barrier to the 
decision-making towards active deprescribing in terms of which drugs to discontinue 
and when. The pharmacists in the study by Palagyi et al. [134] further commented 
on poor acquisition and documentation of patient information from the nurses: 
 
 “It’s a matter of educating them [nursing staff] to understand that they don’t 
need to know the medicines… they don’t need to know specific details, they need to 
provide information about that resident that’s documented well and correctly so that 






The lack of an evidence base on the use of a particular drug by older patients was 
reported in many studies as a limitation to structured deprescribing mainly due to 
the exclusion of multimorbid older patients in clinical trials [70, 119, 121, 123, 124, 
129, 130, 132, 133, 135, 139]. The evidence base was perceived  as insufficient with 
regards to the effect of multiple drug therapies in the older patients [132] and the 
effects of preventive medication in the oldest patients, with a need for more 
information about the benefit/risk-ratio of these medications in patients with short 
life-expectancy [70, 124, 130]. As a result of the lack of evidence, treatment 
guidelines for this particular patient group are lacking, with the current guidelines 
perceived to be limited because of: 
 i) being based on trial data involving younger patient populations [130],  
ii) only giving a standardised set of recommended medications per indication 
regardless of the patient’s additional comorbidities [130],  
iii) being too disease-specific [125, 140], and  
iv) not including recommendations for deprescribing [124, 126, 131, 133, 135, 
140].  
  
As a result, prescribers felt under pressure to adhere to prescribing guidelines instead 
of prioritising the medical treatment and deprescribing where appropriate [70, 122, 
130]. This onus, was however not experienced by the majority of the participants 
(67%) in the study by Harriman et al. [127], with 24% being unsure about applicability 
of prescribing guidelines.  
Some studies described a minimal use of existing guidelines to deprescribing 
explained by limited access to those [120, 121]. Easier access to guidelines was 






The patient was described to influence the deprescribing process, through the 
following pathways:  
i) some patients’ unintentional withholding of information about ADRs 
because they attributed these to aging rather than side effects of medicines 
[70],  
ii) some patients being more likely than others to report their symptoms to 
healthcare professionals other than their GPs, (such as hospital specialists or 
nurses),  resulting in the GP not being fully aware of the actual problems 
experienced by the patient [70],  
iii) patient characteristics, such as cognitive impairment, functional 
dependency, level of education and old age, hindered the explanation of the 
patient’s issues with their current medication list and the desire for 
deprescribing [70, 132],  
iv) some patients’ strong attachment to certain familiar medications and 
consequent poor inclination to cease these medications [70, 119-122, 129, 
131],  
v) some patients’ demands, wishes and expectations, and those of their 
families [119, 122, 125, 126, 130, 132, 134, 137, 140], and  
vi) some prescribers’ reluctance to communicate with patients about their 
life-expectancy [70, 119, 140].  
 
Patient expectations were believed to result in conflicts between medical treatment 
desired by the patient versus that of the practitioner in the study by Fried et al. [125]. 
Following this, the prescribers in studies by Moen et al. [130] and Anthierens et al. 
[122] thought that the patients shared the responsibility of their medication lists with 
the prescribers due to their treatment demands and frequent self-medication. The 
study by Schuling et al. [70] reported how the prescribers were reluctant to initiate 




fear among patients who may misinterpret deprescribing as a sign of a nihilistic 
healthcare system losing interest in them due to their old age.   
 
 “People may then get the feeling, ‘Don’t I count anymore, am I not 
 important?’” [70]  
 
Moen et al. [130] commented that the challenges in communication with patients 
were believed to be the factor principally responsible for the continuation of medical 
regimens for longer than appropriate. The study by Harriman et al. [127] and 
Ailabouni et al.[119] reported that some prescribers perceived that it was easier or 
more reasonable to continue a medication that seems to have no negative effects on 
the patient rather than to deprescribe it. In contrast, Ní Chróinín et al. [132], reported 
that a driver of deprescribing was the older patients’ often limited life-expectancy, 
with physicians being more likely to deprescribe multiple medicines in patients with 
increasing dependency and cognitive impairment.  
Additional challenges identified within this theme were patients’ perceptions 
of the GP and their perceived lack of knowledge, understanding and awareness of 
deprescribing and medical therapy in general. Two studies [119, 129] described that 
some patients perceived specialised prescribers (e.g. hospital physicians and clinical 
pharmacologists) as being more knowledgeable than their GP and this sometimes 
disrupted the patient-GP relationships. Patients would not accept the GP’s 
recommendations to the same extent as the recommendations made by specialists 
[119, 129]. 
 
 Environmental needs 
Across the studies, factors pertaining to the working environment were reported to 
influence deprescribing. Lack of time and financial support to review medicines and 
to deprescribe were perceived barriers across studies [119-121, 123, 126, 131, 137, 




[126, 129, 131, 138], and to create and advance decision support/computer systems 
to help facilitate deprescribing [119, 126, 140]. 
 
2.6 Discussion 
A reluctance to deprescribe was apparent when the ‘deprescriber’ was not the 
original prescriber [127, 134]. However, the physicians in the study by Harriman et 
al. [127] denied that this reluctance to deprescribe was due to concerns about 
damaging their relationships with specialists, as it was perceived to be in the study 
by Palagyi et al. [134]. Similarly, a previous study by Cantrill et al. [141] has described 
how a reluctance to change another practitioner’s prescription is due to the fear of 
causing a ‘professional dilemma’. In turn, many GPs feel obliged to continue the 
medical treatment initiated in hospital without changing or questioning the decision. 
They also expressed the concern that ignoring the advice from the hospital 
practitioners would undermine the patient’s confidence in the healthcare system 
[141]. The medical culture described by Moen et al. [130] with infrequent contact 
between GPs and organ specialist is noteworthy. The existence of a tacit agreement 
not to challenge the motivations for any prescription made by specialists may also 
add to GPs’ reluctance to deprescribe. As described by Sinnott et al. [142], poor 
communication by some hospital specialists with the GPs can hinder the coordination 
of a patient’s medical treatment and thereby result in poor therapeutic oversight 
with consequent inappropriate medication use. 
  An interesting finding of this review was the agreement on the GP’s role in 
coordinating the patient’s medical treatment. GPs in the studies by Anthierens et al. 
[122], Harriman et al. [127] and Palagyi et al. [134], all believed that they were 
responsible for keeping a holistic view of the patient’s treatment and to taper and 
discontinue certain medications, and finally follow the effects of these changes over 
time. The data from junior doctors in Jubraj et al. [128] and from specialist physicians 
in Shemeili et al. [136] suggested that the overall responsibility for polypharmacy 




  It is thus interesting to note that there seems to be general consensus about 
the GPs’ role in overall medicine management in multimorbid patients on 
polypharmacy and the supportive role of pharmacists. Randomised controlled trials 
[143-145], have shown that pharmacist-led medication reviews do not have a 
significant effect on reducing hospital admissions or mortality in older patients. 
However, the medication reviews led by pharmacists have been shown to reduce the 
number of prescribed drugs and appear to have a positive effect on medication 
adherence [143-145].  
  Deprescribing in older patients with multimorbidity was perceived to be 
particularly hindered by the lack of appropriate and updated guidelines for this 
patient group. Previous studies by Hughes et al. [146] and Boyd et al. [147] have 
criticised current treatment guidelines for being disease-specific and not addressing 
old age, multimorbid illness and adherence, as well as failure to provide any guidance 
on achieving patient-centred care. Hence, current disease-specific treatment 
guidelines are another challenge to deprescribing and there is a clear need for 
patient-centred guidelines. 
  The patients themselves were another factor influencing the deprescribing 
process, with most patients disinclined to discontinue long-term medications [122, 
130]. Reeve et al. [104] maintain that these patient barriers are the result of 
disagreement with deprescribing decisions, lack of support from other healthcare 
professionals, lack of knowledge on how to discontinue certain medications, previous 
negative experiences with deprescribing and finally, fear of negative clinical and legal 
consequences of medication withdrawal. Many of the included studies reported how 
GPs struggled in their communication on this issue with patients and their families, 
especially at the latter stages of life [70, 125, 130, 136]. This may be a contributing 
factor to the lack of patient understanding of the appropriateness of deprescribing.  
 The environment in which deprescribing takes place is too busy to allow for a 
thorough deprescribing process, and studies highlighted the need for financial 
support and dedicated time and resources to deprescribe [119-121, 123, 126, 131, 




shared patient information may be some suggestions to facilitate deprescribing in 
practice.  
 Another interesting finding of this narrative review was that studies on 
deprescribing were limited to a small number of countries. These countries, i.e. 
Australia, Canada, Denmark, Sweden, the Netherlands and the United Kingdom (UK), 
have advanced healthcare systems and are at the forefront of ensuring rational 
medication use [148].  Therefore, it is not surprising that these countries are 
exploring strategies for deprescribing and are included in this narrative review. 
Additionally, the reported openness to the pharmacist role in supporting 
deprescribing may also be linked to the transition of the pharmacist role in these 
countries. Over the past decades, the role of the pharmacist in these countries has 
shifted from the traditional medication focus to a more advanced patient care focus. 
This advancement in the role of pharmacists requires them to be part of the broader 
health care team, providing better health care for the patients, and contributing to 
rational medication use [59]. With this shift in the role, clinical pharmacist support 
and pharmacist-led medication reviews have become integral parts of patient care, 
in these countries, particularly in the hospital setting [60-63]. In addition, the 
supportive role of the pharmacist in patient care has shifted from a hospital-only 
focus to a community setting focus. Pharmacists in the UK [149] and Australia [150] 
are increasingly entering the general practice teams with the purpose of supporting 
GPs in medicines management and patient care. Other services such as the 
administration of certain medicines, e.g. the seasonal influenza vaccine, have also 
been transferred to community pharmacists in the UK, Australia, Canada, Denmark 
and New Zealand [151]. This expansion of the pharmacist role in patient care in both 
hospital and community setting may explain the suggested pharmacy support in 
deprescribing as a means of overcoming some of the challenges in this review. 
Similarly, the role of the pharmacist in Ireland has also expanded over the past 
decades. Clinical pharmacists in Ireland are also entering the hospital setting, and 
Irish community pharmacists are administering the seasonal influenza vaccine and 








The studies included in this review did not all focus specifically on the deprescribing 
process. However, each study did deal with medicines management in the older 
population. Factors influencing medication management in general may differ from 
the factors specific to deprescribing. To overcome this, data on discontinuation and 
deprescribing processes within the medication management process were extracted 
from the studies. The included studies were a mixture of qualitative studies and 
quantitative studies, and limitations to these study designs may present a bias in the 
quality of the included studies. Review articles may have provided important sources 
of information. Despite this, it was decided in this study to only include primary 
literature on healthcare professionals’ views on deprescribing.  
 
2.7 Perspective 
With the increasing complexity in the treatment of multimorbid older people, the 
pharmacist was suggested to offer a potential source of support in deprescribing. 
Pharmacists have a unique skill set due to their training and knowledge in 
pharmacology, pharmaceutical chemistry, pharmaceutics and clinical practice and 
bringing in the ‘medication expert’ may thus be a strategy to help guiding the 
deprescribing process. As reported in some of the included studies, GPs have the 
overall responsibility for medicines management, however we know that GPs already 
carry a heavy workload. Improving the collaboration between GPs and community 
pharmacists may lessen this load and enhance deprescribing in primary care settings. 
However, more research is needed to understand the challenges and benefits of this 






This narrative review of the literature has shown that the challenges of deprescribing 
in older patients are compounded by the need to manage the shared treatment of 
multiple conditions by several prescribers from different specialities based on 
disease-specific guidelines without evidence on the older, frailer, multimorbid 
patient population. The findings highlight a need to improve the interdisciplinary 
approach to the treatment of older patients with multimorbidity to ensure that the 
patient is managed holistically and not merely treated for the individual conditions 
that the multimorbid patient has, according to evidence-based guidelines. 
 Based on the findings of the narrative reviewed literature, the following areas 
of focus for achieving beneficial deprescribing are highlighted:  
• more evidence and guidelines on effective deprescribing practices in the 
older patients,  
• standardised procedures for medication reviews and systematic approaches 
to deprescribing,   
• practical and user-friendly tools for medication reviewing,  
• improved intra- and inter-disciplinary communication and documentation, 
including more pharmacist support and clarification of the roles and 







3 Identification of behaviour change techniques in 
deprescribing interventions: a systematic review and meta-
analysis. 
 
3.1 Chapter description 
In chapter 2, the challenges and facilitators of deprescribing as viewed by healthcare 
professionals were identified. It was then decided to examine the published evidence 
of deprescribing interventions. A meta-analysis was done to assess whether previous 
interventions had been effective in reducing the number of medicines or 
inappropriate prescribing. Additionally, in order to understand how these 
interventions changed the behaviours of the participants to enhance deprescribing, 
a behaviour change technique analysis was performed.  
 
3.2 Publication  
The work of this chapter has been published as Hansen CR, O’Mahony D, Kearney 
PM, Sahm LJ, Cullinan S, Huiber CJA, Thevelin S, Rutjes AWS, Knol W, Streit S, Byrne 
S. Identification of behaviour change techniques in deprescribing interventions: a 
systematic review and meta-analysis. British Journal of Clinical Pharmacology. 2018; 





Older people i.e. above the age of 65 are more vulnerable to medication-related 
harm and inappropriate prescribing than younger chronically medicated people [152, 
153].  Age-related physiological changes contribute to iatrogenic vulnerability in 
older people, as does multimorbidity and frequent use of multiple medications i.e. 
polypharmacy [19, 55, 82, 124, 152, 154]. Physiological vulnerability, multimorbidity 
and polypharmacy represent complex challenges in the care of older people and 
often exclude them from participating in clinical trials [82, 85, 155, 156]. Therefore, 
some prescriptions in multimorbid older people are without a clear-cut evidence 
base to support them and inappropriate prescribing is highly prevalent [34, 46, 157]. 
Excessive inappropriate prescribing in older people has turned the focus of current 
research towards deprescribing - the systematic process of identifying and 
discontinuing drugs in patients for which real and potential harms outweigh the 
benefits [94]. Making informed decisions to deprescribe with the goal of reducing 
inappropriate prescribing and improving patient outcome is hampered by a lack of 
evidence regarding the effects of medication withdrawal in older people and is 
further challenged by prescriber- and patient-related factors [104, 115].  
Research has demonstrated safety and efficacy of deprescribing in older 
people (aged ≥65 years) [71] whilst reluctance of prescribers to deprescribe a 
medication commenced by another prescriber is described as well [158]. Although 
evidence suggests that pharmacist involvement and patient-centred interventions 
are effective, the best approach to engage and support prescribers in deprescribing 
remains unclear [52, 53, 104, 106, 159, 160]. Previous reviews examining the effects 
of deprescribing interventions on clinical outcomes call for a better understanding of 
successful implementation of deprescribing [71, 82, 106, 158].  
This systematic literature review focussed on interventions that were 
expected to change the behaviours of both healthcare professionals and patients 
towards successful and safe deprescribing. Within the clinical context of patient care, 
there is a need to ensure that behaviour change is a part of any intervention design 
in order to maximise the likelihood that prescribers act upon recommendations [161-
164]. Recent advances in behavioural science have provided valuable insights into 




taxonomy version 1 (BCTTv1) [165] is designed to assist in the identification of BCTs 
of effective interventions. A BCT is defined as “an observable, replicable, and 
irreducible component of an intervention designed to alter or redirect causal 
processes that regulate behaviour” [166]. It is anticipated that a clear description of 
BCTs will clarify the essential content of these complex interventions in a consistent 
way so as to assist in future replication of effective interventions [167]. The 
application of the BCT taxonomy to deprescribing is novel. This review was designed 
to complement previous reviews [71, 82, 106] on deprescribing by offering a broader 
analysis of behaviour change techniques in deprescribing interventions.  
 The aims of this systematic review are: (i) to identify BCTs used more 
frequently in interventions that are effective in reducing the number of daily drugs 
and inappropriate prescribing, (ii) to describe other characteristics of deprescribing 
interventions, and (iii) to determine intervention impact on drug use, prescribing 
appropriateness and Medication Appropriateness Index score in meta-analyses. 
 
3.4 Methods 
A systematic search of the primary, secondary and grey literature to identify 
randomised controlled trials (RCTs) on deprescribing was undertaken on December 
14, 2016 and again on February 25, 2019 to identify newly published literature. This 
chapter will report the combined search of literature and findings. This systematic 
review was reported according to the PRISMA guidelines for systematic reviews and 
meta-analyses [168] (see PRISMA checklist in Appendix IV), and was registered with 
Prospero (record no. CRD42016037730, see Appendix V).  
 
3.4.1 Search strategy 
The search strategy was designed in conjunction with an experienced medical 
librarian who was trained in systematic review methodology. A combination of text 
words and subject headings (such as MeSH terms) related to the intervention was 






Table 3-1 Search terms used 
Population Intervention Outcome Filters 
Aged, aged 80 and 
over, adult*, older 





















The following electronic bibliographic databases were searched: MEDLINE, EMBASE, 
Web of Science and Academic Search Complete. Grey literature was searched via the 
Google Scholar® search engine and from screening reference lists of included studies 
as well as relevant systematic reviews. Additional searches were done in the System 
for Information on Grey Literature in Europe (OpenSIGLE) and the clinical trial 
registries i.e. ClinicalTrials.gov, International Standard Registered Clinical/soCial 
sTudy Number (ISRCTN), WHO International Clinical Trials Registry Platform (ICTRP) 
and the Australian New Zealand Clinical Trials Register (ANZCTR).   
 
3.4.2 Study selection 
I, as the primary researcher, screened titles of all retrieved citations. Dr. Shane 
Cullinan (a post-doctoral academic pharmacist and one of the publication co-authors) 
and I independently screened abstracts and article full-texts for eligibility according 
to the protocol defined inclusion and exclusion criteria. Any disagreements between 
us were resolved by consensus and we both agreed upon the final list of studies.  
3.4.3 Inclusion and exclusion criteria 
Inclusion was restricted to randomised controlled study design, i.e. randomised 
controlled trials (RCTs) and cluster RCTs. The control group could involve either active 
or inactive interventions, e.g. sham or no intervention. This study design was chosen 
to allow for between study comparison of intervention effectiveness in meta-
analyses. Studies were included if they reported on interventions encouraging the 
deprescribing of existing drugs or the reduction of existing inappropriate prescribing. 




professional with prescribing, dispensing or administration authority were included. 
No restrictions were applied to language, clinical setting of the intervention, sample 
size, blinding procedures or other design characteristics. Interventions specifically 
focusing on the clinical effects of withdrawing a specific drug/drug class, e.g. opioid 
withdrawal effects were excluded.  
 
3.4.4 Risk of bias assessment 
Risk of bias was assessed using the Cochrane Collaboration Tool for randomised 
controlled studies [169] with a descriptive purpose of summarising  the quality of the 
studies that met inclusion criteria. Studies were not excluded from data analysis 
because of methodological flaws if they otherwise met inclusion criteria. Incomplete 
outcome data were in general rated as high risk of bias if the loss of patients to 
follow-up was 20% or higher and rated as low risk of bias if the loss was 10% or less. 
Imbalance in the numbers lost to follow-up between intervention and control groups 
was also considered to introduce bias. Random sequence generation and allocation 
concealment were judged to be at low risk of bias if methods for both were described 
in sufficient detail to determine its adequateness. Inadequate sequence generation 
methods (such as date of entry) and concealment methods were judged to have high 
risk of bias. Blinding procedures were considered to carry a low risk of bias if the 
description of the procedure reflected blinding. Absence of blinding or unblinding of 
participants and personnel were both deemed to introduce high risk of bias. Selective 
outcome reporting was assessed at low risk of bias if all patient-relevant outcomes 
described in the methods section were fully addressed in the paper. Unclear risk of 
bias was judged for any study element for which there was insufficient information. 
 
3.4.5 Data extraction strategy 
Data were collected using a data extraction form (see Appendix VI) developed by me, 
the primary researcher and agreed with one of my supervisors, Dr. L. Sahm (L.S.).  L.S. 
and I independently pilot tested the data extraction form on two randomly chosen 
studies, both of which were later included in the review. Thereafter data extraction 




3.4.6 Outcome measures 
Primary outcome measures were: (i) number of total, and potentially inappropriate 
prescriptions, and/or drugs as defined in the individual studies according to 
prescribing appropriateness criteria, e.g. STOPP criteria [77], Beers’ criteria [170] and 
local or national prescribing guidelines; (ii) proportion of participants with a 
reduction in number of total and potentially inappropriate prescriptions and/or 
drugs; (iii) and implementation of recommendations. A secondary outcome was 
change in Medication Appropriateness Index (MAI) score.  
 
3.4.7 Behaviour change techniques coding 
Coding of BCTs was performed independently by me, for all the included studies and 
three of the publication co-authors, (L.S., S. Thevelin and C.J.A. Huibers) coded a 
subset of studies. BCTs were identified for each intervention, using the Behaviour 
Change Technique Taxonomy version 1 (BCTTv1)  [165]. I had completed online 
training in BCTTv1 prior to the coding. I created a coding manual and instructions, 
and these were given to the three co-authors and exercises from the online training 
were made available. Any queries about the coding were resolved by discussion and 
consensus between myself and the three co-authors. The target behaviour was the 
decision-making to discontinue a drug, or an inappropriate prescription. I tabulated 
the findings across studies by computing frequencies. The information was used to 
determine the BCTs used more frequently in studies that reported effectiveness of 
interventions to reduce number of drugs and/or improve prescribing 
appropriateness.  
 
3.4.8 Statistical analysis 
I, the primary researcher, calculated Odds Ratios (OR) with standard deviations (SD) 
for each of the reported outcomes and used RevMan version 5.3 software to 
statistically combine the outcome data [171]. Continuous outcomes were expressed 
as difference in means between groups with a 95% confidence interval (95% CI). The 
level of between study heterogeneity was evaluated by calculation of the I-squared 
and Chi-squared statistics. Where possible, stratified random effects meta-analyses 




were performed by risk of bias assessment, intervention setting and intervention 
target. If the level of reporting did not allow for inclusion of a study in one or more 
meta-analyses, additional information was sought from the study authors. If the 




3.5.1 Literature search and review process 
The database search identified 2,048 records, and grey literature yielded 175 records. 
After removal of duplicates and title screening, 256 abstracts were screened for 
eligibility and 86 of these met the inclusion criteria. Assessment of full texts resulted 
in 31 studies being included in this systematic review. Study selection and reasons 





Figure 3.1 PRISMA flow chart of study selection for the systematic literature review 
Records identified through 
database searching (n = 2,048) 
Additional records identified 
through other sources (n = 175) 
 
Records after duplicates removed (n =  2,009) 
Record titles screened 
(n =  2,009) 
Records excluded 
(n =  1,753) 
Reason for exclusion: Intervention not 
relevant to the review or not a 
randomised controlled trial (RCT) design 
Abstracts screened 
(n = 256) 
Records excluded (n = 170) 
Reason for exclusion:  
Not an RCT design (n = 95)  
Intervention not relevant (n = 27) 
Age <65 years (n = 25) 
Outcomes not relevant (n = 17) 
Study protocol only (n = 6) 
Full-text articles 
assessed for eligibility 
(n = 86) 
Studies included in the  
systematic review 
(n = 31) 
Studies included in  
meta-analysis (n = 21) 
Studies included in  

























(n = 55) 
Reason for exclusion:  
Not an RCT design (n = 7) 
Intervention not relevant (n = 21) 
Age <65 years (n = 13) 
Outcomes not relevant (n = 8) 




3.5.2 Study characteristics 
Included studies were RCTs (n=26) and cluster RCTs (n=5) with a follow-up period 
from 30 days [172] to 13 months [173]. A total of 22,662 patients were enrolled in 
the studies ranging from 50 [174] to 1188 per study [144]. Detailed study 
characteristics are provided in Table 3-2. Three studies aimed primarily to reduce the 
number of drugs taken by patients [102, 175, 176]. Other objectives included 
reduced prevalence of inappropriate medications [172, 173, 177-183], improved 
prescribing appropriateness [41, 144, 174, 184-192], or better patient health 
outcomes and medicines management [185, 193-196]. Thirteen out of the 31 studies 
included in this review has shown evidence to support intervention effectiveness [41, 
102, 145, 174, 175, 182, 185, 187, 190, 192, 194, 195, 197]. Most of the studies 
reporting intervention effectiveness of the key outcomes of this review delivered 
recommendations or feedback to the prescriber orally, often face-to-face, and many 
of them followed up on the recommendations/feedback given. Recommendations 
and feedback were given immediately after identification of a problem or at the time 
of prescribing using an on-demand service. For studies reporting no intervention 
effectiveness on the key outcomes, some of them delivered recommendations using 
written communication and many of the interventions did not follow up on the 
recommendations with the prescriber. None of the included studies reported the use 
of explicit theories of behaviour change as part of the interventions and no study 
reported the use of a systematic and theoretical approach, such as the UK Medical 
Research Council’s complex intervention framework [198], in the intervention 
design. Reported educational interventions were based on the principles of 
constructive learning theory in one study [181] and social constructivist learning and 










Table 3-2 Characteristics of studies included (n=31) in the systematic literature review.  











Delivered by (D) 
Target behaviour 
 
Target person(s) (P) 






80.6 (4.5) (I) Medication review and suggestions made and mailed 
to GPs. 
 
(D) Multidisciplinary team of physicians, pharmacists and 
nurses. 













76.5 (7.2) (I) Interactive educational meeting (single intervention) 
and combined with individualised feedback on prescribed 
medication (combined intervention).  
















(I) Medication review and recommendations provided 
based on the STOPP/START criteria and GP-GP algorithm 
(D) Clinical pharmacist 
Improving prescribing 
appropriateness 
(P) Primary care physicians 
















(I) Computer alerts based on geriatric explicit criteriab 
assessed for clinical relevance and recommendations 
formed. 
(D) Study pharmacist 
Discontinuation of PIM and 
dosage decrease 
(P) Treating hospital physician 







84.5 (5.0) (I) Medication review and case conferences. 
(D) Multidisciplinary team of geriatrician, pharmacist, 





(P) Residential care staff and 
residents’ GPs. 









(I) Medication review and recommendations provided to 
discontinue medications based on the STOPP criteria. 
(D) Multidisciplinary team of nurses, geriatricians, 
dietician, occupational therapist, physiotherapist, speech 
therapist and psychologist 
Discontinuation of PIMs 
 















Delivered by (D) 
Target behaviour 
 
Target person(s) (P) 
 









Not specified (I) Decision support service comprising educational 
brochure, list of suggested inappropriate medications 
based on the STOPP criteria, and list of patients with 
STOPP criteria identified. 
(D) Research team and expert panel of physicians and 
pharmacists 
 
Changing prescribing behaviour 









82.7 (8.7) (I) Medication review and recommendations provided 
based on the STOPP/START criteria.  
(D) Study pharmacist. 
Improving clinical and economic 
outcomes by giving 
STOPP/START 
recommendations. (P) Chief 
physicians.  








40.6% aged  
65-70 




(I) A computer-generated patient-specific medicines 
management report for the clinician and a short report 
for the patient.  
(D) Computer and research team 
Improve shared decision-
making about medications 
between patients and clinicians 
to improve medication regimen.  
(P) Clinician and patient 







75.6 (7.3) (I) Medication review and recommendations provided to 
change medications based on the STOPP/START criteria. 
(D) Research physician. 
Improving prescribing 
appropriateness 
(P) Hospital physician and 









84.4 (12.7) (I) Educational workshops, material and on-demand 
advice on prescriptions.  
(D) Nursing home physician with geriatric expertise. 
 
Improving the quality of 
prescriptions 
(P) Nursing home physicians 



























Delivered by (D) 
Target behaviour 
 
Target person(s) (P) 
 










84.3‡ (I) Medication review and development of action plan of 
agreed amendments. 
(D) Pharmacists. 
Reducing hospital admissions 
and number of drug items 
prescribed 
(P) GPs and patients 
 









(I) Educational brochure to patients and educational 
material in the form on an evidence-based 
pharmaceutical opinion that pharmacists used to 
communicate recommendations. 
(D) Community pharmacists 
Reducing inappropriate 
prescriptions 
(P) Primary care physicians and 
patients 







80.0 (8.0) (I) Medication review and development of action plan to 
address identified problem. 
(D) Multidisciplinary team of physicians, nurses and 
pharmacists. 
 
Improving medication use 
(P) Nurses and patients 








87.4 (5.7) (I) Medication review and feedback given to physician on 
drug-related problems. 
(D) Pharmacists. 
Reducing the number of 
patients using PIMs 
(P) GPs 






77.7 (±6.6) (I) Interdisciplinary medication review to identify 
inappropriate use of anticholinergic drugs and to 
recommend discontinuation or substation to a safer 
alternative. 
(D) Pharmacists and physicians 
Inappropriate use of 
anticholinergic drugs. 
(P) Patients 






83.0 (7.2) (I) Staff training and list of harmful medication provided 
to encourage nurses to bring this to the physician’s 
attention. 
(D) Research team. 
 


















Delivered by (D) 
Target behaviour 
 
Target person(s) (P) 






82.9‡ (I) Clinical assessment by a senior doctor and 
multidisciplinary medication review using Beer’s criteria. 
Recommendations given to GP.  
(D) Consultant or senior specialist registrar and a 
multidisciplinary panel of consultant geriatricians, 
specialist registrars, hospital pharmacists and senior 
nurse practitioners. 
 
Reducing the number of drugs 
prescribed 
(P) GPs 






84.0 (7.0) (I) Medication review and cessation plan of non-
beneficial medications. 
(D) Research team of GP and geriatrician. 
Reducing the total number of 
medicines taken 











80.4 (4.1) (I) Pharmaceutical care including medication reviews. 












82.1 (5.0) (I) Comprehensive geriatric assessment and treatment of 
all illnesses.  
(D) Multidisciplinary team of geriatrician, nurses, 
residents, occupational therapists and physiotherapists.  
 
Increasing the number of drugs 
withdrawn 
(P) Medical care team 






46% aged  
65-73 
54% aged  
≥74 years 
 
(I) Treatment in a geriatric evaluation and management 
unit (GEMU) in either inpatient or outpatient care or 
both.  
(D) Pharmacists and a multi-disciplinary team of 
geriatrician, social worker and nurse. 
Improving prescribing 







82.2 (6.6) (I) Pharmaceutical care including medication review and 























Delivered by (D) 
Target behaviour 
 
Target person(s) (P) 








75.4 (6.3) (I) Electronic alerts instituted in the electronic patient 
prescription record to identify prescribing problems. 













75.0 (6.3) (I) Educational booklet to empower and encourage 
patients to discontinue benzodiazepines. 













76.6 (6.5) (I) Medication review and prescribing recommendations 
provided. 
(D) Pharmacists 
Reducing the number of 











76.9‡ (I) Electronic messages sent to physician via electronic 
medication record to give prescribing recommendations. 
(D) Pharmacist and geriatrician. 
 
Reducing medication use  
(P) GPs 







73.7 (5.9) (I) Medication review based on MAI and prescribing 

















(I) Training about conducting multidisciplinary 
medication review 
(D) Research team 
Discontinuation of 
inappropriate medication. 












73.5 (6.5) (I) Prescription review and treatment recommendations 
given to patients. 
(D) Pharmacist and physician.  
Making changes to repeat 
prescriptions and reducing the 





 aThe randomisation was performed on hospitalisation-level rather that patient-level. This meant that a patient could be included more than once, and the 
254 hospitalisations occurred in 231 patients. The baseline characteristics in the study are reported for the hospitalisations. bThe set of criteria was based on 
the Beers criteria and the STOPP criteria. cThe low proportion of females reported was explained by the nature of male patients in veterans’ affairs clinics.  
 † The low percentages of females reported was explained by the nature of male patients in Veterans Affairs (VA) clinics. ‡ The SDs were not reported and could 




3.5.3 Risk of bias 
Risk of bias assessment is illustrated in Figure 3.2. Risk of bias not pertaining to any 




Figure 3.2 Results of risk of bias assessment 
 
Table 3-3 Description of ‘other bias’ detected for the included studies.  
Study Judgement of 
other bias 
Justification 




No information on how the study chose which 
physician to contact for each patient, i.e. no 
information of whether it was the primary prescriber 
or the prescriber who prescribed most of the 
medications. This may have had an effect on their 
actions on the recommendations given and their 
collaboration.  
Some of the prescribers had patients in both 
experimental and control group and there may have 
been a carry-over-effect. However, the study 




Study Judgement of 
other bias 
Justification 
No control for number of prescribers and some 
patients had multiple prescribers which may have had 
an effect on the outcomes.  
Cossette et al. 
(2017) 
High risk The randomization was conducted by hospitalization; 
therefore, a patient could be included in the 
intervention and control groups during separate 
hospitalizations. This was the case for 10 patients. 




The study is a cluster-RCT, but the clustering was not 
accounted for in the data analysis. Rather than 
analysing the data at cluster-level, the data were 
analysed at patient-level by pooling the data for the 
intervention clusters into one group and pooling the 
data for the control cluster into one group (i.e. one 
control group and one within-facility control group). 
The study did not account for correlation between 
observations for patients in the same cluster.   




During the 6-month follow-up after the end of the 
study, the study mentioned that: “During our study 
period, major changes occurred in the primary care 
physician network, with 78 primary care providers 
leaving the network, 129 joining the network….so we 
did not conduct a further analysis of PIM use at the 
provider level”. 
Fried et al. 
(2017) 
High risk Physicians were treating both control and 
intervention patients. Although, not simultaneously, 
this may have contaminated the control group and 
affected the true findings of the intervention 
effectiveness. 




There may have been potential contamination if 
some of the healthcare professionals worked in 




Study Judgement of 
other bias 
Justification 




Prior to admission, the suitability of each patient for 
admission to a continuing-care ward had been 
assessed by a multidisciplinary panel chaired by a 
consultant geriatrician. Some medication-related 
problems may have been solved prior to 
randomisation. The study commented on this.  
GPs in the control group had access to specialist 
geriatric medicine advice on request. The study did 
not report how often the GPs requested this and 
what the outcome was. This may have affected the 
outcomes for the control group and “hidden” the 





The study had underestimated the number of drugs 
prescribed to patients at the final time point used in 
the study. As a result, there was a significant 
difference in the mean number of drugs shown on 
prescription at the final time point compared with the 
number over the four previous months 
(difference=1.14, 95% CI 1.01, 1.27). The number of 
drugs affects the UK-MAI score (primary outcome), 
and this appeared to indicate that medication 
appropriateness had improved at the final follow-up 
time point. The study commented on this and 
corrected for this.  




 “Suitable patients were screened when there was a 
free bed in the specialist ward. Eligible patients who 
had been recently admitted to the department were 
preferred over those who had been there longer.” 
This could have introduced a selection bias which 
could have affected the generalisability of the 









 Low risk 
 
Because the same physicians were caring for control 
and intervention patients, contamination of control 
patients was possible. To assess this bias, two 
investigators applied the outcome assessment to a 
random sample of 90 patients to the unit 1 year 
before the study, i.e. a “historical control group”. This 
could only be done for two of three primary outcome 
measures. 
Tamblyn et al. 
(2003) 
Unclear risk  
 
The study experienced two problems that influenced 
the effectiveness of the computer-system 
intervention, these being co-payments for 
prescription drugs increased when the study began 
and many software problems that resulted in 
information downloaded less often.  
Another potential bias was the study design using 
cluster-randomisation. However, the study did 
account for the clustering in the data analysis: 
“Physicians were identified as the clustering factor 
within which rates were examined, and an 
exchangeable correlation structure was used to take 
into account the dependence of observations for 
patients of the same physician.” We consider no risk 
of bias associated with clustering and data analysis.  
Tannenbaum 
et al. (2014) 
Low risk 
 
The study design was a cluster-RCT with community 
pharmacies as the clusters. When assessing the 
primary outcome (complete cessation of 
benzodiazepine use) the study used the participant as 
the unit of analysis, the community pharmacy as the 
cluster, an exchangeable correlation coefficient to 
account for clustering effects of participants within 




Study Judgement of 
other bias 
Justification 
Wouters et al. 
(2017) 
High risk Although the study used a cluster randomized design 
to prevent contamination bias, physicians from the 
intervention group collaborated closely with 
physicians from the control group. This could have 
increased the change that actual effects of the 
intervention are not detected. 
 
3.5.4 Behaviour change techniques 
All but one study [193] reported the behaviour change components underpinning the 
intervention and 30 of the 31 studies were included in the BCT analysis. The BCT 
coding is presented in Table 3-4. Examples of behaviours described in the included 






Table 3-4 Behaviour change techniques taxonomy version 1 (BCTTv1) applied to the included studies 
and the prevalence of each BCT and BCT cluster [165]. 





















1. Goals and planning 19 11 24 8 13 
1.1 Goal setting 
(behaviour) 
1 1 2 0 0 
1.2 Problem solving 6 3 6 3 5 
1.3 Goal setting 
(outcome) 
3 2 4 1 2 
1.4 Action planning 8 4 9 4 7 
1.5 Review behaviour 
goal(s) 
1 1 2 0 0 
2. Feedback and 
monitoring 
29 10 22 19 31 
2.1 Monitoring of 
behaviour by others 
without feedback 
4 2 4 2 3 
2.2 Feedback on 
behaviour 
14 4 9 10 16 
2.3 Self-monitoring of 
behaviour 
3 2 4 1 2 
2.4 Self-monitoring of 
outcome(s) 
2 0 0 2 3 
2.7 Feedback on 
outcome(s) of 
behaviour 
6 2 4 4 7 
3. Social support 12 5 11 7 12 
3.1 Social support 
(unspecified) 
10 5 11 5 8 
3.2 Social support 
(practical) 
2 0 0 2 3 
4. Shaping knowledge 21 10 22 13 21 
4.1 Instruction on 
how to perform a 
behaviour 
21 11 24 11 18 
4.3 Re-attribution 1 0 0 1 2 
5. Natural 
consequences 

























5.1 Information about 
health consequences 
9 5 11 4 7 
5.2 Salience of 
consequences 
1 1 2 0 0 




1 0 0 1 2 
6. Comparison of 
behaviour 
4 2 4 2 3 
6.1 Demonstration of 
the behaviour 
3 1 2 2 3 
6.3 Information about 
others’ approval 
1 1 2 0 0 
7. Associations 4 0 0 4 7 
7.1 Prompts/cues 4 0 0 4 7 
8. Repetition and 
substitution 
6 2 4 4 7 
8.1 Behavioural 
practice/rehearsal 
3 1 2 2 3 
8.2 Behaviour 
substitution 
3 1 2 2 3 
9. Comparison of 
outcomes 
19 7 15 9 15 
9.1 Credible source 16 9 19 10 16 
10. Reward and 
threat 
1 0 0 1 2 
10.4 Social reward 1 0 0 1 2 
11. Regulation 1 1 2 0 0 
11.1 Pharmacological 
support 
1 1 2 0 0 




1 1 2 0 0 
12.5 Adding objects 
to the environment 
3 1 2 2 3 



























1 1 2 0 0 
 
Table 3-5 Examples of behaviours from the included studies coded into the BCT codes and clusters. 
BCT cluster BCT code Examples of behaviour descriptions from the 
included studies 
Goals and planning Action 
planning 
“For patients in the intervention group, the 
pharmacist composed a list of recommended 
changes to medications (…) Within 2 weeks after 
the date of inclusion, these recommendations 
were discussed with the GP according to a fixed 
format in which the DRPs and recommendations 
were classified. (...) The consultation with the GP 
ultimately resulted in a mutually accepted list of 








“Alerts were instituted to identify 159 clinically 
relevant prescribing problems in the elderly (…) 
The alerts appeared when the electronic chart 
was opened, when prescription record updates 
were downloaded, and when current health 
problems and prescriptions were recorded by the 
physician in the chart.  Each alert message 
identified the nature of the problem and possible 
consequences and suggested alternative therapy 






“Primary care physicians participated in an 
interactive educational meeting on the subject of 
polypharmacy and appropriateness of 
prescribing. The meeting included background 
information on the causes and consequences of 
polypharmacy, areas of concern in the treatment 







“Patients were informed that their primary 






“An experienced clinical pharmacist reviewed the 
drug lists and made recommendations. The 
pharmacist then discussed recommendations for 
each drug with the physician to come up with a 





Based on the studies reported results, 13 of the 30 studies showed an effect on the 
key outcomes (i) or (ii) of this systematic review when comparing the intervention 
group to the control group [41, 102, 145, 175, 182, 185, 187, 190, 192, 194, 195, 197]. 
No clear relationship was seen between the number of individual BCTs used and 
reported intervention effectiveness. The median number of BCTs used were similar 
for studies reporting effective and non-effective interventions (6 BCTs, IQR 3-8 and 5 
BCTs, IQR 4-7, respectively). BCT clusters coded more frequently in studies reporting 
effectiveness compared to studies reporting no effectiveness were:  goals and 
planning; shaping knowledge; natural consequences; comparison of behaviour; 






Figure 3.3 Frequency of behaviour change techniques (BCTs) coded for studies reporting intervention effectiveness on the key outcomes of this review compared to studies reporting 
no effectiveness of interventions. The frequencies are weighed values based on the number of studies in each group, i.e. effectiveness versus no effectiveness. 
0 5 10 15 20 25 30
1. Goals and planning
1.1 Goal setting (behaviour)
1.2 Problem solving
1.3 Goal setting (outcome)
1.4 Action planning
1.5 Review behaviour goal(s)
2. Feedback and monitoring
2.1 Monitoring of behaviour by others without feedback
2.2 Feedback on behaviour
2.3 Self-monitoring of behaviour
2.4 Self-monitoring of outcome(s)
2.7 Feedback on outcome(s) of behaviour
3. Social support
3.1 Social support (unspecified)
3.2 Social support (practical)
4. Shaping knowledge
4.1 Instruction on how to perform a behaviour
4.3 Re-attribution
5. Natural consequences
5.1 Information about health consequences
5.2 Salience of consequences
5.3 Information about social and environmental consequences
6. Comparison of behaviour
6.1 Demonstration of the behaviour
6.3 Information about others’ approval
7. Associations
7.1 Prompts/cues
8. Repetition and substitution
8.1 Behavioural practice/rehearsal
8.2 Behaviour substitution
9. Comparison of outcomes
9.1 Credible source





12.1 Restructuring the physical environment
12.5 Adding objects to the environment
13. Identity
13.2 Framing/reframing
Weighted frequency for studies reporting effect




3.5.5 Intervention effectiveness 
 
 Drug use 
Overall, the mean number of drugs post-intervention was significantly lower among 
intervention participants compared to the control participants in the presence of 
moderate between study heterogeneity (mean difference -0.96, 95% CI -1.53, -0.38, 
heterogeneity I2=70% and P=0.002, Figure 3.4).  
 
 
Figure 3.4 Mean number of drugs per patient post-intervention comparing experimental 
(intervention) group and control group. 
 
Regarding the difference in change in the number of drugs taken per patient, 
deprescribing interventions lowered the number (-0.72, 95% CI -1.17, -0.27), but 
effects varied largely across studies (I2=91%, P<0.001) (Figure 3.5). Stratified analyses 
by: (i) whether the intervention was patient-centred or targeting solely healthcare 
professionals (Figure 3.6), (ii) intervention setting (Figure 3.5) and (iii) study quality 
(Figure 3.7) showed no effect of these factors on summary estimates. In addition, the 






Figure 3.5 Mean difference in the change in number of drugs comparing experimental (intervention) 




Figure 3.6 Subgroup analysis on target person (patient or healthcare professional) for mean 





Figure 3.7 Subgroup analysis on risk of bias assessment (random sequence generation) for mean 
difference in the change in number of drugs per patient. 
 
 Discontinuation of drugs 
Four of the included studies reported on the number of discontinuations of 
drugs/inappropriate drugs [172, 182, 183, 192].  This outcome was reported as the 
number of patients with a drug discontinuation post-intervention compared across 
three of the studies  [182, 183, 192] and the findings were summarised in a meta-
analysis (Figure 3.8). The proportion of control participants experiencing a drug 
discontinuation was significantly smaller than the proportion of intervention 
participants, but confidence intervals were wide, and a high level of heterogeneity 
was present. This finding is illustrated as a signi (Figure 3.8).  The fourth study by 
Cossette et al. [172] reported a significant increase in drug cessations and dosage 
decreases in the intervention group compared to the control group at 48h post-alert 
(+30.0% ) and at hospital discharge (+20.8%). However, this increase was not 
significant when looking at drug cessation only at hospital discharge (+10.7%, 95%CI 






Figure 3.8 Number of participants experiencing a drug discontinuation comparing experimental 
(intervention) group and control group. 
 
 Prescribing appropriateness 
Deprescribing interventions demonstrated a relatively small effect and a high level 
of heterogeneity on the number of inappropriate drugs per participant comparing 
intervention and control groups post-intervention (-0.19, 95% CI -0.40, 0.02, 
heterogeneity I2=90% and P=0.07, Figure 3.8). The proportion of participants with at 
least one inappropriate drug, as defined in the individual studies, were reduced when 
a deprescribing intervention was applied, but confidence intervals were wide, and a 
high level of heterogeneity was present (Figure 3.9).  
 
 
Figure 3.9 Mean difference in the number of inappropriate drugs per participant comparing 






Figure 3.10 Number of participants with inappropriate drugs comparing experimental (intervention) 
group and control group. Subgroup analysis on risk of bias assessment (allocation concealment). 
 
3.5.6 Implementation of recommendations 
Seven studies reported implementation rates of recommendations to discontinue a 
medication or change a medication [179, 180, 183, 186, 192, 196, 199]. Action was 
taken in 55.1% of recommendations given by a pharmacist compared to only 19.8% 
of the nurse recommendations as part of usual pharmaceutical care by Hanlon et al. 
[186]. In the study by Vinks et al. [199], 27.7% of pharmacists recommendations were 
implemented, and action was taken in 56% of drug-related problems identified by a 
pharmacist in Milos et al. [180]. The study by Wouters et al. [183] reported that 97% 
of the interventions were implemented. The study by Campins et al. [192] showed 
that the patients’ physicians accepted 80.9% of the clinical pharmacist’s 
recommendations about PIP, while 29.7% of recommendations were implemented 
in Fried et al. [196]. A lower recommendation implementation rate of 15.4%  was 
shown in Fick et al. [179] . This result was based on self-reported action taken by the 
physicians; only 71% of physicians reported this, which may explain the lower 







3.5.7 Medication Appropriateness Index (MAI) score 
Eight studies reported changes in MAI scores for participants pre- and post-
interventions [41, 174, 184, 186, 188, 190, 191, 193], but only five of these studies 
provided sufficient data to be included in the meta-analysis (see Figure 3.10). Across 
studies, deprescribing interventions demonstrated a significant effect on reducing 
the MAI score (i.e. improving medication appropriateness) comparing intervention 
and control groups post-intervention (-5.04, 95% CI -7.40, -2.68, heterogeneity 
I2=88% and P<0.0001, Figure 3.10). The study by Moga et al. [174] did not report the 
actual MAI-scores post-intervention but only the change in scores, and it was not 
possible to retrieve these values. Therefore, the results could not be included in the 
meta-analysis in Figure 3.10. However, the study showed a statistically significant 
reduction in MAI scores among intervention participants compared to control 
participants when adjusting for Clinic Dementia Rating global scores (-3.6 ±SE 1.1 
versus -1.0 ±SE 0.9, P=0.04) [174].  
 
 
Figure 3.11 Mean difference in the change in MAI score per participant comparing experimental 
(intervention) group and control group. 
 
3.6 Discussion 
Effectiveness of deprescribing interventions is determined by a combination of 
factors. Consistent with the findings of recent reviews [71, 82], our meta-analysis 




drugs and inappropriate prescribing (reduced MAI-scores) in older people, although 
the evidence is heterogeneous.  
Based on the findings of the BCT coding exercise, effective deprescribing 
interventions included (i) a goal and an action plan to solve prescribing problems, (ii) 
monitoring of behaviour, (iii) social support and the use of a credible source, (iv) clear 
instructions and guidance on implementation to the prescriber and information 
about health consequences of doing/not doing the behaviour. Support from 
colleagues and information about potential risks and benefits to the patients in the 
presence/absence of a behaviour change may also be effective techniques of 
deprescribing  
Differences in the delivery of prescribing recommendations were seen in the 
studies reporting intervention effectiveness compared to studies reporting no effect 
on key outcomes of this review. Studies reporting effectiveness [41, 102, 145, 175, 
185, 187, 190, 194, 195, 197] used oral and face-to-face communication to discuss 
and implement deprescribing recommendations consistent with the principles of 
educational outreach to inform clinical decision making as described by Soumerai et 
al. [200]. Investigation of the delivery of recommendations to deprescribe may 
provide useful information on the delivery of a successful deprescribing intervention 
in addition to the use of BCTs.  
Pharmacist recommendations to reduce drug intake and inappropriate 
prescribing were frequently acted upon in some studies [180, 186], consistent with 
previous literature reporting benefits of pharmacist-led interventions to optimise 
medication use in older people [53, 201]. Other studies [179, 199] reported a lower 
acceptance rate of pharmacist recommendations, between 15% and 28% of 
recommendations implemented. Some recent research studies have demonstrated 
a high level of agreement between prescribers and pharmacists in the assessment of 
potential target medications for deprescribing [202, 203]. In contrast, other research 
indicates that acceptance rates for recommendations made by pharmacists are lower 
than the ones made by their physician colleagues [204]. The lower uptake of 
pharmacist recommendations despite a high level of agreement about deprescribing 
is noteworthy. It may indicate that challenges to deprescribing are in fact dependent 




there is a question of behaviour change. Based on the findings of this review, we 
suggest that future research should investigate the behaviours associated with the 
acceptance and rejection of deprescribing recommendations in order to gain a better 
understanding of a successful delivery of deprescribing interventions. 
This is the first systematic review to identify BCTs in deprescribing 
interventions necessary to achieve a change in behaviours towards deprescribing. 
Our findings complement previous reviews on deprescribing [71, 106] by offering a 
broader analysis of BCTs that are effective for deprescribing.  
 
3.6.1 Limitations and strengths 
The review findings are based on a comprehensive search of the literature. The novel 
aspect of this systematic review is in the use of a validated taxonomy to describe 
intervention content that facilitates behaviour change. Limitations of this review 
reside mostly in the limited data available. RCTs to date are of a relatively small size 
(often ≤100 participants) and usually with short follow-up periods. Other limitations 
relate to the high-risk blinding procedures; these were needed because of the 
interventions in questions required blinding of the personnel whose behaviour was 
targeted, and this was logistically difficult. Absence of blinding procedures for 
outcome assessors was not considered to introduce important bias because the 
study outcomes, e.g. number of drugs taken, was not a very subjective measure. 
Random sequence generation and allocation concealment were considered highly 
important biases in this review because participant characteristics such as 
multimorbidity, age and polypharmacy could have an impact of the number of drugs 
taken and risk of inappropriate prescribing [55, 82, 85, 124, 152]. The meta-analysis 
was reliant on published or reported data, and while some studies reported 
outcomes that were adjusted for baseline patient characteristics others did not, 
which makes the direct comparison of intervention effect on specific outcomes open 
to question. 
 Similarly, and as described in a previous review [166], the BCT coding was 
limited to the intervention descriptions reported in the studies. Limited reporting on 
interventions used to encourage deprescribing could have resulted in BCTs being 




used based on the information available. For example, it was assumed that the 
reporting of prescribing recommendations given to the prescriber would involve BCT 
codes: instructions on how to perform a behaviour and feedback on behaviour. 
Prescribing recommendations were a commonly used intervention in the studies, 
and this may have resulted in these two BCTs being over-coded. One study was also 
excluded from the BCT coding due to lack of information which could have potentially 
influenced the true findings of this review. Furthermore, it was not possible to code 
BCTs in the control groups due to limited reporting of the control conditions. The 
control conditions such as usual care in hospital settings or in outpatient settings 
could include BCTs with potential implications on the interpretation of the review 
findings. Since many interventions target multiple behaviours and outcomes, it can 
be difficult to explicitly link BCTs to a specific prescribing behaviour. Reporting of 
future behaviour change interventions would benefit from a more detailed 
description of the person whose behaviour is targeted for change and the 
intervention components implemented to change this behaviour. Reporting of this 
will enable future BCT analyses to better identify BCTs explicitly linked to changing 
the targeted behaviour. Future interventions may thus consider the use of 
comprehensive checklists, such as the TIDieR [205] when reporting the intervention 
in order to give reviewers the ability to adequately code BCTs and extensively 
appraise the reporting quality of such interventions [166]. This will improve the 
identification of relationships between BCTs used and behaviour(s) changed and 
inform the design of future interventions.  
The main limitation of our pooled estimates is the presence of typically large 
between study variation and, for some of the analyses, the wide confidence intervals 
including trivial effects. Some may argue that a meta-analysis should not be done in 
the presence of substantial heterogeneity. Meta-analytical methods however allow 
for the exploration of sources of heterogeneity and therefore the magnitude of the 
summary estimates should be interpreted with caution. To minimise the level of 
heterogeneity due to different study designs, it was decided to limit the inclusion 
criteria to randomised controlled studies and cluster randomised controlled studies 




effect was highly variable due to imprecision and risk of bias issues that lower the 
level of confidence in the estimates of effect.  
Despite a comprehensive search of the literature, it cannot be assured that 
all relevant literature was identified and reviewed. This is a limitation of all literature 
reviews as it was in this systematic review. Inclusion and exclusion criteria applied to 
the screening of eligible literature may further be a limitation to the inclusion of all 
relevant literature. The focus of this systematic review was on healthcare 
professionals’ views of the deprescribing process including the barriers and 
facilitators with deprescribing.  Studies specifically focussing on the clinical effects of 
drug withdrawal were excluded. The clinical outcomes of drug withdrawal provide a 
crucial evidence-base to guide the deprescribing process and may influence 
deprescribing behaviours of healthcare professionals. Despite this, drug withdrawal 
interventions focussing specifically on clinical outcomes were excluded if they did not 
include the views of healthcare professionals on the deprescribing process, which 
was the primary focus of this review.  
 
3.7 Conclusion 
Deprescribing interventions are effective in reducing the number of drugs taken by 
patients and improving prescribing inappropriateness. Their success may be 
explained by a combination of BCTs spanning a range of different intervention 
functions, although this could not be shown empirically. The use of BCTs and delivery 
of such behaviour change interventions should be considered of importance to 
facilitate successful implementation of deprescribing. This systematic review 
contributes to the existing evidence by critically analysing the content of 
deprescribing interventions in terms of behaviour change, demonstrating clearly that 







4 Longitudinal patterns of potentially inappropriate prescribing 
in early old aged people  
 
 
4.1 Chapter description 
It is well-established that PIP is highly prevalent among older adults, with reported 
prevalence ranging from 21% to 77%, depending on the clinical setting [38, 41, 206]. 
PIP has been shown to be associated with an increased use of healthcare services 
and number of medications taken per patient. However, little is still known about the 
longitudinal pattern of PIP and the long-term effect on clinical outcomes.  
This chapter examined the pattern of PIP over 5-year period among people in early 
old age (60-74 years) and provided a basis for understanding the long-term 
prevalence of PIP in this age group.  
 
4.2 Publication 
The work of this chapter has been published as Hansen CR, Byrne S, Cullinan S, 
O’Mahony D, Sahm LJ, Kearney PM. Longitudinal patterns of potentially 
inappropriate prescribing in early old-aged people. European Journal of Clinical 







Optimisation of pharmacotherapy is a core part of good medical care of older people 
[49, 207]. Medical treatment in older people is often challenged by age-related 
physiological changes affecting pharmacokinetic and pharmacodynamic responses to 
drugs, with higher risk of adverse drug-disease and drug-drug interactions [29, 49]. 
For that reason, many drugs must be used with caution in older people [49, 207]. The 
use of five or more daily drugs (i.e. polypharmacy) is increasing in older people and 
is associated with a higher risk of potentially inappropriate prescribing (PIP) for this 
population [115, 117]. PIP includes both the omission of a medical treatment that is 
clinically indicated in the patient for irrational or ageist reasons, potential prescribing 
omissions (PPOs) or the use of a medical treatment in which the risks outweigh the 
benefits through the use of potentially inappropriate medications (PIMs) [29, 37, 41].  
Recent work by Cooper et al. [92] indicates high PIP prevalence in middle aged 
(45-64 years) people using Prescribing Optimally in Middle-aged People’s Treatments 
(PROMPT) criteria. Using prescription databases, PIP prevalence rates among middle-
aged people were found to be 21.1% and 42.9% in Northern Ireland and the Republic 
of Ireland, respectively [208]. The high level of PIP in middle age suggests that the 
well-recognised high prevalence of PIP in established old age (i.e. those aged ≥75 
years) arises in late middle age/early old age [92]. However, to date, there are limited 
data with which to explore when in the life course the problem of PIP emerges.  
PIP is well described in the older population [38, 46, 209, 210] and is shown 
to be associated with increasing age [29, 46] which in turn is associated with 
increasing multimorbidity. The acknowledged high prevalence of PIP in late life is 
thought to result directly from high levels of multi-morbidity and polypharmacy in 
this population [29, 38, 46, 194]. More information is needed on PIP in younger 
populations to assess potential opportunities of minimising PIP before people enter 
older age. Given the lack of published data on PIP in the pre-‘old-old’ age phase of 
life, we aimed to determine the longitudinal pattern of PIP in people aged between 
60 and 74 years.  
The central aim of the present study, therefore, was to assess the levels of 
PIP in early old age and to follow the trend of PPO and PIM prevalence over a 5-year 





4.4 Methods  
This study involved secondary analysis of a previously described population-based 
cohort from a large primary-care centre in Ireland, the Mitchelstown cohort [211]. 
The cohort included a total of 2,047 men and women aged 50-69 years at recruitment 
in 2010-2011, and provided information on demographics, general health, 
medication use and private health insurance status. Updated information on clinical 
status, diagnoses and medications were obtained by researchers from annual 
screening of electronic patient records, and thus provided ongoing passive follow-up 
of participants between periods of active data collection. The follow-up screenings 
were scheduled every year, the first one commencing in April 2010 until April 2011, 
and following the patients to the end of the 5-year follow-up in October 2015. 
Patients were lost to active follow-up of the original cohort study [211] but this did 
not affect the passive follow-up data that were used in this study. I obtained detailed 
information on all prescribed medications from electronic patient records from 
enrolment in 2010-2011 until the end of 2015 [211]. The original medication data 
from baseline and all annual screenings were coded according to the WHO 
Anatomical Therapeutic Chemical (ATC) classification system [212]. Management of 
the original clinical data at baseline was completed and linked at patient-level to the 
coded medication data.  
The Screening Tool to Alert doctors to Right Treatment (START) and Screening 
Tool for Older Persons’ Prescriptions (STOPP) version 2.0 criteria  [77, 213] were 
retrospectively applied to the medication data from baseline and annual screening 
of the electronic patient records in order to determine the prevalence of PPOs 
(START) and PIMs (STOPP) at annual time points over a prospective five-year period 
[77]. Participants were dichotomised according to presence or absence of any PPOs 
and PIMs at baseline. For a sub-analysis, the START/STOPP criteria triggered by the 
presence of more than one drug were removed to explore the effect of polypharmacy 






The study population was summarised using descriptive statistics including means 
and standard deviations or median and interquartile range as appropriate for 
continuous variables, and proportions and percentages for categorical variables. 
Participant groups were compared using Pearson’s chi-square test or Fisher’s exact 
test for categorical variables, Mann-Whitney U test for nonparametric continuous 
variables, and paired t-test for normal distributed continuous variables. The 
proportions of patients with any PPOs or PIMs were compared for two consecutive 
years and for baseline and end of follow-up (year 6) using McNemar’s test for paired 
groups [214]. Negative binomial regression models or Spearman’s rank correlation 
model, where appropriate, were used to describe the correlation between the 
presence of any PPOs and any PIMs and the reported number of medicines and age 
for each year of follow-up. Generalised estimating equation (GEE) models with 
exchangeable correlations were fitted for overall PPO and PIM prevalence from 
baseline to follow-up, and followed by multivariate GEE analysis which adjusted for 
gender, age, number of medicines and number of new diagnoses over the five-year 
time frame to determine associations between these and PPO and PIM prevalence 
[215, 216]. The results are presented as both unadjusted and adjusted odds ratios 
(OR and aOR, respectively) with 95% confidence intervals (95% CI). Data analyses 
were performed using Stata software version 13 (StataCorp. College Station, TX. 
2013) with a significance level of p<0.05.  
 
4.5 Results  
 
4.5.1 Baseline characteristics 
From the total cohort of 2,047 patients, 978 participants (47.8%) were aged 60 to 74 
years at recruitment and were eligible for inclusion in the current study. Due to 
incomplete data, four participants were not included in the analysis. Baseline 
participant characteristics are presented in Table 4-1. There were no significant 
differences in baseline characteristics between participants with PPOs and without 
PPOs. The proportion of people with ≥2 medications was higher for participants with 




expected, given the known association between polypharmacy and PIM occurrence 
[29, 38, 46, 208, 209]. Differences between participants with and without PIMs were 
non-significant for all other characteristics (Table 4-1).  
4.5.2 STOPP/START 
Based on data availability, 27 of 34 (79.4%) START criteria and 64 of 80 (80.0%) STOPP 
criteria were applied into this cohort. PPOs were detected in 304 participants (31.2%) 
and PIMs were identified in 347 participants (35.6%) at baseline (Table 4.1). Anxiety 
and rheumatological disorders were most often associated with PPOs, whilst hypno-
sedatives (benzodiazepines and Z-drug hypnotics) and angiotensin-converting-
enzyme (ACE) inhibitors were the most common drug classes accounting for PIMs 
(see the STOPP/START application in Appendix VIII). Three START criteria and 10 
STOPP criteria are triggered by drug combinations and a subgroup analysis excluding 




Table 4-1 Baseline characteristics of the total study sample (n=978) and for the study sample (n=974) dichotomized into people with and without PPOs and PIMs. 
Four participants had incomplete data and were excluded from the population dichotomized.  
Baseline 
characteristics 
 Entire study 
population 
















Population, n  978 978 974 974  974 974  
Age, years Mean 
(SD) 
64.8 (2.96) 64.3 (3.00) 64.7 (2.99) 64.8 (2.96)  64.9 (2.92) 64.8 (2.99)  















60-64 years N (%) 499 (51.0)  53 (55.2) 153 (50.3) 343 (51.2)  169 (48.7) 274 (51.6)  
70+ years N (%) 15 (1.5) 1 (1.0) 3 (1.0) 12 (1.8)  7 (2.0) 7 (1.3)  
Gender, female N (%) 505 (51.6) 46 (47.9) 148 (48.7) 353 (52.7) 0.247 184 (53.0) 271 (51.0) 0.564 
Chronic  
conditions 
     0.200    
0 N (%) 225 (23.0) 22 (22.9) 80 (26.3) 142 (21.2) 79 (22.8) 121 (22.8)  
1 N (%) 238 (24.4) 30 (31.3) 69 (22.7) 169 (25.2) 80 (23.0) 128 (24.1) 0.931 
≥2 N (%) 515 (52.8) 44 (45.8) 155 (51.0) 359 (53.6) 188 (54.2) 282 (53.1)  




2.1 (3.1) 0 (0) 2.4 (3.6) 2.0 (2.9) 0.144 3.2 (4.3) 1.8 (1.9) 
 
 
0 N (%) 100 (10.2) 96 (100.0) 33 (10.9) 63 (9.4) 0 (0) 0 (0)  
1 N (%) 682 (69.7) 0 (0) 200 (65.8) 482 (71.9) 250 (72.0) 432 (81.4) <0.001* 
≥2 N (%) 196 (20.0) 0 (0) 71 (23.4) 125 (18.7) 97 (28.0) 99 (18.6)  
Current smoker N (%) 108 (11.0) 11 (11.5) 37 (12.2) 71 (10.6) 0.552 36 (10.4) 61 (11.5) 0.499 




582 (59.5) 58 (59.5) 186 (61.2) 393 (58.7) 0.457 213 (61.4) 308 (58.0) 0.319 
Living situation      0.379    
Living alone N (%) 146 (14.9) 12 (12.5) 41 (13.5) 105 (15.7) 57 (16.4) 77 (14.5)  
Living with  
others 
N (%) 638 (65.2) 67 (69.8) 203 (66.5) 435 (64.9) 218 (62.8) 353 (66.5) 0.352 
Unspecified N (%) 194 (19.8) 17 (17.7) 60 (19.7) 130 (19.4)  72 (20.7) 101 (19.0)  




4.5.3 PPO prevalence 
The number of patients with at least one PPO increased significantly between 
consecutive years from baseline until year 3 of follow-up with a continuing 
increasing, but non-significant, trend until the end of follow-up. After 5 years, an 
additional 11% of participants (n=33) had at least one a PPO (p<0.001 Table 4-3). This 
finding shows that new patients were acquiring PPOs each year. However, the mean 
number of PPOs per participant did not significantly change from baseline to end of 
follow-up with a mean of 0.45 (SD 0.82) PPOs per participant at baseline compared 
to 0.42 (SD 0.49) at year 6 (p=0.259). This finding shows that the patients did not 
accrue more PPOs over time across the study population. Some of the principal PPOs 






Table 4-2 PPOs and PIMs identified most frequently in the study population 
 Range of the number of 
patients in which the 
criterium was identified 
between baseline and 
follow-up 
START criteria 
Antiplatelet therapy with a documented history of 
coronary, cerebral or peripheral vascular disease 
28-59 
Regular inhaled beta-2 agonist or antimuscarinic 
bronchodilator for mild to moderate asthma or COPD 
31-57 
Non-TCA antidepressant drug in the presence of 
persistent major depressive symptoms 
39-53 
SSRI for persistent severe anxiety that interferes with 
independent functioning 
72-75 
Disease-modifying anti-rheumatic drug with active, 
disabling rheumatoid disease 
77-83 
Vitamin D and calcium supplement in patients with 
known osteoporosis 
36-52 
Bone anti-resorptive or anabolic therapy in patients 
with documented osteoporosis 
36-55 
STOPP criteria 
Any duplicate drug class prescription 127-256 
Benzodiazepines for ≥4 weeks 77-117 
Acetylcholinesterase inhibitors with a known history 
of persistent bradycardia, hear block or recurrent 
unexplained syncope or concurrent treatment with 
drugs that reduce heart rate 
74-80 
Benzodiazepines 100-134 






Table 4-3 PPO and PIM prevalence over a five-year period (2010-2015) for the study population 
(n=974 for PPO and n=878 for PIM) identified by START and STOPP criteria version 2.0 and compared 
between each consecutive year and between baseline and five-year follow-up. 
 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 



































P value - <0.001* 0.001* 0.002* 0.052 0.035* 0.845 
 



















































P value - <0.001* <0.001* 0.933 0.550 0.525 <0.001 
Comparing baseline and year 6. PPO Difference, % (95% CI) 11.0 (8.7; 13.3), 
P<0.001 
Comparing baseline and year 6. PIM Difference, % (95% CI) 5.9 (3.9; 7.9), P 
<0.001 
*p<0.05, i.e. statistically significant. athe confidence interval was 0.003; 0.029, and did not included 
zero explaining the slightly significant value of P.  
 
Unadjusted odds ratio (OR) showed a significant increase in the PPO prevalence 
comparing 5-year follow-up to baseline (OR 1.08, 95% CI 1.07; 1.09, Table 4-4). The 
multivariate GEE model showed that number of medicines and number of new 
diagnoses were significantly associated with change in PPO prevalence and the 
change in prevalence comparing follow-up to baseline was not significant after 
adjusting for these variables. The multivariate analysis showed no significant 






Table 4-4 Univariate and multivariate GEE models for PPO and PIM prevalence showing the changes 
in the proportion of patients with a PPO or PIM during the study period and the association with the 
potential covariates; gender, age and number of medicines. Study population n=974 for PPO and 
n=878 for PIM, excluding n=96 with no medications at baseline. 
 Any PPO Any PIM 
Unadjusted odds ratio (95% CI)   
Follow-up vs. baseline 1.082* (1.071; 1.093) 1.042* (1.029; 1.055) 
 
Adjusted odds ratio (95% CI) 
  
Follow-up (vs. baseline) 1.037 (0.995; 1.080) 1.005 (0.963; 1.047) 
Age (per year older) 1.033 (0.992; 1.075) 1.023 (0.984; 1.065) 
Gender (female vs male) 0.813 (0.639; 1.033) 0.909 (0.717; 1.151) 
Number of medicines (per higher 
number) 
1.021* (1.011; 1.030) 1.103* (1.084; 1.123) 
Number of new diagnosesa (per higher 
number) 
1.054* (1.043; 1.065) 1.016* (1.022; 1.030) 
 *p<0.05, i.e. statistically significant. anew diagnoses refer to the diagnosed conditions after baseline 
data collection. 
 
A positive but non-significant correlation was found between the number of PPOs 
and older age for all years of follow-up (Table 4-5).  
 






































The number of PPOs and number of medicines were positively correlated for all years 





Table 4-6 Correlation between number of medicines and new diagnoses and number of PPOs and 
PIMs for the study population (n=974 for PPOs and n=878 for PIMs) 
Correlation 





Year 2 Year 3 Year 4 Year 5 Year 6 
 
PPO and  


























PPO and  




















PIM and  




























































When excluding the START criteria triggered by drug combinations (e.g. prescribing 
bisphosphonates and vitamin D and calcium, in patients taking long-term systemic 
corticosteroid therapy) a higher number of medicines and new diagnoses were still 
significantly associated with the change in PPO prevalence in the multivariate GEE 
analysis (aOR 0.99, 95% CI 0.98; 0.99 and aOR 1.06, 95% CI 1.05; 1.07, respectively). 
The number of PPOs was not positively correlated with number of medicines after 




Table 4-7 Correlation between number of medicines and number of PPOs and PIMs - excluding 
STOPP/START criteria triggered combination of drugs: 
Correlation 





Year 2 Year 3 Year 4 Year 5 Year 6 
 
PPO and  























PIM and  
























4.5.4 PIM prevalence 
Prevalence of PIMs (described as the proportion of people with at least one PIM) 
increased significantly between consecutive years from baseline to year 2 of follow-
up and decreased slightly thereafter ending with a significant decrease between year 
5 and year 6 (Table 4-3). Despite this, the overall PIM prevalence from baseline to 
end of follow-up increased significantly from 39.5% of participants receiving one or 
more PIMs at baseline to 45.6% at end of follow-up. The unadjusted GEE model 
showed a significant increase in the PIM prevalence comparing follow-up to baseline 
(OR 1.04, 95% CI 1.03, 1.06, p<0.001; Table 4-4). This finding shows that new patients 
were acquiring PIMs each year.  The mean number of PIMs per participant did, 
however, decrease significantly from 0.82 (SD 1.53) at baseline to 0.45 (SD 0.5) at 
end of follow-up (p<0.001). This finding points towards a subset of the population 
accumulating PIMs rather than an increase in the mean number of PIMs across the 
whole population. Some of the principal PIMs identified in this study population are 
provided in Table 4-2. 
 
Adjusted odds ratios showed that higher numbers of medicines and higher numbers 
of new diagnoses were positively and significantly associated with change in PIM 
prevalence (aOR 1.10; 95% CI 1.08; 1.12 and aOR 1.02, 95% CI 1.00; 1.03, 
respectively), consistent with the published literature. No significant association was 
found between PIM prevalence and age or gender (Table 4-4). The regression models 
showed a significant positive correlation between number of daily medications and 
the number of PIMs prescribed at baseline during all years of follow-up (Table 4-6). 




(Table 4-5). The odds of receiving any PIM was affected by the number of new 
diagnoses but there was no significant correlation between the number of PIMs and 
number of diagnoses (Table 4-6). 
 
Excluding the STOPP criteria triggered by drug combinations both a higher number 
of daily medications and new diagnoses were still significantly associated with the 
change in PIM prevalence in the multivariate GEE analysis (aOR 1.07, 95% CI 1.06; 
1.08 and aOR 1.02, 95% CI 1.01; 1.03, respectively).  A positive correlation between 
the number of PIMs and number of medications was still shown for all years of 
follow-up when excluding the STOPP criteria triggered by drug combinations (e.g. 
STOPP C5 criterion i.e. to discontinue Aspirin in combination with, vitamin K 
antagonist, or direct thrombin inhibitor or, factor Xa inhibitors, in patients with 
chronic atrial fibrillation), see Table 4-7.   
 
4.6 Discussion 
This study illustrates that inappropriate prescribing is present even in early old aged 
community-dwelling people. This prescribing challenge comprises both prescribing 
omissions and use of inappropriate medications to similar degrees. It is also a 
persistent problem with a tendency to increase over time as people progress to more 
advanced old age.  
Our findings showed that over time the number of people with a PPO 
increases significantly, and that the odds of receiving a PPO increases with higher 
number of medicines and new diagnoses independent of PPOs triggered by drug 
combinations. These findings are similar to those of Moriarty et al. [46] that showed 
an increasing trend in PPO prevalence in people aged ≥65 years significantly 
associated with age, higher number of medications and higher number of chronic 
conditions. The associations between higher number of medications with PPO 
prevalence found in Moriarty et al. [46] and the current study may indicate that older 
people experience side effects from their medications resulting in new diagnoses 
that  generates a higher number of PPOs. Similarly, a continuing prevalence of 




health outcomes. A recent study by Wauter et al., [217] has shown that in community 
dwelling persons aged ≥80 years every additional PPO significantly increases the rate 
of hospitalisation (by 26%) and mortality (by 36%).   
In early old aged people, our findings showed that the odds of receiving a PIM 
increased slightly but significantly over time (OR 1.04, 95% CI 1.03, 1.06), a finding 
similar to that in an Irish older person population studied by Moriarty et al. [46]  with 
an odds ratio of PIM prescription of 1.08 (95% CI 1.03, 1.13). Polypharmacy was found 
to be significantly associated with a higher risk of PIMs in our study, a finding that is 
well documented in the literature [29, 38, 46, 208, 209], and was also shown to be 
independent of PIMs triggered by drug combinations. In addition, our findings 
showed a significant impact of the number of new diagnoses on PIM prevalence. 
Although PIM prevalence increased, the mean number of PIMs per patient decreased 
over time. This finding points towards that a subset of this cohort that was 
accumulating PIMs rather than an increase in mean number of PIMs across the whole 
cohort. A preliminary characterisation of this subset of participants showed a similar 
mean age compared to the entire study population (65.0 versus 64.8 years) and a 
similar gender distribution (48.3% male versus 51.6% female). This subset of patients 
was taking a higher number of medicines at baseline compared to the entire 
population (9.2 versus 2.1) and a third of the subset suffered from hypertension 
(33.3%), a quarter (26.7%) suffered from low back pain and nearly a fifth (18.3%) had 
osteoarthritis at baseline. This is an area of research that needs further enquiry in 
order to identify factors that heighten the risk of community dwelling older people 
acquiring PIMs. Future studies should examine in more detail how clustering of 
patients based on their number of PIMs occurs.  
Our data did not show a significant association between change in either PPO 
or PIM prevalence and age in this early old aged cohort (mean age 64.8 years (SD 
3.0). In contrast, Moriarty et al. [46] found that advancing age was significantly 
associated with both increasing PPO and PIM prevalence in people aged ≥65 years 
(mean age 74.8 years, SD 6.2 years). These contrasting findings suggest that in early 
old aged patients, age in itself may not have the same influence on PPO or PIM 
prevalence as it does in patients after the age of 70 years. It has also been observed 




longer have such a significant impact on PPO and PIM prevalence, as was recently 
found by Wahab et al. [29].  
The present study findings indicate that PPOs and PIMs, which are recognised 
to be highly prevalent in the older population aged 75-84 years [218] and ‘old old’ 
population aged ≥85 years [29, 208], are also present in early old age. Our data 
indicate that both PPO prevalence and PIM prevalence gradually increases over a 
five-year period as people progress from early old age towards more advanced old 
age.  
This study was not designed to determine the association between 
prevalence of PPOs/PIMs and clinical outcomes. However, a trial conducted in 
hospitalised older patients in Ireland has demonstrated that improving prescribing 
appropriateness reduces the prevalence of falls and all-cause mortality [41]. In 
addition, the trial showed a reduction in the risk of drug-drug interactions, drug-
disease interactions and under prescribing when improving prescribing 
appropriateness. Preventing a lack of prescribing of appropriate medications may 
thus prevent disease deterioration and accompanying diseases, e.g. a controlled and 
well-medicated blood glucose level in diabetic patients may result in better clinical 
outcomes and lower risk of diabetes-related morbidities [41]. Another Irish study in 
an older community dwelling population (aged ≥70 years) showed an association 
between the prevalence of PIP and ADEs. Patients with ≥2 PIMs were twice as likely 
to experience an ADE [49]. In the study, antithrombotic agents, aspirin and warfarin 
in particular, were the drugs most frequently associated with a higher prevalence of 
ADEs, and 59% of patients in the cohort reported bruising, bleeding, indigestion or 
heartburn. Analgesics, psychoanaleptics and psycholeptics were frequently 
associated with ADEs such as dizziness, unsteadiness on feet and constipation [49]. 
Considering the results of these two previous studies, reducing the prevalence of 
PIMs and PPOs may result in improved clinical outcomes for the older patients.  
Although it is known that a substantially high prevalence of PIP has a negative 
impact on medication management and adherence in older patients, this is an area 
that has received little attention. Non-adherence to medication increases the 
likelihood of ADEs and drug-related hospital admissions caused by overuse, underuse 




to be associated with a higher number of daily medicines, such that there is an 
estimated increase of 16% non-adherence for each additional daily medication taken 
[219]. Improving medication adherence by preventing PIP could therefore play an 
important role in reducing the need for healthcare services among older adults and 
improve the overall quality of their pharmacotherapy. In the elderly multi-morbid 
hospitalised population, STOPP/START criteria have been shown to significantly 
improve prescribing appropriateness [41] and to minimise adverse drug reactions 
(ADRs) [220].  It is likely (although not yet proven) that routine application of 
STOPP/START criteria in late middle-aged/early old aged patients in the primary care 
setting would significantly improve the medication appropriateness, medication 
adherence and reduce the incidence of both ADRs and ADEs in this cohort also.  
Routine application of  the STOPP/START criteria to medication data requires 
a thorough therapeutic and pharmacological understanding and knowledge of the 
patient’s clinical status. Additionally, individual patient preferences, and level of 
medication adherence is important to know when applying the STOPP/START criteria 
in practice. Reviewing a patient’s medication can thus require the consultation of 
several information sources (e.g. hospital discharge letters, prescribed medications, 
pharmacy-dispensed medications, use of over-the-counter (OTC) medications, 
herbal medicines, and patient interviews) and adds to the workload of applying 
STOPP/START criteria in practice. Currently in Ireland, the GP oversees the patient’s 
overall medical treatment. As described in Chapters 2, 6 and 7, GPs in Ireland already 
have a considerable workload and welcome support from pharmacists. Supporting 
the application of STOPP/START in primary care, the community pharmacist may be 
useful in gathering the information needed, e.g. conducting patient interviews and 
looking at medicines dispensed, and OTC medicines used. Combined with their 
pharmacological knowledge, community pharmacists may provide a useful support 
to the GP in the application of STOPP/START criteria to improve prescribing 
appropriateness. Future studies should focus on the community pharmacist-GP 
collaboration in applying STOPP/START criteria with the aim to reduce the prevalence 





4.6.1 Strengths and limitations 
The present study is the first, to my knowledge, to report the pattern of PIM and PPO 
prescribing over a five-year period in early old aged people (60-74 years). The use of 
longitudinal data describing prescription medication in this study provides important 
information on long-term patterns of PIP. However, the study was not without 
limitations. The STOPP criteria have been developed for people aged ≥65 years and 
the applicability of the criteria to a younger population is questionable. However, the 
study population all entered the age group of ≥65 years at end of follow-up and thus 
in scope for the STOPP criteria population. It was therefore deemed appropriate to 
apply the criteria to the study population aged ≥60 years at recruitment. The study 
was also limited with regards to the available clinical information when applying the 
STOPP/START criteria. Information on treatment failures, improvement or worsening 
of symptoms was not available and laboratory values were only available at baseline. 
Consequently, it was assumed that the laboratory values were still valid during the 
years of follow-up and not all STOPP/START criteria could be applied due to the lack 
of clinical information. Additionally, some criteria may have been over triggered due 
to a lack of detail for diagnoses such as anxiety. Prolonged use of benzodiazepines 
(more than four weeks) may be appropriate among patients with severe mental 
illnesses or personality disorders. Equally, omission of medical treatment of mild 
forms of anxiety would not necessarily reflect an omission of treatment since some 
of these patients may have been treated appropriately using non-pharmacological 
approaches e.g. cognitive behavioural therapy, not recorded in this study. Another 
limitation of the current dataset is that it lacks any information on medication 
adherence and individual preferences. Data on medication use obtained from 
electronic patient records do not provide any evidence that the patients are taking 
the medication or taking the medication as prescribed. This information would have 
been useful in ensuring that the actual medication use was analysed. The data 
analysed were also not reporting individual patient preferences in terms of medical 
treatment or other non-medical therapies. Finally, patients who had died during the 
follow-up were not excluded from the data analysis. Although only 16 participants 
(1.6%) died during the years of follow-up this could impact the results and is a 




likely contributes significantly to the high prevalence of PIP in more advanced old 
age. Based on the similarities of the study findings with comparable studies [38, 46, 
217], the study findings are considered to be relevant to other European countries.  
 
4.7 Conclusion 
In conclusion, this is the first study to examine the longitudinal pattern of PIP among 
people in early old age in the primary care setting. The data show that approximately 
one in three persons aged 60 to 74 years living independently in the community has 
one or more PIMs or PPOs and that over a 5-year follow-up interval, PPO prevalence 
rises significantly to over 40% whilst PIM prevalence exceeds 45%. Polypharmacy and 
multimorbidity have a significant impact on the odds of receiving PPOs and PIMs 
independent of those triggered by drug combinations. These findings alongside the 
data emerging from recent clinical trials [41, 220] that describe the positive impact 
of STOPP/START criteria as an intervention support the use of STOPP/START criteria 
in the routine review of medication lists of patients in early old age (60-74 years) in 





5 Application of STOPP criteria version 2.0 - potential cost 
reductions in an Irish primary care cohort  
 
5.1 Chapter description 
In Chapter 4, a high and increasing prevalence of PIP was demonstrated among early-
old aged people (aged ≥60 years). The published literature has suggested negative 
patient-related outcomes of PIP with an increasing use of healthcare services. PIP has 
been described as a burden to the healthcare system, clinically as well as 
economically. However, little research has focused on the potential associated cost 
reductions by applying explicit guidelines to reduce PIP. Therefore, this study was 
conducted to identify potential financial benefits of applying the STOPP criteria in a 
primary care cohort. The results of this study will add to the thesis discussion of the 
potential benefits of deprescribing in primary care settings.  
This study was a secondary analysis of data collected from a primary care cohort as 
part of a previously published study [211]. I did not contribute to the data collection, 
but the data were made available for my analysis in this chapter.  I applied the 
STOPP/START criteria version 2 and calculated the associated drugs costs when 






Older people (defined as 65 years and older) frequently live with multiple 
comorbidities requiring complex pharmacotherapy regimens [158, 221].  As a result, 
the multimorbid, older patient often bears the burden of polypharmacy; commonly 
defined as the daily use of five or more medicines [158, 221]. If implemented 
correctly, polypharmacy may be both appropriate and necessary. Nonetheless, 
polypharmacy is associated with increased risk of adverse drug events (ADEs), falls, 
and drug-drug interactions [20, 222].  Achieving optimal polypharmacy in multi-
morbid older people is challenging and potentially inappropriate prescribing (PIP) is 
a frequent and well-described phenomenon in this patient population [27, 34, 38, 44, 
49, 153, 158, 207, 210, 223]. Exposure to PIP is associated with poorer patient 
outcomes and presents a clinical burden worldwide [24, 49, 50, 224-230].  
 Several explicit tools for identification of PIP exist including the STOPP/START 
explicit criteria [77]. Applying STOPP/START in the Irish healthcare setting has 
demonstrated a PIP prevalence of 42% amongst older people (aged ≥70 years) is 
associated with increased ADEs, poorer health outcomes and higher rates of visits to 
hospital emergency departments [49]. These higher rates of PIP, and associated 
healthcare services utilisation present an economic burden to the healthcare system 
as well as a clinical one [228]. Among the older people in the study (aged ≥70 years), 
36% experienced PIP equivalent to healthcare expenditure of €45 million, comprising 
9% of the total pharmaceutical expenditure for this age group [228].  
 In addition to increased healthcare services utilisation, prescribing of 
potentially inappropriate medicines (PIMs), a significant part of PIP, may also give 
rise to unnecessary drug expenditures to both patients and the healthcare system. 
In Ireland, PIMs have been identified in 36% of those aged 70 years and older in 2010 
[37], and later in 2015, 65% of Irish people aged 65 years and older received at least 
one PIM [46]. Looking specifically at the PIP of proton pump inhibitors (PPIs), it seems 
that a prescribing culture of adding on medicines exists rather than discontinuing 
them. The total expenditure of PPIs reimbursed in Ireland has increased significantly 
from €7 million in 1995 to €95 million in 2009 i.e. almost a 14-fold increase. Switching 
a patient’s PPI to a less expensive generic PPI or reducing it to a maintenance dose 




may also have positive impact on patient health outcomes and pill burden [231]. 
These high rates of inappropriate medicine use, not just for PPIs, may thus point to a 
need to discontinue PIMs to reduce costs. 
 Despite the existing evidence of the PIP and PIM prevalence among older Irish 
people and the associated health expenditures, the evidence is limited on the trends 
in PIMs and medication costs over time. Therefore, this study aimed to estimate the 
prevalence of PIMs and associated costs in an older patient population (aged ≥65 
years) over a three-year period from 2015 to 2018 in a primary care setting. The 
findings of this study will inform the discussion of the potential cost reductions of 
applying the STOPP criteria to identify and reduce PIMs as a strategy to reduce overall 




5.3.1 Study population 
This study was a secondary analysis of a population-based cohort from a large 
primary care centre in southern Ireland described in detailed elsewhere [211]. In 
summary, the Mitchelstown cohort study was part of the original Cork and Kerry 
Diabetes and Heart Disease Study undertaken in 1998. The Cork and Kerry Diabetes 
and Heart Disease Study was conducted in two phases, and as part of phase II, the 
new Mitchelstown cohort was recruited. The Mitchelstown cohort was recruited 
from a single large primary care health centre, the ‘Livinghealth Clinic’ in 
Mitchelstown, county Cork. The Mitchelstown cohort study included collection of 
qualitative and quantitative data in an effort to describe the current health status in 
Ireland, and to assesses individual determinants, behavioural factors and social 
circumstances on health. Recruitment of the Mitchelstown cohort was undertaken 
from 2010 to 2011. Patients were randomly selected from all registered patients 
aged 50-69 years attending the Livinghealth Clinic in Mitchelstown. In total, 3,807 
potentially eligible participants were identified from the practice registry, and after 
exclusion of duplicates, deaths and ineligibles, 3,051 were invited to participate in 
the study. An invitation letter signed by a GP in the practice was sent out to all 3,051 




weeks. Of the 3,051 invited, 2,047 completed the baseline assessment (response 
rate: 67%). As the cohort was embedded in the single large primary care health 
centre with electronic patient records, it was possible to access measurements 
undertaken at routine GP and / or nurse visits. These data provided ongoing passive 
follow-up of participants between waves of active follow-up. Annual rescreens of the 
practice electronic records extracted information on vital status, number of GP visits, 
new diagnoses, specialist referrals and medications [211].  During the eight years of 
follow-up; 45 people had died when year 6 of follow-up was started. The previous 
study (Chapter 4) reported on the study population aged ≥60 years at recruitment in 
2010-2011 and the prevalence of PIP from baseline to year 5 of follow-up, i.e. from 
April 2010 to October 2015. This present study follows on from the previous work 
(Chapter 4) by looking at the same study population and the level of PIP from April 
2015 to January 2018 (i.e. follow-up years 6, 7 and 8) and the associated costs. This 
population aged ≥60 years at recruitment was chosen as these participants would all 
have entered old age defined as ≥65 years at end of follow-up.  
 
5.3.2 Medication data 
Detailed information on all prescribed medications was obtained from electronic 
patient records. The medications were coded using the WHO - Anatomical 
Therapeutic Chemical (ATC) Classification System [212] which is a seven-digit code. 
This hierarchal ATC system divides medicines into different groups according to the 
organ, or system upon which they act and/or, their therapeutic and chemical 
characteristics. These codes were then used in data analysis [232]. Unlike the data 
used in the previous study (Chapter 4), information on the brand name of the 
medication prescribed, dose and frequency of dosing, was available for the follow-
up data used in this study.  
 
5.3.3 PIP prevalence 
STOPP version 2.0 criteria [77] were retrospectively applied to the medication data 
from the annual follow-up screenings between 2015 and 2018 in order to determine 




When applying the STOPP criteria to the dataset, a number of assumptions were 
made. Despite very comprehensive information on current diagnoses and prescribed 
medications (including dosage, frequency and brand name), information was lacking 
on up-to-date laboratory values, medications tried before recruitment and 
persistence in symptoms/provoking disease factors throughout the study period. 
These assumptions were made in agreement between one researcher and a hospital 
physician who were both familiar with the STOPP criteria. The hospital physician was 
a specialist Registrar in geriatric medicine who was experienced in applying the 
STOPP criteria to geriatric patients. Examples of assumptions made were: 
 
• For STOPP criteria considering the estimated Glomerular Filtration Rate 
(eGFR), it was assumed that if the criteria were relevant with regards to 
baseline eGFR value that it was then reasonable to trigger the criteria again 
during follow-up, e.g. direct thrombin inhibitors or metformin if eGFR <30 
ml/min/1.73m2. 
• The STOPP criterion for long-term aspirin at doses greater than 160 mg per 
day was assumed triggered if aspirin was prescribed at doses greater than 160 
mg for two consecutive years of follow-up. 
• The STOPP criterion for loop diuretic prescribed as first-line treatment for 
hypertension was assumed triggered if (i) the patient did not have any other 
indication for loop diuretic (heart failure, valvular heart disease, chronic 
kidney disease or liver cirrhosis/failure) and (ii) the only possible indication 
was hypertension, and (iii) no other antihypertensives were prescribed.  
 
5.3.4 Costs analysis 
The net ingredient cost (NIC) was calculated in Euro (€) for each medication identified 
as potentially inappropriate by the STOPP criteria. The NICs were retrieved from the 
July/August 2018 issue of the Monthly Index of Medical Specialties (MIMS) Ireland 
[233]. These NIC data were the prices to wholesalers of medicines and provided for 
medicines reimbursed on the Irish General Medical Scheme (GMS), the High-Tech 




GP and hospital services and medicines for eligible patients. The patients pay a 
prescription levy of €2.00 per prescription item, up to a maximum of of €20.00 per 
month. The High-Tech scheme facilitates the supply of certain medicines which were 
previously supplied primarily in the hospital setting [234]. The NICs enable the 
prescriber to compare the cost of proprietary medicines but do not bear any relation 
to the retail costs of drugs, nor to the cost of drugs obtained on private prescriptions. 
The NIC of the brand prescribed was used in the present study. If the brand name 
was not provided or that brand was no longer available at the time of the data 
analysis, the cost of the cheapest available generic was used. The NIC was then 
calculated for the supply as stated in the medication information and based on the 
dosing frequency specified on the prescription. If information of the dosing 
frequency was missing a dosing frequency of maintenance dose for the specific drug 
was used. Most prescriptions were for a one-month supply i.e. 30 days. The cost of a 
drug for a month supply was either for 28 days or 30 days depending on the pack size 
available for the drug. The NIC was then used to estimate the cost implications of 
STOPP medications. The pricing represents the NIC alone and does not account for 
associated dispensing fees. Costs were adjusted for claimants receiving the same 
medications for more than one criterion. For amitriptyline, the cost of this drug was 
not available from the Irish MIMS. Amitriptyline (10 mg) is prescribed on a named-
patient basis in Ireland, whereas Amitriptyline 25 mg is the licensed dose in Ireland. 
The prices for Amitriptyline 10 mg and 25 mg were retrieved from an Irish Pharmacy 
database based upon invoice price.  
 
5.3.5 Statistical analysis 
The study population was summarised using descriptive statistics including means 
and standard deviations (SDs) for continuous variables, and proportions and 
percentages for categorical variables. The prevalence of PIMs identified by the STOPP 
criteria was calculated as a proportion of the eligible study population. The 
prevalence of PIMs between consecutive follow-up years was compared using 
McNemar’s test for paired groups [214]. Logistic regression models were used to 




new diagnoses and the odds of receiving PIMs. Data analyses were performed using 
Stata® software version 14 (StataCorp. College Station, TX. 2013). Statistical 
significance was assumed with a p-value of < 0.05.  
 
5.4 Results  
From the original cohort, a total of 978 participants (47.8%) were aged 60 to 74 years 
at recruitment in 2010-2011. Similar to Chapter 4, four participants had incomplete 
data and were excluded from the data analysis. At baseline, there was an almost 
equal distribution of gender in the study population, with 505 female (51.6%) 
participants. The mean age of participants was 64 years (SD ±2.99) at baseline. 
Characteristics of the participants at all years’ follow-up between 2010 and 2018 are 
presented in Table 5-1. During follow-up from year 1 to year 8, a total of 45 






Table 5-1 Cumulative data on the study characteristics and prevalence of STOPP criteria applied to 



























5.2 (4.39) 466 (47.8) N/A 347 (35.6) 2.1 (1.83) 
Year 1 
(n=974) 
6.42 (5.59) 548 (56.4) 0.3 (0.64) 393 (40.5) 2.4 (1.96) 
Year 2 
(n=974) 
8.2 (7.53) 625 (64.4) 2.2 (4.23) 463 (47.7) 2.5 (2.06) 
Year 3 
(n=974) 
8.4 (7.50) 614 (63.5) 2.1 (4.72) 460 (47.6) 2.7 (2.33) 
Year 4 
(n=974) 
8.1 (7.17) 609 (63.1) 2.1 (4.24) 452 (46.8) 2.8 (2.54) 
Year 5 
(n=974) 
8.1 (7.32) 600 (62.6) 1.8 (3.50) 391 (40.8) 2.6 (2.57) 
Year 6 
(n=954) 
6.51 (5.17) 498 (52.2) 1.6 (3.29) 485 (50.8) 3.0 (2.85) 
Year 7 
(n=941) 
6.32 (4.16) 475 (50.5) 1.9 (3.47) 446 (47.4) 2.8 (2.52) 
Year 8 
(n=928) 
5.32 (4.12) 463 (49.9) 1.4 (2.67) 482 (51.9) 3.0 (2.79) 
*For people with ≥1 PIM criteria applied to their data. 
5.4.1 STOPP criteria 
STOPP criteria version 2.0 consists of 80 criteria divided into 13 categories by 
physiological system [77]. Of the 80 STOPP criteria, a total of 74 criteria (92.5%) were 
applied to the data for the present study population for the follow-up years 6 to 8. 
The STOPP criteria applied to the year 0 to year 5 are presented in the previous study 
(Chapter 4). Due to lack of clinical information ten criteria could not be applied to the 
data set (see Table 5-2). The STOPP criteria were applied and the frequency of each 





Table 5-2 STOPP criteria version 2 not applied to the dataset due to insufficient information 
STOPP criteria not applied to the data 
A1 - Any drug prescribed without an evidence-based clinical indication. 
A2 - Any drug prescribed beyond the recommended duration, where treatment 
duration is well defined. 
B4 - Beta blocker with symptomatic bradycardia (< 50/min), type II heart block or 
complete heart block (risk of profound hypotension, asystole). 
B11 - ACE inhibitors or Angiotensin Receptor Blockers in patients with 
hyperkalaemia. 
C3 - Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin 
inhibitors or factor Xa inhibitors with concurrent significant bleeding risk, i.e. 
uncontrolled severe hypertension, bleeding diathesis, recent non-trivial 
spontaneous bleeding) (high risk of bleeding). 
D7 - Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of 
neuroleptic medications (risk of anticholinergic toxicity), 
H3 - Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain 
where paracetamol has not been tried (simple analgesics preferable and usually as 
effective for pain relief) 
H4 - Long-term corticosteroids (>3 months) as monotherapy for rheumatoid 
arthritis (risk of systemic corticosteroid side-effects). 
H6 - Long-term NSAID or colchicine for prevention of relapses of gout where there 
is no contraindication to a xanthine-oxidase inhibitor e.g. allopurinol, febuxostat 
(xanthine-oxidase inhibitors are first choice prophylactic drugs in gout). 
L1 - Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, 
buprenorphine, diamorphine, methadone, tramadol, pethidine, pentazocine) as 






Table 5-3 Frequency and cost of STOPP criteria applied to the study population for year 6 to year 8 of follow-up sorted by the criterion with the highest cost. 
 Total times the criterion 
was applied 
Total cost of criterion (€) 












D10: Neuroleptics as hypnotics 42 40 37 1061.12 973.54 970.75 
K2: Neuroleptic drugs 54 51 47 1061.12 968.63 945.84 
L3: Long-acting opioids without short-acting opioids for break-through pain 26 21 18 849.61 753.77 716.07 
L2: Use of regular opioids without concomitant laxative 26 59 43 478.81 694.07 659.37 
H2: NSAID with hypertension or heart failure 42 44 47 389.91 404.41 435.91 
D11: Acetylcholinesterase inhibitors with a known history of persistent bradycardia etc. 81 79 79 341.29 321.78 322.26 
A3_SSRI: duplicate SSRI therapy 44 42 42 323.74 311.36 311.36 
M1: Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties 14 14 14 251.82 251.82 251.82 
A3_ 
Benzodiazepine: duplicate benzodiazepine therapy 
40 36 36 238.44 234.2 234.2 
K1: Benzodiazepines 143 122 118 248.20 211.49 204.37 
K4: Hypnotic Z-drugs 85 81 79 252.46 237.06 232.05 
F2: PPI at full therapeutic dosage for > 8 weeks 16 20 20 221.23 278.56 278.56 




 Total times the criterion 
was applied 
Total cost of criterion (€) 
A3_ACE inhibitor: duplicate ACE-inhibitor therapy 25 25 25 181.78 181.78 181.78 
C9: Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary 
embolus 
8 8 8 137.26 137.26 137.26 
H7: COX-2 selective NSAIDs with concurrent cardiovascular disease 7 8 11 132.3 118.13 165.38 
J3: Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes 44 47 50 129.16 143.52 154.69 
F3: Drugs likely to cause constipation 6 9 6 90.67 142.15 90.67 
C8: Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep 
venous thrombosis without continuing provoking risk factors for > 6 months 
5 5 5 71.48 71.48 71.48 
A3_NSAID: duplicate NSAID therapy 9 9 8 70.48 70.48 70.48 
A3_Beta blocker: duplicate beta-blocker therapy 19 18 18 58.95 54.5 54.5 
J5: Oestrogens without progestogen in patients with intact uterus 10 9 9 60.72 54.35 54.35 
D6: Antipsychotics  in those with parkinsonism or Lewy Body Disease 4 4 5 49 49 56.52 
B6: Loop diuretic as first-line treatment for hypertension 22 25 27 49.49 59.13 57.25 
H8: NSAID with concurrent corticosteroids without PPI prophylaxis 7 7 7 44.41 44.41 44.41 
B12: Aldosterone antagonists with concurrent potassium-conserving drugs 8 8 8 43.4 43.4 43.4 
C10: NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in 
combination 




 Total times the criterion 
was applied 
Total cost of criterion (€) 
D8: Anticholinergics/antimuscarinics in patients with delirium or dementia 2 2 2 34.06 34.06 34.06 
D12: Phenothiazines as first-line treatment 13 12 12 31.33 31.33 31.33 
H9: Oral bisphosphonates in patients with a history of upper gastrointestinal disease 4 5 5 26.69 31.36 31.36 
A3_Loop diuretic: duplicate loop diuretic therapy 11 11 11 13.58 13.58 13.58 
B9: Loop diuretic for treatment of hypertension with concurrent urinary incontinence 5 6 6 12.43 14.28 14.28 
H1: NSAID with history of peptic ulcer disease or gastrointestinal bleeding, unless with 
concurrent PPI or H2 antagonist 
1 1 1 10.39 10.39 10.39 
H5: Corticosteroids for osteoarthritis 8 8 1 9.9 41.85 2.97 
F4: Oral elemental iron doses greater than 200 mg daily 2 2 0 8.12 8.12 0 
B3: Beta-blocker in combination with verapamil or diltiazem 3 3 3 7.38 7.38 7.38 
K3: Vasodilator drugs with persistent postural hypotension 1 2 2 7.37 13.22 13.22 
D9: Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of 
dementia 
1 1 2 5.81 5.81 13.33 
B7: Loop diuretic for dependent ankle oedema 2 3 3 3.7 6.18 6.18 
D2: Initiation of tricyclic antidepressants as first-line antidepressant treatment 3 3 3 2.49 2.49 2.49 
C5: Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa 
inhibitors in patients with chronic atrial fibrillation 




 Total times the criterion 
was applied 
Total cost of criterion (€) 
G4: Benzodiazepines with acute or chronic respiratory failure 1 3 3 1.54 3.34 3.34 
C4: Aspirin plus clopidogrel as secondary stroke prevention 1 1 1 0.95 0.95 0.95 
D3: Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects with a 
history of prostatism or previous urinary retention 
1 1 1 0.74 0.74 0.74 
B1: Digoxin for heart failure with preserved systolic ventricular function 1 1 1 0.471 0.471 0.471 
B2: Verapamil or diltiazem with NYHA Class III or IV heart failure 0 0 0 0 0 0 
B5: Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias 0 0 0 0 0 0 
B8: Thiazide diuretic with current significant hypokalaemia, hyponatraemia hypercalcaemia 
or with a history of gout 
0 0 0 0 0 0 
B10: Centrally-acting antihypertensives 0 0 0 0 0 0 
B13: Phosphodiesterase type-5 inhibitors in severe heart failure 0 0 0 0 0 0 
C1: Long-term aspirin at doses greater than 160mg per day 0 0 0 0 0 0 
C2: Aspirin with a past history of peptic ulcer disease without concomitant PPI 0 0 0 0 0 0 
C6: Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa 
inhibitors in patients with stable coronary, cerebrovascular or peripheral arterial disease 
without a clear indication for anticoagulant therapy 
0 0 0 0 0 0 




 Total times the criterion 
was applied 
Total cost of criterion (€) 
C11: NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis 0 0 0 0 0 0 
D1: Tricyclic antidepressants with dementia, narrow angle glaucoma, cardiac conduction 
abnormalities, prostatism, or prior history of urinary retention 
0 0 0 0 0 0 
D4: Selective serotonin re-uptake inhibitors (SSRIs) with current or recent significant 
hyponatraemia 
0 0 0 0 0 0 
D13: Levodopa or dopamine agonists for benign essential tremor 0 0 0 0 0 0 
D14: First-generation antihistamines 0 0 0 0 0 0 
E1: Digoxin at a long-term dose greater than 125µg/day if eGFR < 30 ml/min/1.73m2 0 0 0 0 0 0 
E2: Direct thrombin inhibitors (e.g. dabigatran) if eGFR < 30 ml/min/1.73m2 0 0 0 0 0 0 
E3: Factor Xa inhibitors (e.g. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 0 0 0 0 0 0 
E4: NSAID’s if eGFR < 50 ml/min/1.73m2 0 0 0 0 0 0 
E5: Colchicine if eGFR < 10 ml/min/1.73m2 0 0 0 0 0 0 
E6: Metformin if eGFR < 30 ml/min/1.73m2 0 0 0 0 0 0 
F1: Prochlorperazine or metoclopramide with Parkinsonism 0 0 0 0 0 0 
G1: Theophylline as monotherapy for COPD 0 0 0 0 0 0 
G2: Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in 
moderate-severe COPD 




 Total times the criterion 
was applied 
Total cost of criterion (€) 
G3: Anti-muscarinic bronchodilators  with a history of narrow angle glaucoma  or bladder 
outflow obstruction 
0 0 0 0 0 0 
I1: Antimuscarinic drugs for overactive bladder syndrome with concurrent dementia or 
chronic cognitive impairment or narrow-angle glaucoma, or chronic prostatism 
0 0 0 0 0 0 
I2: Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic 
hypotension or micturition syncope 
0 0 0 0 0 0 
J1: Sulphonylureas with a long duration of action  with type 2 diabetes mellitus 0 0 0 0 0 0 
J2: Thiazolidenediones in patients with documented heart failure 0 0 0 0 0 0 
J4: Oestrogens with a history of breast cancer or venous thromboembolism 0 0 0 0 0 0 
J6: Androgens in the absence of primary or secondary hypogonadism 0 0 0 0 0 0 





5.4.2 PIP prevalence for year 6 to year 8 of follow-up 
Between 46% and 52% of the participants received one or more PIMs, and the mean 
number of PIMs per participant varied between 2.8 and 3.0 (±SD 2.52 to 2.85), 
respectively (Table 5-1). The McNemar’s tests showed that the proportion of people 
with at least one PIM significantly decreased between years 6 and 7 of follow-up 
(from 50.8% to 47.4%, difference in proportions -0.05, 95% CI -0.07; -0.03, 
McNemar’s Chi2=28.10, p<0.001), but then significantly increased from years 7 to 8 
of follow-up (from 47.4% to 51.9%, difference in proportions 0.05, 95% CI 0.03; 0.07, 
McNemar’s Chi2=42.32, p<0.001). When comparing year 6 to year 8 of follow-up the 
difference in the prevalence of STOPP PIMs was not statistically significant 
(difference in proportions -0.003, 95% CI -0.02; 0.01, McNemar’s Chi2=0.26, p=0.612).  
 A higher number of prescription medicines was statistically significantly 
associated with higher odds of receiving a PIM for all three years of follow-up (Table 
5-4). At year 6 and 8, participants with a higher number of medicines were more than 
twice as likely to receive a PIM compared to people with a lower number of 
medicines. No significant associations between age, sex, life status and the odds of 
being prescribed a PIM were shown for all three years of follow-up (Table 5-4). 
Number of new diagnoses was significantly associated with the odds of any PIM for 






Table 5-4 Adjusted odds ratio (aOR) for the association between the presence of a PIM and age, 
gender, number of drugs, new diagnoses and life-status (n=978). 


























































A significant and positive correlation was shown for the number of prescribed drugs 
and the number of PIMs for all years of follow-up (Table 5-5). 
Table 5-5 Correlation between the number of PIMs and the number of ATC-coded drugs. 
Number of STOPP criteria and number of drugs 
Correlation Coefficient (CC) CC 95% CI p 
Year 6 (n=954) 0.184  (0.169;0.200) <0.001 
Year 7 (n=941) 0.233 (0.212;0.253) <0.001 
Year 8 (n=928) 0.235  (0.217;0.253) <0.001 
 
5.4.3 Cost 
The total NIC of the PIMs was €87,152.04 per annum at year 6 and increased to 
€86,112.48 per annum at year 8 of follow-up. The mean cost of PIM per participant 
per year was €179.64 in year 6; to the mean PIM cost was €178.68 in year 8 of follow-






Table 5-6 Estimated NIC of the PIMs.  






Cost of all PIMs per month €7262.67 €7288.35 €7176.04 
Cost of all PIMs per year €87,152.04 €87,460.20 €86,112.48 
Cost of PIMs per person per month 
(participants with ≥1 PIMs) 
€14.97 
 
€16.72  €14.89 
Cost of PIM per person, per year 
(participants with ≥1 PIMs) 
€179.64  €200.64 €178.68 
*All cost estimates in this table are adjusted for the same drug triggering more than one criterion.  
 
5.5 Discussion 
This study demonstrated that approximately half of an older community-based 
population (46%-52%) in southern Ireland were receiving at least one PIM according 
to the STOPP criteria.  
A decrease in the number of participants with ≥1 PIM was seen between year 
6 and 7. This could be explained by the number of participants who died between 
year 6 and 7; 13 participants died of which 11 had ≥1 PIM in year 6. The prevalence 
of PIM did however increase in year 8 back to a similar level as for year 6.  This 
increase may be related to the higher number of new diagnoses in year 7 compared 
to both year 6 and year 8. It is likely that a higher number of new diagnoses in year 7 
resulted in new medicines prescribed to treat the new diagnoses and these may have 
been appropriately prescribed in year 7. In year 8, these new medicines could have 
been identified as inappropriate due to the duration of the medicine now having 
exceeded the level of appropriateness or that the new diagnoses in year 7 was no 
longer present in year 8, making the use of the prescribed medicines inappropriate. 
Finally, the proportion of people with ≥1 PIM between year 6 to year 8 of follow-up 
is varying with -3% to +4% and some of this variation may also be explained by 
prescriber variation and year to year variation in prescribing patterns.  
A higher number of medicines significantly increased the odds of PIMs 
according to STOPP criteria. This adds to the evidence of the association between 




literature [37, 38, 208, 209]. This association persisted despite a reduction in the 
mean number of prescribed drugs for year 6 to 8 of follow-up compared to the 
previous five years of follow-up reported in Chapter 4. This change in the number of 
prescribed drugs is to some extent explained by the exclusion of participants who 
had died during follow-up from the study analysis in this study, while these were not 
excluded in Chapter 4, which was a limitation of Chapter 4. However, this only partly 
explains the difference in the mean number of drugs prescribed. The Mitchelstown 
study was conducted from 2010 to 2018. During that time, inappropriate prescribing, 
stopping unnecessary drug use and excessive prescribing of drugs has gained more 
attention. This was seen in Chapter 2 and 3 with the high number of citations 
retrieved when searching for literature on deprescribing, inappropriate prescribing 
and polypharmacy management. In chapter 6 and 7, community pharmacists and GPs 
also describe an awareness of the issues around PIP and the need for deprescribing 
showing that these areas are also gaining more attention in the Irish primary care 
setting. Hence, it is likely that this increased focus could have affected prescribing 
behaviours of the prescribers and patients in the Mitchelstown study resulting in a 
lower number of drugs prescribed in the latter years of follow-up. However, the 
findings of this study still show a high prevalence of PIMs among older people that 
does not attenuate over a three-year period. The associated cost of PIM use is high 
and may be a useful opportunity for cost reduction by applying STOPP criteria 
proactively to identify and discontinue PIMs in community dwelling older people. 
 The total NIC per participant per annum found in our study was lower than 
the one found in the previous published Irish study by Cahir et al. [37] (€178.68-
€200.64 versus €318). Explanations of this difference may be found in the study 
population. The population in Cahir et al. [37] was older compared to our study. Cahir 
et al. [37] included only people aged 70 years and older with 62% of participants aged 
≥75 years and showed that PIM was significantly more likely in people aged ≥75 years 
than the younger participants. Our study included people aged 60-74 years at the 
time of recruitment such that the oldest participant would be 82 years old at the end 
of follow-up. As shown in previous studies, the so-called ‘old old’ population, often 
defined as 85 years and older usually have more medications than their ‘young old’ 




results, that the prevalence of PIP is significantly and positively associated with higher 
numbers of medicines, this may explain the difference in cost of PIP. Even though our 
findings suggest lower costs of PIM compared to the data published by Cahir et al. a 
decade previously [37], our findings highlight the fact that we may have reached a 
plateau, and that we are not reducing PIM prevalence and costs, beyond this point.  
 Benzodiazepines, hypnotic Z-drugs and acetylcholinesterase inhibitors were 
among the most commonly drug classes associated with the PIMs identified in this 
study. These drug classes are known to be associated with ADEs such as falls, hip 
fractures, confusion and impaired cognitive function [235-237]. Reducing the 
prevalence of these drugs when prescribed inappropriately will reduce prescribing 
budgets as shown in this study but may also reduce indirect costs of healthcare 
services utilisations associated with the adverse outcomes of these drugs. 
Unnecessary drug class duplication was another common cause of the PIMs 
identified. Duplicate therapy of drugs added unnecessary medicines expenses as 
shown in this study and is an important source for reducing prescribing costs in older 
people. Additionally, duplicate drug therapy may increase the risk of adverse patient 
outcomes and adds to the pill burden in polypharmacy patients already taking a high 
number of medicines daily.  
 
5.5.1 Strengths and Limitations 
The strength of this study is in the detailed information of prescribed medication over 
a period of years from 2015 to 2018. When applying STOPP criteria, the 
comprehensive history of the patient’s conditions and medication use strengthens 
the application.  
 The study had some limitations including the use of STOPP criteria on a 
population aged ≥60 years at recruitment. The STOPP criteria have been developed 
for people aged ≥65 years and the applicability of the criteria to a younger population 
is questionable. However, the study population all entered the age group of ≥65 
years at end of follow-up and thus in scope for the STOPP criteria population. It was 
therefore deemed appropriate to apply the criteria to the study population aged ≥60 




a dataset without being able to contact patients, their carer, or prescribers, directly, 
to check the clinical relevance of the PIP identified. This also means that in some 
instances, medicines defined as inappropriate in this study may in fact be 
appropriate, once the full clinical picture emerges. As with any other study applying 
explicit PIP criteria to a database, it is important to stress that the medicines are 
identified as ‘potentially inappropriate’, and as distinct from ‘definitely 
inappropriate’. When considering the appropriateness of a patient’s 
pharmacotherapy, both the prescriber and the patient should agree whether a 
medication is actually inappropriate and not merely potentially inappropriate but 
reasonable to continue considering all circumstances.  
Another limitation was the identification of drug class duplication. Drug class 
duplication could be appropriate in some patients for which a strength of a 
medication was needed that was not commercially available. Drug duplication could 
also be appropriate for patients in which the dosage regimen prescribed was 
different doses at different time points, e.g. 10 mg in the morning and 20 mg in the 
evening.   
 The information on the duration of treatment was not available from the 
dataset and the medications prescribed were a ‘snapshot’ of a single month’s 
prescriptions during each year of follow-up. Thus, when applying STOPP criteria, for 
which the duration of treatment is crucial, e.g. PPIs at full therapeutic dose for 8 
weeks or more, it was assumed that the patient had been taken the medication for 
one year, if the medication was prescribed over two consecutive years. Another 
limitation was the lack of up to date laboratory values such as the sodium levels, so 
that the use of a drug that has previously caused hyponatraemia may not be clinically 
relevant anymore if the patient’s serum sodium concentration has reached the 
normal range at the time of assessment for PIMs. Medication data were obtained 
from the patient’s electronic records and were data on medication prescribed. For 
that reason, this study was limited in that it was not possible to identify if the patients 
were dispensed the medication prescribed, whether a cheaper brand was dispensed 
or if the patients were actually taking the medication as prescribed. When stopping 




withdrawal symptoms. Also, it could be necessary to switch the patient to another 
drug class rather than discontinuing drug treatment completely. This was not 
accounted for in this study and could have influenced the actual cost reductions of 
applying STOPP criteria to medication data in primary care.  
The pharmacist’s dispensing fee and the cost of a healthcare professional 
reviewing and communicating the identified PIMs was not included in the cost 
estimates and both of these may be important further sources of cost if PIMs were 
to be identified and prevented regularly in the primary care setting. Finally, this study 
did not consider potential prescribing omissions (PPOs). As shown in Chapter 4, the 
prevalence of PPOs rose significantly in the same study population over a 5-year 
follow-up period and was present in over 40% of people at end of follow-up. Failure 
to prescribe appropriate medicines for disease prevention and symptom relief could 
have a substantial impact on clinical outcomes, such as disease progression in the 
older population with a need for more monitoring, hospitalisations etc. Reducing the 
prevalence of PPOs may thus have important financial implications in terms of 
reducing the healthcare services utilisation. Additionally, stopping inappropriate 
medicines could in some instances warrant the starting of appropriate medicines and 
this would have affected the true cost reductions of identifying and eliminating PIMs 
in this study. As such, the START list to identify PPOs has been created to be used in 
tandem with the STOPP criteria to give a more complete assessment of the PIP in 
older people. The findings from Chapter 4 indicate that PPOs of essential medicines 
in older people are at least as prevalent as the prescribing of PIMs which should be 
avoided in older people. It is thus a weakness of this study not to consider PPOs and 
the potential cost reductions of reducing the prevalence of PPOs. Acknowledging 
these study limitations, this study still provided useful insights into PIM prevalence 
in recent years in an Irish older population and associated costs.  
 
5.5.2 Implications for future practice 
Although there are clear cut potential savings from PIM curtailment amongst 
community-dwelling older people, the high and persistent PIM prevalence points 




Interventions are needed to target primary care where a large proportion of 
prescribing takes place as well as continuation and transcribing of prescriptions from 
hospitals and specialists [228]. For multimorbid community-dwelling patients with 
polypharmacy and in high risk of receiving PIMs, it is likely that they will visit the 
community pharmacy on a monthly basis to collect their prescription medications. 
Community pharmacists will thus dispense prescriptions monthly and review these 
prescriptions upon each dispensing. This could provide an opportunity for 
community pharmacists to identify PIMs during medicines dispensing and advising 
the GP to discontinue/review these. However, the identification of PIMs requires an 
assessment of the patient’s medicine and clinical history. Today, no system exists in 
Ireland, in which patient information is shared with the community pharmacies. 
Future interventions aiming to reduce PIMs in primary care should focus the 
attention towards sharing information to enable community pharmacists to identify 
PIMs and advising GPs to reduce/review these. This could be an important way of 
preventing long-term iatrogenic harm in a setting which is built to maintain long-term 
treatment and relationships with the patients. However, involving community 
pharmacists in the reduction of PIMs in primary care raises the question of a potential 
conflict of interest for the pharmacy business owner. If community pharmacists are 
asked to identify PIMs, with a goal to reduce the number of PIPs dispensed, it reduces 
the dispensing fees for the pharmacy and may cause a loss of earnings to the 
pharmacy. Intervention designers needs to address this potential conflict of interest 
if interventions to reduce PIMs are to be implemented in practice.   
 
5.6 Conclusion 
This study estimated a high prevalence of PIMs (46% - 52%) and associated costs 
(€86,112.48 - €87,460.20) in older people between 2015 and 2018. The findings 
reveal a high and unchanging prevalence of PIMs in recent years despite the 
increasing focus on PIMs in the literature and existing PIMs guidelines based on 
explicit measures of PIP. Benzodiazepines, hypnotic Z-drugs, ACE-inhibitors were 




prescribed inappropriately may, in addition to reduction in prescribing budgets, also 





6 Qualitative analysis of community pharmacists’ opinions on 
their involvement in reducing potentially inappropriate 
prescribing  
 
6.1 Chapter description 
From the previous chapters, pharmacist support in deprescribing is a suggested 
strategy to reduce PIP. However, several barriers to pharmacist participation in 
deprescribing exist as viewed by other healthcare professionals.  Given the lack of 
published qualitative research exploring the views of community pharmacists on 
their role in reducing PIP, the aim was to carry out a qualitative study to add to the 
literature as well as guiding the next research for this thesis.   
 
6.2 Publication 
The work of this chapter has been published as: Hansen CR, Byrne S, O’Mahony D, 
Kearney PM, Sahm LJ. Qualitative analysis of community pharmacists’ opinions on 
their involvement in reducing potentially inappropriate prescribing. European 
Journal of Clinical Pharmacology. 2018; 75(2):265-274. Doi: 10.1007/s00228-018-




6.3 Introduction  
Older multi-morbid people are at substantial risk of having potentially inappropriate 
prescribing (PIP) [41, 77]. The risk of PIP increases as people grow older and is 
strongly associated with the higher number of daily medicines used to treat multi-
morbid illness [46, 238, 239]. Patient safety is at risk when older people are exposed 
to PIP because of the associated ADEs and drug-related hospitalisations directly or 
indirectly related to PIP [206, 240]. Previous studies indicate a high prevalence of PIP 
among independently living older people in the primary care setting in Ireland, with 
reported prevalence estimates of 21% - 57% [46, 49, 153, 238]. Similar prevalence 
estimates have been described in Northern Ireland (34%) [38] and in other European 
countries, e.g. Spain (38% - 46% ) [241] and the Netherlands (35% - 85%) [239]. No 
intervention has so far succeeded in reducing the substantial PIP prevalence in 
primary care despite the existence of explicit criteria to identify PIP being available 
for over 10 years, as well as the evidence that when heeded and acted upon, they 
are effective in reducing PIP in hospitalised, older patients [41, 239, 242]. The two 
most commonly cited sets of PIP criteria in the published literature are Beers’ criteria 
[87-91] and Screening Tool of Older People’s Prescriptions (STOPP)/Screening Tool 
to Alert to Right Treatment (START) criteria [77].  There are currently published four 
randomised clinical trials showing the clinical efficacy of applying STOPP/START 
criteria to reduce PIP [41, 178], falls incidence and overall medication cost [194], as 
well as incidence of ADRs [242] in the hospital and nursing home settings.  
 Detailed assessment of new and repeat prescriptions and formal structured 
medication review are recognised ways of identifying PIP. Medication review is a 
broad term covering several interventions carried out by prescribers themselves or 
by other practitioners providing advice to prescribers (e.g. pharmacists) with the 
overall aim of improving the quality, safety and appropriateness of use of medicines 
[243]. Studies in primary care settings have demonstrated a significant positive effect 
of pharmacist-led medication reviews on prescribing appropriateness in older 
people, either measured by an improvement in the MAI scores, a prevalence of drug-
related problems or a reduction in the number of PIMs [53, 199, 244]. Despite 
variations in study setup, these interventions all showed the positive outcomes of 




given by the pharmacists to the prescribing physician. Recommendations given 
varied between the interventions and included: (1) recommendations to stop a 
medication; (2) highlighting inappropriate prescribing; (3) suggesting changes to the 
dosing or dosing interval; (4) recommending changing to an alternative medication 
etc.  Systems for providing feedback to the prescribing physician varied in the studies 
from (i) face-to-face discussions, (ii) written feedback and (iii) telephone 
conversations. Despite these study variations, the current studies point towards 
pharmacist-led medications reviews followed by feedback to the prescribing 
physician as a strategy to reduce PIP [57, 180, 186, 188, 199, 245]. Considering the 
findings of these previous studies, pharmacists are in a favourable position to identify 
and help reduce PIP through conducting medication reviews and providing feedback 
to the prescriber. However, prevalence data of PIP among community-dwelling older 
people indicate that pharmacists are not undertaking the potentially important role 
of identifiers of PIP with a connected remit of PIP prevention [246-248].  
An important question to ask is whether community pharmacists are 
equipped to take on this role in terms of their current knowledge, resources needed 
to conduct medication reviews in practice and the clinical information available to 
them to make clinically relevant recommendations. Hence, when designing an 
intervention to change traditional working practice, it is fundamental to understand 
the processes, barriers and facilitators (e.g. resources, knowledge and available 
information) underlying the behaviour in relation to the particular work practice in 
question such as the barriers and facilitators [249, 250]. In this study, the 
pharmacists’ behaviours in reducing PIP were expected to change, and it was deemed 
essential to understand the barriers and facilitators for the involvement of 
community pharmacists in reducing PIP. The Theoretical Domains Framework (TDF) 
was originally  developed by Michie et al. [251] with 12 domains and later updated 
to 14 domains by Cane et al. [252]. The TDF considers a wide range of possible 
theoretical explanations for the relevant behaviours [249, 253, 254] and has been 
widely used in health research to define behaviours and to identify barriers and 
facilitators to those behaviours . The 12 domain TDF [251] has been widely used in 
health research to define behaviours and to identify barriers and facilitators to that 




barriers and facilitators of pharmacist involvement in reducing PIP. The 14 domain 
TDF has previously been used to explore a similar topic: the utilisation of a screening 
tool in medicines use reviews (MURs) by community pharmacists [256]; and was 
deemed appropriate to investigate their involvement in reducing PIP.  
Whilst large randomised controlled trials have examined various ways to 
assess the interventions targeted at prevention of PIP in hospital care settings [41, 
83, 84], little research has been carried out in primary care.  To date, the views of the 
community pharmacists on reducing PIP have received little attention [256]. 
Therefore, this study aimed to explore the views of community pharmacists on their 
potential involvement in reducing PIP, and to determine the perceived barriers and 




6.4.1 Compliance with Ethical Standards 
Ethical approval for this study was granted by the Clinical Research Ethics Committee 
of the Cork Teaching Hospitals prior to recruitment (Appendix X). Written informed 
consent was obtained from all participants included in the study. 
 
6.4.2 Sampling  
Community pharmacists working in the vicinity of Cork City and its surrounding 
hinterland were recruited using convenience sampling based on a sampling matrix. 
The convenience sampling method was chosen due to time constraints of the study 
and to increase the likelihood of respondents. Hence, a close geographic proximity 
allowed the researcher to conduct face-to-face interviews with participants at 
suitable location.  Currently working in community practice was the only inclusion 
criterion, and there were no exclusion criteria.  
A sampling matrix was designed to ensure variation of important participant 
characteristics in the study population. The design of the matrix was informed by the 
experience and knowledge of me, the primary researcher, two PhD supervisors and 




backgrounds in both academia and community pharmacy practice. The final matrix 
design was approved by me and the four PhD supervisors and co-authors of the 
publicaton. Matrix parameters chosen were: (i) experience working with nursing 
home residents (either from working in a nursing home or from working in a 
pharmacy serving nursing homes), (ii) years of experience working as a community 
pharmacist (<3 years, ≥3 years and ≥10 years), and (iii) number of pharmacists 
working simultaneously in the pharmacy. A cut-off of 3 years of community 
experience was chosen as a matrix parameter because community pharmacists in 
Ireland after a 3-year period can choose to take up employment subsequently as 
Supervising / Superintendent Pharmacists1. Being a supporting or supervising 
pharmacist was considered to influence the level of confidence and knowledge 
regarding PIP.  A threshold of 10 years or more experience was then agreed by the 
researchers and the expert panel because seniority of ≥10 years was likely to 
influence their opinions and answers. Experience of working in a nursing home was 
considered to have an influence on the pharmacists’ answers relating to medication 
reviews as these are commonly undertaken by pharmacists in Irish nursing homes. 
The number of registered community pharmacists on duty in the pharmacy at any 
one time was believed to have an impact on their perceived capability to perform 
medication reviews compared to those pharmacies with a single community 
pharmacist on duty and was included as a matrix parameter. Although not matrix 
parameters, the areas in which the pharmacists worked i.e. urban or rural setting as 
well as local community affluence or disadvantage were considered when recruiting 
participants. Areas with social affluence or disadvantage were identified from the 
deprivation index viewer (available from www.pobal.ie ) [257]. See the sampling 
matrix in Table 6-1. 
  
                                                          
1 The Supervising/Superintendent pharmacists is the person responsible for the day-to-day 
management and operation of the pharmacy and must have a minimum of three years’ post-
registration experience (http://www.thepsi.ie/gns/Pharmacy_Practice/practice-





Table 6-1 Sampling matrix used for the recruitment of community pharmacist 
X: pharmacy with 1 licensed pharmacist 
on duty 
 
O: pharmacy with 2 licensed pharmacists 
on duty 
<3 years of 
experience 
3-9 years of 
experience 
≥10 years of 
experience 












Sum 4 4 4 




Pharmacies located in Cork City and County were identified. An initial list of 
pharmacies was created considering: (i) the characteristics of the area in which the 
pharmacy was located (i.e. urban, rural, disadvantage or affluent), and (ii) if the 
pharmacy was an independent pharmacy individual or a chain pharmacy (i.e. 
pharmacies owned by the same pharmacy chain were initially avoided). The 
pharmacies were contacted by telephone. I, the primary researcher introduced the 
study to the pharmacist on duty and asked if he/she would consider taking part in 
the study. Written information about the study was offered (by email) prior to the 
interview. An agreed interview date, time and location were then arranged. During 
the interview, pharmacists were asked about (i) their numbers of years practising in 
community pharmacy, (ii) experience of working in a nursing home, and (iii) number 
of pharmacists on duty daily to ensure that all matrix parameters were fulfilled at the 
end of recruitment. In addition, a ‘snowballing’ sampling method was used to recruit 
pharmacists, whereby a community pharmacist interviewed identified other 
community pharmacists who would fulfil certain matrix parameters.  
 
6.4.3 Interview topic guide 
The interview topic guide (see Appendix XI) was designed to explore the 14 domains 
of the TDF framework [251, 252] whilst also allowing the participants to freely share 
their opinions. Using the TDF to design the topic guide is a helpful way of formulating 




barriers and facilitators to that behaviour. The use of a TDF-formulated topic guide 
has also been shown to effectively elicit responses from the interviewees that they 
would not otherwise report [250]. The topic guide was refined by consensus among 
all researchers and with an expert panel of experienced pharmacists with 
backgrounds in academia and community pharmacy practice. The topic guide was 
pilot tested in two community pharmacists. During the study it was refined on an 
iterative basis after each interview was transcribed to allow for emerging themes to 
be explored in subsequent interviews. Interviews were conducted until the point of 
thematic saturation as described by Francis et al. [258] was achieved. The interviews 
were introduced with some general questions regarding their awareness and beliefs 
about PIP and medication reviews. Participant demographic details were also 
collected including gender, age, number of years of experience in community 
pharmacy. Participants were shown the recently developed deprescribing algorithms 
and asked to give their opinion about the content, layout and usefulness in their daily 
practice [80, 96-98]. These deprescribing algorithms have been developed to create 
decision-support tools for deprescribing. The algorithms and accompanied guidelines 
provide a rationale for evidence-based deprescribing and the steps of a safe 
deprescribing process for health care professionals and patients. At the time of the 
study, deprescribing algorithms were available for four drug classes: proton pump 
inhibitors (PPIs), antipsychotics, antihyperglycemics and benzodiazepine receptor 
agonists  [80, 96-98]. Since the study, another deprescribing algorithm has been 
published for cholinesterase inhibitors and memantine [99].   
 
6.4.4 Data collection 
Semi-structured interviews with pharmacists working in community pharmacies in 
Ireland were conducted by me, the primary researcher. This type of interview was 
chosen as it encourages interviewees to share the views and opinions that were 
important to him/her at that time [259]. Interviews were all conducted face-to-face 
at the pharmacist’s place of work but telephone interviews were also offered. At the 
time of the interviews the participant received an information letter and gave their 





6.4.5 Qualitative data analysis 
Transcripts were anonymised and transferred to QSR NVivo® Version 11 software. In 
line with framework analysis, a familiarisation process took place whereby I, as the 
primary researcher, repeatedly listened to the interview audio-recordings and read 
the interview transcripts. From the transcribing and familiarisation process the 
primary researcher attained an overview of specific beliefs within the data [260]. 
Following this step, excerpts from the interview transcripts were coded into one or 
more of the 14 TDF domains. Three randomly selected transcripts were coded by a 
PhD supervisor (L.J. Sahm) to ensure validity and reliability of the data analysis. 
Disagreement in coding between the two researchers was resolved through 
discussion and consensus. Domains for which transcript excerpts were encoded were 
summarised. Supporting excerpts were attached to each domain summary. The two 
researchers then determined the domains of relevance for PIP reduction using a 
similar approach to previous studies [249, 256]. A domain was deemed relevant if 
excerpts were coded frequently or if the participants emphasised the significant 
impact of barriers and/or facilitators within a domain on their involvement in 
reducing PIP.   
 
6.5 Results  
A total of 21 community pharmacists were approached of whom 18 agreed to 
participate in the study; one pharmacist declined to participate, and two others were 
unavailable at the time of the study. Interviews were conducted in the 3-month 
period from June to August 2017. The interviews had an average duration of 19 
minutes (SD±6.00 minutes) and took place at the pharmacy in which the participant 
worked. Data saturation was reached after 15 interviews with no new themes 
emerging from conducting an additional three interviews, i.e. a total of 18 interviews. 





Table 6-2 Characteristics of interview participants (N = 18) 
Characteristics Value 
Pharmacists working in urban areas, N (%) 15 (83%) 
Pharmacists working in rural areas, N (%) 3 (17%) 
Areas categorised as affluenta, N (%) 5 (83%) 
Areas categorised as depriveda, N(%) 13 (17%) 
Gender, females, N (%) 12 (67%) 
Age, years, median (IQR) 30 years (27-35 years) 
Years of experience, median (IQR) 6 years (IQR 3-8 years) 
Pharmacists graduated before 2010, N (%) 7 (39%) 
Pharmacists working in a pharmacy with only one licensed 
pharmacist on duty, N (%) 
8 (44%) 
Pharmacists with nursing home experience, N(%) 8 (44%) 
adata obtained from pobal [257]. 
 
Community pharmacists were familiar with the term ‘inappropriate prescribing’ and 
defined this as: (i) any medication prescribed that has the potential to cause harm, 
side-effects or drug interactions; (ii) overprescribing or prescribing without a 
documented indication; (iii) prescribing a medicine to relieve side-effects of another 
medicine that the patient is taking; (iv) prescribing any medication for longer than 
indicated; and (v) prescribing a medicine not suitable for older people. A few 
pharmacists mentioned explicit  STOPP/START criteria [77, 213] to identify PIP but 
the majority referred to treatment guidelines such as those produced by the NICE  
[261] [261] no pharmacist used an explicit set of criteria to identify PIP in their routine 
work. The pharmacists perceived the presented deprescribing algorithms [80, 96-98] 
to give a good overview and to be user-friendly. However, some pharmacists also 
believed that the information on the algorithms was well-known among pharmacists 
and did not believe algorithms to have significant influence on their involvement in 
reducing PIP. 
Pharmacists described medication reviews as the systematic process of 
reviewing patients’ medications and identifying drug-related problems. No 




setting in Ireland, but some had experience from educational sessions or from 
working in hospitals or nursing homes. No pharmacist interviewed was carrying out 
medication reviews for older patients as part of their current routine practice.  
 
6.5.1 Qualitative analysis themes 
Transcript excerpts were most frequently coded into five domains: (i) beliefs about 
capabilities, (ii) environmental context and resources, (iii) knowledge, (iv) social 
influences and (v) social professional role and identity. The two domains of memory, 
attention and decision processes and reinforcement were less frequently coded. 
However, those participants who made comments coded into these domains 
attached significant importance to the factors identified. The interview data coded 
into these seven domains are summarised below with illustrative quotations. The 
remaining TDF domains were coded infrequently and three of them; beliefs about 
consequences, emotion, goals and skills were not coded at all.  
 
 Beliefs about capabilities 
Pharmacists perceived themselves as appropriate healthcare providers to identify 
PIP. Competencies were attributed to: being trained to do it; being good at 
identifying PIP; having a good relationship with patients due to the nature of patients 
visiting their pharmacy more often than their General Practitioner (GP); and looking 
at older patients’ prescription drugs with a fresh perspective. 
Beliefs about capabilities were affected by a pharmacist’s level of confidence 
and this subsequently influenced the likelihood of the pharmacist communicating 
any recommendations to the GP. One pharmacist’s self-perceived duty as a 
pharmacist gave her the confidence to act when an instance of PIP was identified.  
 
“I’d be fairly confident. I’d be kind of, just thinking in my own head: ‘Look, I 
have a duty of care’ and if the doctors are a little bit annoyed with me, I’ll take 





Another, younger pharmacist (1.5 years of experience) described how her lack of 
confidence restrained her from actively giving her input despite her beliefs about her 
role: 
 
“I wouldn’t go down the route and ring up a doctor and saying: ‘You shouldn’t 
be on this’. The patient has been on this for longer than two weeks, you 
shouldn’t be giving this anymore’. I just don’t. That is probably my role to some 
extent, but I wouldn’t like going down that route of complaining to another 
healthcare professional about what they are doing, so.” [Pharmacist 6, 
female, support pharmacist, 1.5 years of experience] 
 
 Environmental context and resources 
Being busy with serving many patients and doing administrative work were believed 
to restrict time to do medication reviews and to have follow-up contact with 
prescribers to discuss potential changes. Pharmacists described a need to prioritise 
their time and focus on more immediately unsafe issues, such as major drug-drug 
interactions, rather than reviewing medication lists for PIP, which was felt to have 
more medium or long-term implications for the patient. Protected time to review 
medications facilitated by extra pharmacist staff was a suggested solution.  
 
“Well it’s just, I guess, everybody’s busy. Things maybe aren’t reviewed as 
often as they should be (…). So, you know, it doesn’t, it it just flies by and you 
know, you’ve got a number of other reasons, which are far more immediate 
in terms of inappropriate prescribing, that you need to look out for. So, you 
know, those are the ones that you’re going to go for, the ones that are 
immediately unsafe, I guess.” [Pharmacist 2, male, supervising pharmacist, 6 
years of experience] 
 
Another challenge was a perceived lack of communication between pharmacists and 
GPs, and this was thought to lead to confusion about medication changes and to 
impede the implementation of these changes. Pharmacists described being unsure 





“I think communication is a huge issue because (…) if something [prescription] 
comes out from the hospital, the GP might not want to stop it. You know the 
hospital’s intention might have been ‘let’s go on this for 6 weeks’. But then 
the GP puts it on the repeat and then it comes to the pharmacist and I’m 
looking at it and they’ve been on it for two months. I’m not going to ring the 
GP after two months and say ‘oh, it’s probably inappropriate for you to stop 
this now’. It’s kind of like who actually [should tackle instances of PIP], and 
where does the buck stop. Who should say ‘this is where it stops’ or ‘this is 
where it starts’ or.” [Pharmacist 16, female, support pharmacist, 1 year of 
experience] 
 
Suggested improvements included more direct lines of communication and 
willingness to collaborate from all parties: 
 
“But the channels need to be a bit more open. Sometimes they’re very closed 
and if they were a bit more open and a bit more receptive to what our role as 
like a professional could be. Which I think some, some of them aren’t, then I 
think it would help a lot (…) It would need to have the agreement of the GP 
and everybody working in unison instead of you going: ‘oh, we’re gonna stop 
this, ‘cause this is’, and they’re not adhering that to stop that (…) So, definitely 
need to be structured. Needs to be all parties working together and definitely 
somebody on either site communicating to go: ‘look we’re going to meet with 
the doctor’ and better to do it face-to-face than over the phone I feel because 
you don’t really get a grasp of what’s going on over the phone.” [Pharmacist 
9, male, support pharmacist, 3.5 years of experience] 
 
Geographic proximity and face-to-face interaction were believed to be key 
facilitators of a good collaborative relationship: 
 
“Well, we are lucky here because we’re in a primary care centre, so I have a 




get back to me. A lot of the time that becomes difficult. So, the majority of my 
prescriptions would be coming from the GPs upstairs and we have a very good 
rapport which makes it much easier.” [Pharmacist 15, female, supervising 
pharmacist, 7 years of experience]  
 
Other challenges pertained to a lack of patient information, e.g. diagnosis or 
indication for a drug. Receiving hospital discharge letters and gaining access to a 
centralised clinical record system for sharing patient information between 
pharmacists and GPs were suggested improvements.  
 
 Knowledge 
Pharmacists believed their pharmacology/therapeutics knowledge to be sufficient to 
identify PIP but stressed the need for continuing professional education to bring their 
knowledge in line with new medications and most up-to-date guidelines. 
Interdisciplinary training was suggested as one way to meet these educational needs 
whilst simultaneously improving collaboration between pharmacists and GPs: 
 
“I think interdisciplinary training would be very good (…) let them [GPs] 
understand how we [pharmacists] work and the position that we are in, 
because we [GPs and pharmacists] often don’t understand our jobs and they 
can explain. I mean we [pharmacists] go to visit the GP for our own thing. So, 
we kind of have a little bit more of an understanding [of the GP’s work]. But 
they [GPs] may never come to a pharmacy and they may not know how we 
operate.” [Pharmacist 6, female, supervising pharmacist, 5 years of 
experience 
 
Guidelines were considered to be valuable information sources partly because of 
their generally easy application to daily practice and partly for the evidence-base 
guidance to pharmacists’ recommendations. However, some pharmacists criticised 
guidelines for limitations such as describing how to identify PIP without specific 





“It is useful [deprescribing algorithms] but at the same time I feel like it’s 
something that we all already know (…) I don’t think it’s the spotting is the big 
problem. It’s what do you do when you do spot it? So, it’s the training of what 
are we actually supposed to do. So, I suppose you do spot it but I don’t 
necessarily know what you’re supposed to do with it.” [Pharmacist 16, female, 
support pharmacist, 1 year of experience] 
 
 Social influences 
Patient demands and their relative interest in medication were noted to strongly 
influence the changing or discontinuation of medication. Some patients were 
described as demanding treatment and not being content to adjust their medication 
due to fear of change or loyalty to the doctors’ prescription orders. Pharmacists also 
noted however that their regular contact with patients put them in a position to 
influence the patients’ behaviours.  
 
“I sometimes, depending on the doctor, encourage the patient to go back and 
ask. If you just say to the doctor, eh to the patient: ‘maybe say to the doctor 
could you check your levels’. So, like you say it in a nice way, so they don’t go 
like: ‘well the pharmacist said’. But you know that they kind of think 
themselves and maybe they should be questioning it. You’re kind of 
empowering them a bit.” [Pharmacist 5, female, supervising pharmacist, 8 
years of experience] 
 
 Social professional role and identity 
Pharmacists described their current role as including: (a) informing patients about 
their medication; (b) maintaining patient safety perspective over financial benefits 





“I kind of think that sometimes you’re the last portal between you know the 
doctor and the patient. So, it’s your, I suppose, responsibility is to identify 
anything that’s inappropriate but then make sure as well at the patient site 
that they can use it, take or use their product as best that they can to get the 
most benefit out of it (…) So, I’d like to see patients more informed and more 
as you say kind of independent in their own health care. But that’s kind of our 
job too to try and encourage that.” [Pharmacist 12, female, support 
pharmacist, 6 years of experience] 
 
Pharmacists agreed that they had a role in PIP prevention but were divided regarding 
the extent to which they should intervene when PIP is detected. A clear description 
of the pharmacist’s role in reducing PIP and an acceptance of this role among 
healthcare professionals was suggested as a way in which to increase the 
involvement of pharmacists: 
 
“The overall responsibility I think is a two-way thing. I think it’s between the 
GP and pharmacy, and I don’t think either holds the overall responsibility.” 
[Pharmacist 13, male, supervising pharmacist, 3 years of experience] 
 
“We should be doing more but we’re doing less [medication reviews and 
preventing PIP]. Whether that’s business or whether that’s some people are, 
not being lazy, but shying away from it because they’re being afraid that 
they’re out of touch. Older pharmacists. I’m not sure, but definitely there’s this 
un-realisation of what our role should be in that for sure.” [Pharmacist 9, 
male, support pharmacist, 3.5 years of experience]  
 
 Memory, attention and decision process 
Raising awareness of PIP among pharmacists, doctors and patients was thought to 




campaigns run by health authorities for patients and/or healthcare providers. The 
purpose of these campaigns should be to inform patients and GPs about particularly 
problematic drug classes and raise awareness:  
 
“Well those IPU [Irish Pharmacy Union] and HSE [Health Services Executive] 
campaigns about generic medications for example, have been very successful. 
I think a similar campaign along the lines of ‘do you need everything you’re 
taking?’. Or encouraging patients to go to their doctor. I think, to a certain 
extent, the prescription levy did this very well. Where people went to their 
doctor and asked: ‘do I really need to be taking all this?’” [Pharmacist 10, male 
support pharmacist, 4.5 years of experience] 
 
 Reinforcement 
State reimbursement, or professional acknowledgement, for doing medication 
reviews were both considered to be motivating factors to do medication reviews. 
However, concerns were raised about the quality of Government-funded mandatory 
medication reviews and how incentives might shift focus away from patient benefits 
to financial and personal benefits instead: 
 
“I suppose it’s [PIP] a bit under the radar in a lot of my daily work because 
you’re not incentivised to look for it” [Pharmacist 2, male, supervising 
pharmacist, 6 years of experience]  
 
“But I think if you try and force people to do it [medication reviews] for even for 
like a financial thing. Reimbursement or anything like this, it’s just going to 
come to like the same thing as we do with say the HSE claims or something. 
Say, you’re doing it for the wrong reasons and even in that case you mightn’t 






6.6 Discussion  
This study used a theoretical approach to explore the views of community 
pharmacists on their involvement in reducing PIP in older people and their perceived 
barriers and facilitators to this. Despite beliefs about capability and responsibility for 
reducing PIP, structured medication reviews and recommendations about stopping 
medications do not form a routine part of daily practice for community pharmacists 
in Ireland. It is clear from this study that for some pharmacists there was a sense of 
conflict in what they knew to be the identifiable instances of PIP and what they 
actually did to reduce PIP.  
 Pharmacists expressed uncertainties about the extent of what their role in 
reducing PIP should be. They described a reluctance to work outside of their current 
defined role and to challenge prescribing decisions taken by GPs, such as 
recommending drug discontinuation. The consequences of uncertainty about the 
pharmacist’s role in patient care, such as reducing PIP, have also been described in 
the literature [247, 262].  In the study by Patterson et al. [262], the varying and 
inconsistent description of pharmacists’ responsibilities in a primary care team was 
considered to hinder collaboration between pharmacists and other healthcare 
professionals. They referred to how some fellow healthcare professionals felt that 
pharmacists do not adequately handle their responsibilities and described a likely 
relationship between this belief and a general lack of awareness of the role of the 
pharmacist [262]. Schindel et al. [247] described how a lack of consistency in the 
community pharmacy service influences patients’ expectations in that they may be 
informed variably about pharmacist services.  
 When asked specifically about stopping medications, pharmacists in this 
study described uncertainty of where final responsibility for PIP avoidance lies. In a 
recent review (see Chapter 2), this same theme caused confusion for GPs and also 
differing opinions among GPs regarding pharmacist support. Extending the role of 
the pharmacist to include direct patient care may therefore require a clear 
description of the roles and responsibilities to be undertaken by pharmacists to be 




 The study findings suggest a need for a shared goal of medicines optimisation, 
and that by having more interdisciplinarity within the training of conducting 
medication reviews, this could be achieved. Consistent with the findings, the study 
by Patterson et al. [262] from the US described that collaboration between 
pharmacists and GPs was challenged by (i) a lack of understanding of each other’s 
professional role in combination with (ii) the busy professional practice environment 
and (iii) the absence of a shared patient information platform. To date, there is no 
centralised system in which patient information is shared between community 
pharmacies and GP practices in the Republic of Ireland. It would be reasonable to 
suggest that having access to diagnoses and co-morbidities would increase the 
clinical relevance of pharmacist recommendations and improve communications 
with other healthcare providers.  Sharing patient clinical data was suggested to be 
one fundamentally important way to improve communication and collaboration 
between community pharmacists and GPs. This was also suggested in the study 
conducted in the US by Bergman et al. [246] as a means of improving satisfaction 
among some GPs with pharmacist recommendations, which were often criticised for 
lacking consideration of patient context. Keller et al. [248] also showed how shared 
patient information enhanced the communication between pharmacists and 
physicians and increased mutual professional trust between them.  
 Pharmacists in the present study welcomed more education and guidelines 
for reducing PIP. These guidelines should ideally: (i) give instructions on the steps 
following the identification of a PIP; (ii) be up-to-date; and (iii) be used by all, 
including prescribers. To date, guidelines on stopping PIMs in older people have been 
criticised for being too disease-specific and not addressing the steps of stopping 
and/or changing a medication identified as inappropriate [124, 125, 263].  There is a 
need to design guidelines that meet the needs of healthcare professionals in busy 
medical and pharmacy clinical practice in terms of content, instructions and 
relevance. Beers’ criteria and STOPP/START criteria as well as the recently developed 
deprescribing guidelines and algorithms by Farrell et al. [80, 96], Bjerre et al. [97] 
Pottie et al. [98], Reeve et al. [99] and the newly developed STOPP Frail criteria [93] 
may meet these requirements for application in routine clinical practice. However, a 




utilisation of screening tools by community pharmacists in routine practice, those 
barriers being similar to those identified in the present study. Future investigation on 
the application of deprescribing guidelines in primary care setting is thus warranted 
and may provide useful insights into the implementation of more deprescribing to 
reduce PIP in primary care.  
  Whilst some studies to date have shown a positive impact of pharmacist 
involvement in reducing PIP in primary care [53], more research is needed into the 
effective implementation of such interventions. The majority of barriers and 
facilitators identified in this study fall under the TDF domains of: environment; 
knowledge; and social professional role and social influences. The design of future 
interventions should target these domains. The findings suggest that future research 
should focus on the creation of guidelines that suit the primary care setting as well 
as investigating new strategies to improve the collaboration and communication 
between healthcare professionals both across and within care settings. Policy makers 
and the educational sector, such as universities and postgraduate training bodies, 
could support the work of community pharmacists in preventing PIP by offering 
continuous training and encouraging interprofessional education, whilst also 
researching new ways of making more patient-specific information available to the 
pharmacist.  
 
6.6.1 Strengths and limitations 
A strength of this study is its use of a robust theoretical framework to analyse the 
interview data. Using the TDF ensures that a large variety of factors on behaviour are 
considered compared to a more restricting set of factors being explored when using 
individual theories of behaviour change [256]. The use of the TDF also allows the 
mapping of findings to theory and is a useful way of identifying mediators of change. 
Although the use of a pre-specified framework to develop the interview topic guide 
and to analyse the data can prevent the emergence of non-predefined themes of 
relevance, nevertheless the TDF has been applied successfully in previous studies to 
describe topics similar to this study [249, 254-256].  
 The purpose of using the TDF in this study was to identify the domains 




all domains to be explored in the interviews while narrowing the focus to the most 
relevant domains as viewed by the community pharmacists interviewed during the 
study and to report these. During the interviews, the topic guide was updated to 
target emerging themes from subsequent interviews. This resulted in the removal 
and addition of interview questions which led to the exclusion of some domains 
whilst adding more questions relating to other domains to investigate those in-depth. 
This iterative update of the interview topic guide was done based on the themes 
assigned high importance to the topic from the interviewees while leaving out 
domains that were not important to the interviewees. This explains why interview 
excerpts were less frequently coded into some domains compared to others. It is, 
however, important to note that the domains not reported in the result section are 
relevant to PIP although not identified as the most important domains in this study. 
Some domains, e.g. optimism and emotion, were either not coded or less frequently 
coded and these individual domains were not identified as highly relevant to PIP and 
thus not reported in the study. However, some of the findings relating to these low 
frequency domains may still be important to PIP and have, to some extent, been 
covered in other domain descriptions reported in the study. As an example, the 
domain emotion, was described by some interviewees, who described a fear of 
upsetting the doctors as a barrier to contacting them about PIP. However, this fear 
was mainly described as a result of the pharmacist’s level of confidence and the 
domain beliefs about capabilities was more frequently coded.  
 This study was not without limitations. The sample size of 18, although 
acceptable for qualitative research, is relatively small. The nature of qualitative 
analysis is subjective and despite the use of a sampling matrix to recruit participants, 
the findings of this study, as with any qualitative research, are not generalisable to 
all community pharmacists. Additionally, the convenience sampling methods has its 
limitations in relation to the generalisability of the study population and the self-
selected study population may have introduced a degree of self-selection biases.  
 Despite the limitations of this study and the differences in healthcare 
practices, the findings of this study are still likely to be relevant to healthcare 
providers in other countries. The collaboration between the community pharmacists 




collaboration to be targeted may be different considering the current collaboration 
between community pharmacists and GPs in a given country. However, as 
highlighted in study, agreeing on clear definitions of what the role of the community 
pharmacist should be in reducing PIP is an important starting point to encourage the 
pharmacists to extent their role and to improve their collaboration with the GP. 
Another target area, not specific to Ireland, is the insufficiency of available guidelines 
to guide PIP reduction. There is a need to ensure that guidelines are up-to-date, are 
used by all healthcare professionals, are relevant and give the instructions needed. 
Hence this study has identified key areas in PIP to be targeted, and although specific 
to Ireland, the key areas, if considered in the country-specific setting, are relevant to 
other countries.  
 
6.7 Conclusion 
Community pharmacists are aware of PIP in older people and its related problems. 
They believe to fulfil a duty of care by ensuring rational use of medication in patients 
and they welcome an extension to their role to include reducing PIP. But today the 
role of the pharmacist in reducing PIP is neither a role that is well-defined, 
implemented in community practice in Ireland nor a role known to healthcare 
professionals and patients.  
Community pharmacists are trained and have sufficient knowledge to identify 
PIP but are lacking the resources, such as time and financial resources, to prioritize 
the reduction of PIP in their daily work over more immediate issues. Conducting 
medication reviews as a basis for PIP identification and clinically relevant 
recommendations should include information of current medication use, patient 
preferences (e.g. medication compliance issues) and clinical patient data. Dispensed 
medication and conducting patient interviews are sources of information available 
to the community pharmacists today which puts them in an ideal position to identify 
PIP. However, clinical patient data is lacking and compromises the clinical relevance 
of pharmacists’ recommendations to reduce PIP. This is a barrier to the collaboration 
between community pharmacists and GPs. 
This study provides useful insights into the target domains for overcoming 




useful in the design of future pharmacist-led interventions to reduce PIP. Although 
exclusive to Irish community pharmacists, the findings may be of use in the expansion 
of the role of the community pharmacist in other countries with similar pharmacist 




7 The role of the community pharmacist in deprescribing - 
views of community pharmacists and general practitioners 
 
7.1 Chapter description 
One barrier to deprescribing identified in Chapter 2 and 6 was the lack of clear 
descriptions of the role of the prescriber and the community pharmacist in 
deprescribing. In this chapter, the current and the potential role of the community 
pharmacist in deprescribing was explored by examining the views of GPs and 







In Ireland, the role of the community pharmacist is still mainly one of safeguarding 
rational use of medicines by dispensing the right medicine, to the right patient, at the 
right time. Decision making in relation to patients’ pharmaceutical care is still firmly 
within the remit of GPs [126, 264]. However, when one looks outside of Ireland, one 
sees in countries like Canada, the United States of America (USA), Australia and the 
United Kingdom (UK) the expansion of the role of the pharmacist in community care 
settings [60, 247, 265, 266]. In these countries, community pharmacists have greater 
involvement in the provision of patient care services, specifically in support of 
medicines management. Examples include the Medication Therapy Management 
(MTM) services in the USA, the Home Medicine Review (HMR) in Australia and the 
Medicines Use Reviews (MURs) in the UK [60, 62]. Community pharmacies in Ireland, 
as in other countries, provide easily accessible sources of information and advice to 
patients in the primary care settings [267]. The inclusion of pharmacists as patient 
care providers in the primary care settings has thus been suggested as a mean of 
overcoming the increasingly complex medicines management needs of our older 
population [266]. 
Pharmacist-led medicine management in community settings has shown to 
significantly reduce the rates of medication-related problems (MRPs), potentially 
inappropriate prescribing (PIP) and related costs [60, 264]. Furniss et al. conducted 
an RCT in 14 nursing homes in England and showed that pharmacist-led medication 
reviews decreased the number of medicines and associated costs [268]. Other 
studies have also demonstrated positive outcomes of pharmacist-led medication 
reviews by showing significant differences in the change in the number of 
medications [269], reduction in the number of prescribed and administered drugs, 
reductions in prescribing costs and number of falls when comparing intervention 
groups to control groups [269, 270]. Published reviews of the literature have also 
highlighted that pharmacist-led interventions appear to produce the desired effect 
on inappropriate prescribing [51-53, 201]. In the review by Castelino et al. [51], two 
of the included studies showed a significant effect of the pharmacist-led intervention 
on inappropriate prescribing demonstrated by lower MAI-scores in the intervention 




showed a reduction in the MAI score, and one study reported a reduction in newly 
dispensed PIMs for intervention group participants. These reviews highlight and 
support the important role that pharmacists play in improving the quality of 
medication use in the elderly. In line with this, the systematic review conducted and 
reported in Chapter 3, also summarized these positive effects of pharmacist 
involvement on number of drugs and prescribing appropriateness. Included studies 
in this review demonstrated that collaboration with pharmacists reduced the mean 
number of drugs prescribed , reduced the number of unnecessary drugs, MAI scores, 
number of inappropriate drugs when comparing intervention groups to control 
groups [190, 192, 197]. 
Considering these proven benefits, it is feasible to imagine provision of 
services to support deprescribing by community pharmacists in Ireland. However, 
such new arrangements are likely to require new strategies to empower the 
community pharmacist whilst simultaneously, being mindful of the risk of 
disenfranchising the GP [264].  
Consensus exists that collaboration between GPs and community 
pharmacists is crucial to medicines management, and several models have been 
developed [271-275]. These different models [271-275] have described the key 
concepts of collaboration. These include communication, skills, trust, 
interdependency, perceptions and expectations about each other, interest in 
collaboration, and role definition. The models suggest that it is necessary to describe 
the current collaborative setting in order to establish a collaborative working 
relationship. Describing the current situation includes an understanding of the 
perceptions GPs and community pharmacists have of each other, of their individual 
skills and expectations in the job, and their interest in collaborative working practices 
[276].  
Research examining the perceptions of community pharmacists and GPs of 
pharmacists’ roles in the era of new initiatives to collaboration with the aim of 
reducing PIP has been minimal. From qualitative interviews with community 
pharmacists in Ireland (Chapter 6), it was clear that they did not believe that they 




PIP was a role that the pharmacist was trained to undertake. The interview study 
showed role ambiguity and lack of clear direction regarding the pharmacist’s 
contribution to patient care in community practice (Chapter 6).  
Before integrating the community pharmacist in patient care and adding 
deprescribing to their role, there is a need to explore the views of GPs and 
community pharmacists on their respective roles in deprescribing and to identify the 
barriers and facilitators to more pharmacist involvement in deprescribing. This study 
is the first to use a qualitative study design aiming to explore the views of community 
pharmacists and GPs on the role of the community pharmacist in deprescribing. This 
study aims to provide insights into how the community pharmacist role is perceived 
and elucidate differences in the views of GPs and community pharmacists on their 
involvement in deprescribing. These findings may be useful to other professionals 
and policy makers wanting to integrate community pharmacists into deprescribing 
management in primary care settings. The findings of this study will contribute to the 





7.3.1 Study design  
A qualitative study design was chosen to explore the views of community 
pharmacists and GPs on current practices of deprescribing, and the future 
developments of new practices with increased pharmacist involvement. In pharmacy 
practice research, qualitative methods are often used to identify, improve and 
develop current practices and are a useful way of understanding existing practices 
and beliefs [277].   
 
7.3.2 Ethical compliance 
Ethical approval was obtained from the Clinical Research Ethics Committee of the 
Cork Teaching Hospitals prior to recruitment of study participants (Appendix XII).  For 




interview. For interviews conducted over the telephone an oral consent was given by 
the participant before the interview and a written, informed consent was obtained 
after the interview by email.   
 
7.3.3 Recruitment 
Participants eligible for inclusion in this study were community pharmacists and GPs 
working in the greater Cork region, in southern Ireland. Participants were recruited 
using a convenience sampling strategy from September to December 2018. 
Convenience sampling relies on data collection from a population who are readily 
available to participate in a study [259]. This recruitment strategy was chosen due to 
time constraints and the need to increase the likelihood of respondents. Community 
pharmacies and GP practices located in the greater Cork region were identified from 
a map. An initial list of pharmacies and GP practices was created based on 
considerations to the location (i.e. located in an urban, rural, affluent or 
disadvantaged area). Community pharmacies previously included in the study 
described in Chapter 6 were not contacted. The community pharmacy and primary 
care practices were contacted by telephone, and the study was presented to the 
pharmacist/practice receptionist. Follow-up phone calls as appropriate were made. 
All community pharmacists and GPs who agreed to participate were included in the 
study as no exclusion criteria were specified to allow for a sufficiently high number 
of participants in the study. A mutually convenient interview date, time and interview 
type (face-to-face or telephone interview) was arranged with each study participant.  
 Since the purpose of qualitative research is often, as in this study, to identify 
patterns pointing to similarities of views and opinions of participants, a minimum 
number of participants was required in order to ensure that all relevant patterns 
would be found. Recruitment was continued until data saturation occurred, i.e. until 
no new themes appear [277]. Data saturation was considered individually for 
interviews with community pharmacists and GPs. This decision was made because 
the two groups had different professional backgrounds and would be expected to 
have different views on the topic. In order to be able to present both the views of 




saturation within each group of participants. A large within-group homogeneity was 
believed to exist in that the participants in each group were practising under the 
same legislation, in the same geographical area, and were therefore likely to have 
the same perspectives on geriatric pharmacotherapy/polypharmacy. The research 
question was believed to be very specific in that it related to one process, i.e. 
deprescribing in a specific population, i.e. older people and with the involvement of 
one profession, i.e. the community pharmacist. Based on these beliefs, I, the primary 
researcher, decided to aim for 10 interviews with community pharmacists and 10 
interviews with GPs. Using the approach described by Francis et al. [258], three 
additional interviews in each participant group were conducted until no new themes 
emerged. If no new information arose from the last three interviews compared to 
the preceding 10, this indicated that data saturation had been reached. If new 
themes emerged in the latter interviews, an additional three interviews would be 
conducted and compared to the previous 13 interviews. This process would continue 
in this manner until data saturation was reached.  
 
7.3.4 Interviews 
Semi-structured interviews with community pharmacists and GPs were conducted by 
me, the primary researcher. This type of interview allows the interviewer and 
interviewee to diverge from the questions as well as the order and weight of these, 
so as to elaborate on some perspectives in greater detail or to pursue new ideas [277, 
278].   This type of interview allows the interviewer and interviewee to diverge from 
the questions as well as the order and weight of these, so as to elaborate on some 
perspectives in greater detail or to pursue new ideas [277, 278].   
Based on the findings of the previous qualitative study [126] the interview 
topic guide was designed and was introduced with questions about the interviewee’s 
understanding and familiarisation with deprescribing (a copy of the topic guide is 
available in Appendix XIII). If a participant was not familiar with the term 
‘deprescribing’, this term was explained to them by me, the interviewer. This was 
done to make sure that all participants fully understood the research topic. The topic 
guide was developed by the primary researcher and the four supervisors of this PhD 




guide was then piloted with a community pharmacist with a background in academia 
to ensure that I was familiar with the questions. This community pharmacist was a 
PhD candidate known to me, the primary researcher. The community pharmacist had 
experience with conducting qualitative interviews with healthcare professionals 
himself and had the knowledge to provide useful input into how the primary 
researcher conducted the interview and the topic guide questions. The topic guide 
was further refined on an iterative basis during the study to allow emerging themes 
to be explored more in subsequent interviews. Minor changes to the topic guide 
were undertaken by me, the primary researcher but more extensive amendments 
were approved by all four supervisors of the PhD study before the topic guide was 
finalised. Interviews were audio-recorded with consent from the participants and 
transcribed verbatim by me, the primary researcher. Transcripts were offered to be 
returned to participants for their review. This allowed the participants to remove or 
revise some of their answers. However, only one participant wanted to review the 
transcript and made no revisions.  
 
7.3.5 Qualitative data analysis 
Transcripts were anonymised and transferred to the QSR NVivo® Version 12 
software. The interview transcript data were analysed by me, the primary researcher, 
using a thematic content analysis (CA) approach described by Braun and Clarke [279]. 
Thematic CA is a useful approach for describing the salient issues for a group of 
respondents, in this study the challenges of deprescribing in primary care and 
community pharmacist involvement. The thematic CA helps reducing the complexity 
of participants’ answers by looking for patterns or ‘themes’ in the data [279, 280]. 
Themes are recurrent concepts that summarise the views and beliefs raised by the 
participants [280]. The findings from interviews with GPs and community 
pharmacists were pooled and thematic CA was applied using the common steps, 
including:  
1) familiarisation with the data from listening to the audio recording, 
transcribing and reading of the transcripts,  




3)  recoding of transcripts according to the list of codes,  
4)  organisation of codes into themes pertinent to the research topic 
[280].  
 
The audio recordings were all transcribed and initially coded by the primary 
researcher who created a list of initial codes. Four interviews were independently 
coded by one of the supervisors of the PhD study (L.J. Sahm) to evaluate the accuracy 
of the coding by me, the primary researcher, and to agree on the final coding system. 
To compare the level of agreement between the primary researcher and L.J. Sahm, 
the kappa coefficient was estimated [281]. The codes were then organised into 
themes by the primary researcher. All four supervisors of this PhD study read four 




A total of 26 interviews were conducted with GPs and community pharmacists. In 
both groups of participants, data saturation was reached after 10 interviews with no 
new themes emerging in the subsequent three interviews. Characteristics of 





Table 7-1 Characteristics of study participants and interviews (n=26) 
Characteristic GPs (n=13) Community 
pharmacists (n=13) 
Total (n=26) 
Response rate (%) 31% 75% 45% 
Gender, female (%) 8 (62%) 9 (69%) 17 (65%) 
Age (years), mean (SD) 47 years (11.2) 34 years (7.9) 40 years (11.5) 
Experience, mean (SD) 16 years (13.0) 9 years (7.1) 13 years (11.0) 
Face-to-face interviews,  
N (%) 
3 (23%) 12 (92%) 15 (58%) 
Telephone interviews,  
N (%) 
10 (77%) 1 (8%) 11 (42%) 
Length of interview,  
mean (SD) 
16:55mins. (4.61) 20:32 mins. (7.30) 18:43mins. (6.26) 
 
Among the participants (both GPs and community pharmacists) there were large 
differences in how familiar they were with the term deprescribing. Ten participants 
(three community pharmacists and seven GPs) were aware of the term 
“deprescribing” and could give a clear description of it. Four participants (three 
community pharmacists and one GP) were partially familiar with the term and could 
describe it to some extent, while six participants (five pharmacists and one GP) were 
not familiar with the term and this was then explained to them. All participants 
believed deprescribing had important patient benefits including better medication 
adherence, fewer side effects, improved quality of life, and lower risk of drug-drug 
interactions as potential benefits.  
 
7.4.1 Inter-rater reliability 
A mean kappa score of 0.841 (SD ± 0.040, Range: 0.800-0.896) was obtained which 
demonstrated a high level of agreement between coders before the coding system 
was finalised. After the comparison of coding, the two coders discussed the 
disagreements in coding to reach consensus of the final coding system. Furthermore, 
all researchers agreed that the themes generated were representative of the content 





7.4.2 Thematic content analysis 
Five themes emerged from the thematic CA:  
(i) the GPs’ role in deprescribing - is there room for a community 
pharmacist?  
(ii) working relationship,  
(iii) the role of the community pharmacist in deprescribing,  
(iv) patients’ interaction with the healthcare system and 
(v) environmental factors.  
 
Summary descriptions of each theme are provided below with supporting 
quotations. 
 
 Theme 1: The GPs’ role in deprescribing - is there room for a community 
pharmacist? 
GPs described their role as keeping a holistic view of a multi-morbid patient’s medical 
treatment seen by multiple prescribers. GPs described their responsibilities in 
deprescribing to be as follows: (i) to initiate the process, (ii) to review a patient’s 
medication for appropriateness, (iii) to assess the risks and benefits of treatment and 
(iv) to eliminate the risk of side effects and drug interactions. These responsibilities 
were believed by some GPs to be part of the routine review of a patient’s medicines 
while others felt that they were not sufficiently involved in deprescribing: 
 
“Well every time you’re doing a repeat prescription to be reviewing the 
medication and the need for them and the indication for them. Making sure 
that things don’t interact and that things are being monitored probably. So, 
yeah I suppose we have a massive responsibility in deprescribing.” [Participant 





Community pharmacists described a similar centrality of the GP’s role and similar 
responsibilities such as regular review of medicines when initiating and renewing 
prescriptions. Despite the centrality of the GP’s role in deprescribing, a reluctance to 
deprescribe by GPs was described by community pharmacists and GPs. Factors 
associated with this reluctance were (i) a professional courtesy not to interfere with 
prescribing decisions made by prescriber colleagues and (ii) a concern about the 
consequences and responsibilities for stopping a medicine:  
 
“I suppose a lot can be started in the hospital setting and GPs are reluctant to 
stop anything unless the Consultant will give them a ‘go ahead’ and a lot of 
the time patients can be on waiting lists for Consultants. So, it [deprescribing] 
doesn’t necessarily happen an awful lot then (…) I think there’s a certain 
amount of worry there that if there’s any issues down the line and they [GPs] 
take the responsibility for stopping something, that it could be a problem 
then” [Participant 11, Pharmacist, male, 9 years of experience] 
 
Even though the GPs believed they had a key role in deprescribing, they welcomed 
the idea of having support from community pharmacists. Community pharmacists 
were perceived as helpful information sources and the advice from a community 
pharmacist was valued and welcomed by all the GPs interviewed. Nonetheless, there 
was a realisation that maybe not all GPs would be open to this: 
 
“But to be able to say: ‘look, I [the pharmacist] was going through this 
patient’s script (sic) and I just wanted to bring it to your [GP] attention that 
ah, due to age, they no longer benefit from statin’. Something like that I think 
would be great. But you know again I think it should be very gently because I 
know doctors can get really rankling if they feel that pharmacists are telling 





Working together with community pharmacists on deprescribing was perceived to 
be a good   way of ensuring continuity of care when both parties would agree on the 
patient’s treatment plan:  
 
“When we put prescription prompts, I suppose we’re hoping that the 
pharmacist will also be picking up on these things, and kind of repeating the 
message to the patient (…) I think sometimes it would be good to close the 
loop of communication because I think patients do sometimes assume that 
we’re all in very intimate communication about everything, but we don’t 
actually know what the patient is saying to the pharmacist about something 
always, and we don’t know what the pharmacist is saying to the patient 
either” [Participant 14, GP, female, 4 years of experience] 
 
A mutual openness and appreciation of pharmacist involvement in deprescribing to 
the one described by the GPs was not experienced by the community pharmacists. 
Prescriber- and age-dependent motivation to involve the community pharmacist was 
considered to be a factor in the lack of openness among GPs. Younger GPs were 
perceived to be motivated to collaborate with community pharmacists whereas older 
and more experienced GPs were described as being inclined to continue their usual 
practice of prescribing. Even for the more receptive GPs, community pharmacists 
were unsure if their advice would be accepted as they observed no action was taken 
after advice was given. In other instances, the community pharmacists were unsure 
if a specific piece of advice was acted upon, due to the passage of time between 
advice being given and a change to the prescription:  
 
“They [GPs] wouldn’t be great at taking on the advice. But you know they are 
pleasant enough to deal with (…) maybe about the benzos and stuff they 
mightn’t be [great at taking on the advice], but you never know because it 
could be in a few months or something they might decide to reduce them 






The perceived lack of openness from some GPs resulted in the community 
pharmacists selectively choosing to interact with the more welcoming GPs and 
avoiding those GPs less inclined to interact with them. Additionally, community 
pharmacists described how they would consider the seriousness of the effects of an 
inappropriate medicine before suggesting changing it to less welcoming GPs: 
 
 “I suppose sometimes you kind of know which GPs may not be so receptive, 
and which then, unfortunately, makes you less likely to approach them, 
because you know sometimes it just makes life very difficult. I mean, obviously 
if you see something completely inappropriate, you contact about that. But 
sometimes with, if it’s just suggestions, not so much.” [Participant 6, 
Pharmacist, female, 9 years of experience]  
 
Community pharmacists also acknowledged that due to the lack of clinical data some 
of their advice was limited in terms of its clinical relevance. Consequently, the 
community pharmacists had a lower expectation of GPs to accept their advice but 
nonetheless hoped to be heard: 
 
“But even when I do raise an issue, I’m well aware that, look it may not be 
possible to do that, it may not even be advisable to do it. There might be a 
very good reason why the patient is on something that I’m not aware of. So, I 
would expect to be heard out alright, but I wouldn’t necessarily expect that it 
would lead to an actual deprescribing or lead to action as such.” [Participant 
12, Pharmacist, male, 7 years of experience]. 
 
 Theme 2: Working relationship  
GPs and community pharmacists commonly interacted but primarily on the initiative 
of the pharmacist. Typical interactions were to: correct prescribing errors and drug 
interactions, clarify prescription discrepancies, request prescriptions, or substitute 




were more common interactions between GPs and community pharmacists in 
contrast to the more strategic preventative actions i.e. deprescribing to avoid 
adverse outcomes from long-term medicine use: 
 
“Now we interact with the community pharmacist every day actually. On a 
daily basis (…) Deprescribing? Probably not as often as other things I would 
say. Not that frequently would be the answer to that question (…) the 
commonest discussion with pharmacists would be probably errors in our 
prescribing, actually. Incorrect dosage, a computer error on prescriptions. 
Query on dosage, query on amount. You know, unavailability of drugs is the 
commonest things at the moment.” [Participant 13, GP, male, 24 years of 
experience] 
 
By being the person who highlighted errors to GPs, community pharmacists 
described how they believed that this negatively affected their relationship because 
they perceived that GPs would feel that the community pharmacists were targeting 
their prescribing practices in a destructive manner: 
 
“I think the issue is that the only point of contact we have with them really is 
when we’re ringing them up and it seems like we’re criticising their practice 
or giving out to them. So, you can kind of feel why they don’t take too kindly 
to you ringing up and being like ‘oh no that’s wrong’” [Participant 2, 
Pharmacist, female, 10 months of experience] 
  
From the GPs’ point of view, the working relationship with the community 
pharmacists was perceived to be good but hindered at times by some community 
pharmacists dispensing full month’s supplies of medicines, in the absence of a 
prescription. This may happen on occasion due to an emergency, however some GPs 
felt that this was a method by which they were obliged to provide a prescription after 





“Some of them are issuing repeat prescriptions to patients on a non-
emergency basis with the full prescription reissued without the patient being 
reviewed, and we are being asked to send them a prescription, post-
dispensing. They find that very convenient some of the elder patients, but I 
don’t know if they are getting the follow-up care that they need or not. So that 
can be a bit antagonistic for us.” [Participant 14, GP, female, 4 years of 
experience] 
 
Good lines of communication were perceived to be important in building a strong 
collaborative relationship. Some community pharmacists described how this was 
challenged by having second-hand communication either with General Practice 
receptionist who acted as gatekeeper for the GP or with the patient who acted as an 
intermediary.  
 
“I think there is a bit of a barrier there to the communication between us and 
the doctors. And then a lot of the time we’re interacting with the secretary 
who then is interacting with the doctor and then things get all muddled up. 
And you know there’s like no straight answers (…) So, it’s all second-handed 
information you’re getting back as well. And then like I suppose the 
enthusiasm isn’t really there to be proposing this like optimal practice.” 
[Participant 2, Pharmacist, female, 10 months of experience] 
 
Other community pharmacists described that communicating deprescribing 
recommendations to GPs was most successfully done when communicating through 






“I find that myself that my most effective means of making recommendations 
can be directly to the patient who takes then the information to the doctor. 
It’s listened to them because there has to be listened to them.” [Participant 
16, Pharmacist, male, 15 years of experience] 
 
Other suggested improvements to building collaborative relationships between GPs 
and community pharmacists in deprescribing were to: (i) introduce clearer 
definitions of the roles of the GP and the community pharmacist in deprescribing, (ii) 
and to encourage knowledge-sharing as an integrated part of their interaction: 
  
“I think it’s to get more agreement between pharmacists and GPs and their 
representative body in terms of what services are going to be provided and 
the roles. What’s expected of the role of the GP and the role of the pharmacist. 
Like that has to be very clear on it.” [Participant 9, GP, female, 17 years of 
experience] 
 
“Like we might see from just studying in college that maybe like, x medication 
shouldn’t be prescribed to a certain patient group but they [GPs] might be like 
‘oh I have loads of experience in prescribing it’. So, even if you got an 
explanation as to why it probably would help expand everybody’s 
understanding. And so, like I could look at that then and you know I could also 
come back to them with my research on it after being told that or something.” 
[Participant 2, Pharmacist, female, 10 months of experience] 
 
 Theme 3: The role of the community pharmacist in deprescribing  
GPs and community pharmacists described the general role of the community 
pharmacists as a safety net for detecting prescribing errors and that community 
pharmacists should act as gatekeepers of dispensed medicines and to highlight any 




“I suppose the most common thing would be a pharmacy query about an error 
in a script (…) it might be naming errors or a dosing error or clarification on 
that (…) So, you know, if we adjust the dose and it’s not clear that have 
changed the dose on the prescription or it’s not clear where the change has 
come from then we might get a call [from the community pharmacist] for 
clarification on that. They are probably the most common. After that there 
might be a call about concerns about a patient and their medication. So, if the 
patient isn’t collecting the medication or if they come into the pharmacy and 
they look very confused about their medication.” [Participant 14, GP, female, 
4 years of experience]  
Some participants (both GPs and community pharmacists) described a potential role 
for the community pharmacist to initiate the deprescribing conversation with 
selected patients and to reinforce and support deprescribing decisions made by GPs 
in cases where patients were uncertain or opposed to deprescribing of certain drugs. 
However, collaboration and communication, such as prescription prompts, between 
the GP and the community pharmacist is warranted and enables the pharmacist to 
understand the GP’s reasons for prescribing changes and, to reinforce them: 
 
“I suppose reinforcing their message and having their back. Because you will 
frequently get, if the GP does try and lower certain medications or stop them, 
the patient will come in and immediately begin complaining about the GP who 
has stopped or lowered their medication. In that case you’re doing the GP no 
favours at all if you side with the patient and it’s very important that you 
reinforce the message as to why the dose is lowered.” [Participant 12, 
Pharmacist, male, 7 years of experience].  
“When we [GPs] put prescription prompts, I suppose we are hoping that the 
pharmacist will also be picking up on these things and you know kind of 
repeating the message to the patient.” [Participant 14, GP, female, 4 years of 
experience] 




these patients would share information with the community pharmacist that they 
might not share with GPs, e.g. personal circumstances and reasons for not taking 
their medicines. Community pharmacists’ regular contact with patients when 
collecting their medicine was also believed to put the community pharmacist in a 
favourable position to identify lack of medication adherence.  
 
I suppose we’re, whereas the GP might only see a prescription, as I said once 
every 6 months or say once every maybe twice a year or once a year, we are 
seeing it every month. You know, we are going through that prescription every 
month. So, we do see it a lot more often. We see the patient probably a lot 
more often (…) So, you know, if something is left on the prescription when it 
shouldn’t be, it would be, I’m sure, beneficial for the GP for at least for us to 
be highlighting it to them.” [Participant 11, Pharmacist, male, 9 years of 
experience] 
 
This information about medication adherence was appreciated by GPs: 
 
“But I suppose say it for a lot, for some of my geriatric patients, you know, if 
there was an issue with compliance or if you know that they were coming back 
in requesting medication before it was due. Often things like that would be 
flagged by the pharmacists that we would deal with, which is very helpful.” 
[Participant 9, GP, female, 17 years of experience] 
 
Looking at expanding the role of the community pharmacist to include prescribing 
and deprescribing, the views among participants were divided. Some community 
pharmacists believed that authorisation for prescribing and deprescribing should be 
granted to them whereas other pharmacists and GPs believed that community 






“I mean, ideally I would like to see pharmacists prescribe (…) I think that the 
whole prescribing competency is key to this ‘cause to me deprescribing is 
gonna be invested in the same people with prescribing competency.” 
[Participant 1, Pharmacist, male, 15 years of experience] 
 
“I wouldn’t necessarily agree with pharmacists prescribing (…) I don’t, because 
we’re not prescribers. We’re not GPs. And I think it’s really important not to 
confuse the two roles, because I’m not a GP. You know, I’m a pharmacist.” 
[Participant 6, Pharmacist, female, 9 years of experience] 
 
“If pharmacists have a good relationship with the GP as we have with our 
pharmacists downstairs here then they can advise us that maybe it’s not such 
a good idea for these tablets to be prescribed” [Participant 13, GP, male, 24 
years of experience] 
Other suggestions to expand the role of the community pharmacist in deprescribing 
were to extend the responsibility for medicines review to community pharmacists 
and extending more services from General Practice to the pharmacy, such as 
monitoring of blood glucose and blood pressure as well as services similar to 
influenza vaccination which is currently routinely administered by some community 
pharmacists in Ireland. A perceived outcome of transferring more services to the 
pharmacy was improved credibility of the community pharmacist role for both 
patients and GPs: 
 
“Can you imagine how the role would change if we were to do medication 
reviews? (…) Now, I have to say when the pharmacy takes on a new role, 
whether it’s diabetes, cholesterol, INR, flu shot, the respect that’s shown is 
second to none. I have experienced such.” [Participant 17, Pharmacist, female, 





 Theme 4: Patients’ interaction with the healthcare system  
The success of deprescribing a medicine was believed to be linked to a patients’ 
perceptions of medicines and their willingness to stop them. Patients’ acceptance of 
deprescribing recommendations was believed to be influenced by either a lack of 
awareness about the risks associated with long-term use of certain medicines and 
the level of awareness about their medicines from online information sources. 
Pharmacist involvement in deprescribing was dependent upon the relationship 
between community pharmacists and patients. Patients who were loyal to one 
pharmacy usually had a good relationship with the community pharmacist. The 
community pharmacist would know their history in detail and the patients would 
have greater confidence in their pharmacist’s recommendations and thereby would 
be more responsive to them: 
 
“Patients listen to pharmacists quite well but they tend to shop around and 
go to different pharmacies, different times. So, yeah it would depend on the 
patient’s relationship with the pharmacist. But if they have a good 
relationship, yes, they certainly will listen to their advice.” [Participant 4, GP, 
male, 5 years of experience] 
 
Participants also highlighted the importance of good GP-patient relationships to 
enhance patients’ willingness to stop certain medicines. In general, there was a sense 
of patients selectively sharing their personal information with GPs and community 
pharmacists depending on the relationship they had with them. This reinforced the 
crucial importance of a close collaboration between GPs and community pharmacists 
in deprescribing: 
“And like on a day-to-day basis you find out different things that, they don’t 
think, they don’t find important. Like you know if they sat down with the 
doctor they’ll be like: ‘Oh, I would never say that to the doctor. That’s a waste 




their care. So, I think the, the pharmacist is definitely very important in terms 
of that.” [Participant 21, Pharmacist, female, 3 years of experience] 
“I suppose, you know, information about the patient’s usage of the 
medication. If there’s feedback from the patient that they [community 
pharmacists] are getting that we might not be getting then that would be 
helpful.” [Participant 14, GP, female, 4 years of experience] 
 
 Theme 5: Environmental factors  
When asking the participants about the challenges to community pharmacist 
involvement in deprescribing, many external factors were mentioned. Time was the 
most frequent factor mentioned. With limited time available to deprescribe, 
prioritisation of the more critical issues over the more preventive actions; such as 
deprescribing of medicines, was a perceived necessity. Linked to a lack of time 
available for deprescribing for both community pharmacists and GPs was the lack of 
enough staff and the absence of financial incentives for deprescribing: 
 
“I would love to see us getting paid for patient medication review (…) Because 
if you were getting paid for it you would have more time and you would be 
able to hire a second pharmacist too, and to actually spend the time with the 
patient because you wouldn’t be under the same pressure.” [Participant 23, 
Pharmacist, female, 16 years of experience] 
 
Interdisciplinary training and shared guidelines between community pharmacists and 
GPs were suggested ways of improving the collaboration between GPs and 
community pharmacists in deprescribing: 
 
“If there was training that brought pharmacists and GPs together, even on a 
small scale. Like the local pharmacy and the local GP within an area, they 
could establish a protocol of like, you know, in a certain case when a 




they just refer on. Because it works with other things. Like over-the-counter 
medications, and I know it’s not the same idea but. There’s a protocol and if 
you follow the protocol it usually is safe.” [Participant 21, Pharmacist, female, 
3 years of experience] 
 
Another suggested way of giving community pharmacists a greater role in 
deprescribing was to make deprescribing a mandatory official role of the community 
pharmacist and the GP by inserting descriptions of the respective roles in 
deprescribing into their contracts. In addition to making deprescribing a formal part 
of the role of the community pharmacist, structuring the deprescribing process was 
also highlighted as a way of enhancing the role of the community pharmacist in 
deprescribing. Current deprescribing practice was considered opportunistic rather 
than systematic. Lack of time, staff and funding were believed to lower the likelihood 
of successful deprescribing particularly when no agreed formal structure for 
deprescribing was in place:  
   
“Well it would definitely help if there was a procedure in place that GPs and 
pharmacists could both buy into, that both were aware of and that would 
allow you if identified to say ‘okay, I’ve identified an issue here, the next step 
is communicate with the GP or whatever’. And if the GP was also aware of this 
process it would help.” [Participant 12, Pharmacist, male, 7 years of 
experience] 
  
Finally, there was an expressed need to raise awareness of deprescribing and the role 
of the community pharmacist among patients. Awareness campaigns, information 
leaflets and educational sessions were suggested initiatives to raise awareness for 
and patients, preferably supported by State agencies and GP and pharmacist unions: 
 
“I think again, even if the HSE did a leaflet, you know ‘can you take less 




you might not need all of the tablets that you’re taking” [Participant 18, GP, 
female, 8 years of experience]  
 
7.5 Discussion 
This study is the first, that I am aware of, to explore the views of GPs and community 
pharmacists on the role of the community pharmacist in deprescribing and the 
barriers and facilitators to this role. From the analysis, these views were grouped into 
five identifiable themes that likely influence the success of deprescribing i.e. (i) the 
GPs’ role in deprescribing - is there room for the community pharmacist? (ii) working 
relationship, (iii) the role of the community pharmacist in deprescribing, (iv) patients’ 
interaction with the healthcare system, (v) environmental factors. The findings of this 
study provide useful insights enabling a better understanding of the barriers and 
facilitators to increased community pharmacist involvement in deprescribing. These 
findings will also help inform what the role of the community pharmacist could be in 
deprescribing.   
 An interesting finding of this study was that community pharmacists and GPs 
had very different perspectives on the current involvement of community 
pharmacists in deprescribing. Whilst GPs described frequent interactions with 
pharmacists, some community pharmacists described difficulties with getting past 
the General Practice receptionist to speak directly with GPs, such that the 
relationship lacked direct interaction. Conversely, GPs described good interactions 
with community pharmacists about immediate issues in medicines management, 
such as changing a drug due to an adverse interaction. Importantly, community 
pharmacists wanted more interaction about long-term preventive actions including 
deprescribing. A Canadian study has described that expectations and appreciation of 
each other’s role in a team approach to medicines management will be affected by 
experiences of doctors and pharmacists working together in a team [247]. In our 
study, the main interaction between community pharmacists and GPs was when 
community pharmacists contacted GPs to propose corrections to immediate issues 
of their prescribing practice. With this being the main interaction, a sense of 




evident, and this rather negative interaction may thus be a hindrance to developing 
collaboration on deprescribing. However, examining the positive experiences, there 
was a sense of the community pharmacist providing a safety-net to the GPs, 
capturing prescribing errors in older patients at the point of dispensing medication. 
If seen in this positive light, the community pharmacist’s role in deprescribing may 
be perceived positively and increase pharmacist involvement in deprescribing.   
 Expanding the role of the community pharmacists will inevitably result in 
overlapping roles with the GP, which may in turn cause confusion about the 
responsibilities, creating a risk of interprofessional tension [247, 282]. As expressed 
by the GPs of the present study, community pharmacists working outside their scope 
and routine dispensing of monthly supplies of medicine on a non-emergency basis 
were felt to antagonise the GP’s role in deprescribing. By giving the community 
pharmacists a more advisory role in deprescribing, some GPs felt that the 
professional role boundaries are being impinged upon. The process of accepting new 
responsibilities within a professional role, such as deprescribing, involves 
understanding and acceptance of the previous roles that are relevant to the new role 
[247]. In this study, GPs considered the community pharmacist a valued source of 
information regarding drug interactions and patient medication non-adherence such 
that this a likely role for them with a wider deprescribing remit. From a survey in the 
USA, primary care physicians believed collaboration with pharmacists would improve 
medication adherence in older patients. This belief was the most significant predictor 
of physician attitude to collaboration with pharmacists [265]. Similarly, this belief 
could be shaping the attitudes among GPs to the role of the community pharmacist 
in deprescribing.  
 Community pharmacists themselves described their regular patient contact 
and patients’ loyalty to their local pharmacy as major advantages for community 
pharmacists’ involvement in medication adherence, and something that could be 
drawn upon for the benefit of older patients. Although GPs did not report a firm 
belief in the loyalty of patients to one pharmacy, most community pharmacists did. 
A public survey in England in 2012 supports this belief held by pharmacists, and 
showed that patients who regularly take medicines and use the pharmacy services 




pharmacy staff know them well [283]. In Ireland, a similar situation exists due to the 
system of reimbursement. Patients under the Drugs Payment Scheme (DPS) are 
advised to use the same pharmacy in a month to avoid paying more than the 
maximum €134 a month. The pharmacy will keep a record of the total amount paid 
by the patient in one calendar month and stop charging the patients once they reach 
the €134 mark [234, 284]. Similarly, patients under the GMS scheme may benefit 
from using the same pharmacy in one month to avoid paying more than the monthly 
prescription levy cap of €20 [234]. Frequent consumers of medicines under the Irish 
medicine schemes may thus be more loyal to one pharmacy than perceived by the 
GPs interviewed in this study.  
 In an era of expanding the role of the community pharmacist, there may also 
be a need to redefine the role of the pharmacy. In many UK rural communities, 
community pharmacists already act as primary care providers due to the fact that 
local GPs are overworked and have limited time, similar to the findings of the present 
study [247]. In such circumstances, patients seek healthcare services in the pharmacy 
because they have fewer options to find them elsewhere [247]. Devolving patient 
care more to the community pharmacy warrants consideration of the role of the 
community pharmacy. If the vision for the pharmacy is to provide quick medication 
supply to customers while they shop for other errands, then moving towards more 
availability and longer opening hours may be the way forward. Changing the role of 
the pharmacy from a shop to a healthcare centre may also change the expectations 
of patients. That is, some older people see themselves as patients and others as 
customers when going to the pharmacy, which in turn may affect their views of the 
community pharmacist as a shopkeeper or healthcare professional [247].   
 Finally, the present study described a need to promote the role of the 
community pharmacist more among older patients.  GPs advocating the pharmacy 
service to their patients may be one way of promoting the community pharmacist’s 
role in deprescribing. In a UK survey, the promotional method judged most effective 
was direct recommendations by GPs [283]. Previous experiences with the community 
pharmacist can positively influence older patients’ expectations of community 
pharmacists and may increase their frequency of pharmacist consultation. 




important in shaping patients’ expectations [247]. The present study findings 
indicate that there is a need to define the role of the community pharmacists, and to 
define the future services to be undertaken by community pharmacies such as 
deprescribing. If the roles and services provided in community pharmacies are well 
defined, then it is likely that patients will change their expectations and start using 
the pharmacies more for patient care issues.  
 
7.5.1 Future implications 
In proposing the expansion of the role of the community pharmacist in deprescribing 
for older people, first there is a need for a clear definition of deprescribing and for 
RCTs with demonstrable evidence that deprescribing works and that pharmacist 
involvement is effective in facilitating the deprescribing process. Secondly, there is a 
need to match pharmacists’ competencies to this supportive new role in 
deprescribing. Interdisciplinary training and shared guidelines as suggested in this 
study, might provide a useful way of teaching new competencies to community 
pharmacists while simultaneously improving collaborative relationships with GPs. 
Today, various tools exist to facilitate appropriate prescribing and optimization of 
medication use, such as, but not limited to, the STOPP/START [77], the STOPPFrail 
[93] and the deprescribing algorithms [80, 96-99].  Educators in clinical pharmacy and 
medicine should consider action in the development of the respective curricula in the 
area of collaborative deprescribing in primary care settings and in the incorporation 
of the existing tools to guide both prescribing and deprescribing. In addition, State- 
and union-led initiatives are needed to define clearly and precisely the role of the 
community pharmacist in deprescribing for older people. There is also a need for the 
State and the unions representing community pharmacists and GPs to mediate and 
agree the collaboration between community pharmacists and GPs in their 
overlapping roles in deprescribing and to jointly agree and negotiate the resources 






As with other types of qualitative research, the views of those represented in our 
study may not necessarily concur with those of other GPs and community 
pharmacists elsewhere in Ireland. A nationwide study might identify regional 
differences in community pharmacists’ and GPs’ views of community pharmacist 
involvement in deprescribing, as well as different descriptions of the role of the 
pharmacist in deprescribing for older people. Using convenience sampling to recruit 
participants facilitated the sampling but can potentially introduce selection bias. The 
GPs and community pharmacists participating in the study could potentially have a 
more positive attitude towards changing practices in relating to deprescribing which 
may have influenced their answers to questions. Those who have an interest in this 
topic, of changing current practice of community pharmacists to be more involved in 
deprescribing, may also be reflected in the difference in response rates for 
community pharmacists and GPs (75% and 31%, respectively). Community 
pharmacists may have had a greater interest in discussing the topic as it relates to 
their profession. However, the difference in response rates may also be linked to the 
different work structure of the two professions. The GPs had to find a time slot during 
their working day to complete the interview and most of them used a consultation 
slot or their lunch break. Although the community pharmacist has also a busy 
working day, most of the pharmacists could find a time during the day or week that 
was usually quiet in the workplace. In addition, most of the pharmacists interviewed 
were working together with other pharmacists, pharmacist technician(s), or 
pharmacy staff, who could stand-in while the pharmacist was doing the interview. To 
ensure that all participants were familiar with the term ‘deprescribing’, each 
interviewee was asked if they knew the term and asked to give a description of the 
meaning of the term at the beginning of the interview. Dependant on how familiar 
the interviewee was with the term, I, the interviewer then gave more detailed 
information of what the term entails or gave a complete description of the term. This 
was done to ensure that all interviewees had a similar understanding of 
deprescribing. However, as there is no standardised approach to deprescribing, 
between-interviewee differences in the understanding of what deprescribing entails 




profession of me, primary researcher (clinical pharmacist), could also in theory, 
introduce a professional bias. For participating community pharmacists this may have 
caused them to give answers that may have been more critical of the GPs’ work 
practices, whereas the GPs may have been more positive towards community 
pharmacist involvement.  
 Interviews were conducted either face-to-face or via telephone. Although 
there could be an expectation of low complexity and comprehensiveness of answers 
via telephone, evidence suggests that there is little difference in the content and 
quality of answers to leading questions obtained in person or via telephone [285]. By 
offering both telephone and face-to-face interviews to the participants, more 
participants were able to participate. The telephone interviews particularly suited 
the GPs, many of whom had difficulties finding a suitable time for these interviews 
during their busy working day. Consequently, most interviews (10 out of 13) with GPs 
were conducted via telephone whereas all but one interview with community 
pharmacists were conducted face-to-face. This difference in interview method 
between GPs and community pharmacists may have resulted in an imbalance of the 
comprehensiveness of the interviews, and the interviews with GPs were on average 
shorter than the ones with the community pharmacists (16:55 mins. compared to 
20:32 mins.)  
 
7.6 Conclusion 
In conclusion, community pharmacists expressed a need for more interaction with 
GPs on deprescribing in older people, while GPs were pleased with their current 
interactions with community pharmacists. Expanding the role of the community 
pharmacist in deprescribing needs clear definitions of the roles and responsibilities 
as well as clear communication of these to both GPs and patients. Community 
pharmacists are perceived as excellent sources of prescription medication 
information and are consequently considered to have a potentially important role in 
deprescribing if a properly structured collaborative relationship is established 
between GPs, community pharmacists and patients. Structuring the deprescribing 




deprescribing. Loyalty among older patients to pharmacies and regular contact with 
these pharmacies are factors to exploit more in centralising the role of the 
community pharmacist in older patient care. Although exclusive to Irish community 
settings, the findings of this study may be of use in the other countries seeking to 
expand the role of the community pharmacist from drug supplier to patient carer in 







This thesis identified the challenges and potential benefits of deprescribing in an Irish 
primary care setting and investigated the potential role of the community pharmacist 
in deprescribing. This chapter will be an interpretation and discussion of the key 
findings presented in the individual study chapters. To start, this chapter will 
summarise key findings of each individual study chapter and interpret them to 
describe implications of the research to practice.  At the end, the chapter will provide 
recommendations for future work and conclusive remarks.  
 
8.1 Summary of findings 
Beginning this doctoral work in 2015, deprescribing was a relatively new term and 
unexploited in the Irish setting. Therefore, the first objective of this thesis was to 
review the existing qualitative and quantitative literature on deprescribing. The 
narrative literature review (Chapter 2) described the challenges to deprescribing in 
older, multimorbid patients as viewed by healthcare professionals. Overall medicines 
management in this patient population was challenged by the involvement of 
multiple prescribers with the perception that individual prescribers followed their 
own speciality treatment guidelines. This challenged the acquisition of a 
comprehensive review of a patient’s medication which should ideally form the basis 
of deprescribing decisions. Consensus across studies was seen for the GPs to assume 
the responsibility for overall medicines management, including deprescribing, for 
older multimorbid people. Nonetheless, there was a reluctance from GPs to interfere 
with decisions made by other prescribers. A reluctance due to the fear of damaging 
professional relationships, poor communication between levels of care, patient 
demands, a lack of knowledge and experience with deprescribing, and a lack of 
guidelines to support deprescribing decisions. Patients’ strong attachments and 
unwillingness to stop certain medications were other challenges described as well as 
a reluctance from the prescriber to communicate with patents about their life-




pharmacists to give recommendations in deprescribing was a welcomed opportunity 
for support viewed by both pharmacists and prescribers in the included studies but 
dependent on the prescriber-pharmacist relationship. Chapter 2 concluded that 
despite agreement of the GPs’ role and the supportive role of the pharmacist in 
deprescribing, there was a need to further explore the interdisciplinary collaboration 
between GPs and pharmacists on deprescribing. Since the GP works in the primary 
care setting, it was deemed appropriate to target this setting and the supportive role 
of the community pharmacist.  
The systematic literature review (Chapter 3) was conducted to summarise 
effectiveness of deprescribing interventions of reducing the number of medicines 
and PIP, and to identify behaviour change components determining the 
effectiveness.  The systematic review found that following a plan, receiving clear 
instructions and social support, preferably from a credible source, were behaviour 
change components associated with intervention effectiveness. Another interesting 
finding in Chapter 3 was that the delivery of deprescribing recommendations, e.g. 
from a pharmacist was a key factor to effectiveness. Pharmacist recommendations 
were frequently enacted on in some studies, whilst a lower acceptance rate was 
demonstrated in other studies. This low uptake existed despite a shared belief of the 
need to deprescribe by pharmacists and GPs and highlights a need to further 
investigate the current collaboration between community pharmacists and GPs.   
The secondary analysis of the population-based primary care cohort in 
Chapter 4 reported patterns of PPOs and PIMs over a five-year period in early-old 
aged people in an Irish setting. This study demonstrated that PPOs and PIMs are 
present in early old-aged community-dwelling people and is a persistent and growing 
problem as people progress to more advance old age. Prevalence of PPO and PIM 
were both significantly associated with a higher number of daily medicines, 
suggesting that preventing inappropriate should be focused on polypharmacy 
patients. The high prevalence of both PPO (31.2% increasing to 42.4%) and PIM 
(39.7% increasing to 45.6%) identified by the STOPP/START criteria substantiated the 
relevance of applying the criteria in primary care settings to identify patients for 




patients’ medication data requires a comprehensive medical and pharmacological 
knowledge, clinical status of the patient and a complete list of the patients’ 
medications. The application of STOPP/START may thus create an opportunity for the 
community pharmacists to support deprescribing by contributing with their 
pharmacological knowledge and knowledge of medications recently dispensed 
(prescription medication) and sold (OTC medications and herbal supplements) to the 
patient in order to identify patients in scope of deprescribing.   
In Chapter 5, the study population from Chapter 4 was analysed for the next 
three years of follow-up, i.e. April 2015 to January 2018. Consistent with the findings 
of Chapter 4, PIMs were highly prevalent among the population (47-52%). This 
finding confirmed that PIP was still a significant problem affecting around half of the 
older population in Ireland. The NIC of PIMs at the final year of follow-up was 
€64,476.24 per annum and was the direct potential cost reduction of applying the 
STOPP criteria regularly to older people (aged 65 years and older). For the 
multimorbid community-dwelling patients with polypharmacy and in high risk of 
receiving PIMs, it is likely that they will visit the community pharmacy on a monthly 
basis to collect their prescription medications. Community pharmacists are thus able 
to review the prescriptions each month for appropriateness. This could provide an 
opportunity for community pharmacists to identify PIMs based on medication data 
and knowledge of the patient and to discuss these with the GP who has the clinical 
history of the patient. As a result, PIM prevalence and associated direct costs could 
be reduced. 
The qualitative interview study described in Chapter 6 was designed to 
explore the views of community pharmacists to address some of the key areas 
identified in the previous chapters: barriers and facilitators to pharmacist support in 
reducing PIP (Chapter 2 and 3), and strategies to reduce the high and persistent levels 
of PIP identified in Chapter 4 and 5. Chapter 6 showed that the identification of PIP 
and recommendations about stopping medicines were not routine practices among 
community pharmacists in Ireland. Community pharmacists described a conflict 
between their perceived responsibility in reducing PIP as per their pharmacy training 




uncertainty of their role in PIP which constrained them from working outside of their 
current role and hindered their collaboration with other healthcare professionals. 
The study shed new light to the need for clearer descriptions of the role of the 
community pharmacist in reducing PIP together with clear communications of this 
role to stakeholders and patients. Collaboration between GPs and community 
pharmacists was believed to be challenged by a lack of understanding of each other’s 
role and the absence of a shared platform with patient clinical information. The busy 
working environment they were both working in was also described to restrict them 
in prioritizing preventive actions such as screening for PIP and deprescribe 
inappropriate medications. Community pharmacists described themselves to be in 
an ideal role to support the reduction of PIP due to their pharmacological background 
and frequent patient consultations but highlighted the need for clinical information 
to improve the clinical relevance of their recommendations and guidelines to instruct 
the management of deprescribing.  
The findings of Chapter 7 on the perceived barriers and facilitators to 
deprescribing and community pharmacist involvement echoed those of Chapter 2 
and 6. Again, common barriers included lack of time and resources to prioritize 
preventive actions such as deprescribing. Other barriers pertained to lack of shared 
guidelines, poor communication and collaboration, patients’ demands, a lack of 
awareness of the role of the community pharmacist, and an unclear role description 
of community pharmacists in deprescribing. Having a good relationship with the 
patient for both the GP and the community pharmacist was highlighted as a 
determinant of the patient’s willingness to stop medicines. Community pharmacists 
and GPs both welcomed more pharmacist involvement in deprescribing. However, 
while GPs were pleased with their current interaction with community pharmacists 
about drug-interaction, switching to another medicine brand and patient medication 
adherence, community pharmacists experienced low uptake of their 
recommendations and had a feeling of picking at the GPs’ practices. Current 
interaction between GPs and community pharmacists was described to be limited to 
rectifying errors identified by the community pharmacists, and this rather negative 




need to improve and advocate the current pharmacist support to GPs with the aim 
to associate new pharmacists’ responsibilities, e.g. advising on deprescribing, to 
existing positive interactions to improve the acceptance by GPs. The findings of 
Chapter 7 suggested that the pharmacy could have a quite central role in 
deprescribing in the community setting. With closer geographical proximity between 
patient and pharmacy compared to the GP practice in some rural areas, the 
pharmacy was a suggested way of bringing patient care services closer to the 
patients. Monitoring the discontinuation process and advocating life-style changes 
were other responsibilities believed to potentially be undertaken by the community 
pharmacist. Suggested ways of implementing new responsibilities to the community 
pharmacist role were to integrate the community pharmacist into the GP practices, 
having a structured process for deprescribing and agreeing on the frequency and 
extent of the pharmacist involvement in deprescribing. Other suggestions pertained 
to making the role more official by State- or union-led initiatives, and to integrate it 
into both the medical and pharmacy contracts and curriculums. Finally, 
interdisciplinary training and shared guidelines were suggested to improve 
collaboration between GPs and community pharmacists. 
 
8.2 Interpretation of findings 
The evidence-base of the improved benefits of deprescribing and pharmacist 
involvement in patient care continues to grow. Over recent years, a large number of 
papers have been published on these topics [72, 85, 112, 160, 175, 269, 286-292]. 
Existing research has explored strategies to integrate the pharmacist into areas of 
patient care, such as medicines usage reviews, patient consultations, vaccine 
administration and blood pressure monitoring [151, 288, 290, 292-294]. Lately, a 
trend of prescribing authority given to pharmacists is seen, and both the UK [295, 
296] and Canada [297-299] have prescriber pharmacists. The principal contribution 
of this thesis has been the generation of evidence to support the role of the 
pharmacist in deprescribing in Ireland. The findings from this thesis adds to the 
evidence-base describing the extended role of the community pharmacist. It is the 




pharmacist in deprescribing in an Irish primary care setting. This thesis substantiated 
that PIP is a persistent problem among Irish community-dwelling early old aged 
people. It is also evident from this thesis, that actions to prevent PIP, such as 
deprescribing, do not form part of a routine practice in the primary care setting. The 
role of the community pharmacist in deprescribing is welcomed both by community 
pharmacists and GPs but the successful integration has yet to be found. The findings 
of this thesis should serve to direct future research. 
 
8.2.1  Extending the role of the community pharmacist to support deprescribing 
With medication being the main focus of treatment to date together with the long-
term preventive and treatment actions and the complexity of deprescribing, there is 
a need to get support from healthcare professionals with medication expertise, such 
as community pharmacists, more in the management of older multi-morbid patients. 
This support can potentially provide a more nuanced approach to the deprescribing 
process by offering inputs based different professional backgrounds, knowledge, 
experiences and expertise. From GPs and community pharmacists interviewed in 
Chapter 7, a suggested role for the community pharmacist is to recommend and 
advise deprescribing to the GP and to initiate the deprescribing conversation and/or 
to reinforce and support deprescribing decisions made by the GP, and to help 
monitor patients during the deprescribing process. As such, the community 
pharmacist could potentially identify patients for whom deprescribing would be 
beneficial, as well as supporting, monitoring, and empowering patients throughout 
the process. Despite this suggested role of the community pharmacist in 
deprescribing, one of the main challenges to the integration of this role into the 
community pharmacist’s routine work was the lack of a clear definition of the role. 
 Defining the role of the community pharmacist 
The first step towards a working definition of community pharmacists’ roles and 
responsibilities in deprescribing is ensuring that none of the stakeholders is 
disenfranchised and that these responsibilities are in line with the needs of GPs. GPs 
interviewed in Chapter 7 felt that their role may be diminished professionally if 




patients, specifically those that they feel clearly fall within their remit.  This finding 
echoes the conclusions of the literature reporting limited support from GPs for 
pharmacist role expansion into areas that could be thought to impinge on the GP’s 
duties [282, 300-302]. The study by Bryant et al.  [282] found that community 
pharmacist’s roles that considered to encroach on the role of the GP were less 
acceptable, such as a role in prescribing. Almost 75% of the community pharmacists 
in the study agreed to a role of supervising repeat prescribing and making dosing 
adjustments to patients’ medicines whereas between 15%-25% agreed to the 
community pharmacists taking these roles [282].  This may in turn partially explain 
GPs’ reluctance to accept/implement pharmacists’ recommendations as described in 
Chapters 3 and 7.  
Another explanation to the low acceptance of pharmacists’ 
recommendations by GPs experienced by the community pharmacists may be 
related to the setting in which community pharmacists practice. A low acceptance 
rate of community pharmacists’ recommendations to medication management is a 
barrier particularly faced in community pharmacy practice settings. A review of 21 
articles reporting community pharmacy interventions described that interventions in 
community pharmacy practice settings were less likely to report favourable 
intervention effects compared to interventions in other settings such as ambulatory 
care settings and hospital settings. The review highlighted that one of the factors 
accounting for the limited effectiveness of the community pharmacy-based 
interventions was the low acceptance rates of pharmacist recommendations [303]. 
Many of the factors that facilitate the effect of pharmacist-led interventions in other 
settings such as hospital settings and ambulatory care settings are rarely present in 
the community pharmacy settings. Community pharmacists usually have limited 
access to clinical patient information other than the medications that have been 
dispensed to them. This limits the clinical relevance of their recommendations, and 
this is a barrier to the uptake of community pharmacists’ recommendations [303]. In 
Ireland, no system exists for sharing patient information with community 
pharmacists such as clinical status, diagnoses, laboratory tests and changes made 




information which limits the clinical ground on which they can build their prescribing 
and deprescribing recommendations to the GPs. Community pharmacists in Chapter 
7 did acknowledge that due to the lack of clinical data, some of their 
recommendations were limited in terms of its clinical relevance. Under these 
circumstances, the community pharmacists had lower expectations of GP acceptance 
rates of their recommendations. In Chapter 5, community pharmacists also stressed 
a need for patient information on diagnoses and indications for medicines to be able 
to enter a more active role in preventing and reducing PIP. If we want to involve the 
community pharmacists more in advising GPs on deprescribing there is a need to 
ensure a clinical relevance of their recommendations in order to enhance the uptake 
of by the GPs. Being involved more in the deprescribing process it is important that 
the community pharmacists are equipped clinically to take on this role by giving them 
access to the required information. Described by Zhou et al. [68] one of the main 
barriers to pharmacist prescribing comparing initiatives from the UK, New Zealand, 
Canada and Australia is the lack of access to patients’ clinical data. Making effective 
prescribing decisions by pharmacist prescribers without access to medical records 
can undermine patient safety [68]. Similarly, for pharmacists to give clinically 
appropriate advice on deprescribing, they need to know the patients’ clinical history.  
8.2.2 Equipping community pharmacists for a role in deprescribing 
There is a need to ensure that any working definition of the role of the community 
pharmacist in deprescribing is used in academia as well as in practice. Community 
pharmacists interviewed in Chapter 6 and 7 refrained from interacting with GPs 
about reducing PIP and effecting deprescribing if they felt that they were working 
outside their scope.  Changing the role of the community pharmacist from a drug-
dispenser to entail more responsibility in clinical services such as advising 
deprescribing and monitoring patients during the cessation of drug asks new skills of 
the community pharmacist. In addition to providing community pharmacists with the 
clinical information needed to support deprescribing, there is a need to ensure that 
they are properly trained and equipped to take on this extended role. Community 
pharmacists interviewed in Chapter 6 also described that they did believe their 
pharmacology and therapeutics knowledge was sufficient to identify PIP but that 




continuing professional education to bring their knowledge in line with new 
medications and most up-to-date guidelines on deprescribing. Some community 
pharmacists also described how they were not confident in recommending changes 
to a GP’s prescription and that they then refrained from contacting the GPs. The 
community pharmacists did welcome more training in PIP and together with the GPs 
to also improve their collaboration. Although the community pharmacists in general 
believed they had sufficient knowledge, their suggestions to get more 
interdisciplinary training with GPs and more guidelines and continuous professional 
development may reflect a feeling of inadequate clinical knowledge to be able to 
recommend deprescribing to GPs. This perception is supported by the findings of 
Bryant et al. [282] reporting that less than 50% of the community pharmacists feel 
adequate dealing with GPs on clinical medicine-related issues, having sufficient 
confidence in their clinical knowledge and feeling sufficiently training [282]. Even 
though community pharmacists may report in the interviews that they have 
sufficient knowledge and we promote pharmacists to be experts in pharmacology 
and medicines, training is needed in diagnoses and clinical aspects of patient care if 
we expect them to be more engaged in deprescribing. As described in a systematic 
review on pharmacist prescribing by Zhou et al. [68], 26 of the included studies 
reported inadequate training of pharmacist related to diagnostic knowledge and 
skills as a barrier to pharmacist prescribing in practice. Barriers to pharmacist 
prescribing reflect that pharmacists do not traditionally have a role in clinical 
diagnosis and treatment, and the call for training in diagnostic knowledge and skills 
was prevalent across the studies [68]. These barriers to pharmacist prescribing could 
to an extent be similar to pharmacist support in deprescribing. Similar clinical 
information and knowledge is needed to identify medications to be deprescribing 
taking into account the patient’s clinical status, prescribed list of medications and 
individual preferences. 
 
8.2.3 Pharmacists involving patients in deprescribing 
With the evidence of the benefits of patient-centred care (i.e. improved patient 




engage patients in the deprescribing process as suggested by Reeve et al. [106]. In 
deprescribing, patient-centred care should include shared decision making, a holistic 
view of the patient and creation of a trusting relationship between the patient and 
the prescriber [106]. In Chapter 6 and 7 patients were described to either have no or 
very little interest in their medical therapy or being strongly attached to certain 
medicines, both barriers to deprescribing. Involving the patients in their medical 
treatment and educating them in the risks and benefits of taking medications were 
highlighted as necessary facilitators of deprescribing. In light of these findings and 
the findings by Reeve et al. [106], patient involvement is a key area to target in 
deprescribing.   
 According to most GPs and community pharmacists interviewed in Chapter 6 
and 7, the Irish healthcare system does not allow sufficient time for non-acute issues 
to be resolved, and both GPs and community pharmacists felt that preventive actions 
receive less priority.   The GPs interviewed reported neither sufficient time nor 
opportunity to discuss deprescribing with their patients during their regular 
consultations, and the topic was rarely brought up in discussion by the GP.  The very 
limited time for most GP consultations points to an opportunity for the community 
pharmacist to counsel patients on deprescribing opportunities and benefits. A 
consultation with a trained community pharmacist may not require booking an 
appointment in advance, may be less costly and could provide a useful supplement 
to GP consultations for older patients with multimorbid illness and associated 
polypharmacy. The accessibility of the community pharmacist for patients with 
chronic diseases can position the community pharmacist well to undertake 
consultations pertaining to deprescribing. International experiences from Denmark 
are beginning to show the positive outcomes from community pharmacists offering 
medication consultations to all patients with chronic illness [304]. Patients with 
chronic conditions report a high level of acceptance of the pharmacist’s consultation 
recommendations and feeling reassured and confident in the advice given during 
those consultations [304]. The community pharmacist in Ireland could have a similar 
role with comparably positive outcomes. Being positioned in the community, most 




Chapters 6 and 7, they are currently an underused healthcare resource. In a trusting 
patient-pharmacist relationship, the community pharmacist would be well 
positioned to inform patients about risks and benefits of medications and to act as 
an independent source of drug information. This pharmacist-patient relationship 
could position the community pharmacist favourably to influence older multimorbid 
patients on deprescribing matters and to empower them to initiate the conversation 
about deprescribing with their GPs.  As demonstrated in the literature [288], 
pharmacist counselling has the potential to improve health-related outcomes by 
directing the counselling to a patient’s health-related needs. Such benefits have been 
demonstrated in the areas of smoking cessation [305, 306], diabetes management 
[307, 308], hypertension [292, 309] and deprescribing of hypnotic Z-drugs [310].  As 
suggested in Chapter 7, pharmacist consultations with patients could provide GPs 
with useful support in the deprescribing process thereby reinforcing and monitoring 
the GP’s deprescribing decisions and assuring patients that their medical treatment 
remains appropriate.  
If extending the role of the community pharmacist to entail more clinical 
services to patients, patients’ receptivity to the pharmacist providing these services 
needs to be considered. Interviewed in Chapter 7, community pharmacists described 
how some patients were willing to share all their clinical information with them and 
in some cases, more information than they would share with their GP. Other patients 
were thought to accept community pharmacist involvement in their treatment to 
little or no degree. Today, patients are mainly visiting the pharmacy to collect their 
prescription medications or buying OTC medications. Medication reviews and 
conversations about deprescribing are not currently part of community pharmacy 
practice in Ireland. Most patients do not expect clinical services to be offered at the 
pharmacy. Therefore, patients may not be aware of the services, understand why the 
services are being offered, know the benefits of these services and how these 
services are coordinated with their care from other healthcare providers, e.g. 
medication changes discussed during a GP-consultation [303]. This further advocates 
the improvement of the GP-pharmacist collaboration in deprescribing to ensure 




offered by GPs and community pharmacists. In addition, it highlights a need to raise 
awareness of the community pharmacist services among patients.  
 
8.2.4 Introducing new roles and responsibilities into practice 
This thesis highlighted a need to consider the existing collaboration between GPs and 
community pharmacists in patient care when introducing new roles and 
responsibilities for the community pharmacist. As highlighted above, the views of 
pharmacists and GPs described in Chapter 7 diverged in terms of their current 
collaboration and this is very likely an area for future improvement. Clear definitions 
of roles as suggested above in deprescribing for community pharmacists and GPs was 
one suggested strategy, but the collaboration could also benefit from a 
complementary interdisciplinary training as suggested in Chapter 6 and 7. 
Interdisciplinary training was recommended by community pharmacists and GPs 
interviewed in Chapter 6 and 7 and that it should form a larger part of the 
undergraduate pharmacy and medical curricula as well as continuing into 
postgraduate practice by introducing it to the list of learning objectives for 
continuous professional development. The evidence supporting interprofessional 
training is well established, with studies showing positive outcomes of 
interdisciplinary training for pharmacy and medical students [311-314]. 
Interdisciplinary training has proven particularly useful in raising awareness of 
healthcare providers roles and contributions to patient care [315]. A US-based study 
compared the knowledge of pharmacy and non-pharmacy students on each other’s 
roles and their contributions to patient care after attending an interdisciplinary 
training day. Nonpharmacy students who attended the interdisciplinary training day 
demonstrated greater awareness of pharmacy services such as patient counselling, 
patient education and dispensing medications than their counterparts who had not 
attended the training day [315].  
In addition to interdisciplinary training, a suggestion raised from the findings 
of Chapter 7 was to improve the collaboration between community pharmacists and 
GPs by building on positive experiences from existing services. The GPs interviewed 




highlighting drug-interactions. They also wished for the community pharmacist to 
provide them with more information about patient medication non-adherence 
identified as this was perceived as valuable information in the deprescribing process. 
Highlighting positive outcomes and enhancing these existing pharmacy services are 
thus potential strategies for encouraging the collaborative work between community 
pharmacists and GPs and to pursue new areas of collaboration such as deprescribing 
in multimorbid older people. A US study with physicians substantiates these beliefs 
[265]. Physicians’ perceptions of collaborating with community pharmacists were 
related to the expected outcomes of this collaboration. The surveyed physicians 
believed that collaborating with community pharmacists would improve medication 
adherence among patients, prevent drug-related problems and increase the use of 
cost-effective medicines. These believed outcomes made the physicians more 
inclined to collaborate with community pharmacists. In particular, the outcome of 
improved medication adherence was a strong predictor of positive attitude toward 
collaboration. Hence, physicians’ beliefs that collaborating with pharmacists can 
result in improved outcomes is very likely to heighten their likelihood of collaborating 
with them. In line with the suggestion from Chapter 7, the US based study suggested 
that establishing new collaborative relationships between physicians and 
pharmacists may benefit from communicating and highlighting the value of the 
existing collaborations first [265].  
Finally, as suggested by GPs and community pharmacists interviewed in 
Chapter 7, along with clear definitions of the community pharmacist’s role in 
deprescribing, there is a need to make the role an official one, and to integrate the 
responsibilities into the pharmacist’s contract to ensure successful implementation 
of deprescribing in practice.  
 
8.2.5 Financial implications of pharmacist involvement in deprescribing 
As demonstrated from the longitudinal data presented in Chapter 4 and 5, PIP is an 
increasingly growing and costly problem among the older population (≥65 years), a 
finding which is consistent with the literature [27, 37, 38, 46, 49, 153, 316]. A novel 




the early old-aged population (≥60 years) and continues to increase when following 
up the same population over an eight-year period. As people age, they are often 
using a higher number of daily medicines which significantly increases their risk of 
PIP. As the population of older people and prevalence of multimorbidity continue to 
grow, these demographic changes will present an ever-increasing challenge to 
healthcare systems. New and expensive diagnostic technologies and treatments add 
to both the complexity and costs of older patients clinical management [317]. The 
high consumption rate of medicines amongst the older population, along with the 
associated increased healthcare services required and the rising cost of the newer 
therapeutic interventions are adding to the pressures on healthcare systems which 
need to show that they are cost-effective [318, 319].  
A report in 2016 by the internationally renowned auditing firm, 
PricewaterhouseCoopers (Pwc®), concluded that with the higher demands and 
increased costs of the ageing population in Ireland, there is a need to redistribute the 
publically funded health budget to achieve better patient health outcomes [320]. The 
report suggested the introduction of a principle of ‘investing to save’, whereby an 
intervention as a preventative measure can stop the condition developing to a higher 
level of acuity. The cost implications of treatment within the report generally 
increase substantially at higher acuity levels (i.e. the cost of a GP visit is c. €55 
whereas the cost of a 24-hour hospital inpatient stay is approximately €1,000). The 
report concludes that if costs can be reduced, then the resultant savings could be 
reallocated more effectively to provide better outcomes [320]. Pharmacists could 
potentially have a significant role in containing / lowering costs by identifying and 
highlighting the high prevalence of PIP identified in Chapter 4 and 5 to the GPs. 
Previous studies have shown that pharmacist services contribute to cost reductions 
in a wide variety of care settings [317]. A pharmacist intervention study examining 
the cost avoidance achieved through the prevention of an ADE, reported a 
substantial net cost benefit of €626,279 and a cost benefit ratio of 8.64:1 [318]. It is 
likely, although not proven, that similar cost avoidance can be obtained if pharmacist 
interventions are deployed in primary care to reduce the prevalence of ADEs. 




older multimorbid people could thus be a successful strategy to reduce the pressure 
on the healthcare system. However, as is evident from Chapter 6 and 7, there is a 
need for financial incentives and resources to expand the community pharmacist role 
in deprescribing as a means of ‘investing to save’. 
 
8.3 Recommendations for future work 
This thesis provides an evidence-base to inform future research that aims to enhance 
deprescribing and the role of the community pharmacist in medication surveillance 
among multi-morbid older people exposed to polypharmacy living independently in 
the community setting. Based on the thesis findings, it is suggested that future 
research should focus on the areas outlined below: 
1) Showing that deprescribing is effective in improving clinical patient outcomes 
2) Standardising the deprescribing process 
3) Defining the role of the community pharmacist in deprescribing based on the 
responsibilities suggested by community pharmacists and GPs. 
4) Upgrading the pharmacy curriculum to reflect the expanded role of the 
pharmacist in community practice.  
5) Strategies to incorporate more interdisciplinary training with other 
healthcare professional students (particularly medical students) focused on 
improved collaboration between pharmacists and other healthcare 
professionals in routine clinical practice.   
6) Effects of sharing lessons learned and communication of the positive 
outcomes of existing pharmacy services on deprescribing. 
7) Interventions to determine the feasibility and effectiveness of a pharmacist-
led application of deprescribing guidelines and supporting standardised 
forms against which deprescribing recommendations are delivered to GPs by 





8.4 Strengths and limitations 
This thesis investigates the potential role of the community pharmacist in 
deprescribing and the perceived barriers and facilitators in an Irish primary care 
setting. Particularly novel was the behaviour change analysis of deprescribing 
interventions described in Chapter 3, and the longitudinal examination of PIP 
patterns among people in early old age (‘young old’) described in Chapter 4. Another 
important novel aspect of this thesis were the views of community pharmacists on 
deprescribing in Chapter 6 and 7. Research pertaining to deprescribing has primarily 
focused on GPs and/or hospital–based prescribers. The community pharmacist is one 
of the most accessible healthcare providers in the Irish healthcare system and a 
potentially useful support to the GP in deprescribing. The attitudes and opinions of 
community pharmacists are important if appropriate, safe and meaningful 
deprescribing is to be achieved, and Chapter 6 and 7 shed new light on their views 
and opinions. Deprescribing and expansion of the role of the community pharmacist 
to support more patient care services are both areas of increasing interest and 
possibly greater investment in the future by healthcare professionals, academics and 
policymakers. The research conducted as part of this doctoral thesis provides an 
evidence-base to guide some of the strategy development needed to enhance 
deprescribing.  
One of the strengths of this thesis was that the individual primary research 
studies (Chapter 4-7) were designed from the findings of a narrative review and a 
systematic review of the available literature (Chapter 2-3). Systematically reviewing 
the literature provided a structured way of synthesising existing knowledge in order 
to make evidence-based decisions to fill the gaps in primary research studies.  
The research described in this thesis had some limitations. The principal 
limitation was the fact that the primary research studies were conducted in one 
geographical area, i.e. the greater Cork region of southern Ireland. This could limit 
both the transferability and generalisability of study findings to other regions of 
Ireland, although the healthcare system in the Cork region is generally very similar to 








The overall aim of this community thesis was to identify challenges of deprescribing 
and to explore the role of the pharmacist in deprescribing in multimorbid older 
people in the primary care setting in Ireland. The findings presented in this thesis 
provide a detailed understanding of the current and potential future role of the 
community pharmacist in deprescribing, the potential benefits of such a role, and the 
barriers and facilitators to achieving that now role. Chapter 4 and 5 demonstrated 
that PIP is a highly prevalent problem with high associated costs among older people 
in Ireland. The pharmacist was identified as a useful but underexploited resource to 
reduce PIP from a supportive role in deprescribing in the other chapters. Several 
complex barriers challenge the deprescribing process in the primary care setting and 
the integration of the community pharmacist into the shared task of medication 
surveillance for PIP and logical and timely deprescribing. A busy working 
environment, suboptimal communication between care providers, a lack of a 
formalised structure or collaboration framework, lack of guidelines and patient 
influences must all be addressed thoroughly to enhance pharmacist involvement in 
deprescribing. Given the complexity and multiplicity of barriers, deprescribing 
interventions involving the community pharmacist are likely to require a 
multifaceted approach. 
 This thesis substantially contributes to the existing literature, through the 
provision of novel research on the areas for which pharmacist support is useful, and 
suggest the actions needed to facilitate the successful implementation of the role 
with regards to deprescribing. The community pharmacist is in a favourable position 
to bring pharmaceutical care closer to the patient through patient counselling and 
close collaboration with the patient’s GP. To integrate the role of the community 
pharmacist with that of the GP in practice, there is a need to consider the mode of 
pharmaceutical service delivery and to expand the collaboration between 




The insights gained from this thesis provide directions for future research into two 
target areas: (i) improved interdisciplinarity between pharmacists and GPs and (ii) 
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Challenges of deprescribing in the 
multimorbid patient 
Shane Cullinan, 1 Christina Raae Hansen, 1 Stephen Byrne, 1 Denis O'Mahony, 2
Patricia Kearney, 3 Laura Sahm 1
ABSTRACT 
Older patients often have multimorbidity, frequently 
resulting in polypharmacy. lndependently, multimorbidity 
and polypharmacy are among the biggest risk factors for 
inappropriate medication, adverse drug reactions, 
adverse drug events and morbidity, leading to patient 
harm and hospitalisations. After a medication review, 
discontinuation of medication or deprescribing is one of 
the most common recommendations but is likely to be 
ignored. The deprescribing process includes same or all 
of the foliowing elements: a review of current 
medications, identification of medications to be 
discontinued, a discontinuation regimen, involvement of 
patients and a review with follow-up. In addition to the 
complexity presented by prescribing or deprescribing for 
alder multi morbid patients, othe r factors aet as barriers 
to discontinuation of medications in these patients; these 
include interprofessional relationships, difficulties with 
medication reviews, deficiencies in knowledge and 
evidence and patients' preferences/resistance to change. 
These challenges are compounded by the need to 
manage the shared treatment of multiple conditions by 
several prescribers from different specialties based on 
disease-specific guidelines without evidence of effects on 
the older, trailer, multimorbid patients. The 
interdisciplinary effort in the treatment of such patients 
needs to improve to ensure that we treat the patient 
holistically and not just the individual conditions of the 
multimorbid patient, according to guidelines. We must 
first, however, equip prescribers to identify instances 
where deprescribing is appropriate and then make the 
necessary changes to pharmacotherapy. 
INTRODUCTION 
Within the 34 member countries of the 
Organisation for Economic Co-operation and 
Development (OECD), people bom today have an 
average life expectancy of 80.1 years. 1 This is a 
10-year increase compared with just 45 years ago.
Sixty-five year olds today have an average life
expectancy of 19.25 years, almost a 6-year increase
from 1960. Of these extra 19 years, nine are likely
to be 'healthy years'.2 In 1960, 8.6% of the OECD
population was aged �65 years. Today, that figure is 
15.4% and set to rise to 27.2% by 2050.3 4 The
global population is ageing. With this come many
socioeconomic burdens and increased pressures at
all levels of care.
Gider patients often have to contend with multi­
morbidity, which in tum leads to polypharmacy. 
Together, multimorbidity and polypharmacy are 
among the biggest risk factors for inappropriate 
medication, adverse drug reactions {ADRs), adverse 
drug events and morbidity, leading to patient harm 
and hospitalisarions.5 6 Suboptimal prescribing in
older patients has been well-established as a signifi­
cant problem in healthcare today. 7-9 In recent 
years, the focus of research into optimisation of 
medicines for older patients has shifted from quan­
titatively measuring the deficiencies in prescribing 
for this cohort, to qualitatively uncovering the root 
causes of suboptimal prescribing. 
Instead of asking how bad the problem is, atten­
tion is now turning to why does it happen and how 
can we deal with it? Published reports of qualitarive 
research attempting ro answer and deal with these 
questions have increased. 10-13 From this research,
new avenues for exploration have emerged that 
may optimise prescribing for older mulrimorbid 
patients through targeted interventions and new 
procedures for medication reviews. 14-16 However, 
one of the most common recommendations after a 
medication review-discontinuation of medication 
or deprescribing-is one of the least likely to be 
followed.17 18 The deprescribing process indudes 
some or all of the following elements: a review of 
current medications, identification of medications 
to be discontinued, a discontinuation regimen, 
involvement of patients and a review with 
follow-up.19 Our review highlights some of the 
potential reasons for this lack of deprescribing and 
the challenges to discontinuing drugs for these 
patients. 
WHY DEPRESCRIBE? 
Recent research by our group examined the effect 
of a structured pharmacist review on the appropri­
ateness of medicarions as well as adverse outcomes 
such as ADRs in patients with multimorbidity and 
polypharmacy. 15 16 In a cluster randomised con­
trolled trial, patients in the intervention group 
underwent a thorough medication review by a 
pharmacist using a computerised decision support 
system (CDSS) to aid the generation of recommen­
dations. Of the 577 recommendations made in 296 
patients about the appropriateness of pharmaco­
therapy, 297 (51 %) advised stopping at least one 
medication, based on the Screening Tool of Older 
Person's Prescriptions (STOPP) criteria.20 21 The 
results of the recommendations were (i) an 
improvement in overall appropriateness of rnedica­
tions (illustrated by a significant improvement in 
Medication Appropriateness Index score), (ii) a sig­
nificant improvement in ADR rates in the interven­
tion group compared with the control group 
(13.9% vs 20.7%, p=0.02), (iii) a shorter hospital 
stay but with no staristically significant difference 
between the groups {8 vs 9 days, p=0.44). While 
discontinuation of medications was not the only 




'appropriateness' recommendation provided to medical teams, it 
was the most cornmon and the most widely implemented. 
However, acceptance rates were still only 45%. Fewer than half 
the deprescribing recommendations were implemented, yet sig­
nificant improvements in ADR rates and medication appropri­
ateness were still achieved. Improving the acceptance rates 
would therefore appear to be a justified exercise. 
CHALLENGES TO DEPRESCRIBING 
The low acceptance rates of deprescribing recommendations 
mentioned above and elsewhere,17 18 invite inquiry into the 
reasons why despite the potential benefits. Deprescribing is a 
difficult task for practitioners in all patients but is further com­
plicated in older multimorbid people owing to the need to con­
sider life expectancy in addition to age-related changes in 
pharmacokinetics (PK) and pharmacodynamics (PD).22 PK/PD
changes are important indicators of deprescribing, enabling us 
to distinguish between drug-related adverse events and general 
age-related symptoms and idenrification of drugs and doses that 
are potentially inappropriate. Prescribing and deprescribing 
should be regarded as equally important in considering the 
drug-induced harm that is to be arneliorated or prevented 
through deprescribing, the benefits and risks and the assessment 
and management of the withdrawal.23 The same insight and
understanding of a patient's clinical situation is thus required to 
facilitate both safe prescribing and deprescribing. 
Despite existing tools such as STOPP, Beer's Criteria, 
Medication Appropriateness Index and Medstopper and clinical 
guidelines on safe withdrawal of drug dependence to guide dis­
continuation of inappropriate drugs safely, there is still a gap in 
the management of polypharmacy and the use of drugs for 
chronic conditions where therapeutic alternatives do not exist.24 
However, factors other than complexity play a part, which 
contribute to prescribers' reluctance to deprescribe. 
INTERPROFESSIONAL RELATIONSHIPS 
In the treatment of multimorbid older patients, the involvement 
of several healthcare professionals is common.25-32 This often
results in individuals foliowing his/her specialty treatment guide­
line (s) and dominating the patient's treatment with their own 
particular focus. 26 Similarly, some physicians believe that they
are solely responsible for the medicines management within 
their specialty and that the overall management is the responsi­
bility of others.31 Lack of communication between the various 
levels of care is a known source of suboptimal prescribing. 11 12 
The literature abounds with studies illustrating this confusion 
over where responsibility lies. In some instances, it has been 
shown that primary care physicians welcome the help of phar­
macists to support them in polypharmacy management and 
most pharmacists are in favour of the suggested clinical role for 
them in treating multirnorbidity.31 However, in other instances
the perceived value of a pharmacist's recornmendations varies 
between the general practitioners (GPs),32 and seems to be 
determined by the relationship between the medical and the 
pharmacy profession. In one study it was shown that junior 
doctors felt that GPs and consultants were the main healthcare 
professionals responsible for deprescribing, followed by senior 
house officers, junior doctors and pharmacists.33 Recent litera­
ture reviews of pharmacy-led interventions34 have described a
positive impact on the appropriateness of prescribing in older 
patients. Promising results were reported from both interven­
tions of pharmacists working independently or as part of a 
multidisciplinary team. Despite different levels of clinical signifi­
cance of the interventions reviewed, both reviews highlighted 
the important role of pharmacists in improving the quality of 
medication use among older patients. 
Elsewhere, it has been reported that GPs feel that the respon­
sibility to review a patient's overall health status and quality of 
life is theirs. Hence, they believe that they have a coordinating 
role in reviewing the patient's medical treatment, including low­
ering the doses, quantifying the medication use and reducing 
the number of inappropriate drugs. However, they also 
described the challenges of these tasks, which indude a heavy 
workload on top of their regular work. 
It' s a great idea to reduce medication if you can do it in a safe 
manner that's not going to make us have to go out to the nursing 
homes 55 more times:32 
Another factor is a reluctance to interfere with medication 
that has been prescribed by a colleague or a specialist. 32 Our
research group has encountered this, both through our work in
developing and implementing the STOPP/Screening Tool to 
Alert doctors to Right Treatment (START) criteria20 21 and our
qualitative work exploring the barriers to appropriate prescrib­
ing in older patients. 10 12 Prescribers described a fear of offend­
ing other doctors, including specialist doctors and GPs.10 If, for
example, a doctor noticed something potentially inappropriate 
in a patient's prescription, they would be less likely to intervene 
if that patient was under the care of a specialist. Similarly, when 
transferring information -for example, from hospital to 
primary care, it was noted that information might be lirnited 
owing to a fear of causing offence to patients' GPs. This fear of 
offending other doctors is compounded by a fear of upsetting a 
medication regimen. There is a culture of 'don't rock the boat' 
when it comes to making changes. 
Doctors described reluctance to discontinue a medication that 
has been taken for a long time by a patient in order to avoid 
worry and spoke of not wishing to disrupt patients' dinical 
stability.10 
It can be argued that the medical treatment of chronic <lis­
eases takes place after hospital discharge and that problems of 
polypharmacy and inappropriate medication use are resolved in 
primary care. The GPs may therefore be the key players. 
However, the focus of the current deprescribing debate is on 
hospital specialists who are called to "take the lead in depre­
scribing". 23 The reported reluctance among practitioners to
interfere with decisions made by a specialist highlights a need to 
change the medical culture and improve the communication 
between levels of care. The transition between primary and sec­
ondary care is often associated with miscommunication and a 
lack of clarity of the roles and responsibility for a patient's 
medical treatment, including deprescribing. A debate as to who 
needs to take the lead in deprescribing and in what setting the 
process should take place may therefore involve a discussion on 
improving collaboration between levels of care to optirnise safe 
medication use. This cultural change and discussion applies to 
the physicians and practitioners, but might also be relevant to 
the roles of hospital pharmacists and pharmacists in primary 
care. 
MEDICATJON REVIEW DIFFICULTIES 
Before any deprescribing takes place, a thorough medication 
review needs to be carried out, which is often challenging in the 
older multimorbid patient. Multiple prescribers usually mean 
that a clear overview of the patient's medical treatment is diffi­
cult to achieve.26 29 31 This is further cornpounded by the lack
of interprofessional communication described above, m 
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particular poor documentation of changes made to a treannent 
- for example, initiation, amendments and discontinuation. In
turn, this poor documentation is a barrier to deprescribing as it
hinders the understanding of other doctors' motivations for the
initiation or continuation of a particular treatment.26 29 31 32 
Apart from poor documemation by prescribers, the difficulty 
in obtaining an updated list of patients' medications further 
hinders deprescribing. Shemeili et a/31 reported that the main 
difficulty with medication review was the need to consult 
several sources-for example, pharmacy, patient, family and GP, 
to complete the list, coupled with uncertainty about which 
source provides the optimal list of drugs taken by the patient. 
Not knowing which medications should be induded on the l ist 
-for exarnple, 'as required' (PRN) analgesics or topical medi­
cines, was another challenge mentioned.31 The literature also
describes how incomplete information is perceived as a barrier
to making a decision about deprescribing-that is, which drugs
to discontinue and when.30 Poor acquisition and documentation
of patient information from nurses has also been suggested as a
barrier to deprescribing:
!t's a matter of educating them [nursing staff] that they need to
provide information about that resident that's documented well
and correctly so that we can use that information. 32 
A medication review is a critical step in assessing a parient's 
pharmacotherapy and ultimately deprescribing for that patient, 
and warrants attention. Our group has investigated the use of a 
CDSS-supported, Structured Pharmacist Review of Medication 
(SPRM) and the Structured History taking of Medication use 
(SHIM) tool to streamline the medication review process. Both 
approaches improved the accuracy and reliability of patient data 
obtained.15 16 35 We did find, however, that any pro forma 
used, still relied on basic communication between levels of care 
and adequate documentation by prescribers. 
KNOWLEDGE AND EVIDENCE BASE 
Simply not knowing what can be safely discontinued or indeed 
what should be discontinued is in itself a barrier to deprescrib­
ing. We have found that medical students and junior doctors are 
not equipped to make these decisions about older patients as 
there is little or no distinction made between them and the 
general adult population in their training, 12 even though they 
are entirely different populations. As previously mentioned, 
altered PKs and PDs, reducing renal and hepatic function and 
altered body fat/lean muscle ratios all make prescribing for older 
patients notoriously difficult. If physicians are not being trained 
to prescribe for them, how can we expect them to effectively 
deprescribe for them? 
It's a different knowledge set. And it's difficult you know because 
there isn't a huge amount of data out there or its not communi­
cated to us very well 12 
The Jack of evidence for the use of or discontinuation of a 
particular drug by older patients limits structured deprescribing, 
mainly owing to the exclusion of multimorbid older patients in 
clinical trials.25-27 30 The available evidence is perceived by
many as insufficient in relation to the effect of multiple dmg 
treatments in older patients25 and the effects of preventive 
medication in the oldest patients. 26 27 30 A low level of evidence
often underlies recommendations in existing treatment guide­
lines and many commonly used recommendations are based on 
expert opinions and 'standard of care'.36 37 As a result, although 
there is an abundance of prescribing guidelines, their application 
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to older, multimorbid patients is unsatisfactory for the following 
reasons: 
1. They are based on trial data involving younger patients.30 
2. They provide only a standardised set of recommended medi­
cations for each indication regardless of a patient's additional
comorbidities. 3 0 
3. They are too disease-specific. 38 
4. They do not include recommendations for deprescribing.27
Despite these misgivings, in the absence of alternative evi­
dence, many clinical guidelines become widely used and prescri­
bers feel under pressure to adhere to them instead of 
prioritising the medical treatment and deprescribing where 
appropriate.26 29 30 A prescriber's tendency to deprescribe may 
therefore be affected by the lack of evidence-based guidelines 
and also by the particular medical culture. The Jack of guidance 
for the multimorbid patient warrants further research. Until 
evidence-based recommendations are incorporated into succinct 
and validated guidelines, any efforts to systematically depre­
scribe will be based on the same 'expert opinion' approach pre­
viously seen. Although this has its benefits, a more standardised 
and robust system for optimising a patient's prescriptions is 
required. A barrier to this has been the exclusion of older, mul­
timorbid patients from clinical trials but, encouragingly, two 
ongoing trials are focusing on these very patients. The 
SENATOR trial is assessing the impact of a CDSS, incorporating 
the STOPP/START criteria, on ADR rates in older multimorbid 
patients (http://www.senator-project.eu/). The OPERAM project 
is also assessing the impact of a CDSS in these patients, with 
drug-related admissions as the primary outcome. It is hoped 
that the findings from these trials will facilitate a significant step 
towards evidence-based prescribing guidance for multirnorbid 
patients. Evidence, or lack of evidence, of ADRs is also some­
thing that influences prescribing decisions. Darnestoy et al39 
reported that many of the physicians interviewed prescribed as 
they did because they did not often see side effects. Dickinson 
et a/40 reported that GPs did not perceive a significant problem 
with long-term prescribing of antidepressants as they had not 
seen any evidence to indicate serious harm to the older patient. 
W hat is not clear in these instances is whether ADRs simply 
were not occurring or the prescriber was just not aware of 
them. 
PATIENT 
The patient has an important influence on the deprescribing 
process because: 
1. Some patients' unintentionally withhold information about
adverse drug events because they attribute these to ageing
rather than rhe side effects of medicines. 26 
2. Some patients are more likely to report their symptoms to
healthcare professionals such as hospital specialists or nurses
other than their GPs , which means that the GP is not being
fully aware of the problems experienced by the patient26 
3. Patient characteristics, such as cognitive impairment, func­
tional dependency, level of education and old age, hinder a
patient's explanation of problems with their current medica­
tions and the need for deprescribing.25 26 
4. Some patients do not wish to stop familiar medications.26 29 
5. Patients' demands, wishes and expectations and those of
their families may have an influence. 25 29 30 32 38 
6. Practitioners are reluctant to talk to patients about their life
expectancy. 26 
In this research group's experience, all of the above can be
significant obstacles to deprescribing-particularly, points (4) 
and (5). We have found that doctors are comrnonly influenced 
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by patients or patients' families when it comes to prescribing, 
which often results in them prescribing something that they 
know may not be technically appropriate or even required.10 12 
Many of the physidans thought patients would seek out another 
physician if they were not satisfied with their prescription and 
they took this into account before prescribing.
10 
As a doctor sometimes, you feel that you have to do something, 
you get pressurized by either nursing staff, relatives or patients. 
You have to give them something. So you end up giving sorne­
thing that you are not 100% happy with.12 
These outside influences are difficult to deal with. However, 
procedures for teaching medical students 'non-technical skills', 
such as dealing with patients and their families, have recently 
been proposed,41 and would appear to be warranted. There is 
also a consensus among the rnedical profession that increased 
targeted patient education would help to improve communica­
tion between doctor and patient. 12
OVERCOMING THE CHALLENGES 
Dealing with the challenges outlined above by improving the 
lines of communication between levels of care, making it expli­
cit who has the ultimate responsibility for ensuring the appro­
priateness of a patient's medical treatment, improving the 
medication review processes, including the patient in the 
decision-making process, better educating our young doctors 
and patient education, will all aid deprescribing. 
However, two areas should be the focus of immediate atten­
tion and the hospital pharmacist is ideally suited to deal with 
both. In order to facilitate deprescribing, we must (i) be able to 
identify instances where discontinuation of medications would 
be appropriate and (ii) know what to change and how. Several 
sets of explicit criteria have been developed to aid in the identi­
fication of instances where deprescribing would be beneficial. 
The rwo most established are the Beers criteria, 42 mainly used 
in the USA, and the STOPP/START criteria, 20 21 developed by 
our team in Cork. While these are useful tools and describe 
clear, practice-based situations where deprescribing might be 
beneficial, we have found rhat doctors are either unaware of 
them or do not know how to implement them.12 Providing pre­
scribers with information about these tools and training is crit­
ical. To know what to do once polypharmacy/inappropriate 
prescribing is detected and to know what to discontinue 
requires experience. But doctors could be given a much better 
start than is currently the case. Major deficiencies in geriatric 
pharrnacotherapy training have been uncovered through inter­
views with doctors. 12 Prescribers need to be made aware at an 
earlier stage the vast differences berween alder and younger 
patients. 
CONCLUSION 
The challenges of deprescribing in older patients are com­
pounded by the need to manage the shared treatment of mul­
tiple conditions by several prescribers from different specialties 
based on disease-specific guidelines which do not contain evi­
dence on the older, frailer, multimorbid patient population. 
Interdisciplinary effort in the treannent of older patients with 
multimorbidity needs to be improved to make sure that we treat 
the patient holistically and do not merely treat the individual 
conditions. We must first, however, equip prescribers to identify 
instances where deprescribing is appropriate and then make the 
necessary changes to pharmacotherapy. 
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AIMS 
Deprescribing interventions safely and effectively optimize medication use in older people. However, questions remain about 
which components of interventions are key to effectively reduce inappropriate medication use. This systematic review examines 
the behaviourchange techniques (BCTs) of deprescribing interventions and summarizes intervention effectiveness on medication 
use and inappropriate prescribing. 
METHODS 
MEDUNE, EM BASE, Web of Science and Academic Search Complete and grey literature were searched for relevant literature. 
Randomized controlled trials (RCTs) were included if they reported on interventions in people aged :::65 years. The BCT taxonomy 
was used to identify BCTs frequently observed in deprescribing interventions. Effectiveness of interventions on inappropriate 
medication use was summarized in meta-analyses. Medication appropriateness was assessed in accordance with STOPP criteria, 
Beers' criteria and national or local guidelines. Between-study heterogeneity was evaluated by 1-squared and Chi-squared statis­
tics. Risk of bias was assessed using the Cochrane Collaboration Tool for randomized controlled studies. 
RESULTS 
Of the 1561 records identified, 25 studies were included in the review. Deprescribing interventions were effective in reducing 
number of drugs and inappropriate prescribing, but a large heterogeneity in effects was observed. BCT clusters including goals 
and planning; social support; shaping knowledge; natura/ consequences; comparison of behaviour; comparison of outcomes; regulation; 
antecedents; and identity had a positive effect on the effectiveness of interventions. 
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CONCLUSIONS 
In general, deprescribing interventions effectively reduce medication use and inappropriate prescribing in older people. 
Successful deprescribing is facilitated by the combination of BCTs involving a range of intervention components. 
lntroduction 
Older people (aged 2:65 years) are more vulnerable to 
medication-related harm and inappropriate prescribing 
than younger chronically medicated people [l, 2]. Age­
related physiological changes contribute to iatrogenic 
vulnerability in older people, but it is equally a conse­
quence of their multimorbidity and frequent use of multi­
ple medications [1, 3-7]. Vulnerability, polypharmacy and 
multimorbidity represent complex challenges in the care 
of older people and often exclude them from clinical trials 
[6, 8-10]. Therefore, some prescriptions in multimorbid 
older people are without clear-cut evidence to support 
them and inappropriate prescribing is highly prevalent 
[11-13]. Excessive inappropriate prescribing in older people 
has turned the focus of current research towards 
deprescribing - the systematic process of identifying and 
discontinuing drugs in patients for which existing and 
potential harms outweigh the benefits (14]. Making 
informed decisions to deprescribe with the goal of reducing 
inappropriate prescribing and improving patient outcome 
is hampered by a lack of evidence of withdrawal effects in 
older people and is further challenged by prescriber- and 
patient-related factors (15, 16]. 
Research has demonstrated safety and effectiveness of 
deprescribing in older people (aged 2:65 years) [17] whilst 
reluctance of prescribers to deprescribe a medication 
commenced by another prescriber is described as well [18]. 
Although evidence suggests that pharmacist involvement 
and patient-centred interventions are effective, the best ways 
to engage and support prescribers in deprescribing remain 
unclear [16, 19-23]. Previous reviews examining the effects 
of deprescribing interventions on clinical outcomes call for 
a better understanding of successful implementation of 
deprescribing [6, 17-19]. 
Within the clinical context of patient care, there is a need 
to ensure that behaviour change is a part of any intervention 
design in order to maximize the chance that prescribers are 
enacting on recommendations [24, 25]. Recent advances in 
behavioural science provide insight into the components of 
complex interventions aiming at behaviour change. The 
Behaviour Change Techniques (BCTs) taxonomy version 1 
(BCTTvl) [26] is designed to assist in the identification of 
BCTs of interventions. A BCT is defined as 'an observable, 
replicable, and irreducible component of an intervention 
designed to alter or redirect causal processes that regulate 
behaviour' [27]. A clear description of BCTs will clarify the 
essential content of these complex interventions in a 
consistent way to assist in future replication of effective 
interventions [28]. The application of the BCT taxonomy to 
deprescribing is novel. This review was designed to comple­
ment previous reviews [6, 17, 19] on deprescribing by offering 
a broader analysis of behaviour change techniques in 
deprescribing interventions. 
The aims of this review are (i) to identify behaviour 
change techniques used more frequently in interventions 
effective in reducing number of drugs and inappropriate pre­
scribing, (ii) to describe other characteristics of deprescribing 
interventions and (iii) to determine intervention effective­
ness on drug use, prescribing appropriateness and Medica­
tion Appropriateness Index (MAI) score in meta-analyses. 
Methods 
A systematic search of the primary, secondary and grey 
literature to identify randomized controlled trials (RCTs) 
on deprescribing was undertaken on December 14, 2016. 
This systematic review was reported according to the 
PRISMA guidelines for systematic reviews and meta­
analyses (29], and was registered in Prospero (record no. 
CRD42016037730). 
Search strategy 
The search strategy was designed in conjunction with an 
experienced medical librarian OM) who was trained in 
systematic review methodology. A combination of text words 
and subject headings (such as MeSH terms) related to the 
intervention was used, without restricting publication date 
or language (Table Sl). 
The following electronic bibliographic databases were 
searched: MED LINE, EMBASE, The Cochrane Central Register 
of Controlled Trials, Web of Science and Academic Search 
Complete. Grey literature was searched via the Google 
Scholar® search engine and from screening reference lists of 
included studies as well as relevant systematic reviews. 
Additional searches were done in the System for Information 
on Grey Literature in Europe (OpenSIGLE) and the clinical 
trial registries, namely ClinicalTrials.gov, International Stan­
dard Registered Clinical/soCial sTudy Number (ISRCTN), 
WHO International Clinical Trials Registry Platform (ICTRP) 
and the Australian New Zealand Clinical Trials Register 
(ANZCTR). 
Study selection 
One reviewer (C.H.) screened titles of all retrieved citations. 
Two reviewers (C.H. and S.C.) independently screened 
abstracts and full-texts for eligibility according to protocol­
defined inclusion and exclusion criteria. Any disagreements 
between reviewers were resolved by consensus and both 
reviewers agreed on the final inclusion of studies. 
Inclusion and exclusion criteria 
Inclusion was restricted to randomized controlled study 
design, including randomized controlled trials (RCTs) and 
cluster RCTs. The control group could involve either active 
interventions or inactivity, e.g. sham or no intervention. This 
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study design was chosen to allow for between-study 
comparison of intervention effectiveness in meta-analyses. 
Studies were included if they reported on interventions 
encouraging the deprescribing of existing drugs or the 
reduction of existing inappropriate prescribing. Only those 
interventions involving older patients (aged 2'.65 years) or a 
healthcare professional with prescribing, dispensing or 
administration authority were included. No restrictions were 
applied to language, clinical setting of the intervention, 
sample size, blinding procedures or other design characteris­
tics. We excluded interventions specifically focusing on the 
clinical effects of drug withdrawal processes, e.g. opioid 
withdrawal effects. 
Risk of bias assessment 
Risk of bias was assessed separately by two reviewers (C.H. 
and A.R.) using the Cochrane Collaboration Tool for random­
ized controlled studies [30] with a descriptive purpose of 
summarizing the quality of the studies that met inclusion 
criteria. Studies were not excluded from data analysis because 
of methodological flaws if they otherwise met inclusion 
criteria. Incomplete outcome data was in general rated as 
high risk of bias if the loss of patients to follow-up was 20% 
or higher and rated as low risk of bias if the loss was 10% or 
less. Imbalance in the numbers lost to follow-up between in­
tervention and control groups was also considered to intro­
duce bias. The risk of bias assessment is described in detail 
in Table S2. 
Data extraction strategy 
Data were collected using a pre-agreed data extraction form 
(see Table 53). Two reviewers (C.H. and L.S.) independently 
pilot tested the form on two randomly chosen studies both 
included in the review. Thereafter data extraction on all 
studies was completed independently by L.S. and C.H. 
Disagreements on study inclusion/exclusion were resolved 
by discussion leading to consensus; where consensus could 
not be achieved, the study was excluded. Primary outcomes 
were: (i) number of total and inappropriate prescriptions 
and/or drugs as defined in the individual studies according 
to prescribing appropriateness criteria, e.g. STOPP criteria, 
Beers' criteria and local or national prescribing guidelines; 
(ii) proportion of participants with a reduction in number of
total and inappropriate prescriptions and/or drugs; and (iii)
implementation of recommendations. Secondary outcome
was change in MAI score.
Behaviour change techniques coding 
Coding of BCTs was performed independently by two 
reviewers (C.H. for all interventions and C.J.A., S.T. and L.S. 
for a subset of interventions each) by identifying BCTs for 
each intervention using the BCTTvl [26]. C.H. had 
completed online training in BCTTvl. A coding manual and 
instructions made by C.H. were given to the other reviewers 
and, exercises from the online training were made available 
to them. Any questions about the coding were solved by 
discussion and consensus between the reviewers. The target 
behaviour was the decision making to discontinue a drug or 
an inappropriate prescription. Findings were tabulated across 
studies by camputing frequencies. The information was used 
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to determine the BCTs used more frequently in studies that 
reported effectiveness of interventions to reduce number of 
drugs and/ar improve prescribing appropriateness. 
Statistical analysis 
We calculated odds ratios (OR) with standard deviations (SD) 
for each of the reported outcomes and used RevMan v5.3 to 
statistically combine the outcome data [31]. Continuous out­
comes were expressed as difference in means between groups 
with a 95% confidence interval (95% CI). The level of 
between-study heterogeneity was evaluated by calculation 
of theJ2 and Chi-squared statistics. Where possible, stratified 
random effects meta-analyses was used to identify factors 
affecting intervention effectiveness. Subgroup analyses were 
performed by risk of bias assessment, intervention setting 
and intervention target. If the level ofreporting did not allow 
for inclusion of a study in one or more meta-analyses, 
additional information was sought from the study authors. 
If the information was not made available, the study was 
excluded from the meta-analysis. 
Results 
Literature search and review process 
The database search identified 1444 records, and grey liter­
ature yielded 117 records. After removal of duplicates and 
title screening, 178 abstracts were screened for eligibility 
and 58 of these met the inclusion criteria. Assessment of 
full texts resulted in 25 studies included in this review 
[32-56]. Study selection and reasons for exclusion are illus­
trated in Figure 1. 
Study characteristics 
Included studies were RCTs (n = 22) [32-41, 43-45, 47, 
49-56] and cluster RCTs (n = 3) [42, 46, 48] with a
follow-up period from 6 weeks [45] to 13 months [42]. A
total of 20 812 patients were enrolled in the studies
ranging from 95 [41] to 1188 per study [55]. Detailed study
characteristics are provided in Table 1. Three studies aimed
primarily to reduce the number of drugs taken by patients
[41, 44, 46]. Other objectives included reduced prevalence
of inappropriate medications [32, 33, 38, 39, 42, 49],
improved prescribing appropriateness [34-36, 47, 50-55],
or better patient health outcomes and medicines manage­
ment [35, 40, 48, 56]. Ten out of the 25 studies included
in this review showed evidence to support intervention
effectiveness [34, 35, 37, 40, 41, 45, 46, 50, 53, 56]. Most
of the studies reporting intervention effectiveness of the
key outcomes of this review delivered recommendations
or feedback to the prescriber orally, often face-to-face, and
many of them followed up on the recommendations/
feedback given. Recommendations and feedback were
given immediately atter identification of a problem or at
the time of prescribing using an on-demand service. For
studies reporting no intervention effectiveness on the key
outcomes, some delivered recommendations using written
communication and many of the interventions did not fol­
low up on the recommendations with the prescriber. None
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Records identified through Additional records identified through 
database searching grev literature search and reference lists 
(n = 1444) (n = 117) 
,L ! 
I Reoords arter duplicates removed (n = 1440) I 
! 
Record titles screened 
(n = 1440) 
Abstracts screened 
(n = 178) 
' 
Full-text artides assessed 
for eligibility 
{n= 58) 
Studies included in 
narrative synthesis 
(n" 2Sl 
Studies included in 
meta-analysis (n = 17) 
Figure 1 
PRISMA flow chart of study selection 
of the included studies reported the use of explicit theories 
of behaviour change as part of the interventions and no 
study reported the use of a systematic and theoretical ap­
proach, such as the UK Medical Research Coundl's com­
plex intervention framework [57], in the intervention 
design. Reported educational interventions were based on 
the principles of constructive learning theory in ane study 
[39] and social constructivist learning and self-efficacy the­
ory in another study [46].
Records exc1uded 
(n = 1262) 
Reason for exclusion: 
; Intervention aim irrelevant to this 
review or not an RCT/quasi-RCT 
design 
Records excluded (n = 120) 
Reasons for exclusion: 
Nota RCT design (n = 65) 
Intervention not relevant (n = 21) 
� 
Age <65 years (n" 16) 
Outcomes not relevant (n = 12) 
Study protocol only (n = 6) 
Records excluded 
(n = 33) 
- Reasons for exclusion:
Nota RCT design (n: 3) 
Intervention not relevant (n = 13) 
Age <65 years (n = 9) 
Outcomes not relevant {n = 8) 
1 
Studies included in 
qualitative synthesis (n = 24) 
Risk ofbias 
Risk of bias assessment is illustrated in Figure 2. Risk of bias 
not pertaining to any of the defined categories were catego­
rized as 'others' and these are described in Table S2. 
Behaviour change techniques 
All but one study [48] reported the behaviour change compo­
nents underpinning the intervention. The BCT coding is 
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Table 1 
Characteristics af included studies (n = 25) 
Author 
(year) Country Settlng 
Allard et al. Canada 
(2001)(32] Community 
Bregnhøj et al. Denmark 
(2009) [47] Primary care 
physician practice 
Crotty et al. Australia 
(2004) [48] Nursing home 
Dalleur et al. Belgium 
(2014) [B] Teaching hospital 
Flck etal. USA 
(2004) [49] Primary care physician 
practice 
Frankenthal et al. lsraelCh ronic care 
(2014) [56] geriatric facility 
Gallagher et al. lreland 
(2011) [34] Teaching hospital 
Garcia-Gollarte Spain 
et al. (2014) [35] Nursing home 
Hanlon et al. (1996) USA 
[36] Ambulatory clinic 
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Mean ageof 
No. of patients patients 
0/ofemale (±SD), years 
266 80.6 (4.5) 
67.7% 
212 76.5 (7 .2) 
66.1% 
154 84.5 (5.0) 
59.6% 
146 85.0 (5.2) 
63.0% 
Not specified Not specified 
239 82.7 {8.7) 
66.6% 
382 75,6 (7.3) 
53.1% 





Intervention (I) Target behavlo11r 
Dellvered by (D) Target person(s) (P) 
(l)Medication review and Reducing the number 
suggestions madeand of potentially inappropriate 
mailed to GPs prescriptions given. 
(D) Multidisciplinary team (P) GPs. 
of physicians, pharmacists
and nurses 
(I) lnteractive educational lmproving prescribing 
meeting (single intervention) appro priateness. 
and combined with individualized 
feedback on prescribed medication 
(P) GPs. 
(combined intervention) 
(D) Clinical pharmacologist 
and pharmacists 
(I) Medication review and case lmproving medication 
conferences appropriateness. 
(D) Multidisciplinary team of (P) Residential care 
geriatrician, pharmacist, staff and residents' GPs.
representative of the Alzheimer' s
Association of South Australia
(I) Medication review and Discontinuation of PIMs 
recommendations provided (P) Hospital physicians
to discontinue medications
based on the STOPP criteria




therapist and psychologist 
(I) Dedsion support service Changing prescribing 
comprising educational behaviour and decreasing 
brochure, list of suggested PIM use. 
inappropriate medications (P) GPs 
based on the STOPP criteria,
and list of patients with
STOPP criteria identified
(D) Research team and 
expert panel of physicians 
and pharmacists
(I) Medication review and lmproving clinical and 
recommendations provided economic outcornes by 
based on the STOPP/ giving STOPP/START 
START criteria recommendations. (P) 
(D) Study pharmacist Chief physicians. 
(I) Medication review and lmproving prescribing 
recommendations provided appropriateness 
to change medications based (P) Hospital physician
on the STOPP /START criteria and medical care team 
(D) Research physician 
(I) Ed ucational workshops, lmproving the quality 
rnaterial and on-demand of prescriptions 
advice on prescriptions (P) N urs in g home physicia ns 
(D) Nursing home physician 
with geriatric expertise 
(I) Medication review lmproving prescribing 
and prescribing appropriateness 








Lenaghan et al. 
(2007) [37] 
Meredlth et al. 
(2002) [50] 
Milos et al. 
(2013) [38] 




Potter et al. 
(2016) [41) 
Rlchmond et al. 
(2010) [51] 
Saltvedt et al. 
(2005) [52] 




Primary care physician 
practice 
USA 
Home health setting 
Sweden 
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Mean age of 
No. of patients patients 
%Female (±SD), years 
136 84.3b 
65.6% 
317 80.0 (8.0) 
74.9% 
374 87.4 (5.7) 
74.9% 




95 84.0 (7.0) 
52.0% 
760 80.4 (4.1) 
43.2% 






Intervention (I) Target behaviour 
Dellvered by (D} Target person(s) (P) 
(D) Pharmacists 
(I) Medication review and Reducing hospital 
development of action admissions and n umber 
plan of agreed amendments of drug items prescribed 
(D) Pharmacists (P) GPs and patients 
(I) Medication review and lmproving medication use 
development of action plan (P) Nurses and patients 
to address identified problem 
(D) Multidisciplinary team of 
physicians, nurses and pharmacists 
(I) Medication review and Reducing the number of 
feedback given to physician patients using PJMs 
on drug-related problems (P) GPs 
(D) Pharmacists 
(I) Staff training and list of lmproving the use of 
harmful medications provided potentially harmful 
to encourage nurses to bring medications 
this to the physician's attention (P) Nurses 
(D) Research team 
(I) Clinical assessment by a Reducing the number 
senior doctor and multidisciplinary of drugs prescribed 
medication review using Beer's (P) GPs 
criteria. Recommendations 
given to GP 
(D) Consultant or senior 
specialist registrar and a 
multidisciplinary panel of 
consultant geriatricians, 
specialist registrars, hospital 
pharmacists and senior 
nurse practitioners 
(I) Medication review and Reducing the total 
cessation plan of non- number of medicines 
beneficial medications taken 
(D) Research team of GP (P) GPs and patients 
and geriatrician 
(I) Pharmaceutical care lmproving prescribing 
including medication reviews appropriateness 
(D) Research team (P) GPs 
(I) Comprehensive geriatric lncreasing the number 
assessment and treatment of drugs withdrawn 
of all illnesses {P) Medical care team 
(D) Multidisciplinary team 
of geriatrician, nurses, 
residents, occupational 
theraplsts and physiot� 
(I) Treatment in a geriatric I m proving prescribing 
evaluation and management 
unit (GEMU) in either 
(P) Medical care team 
inpatient or outpatient 
care or both 
(D) Pharmacists and a 
multi-disciplinary team 
of geriatrician, social 
worker and nurse 
(continues) 
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Spinewine et al. 
(2007) [54] 
Tamblyn et al. 
(2003) [42] 






Williams et al. 
(2004) [45] 

















Primary care physician 
practice 
















Meanageof Intervention (I) 
patients 
(±SD), years Dellvered by (D) 
82.2 (6.6) (l) Pha rmaceutical care 
including med ication 
review and development 
of a therape utic care plan 
with prescribing 
recommendations 
(D) P harmacists 
75.4 (6.3) (I) Electronic alerts instituted 
in the electronic patient 
prescription record to 
identify prescribing problems 
(D) Research team
75.0 (6.3) (I) Educational booklet 
to empower and encourage 
patients to discontinue 
benzodiazepines 
(D) Research team 





76.9b (I) Electronic messages 
sent to p hysicia n via 
electronic medication 





7S.7 {5.9) (I) Medication review 
based on MAI and 
prescribing recommendations 
provided and action plan made 
(D) Pharmadsts 
73.5 (6.5) (I) Prescri ption review 
and treatment recom mendations 
given to patients 
(D) Pharmacist and physician 
•rhe low percentages of females reported was explained by the nature of male patients in Veterans Affairs 0/A) clinics 
t>rhe SDs were not reported and could not be retrieved from the authors 
Target behaviour 
Target person(s) (P) 
l mprovi ng prescribing 
appropriateness 





Discontinu ation of 
benzodiazepines 
(P) Patients 
Reducing the number 
of potential DRPs and the 
number of drugs prescribed 
(P) GPs 






Making changes to repeat 
prescriptions and reducing 
the number of medicines 
taken 
(P) Patients 
presented in Table S4. Based on the reported results, 10 of 
the 25 studies showed an effect on the key outcomes (i) 
or (ii) of this review when comparing the intervention 
group to the control group [34, 35, 37, 40, 41, 45, 46, SO, 
53, 56]. No direct pattem was seen between the number 
of individual BCTs used and reported intervention effec­
tiveness. The median number of BCTs used were similar 
for studies reporting effective and non-effective interven­
tions (6 BCTs, IQR 3-8 and 5 BCTs, IQR 4-7, respectively). 
BCT clusters coded more frequently in studies reporting 
effectiveness [34, 35, 37, 40, 41, 45, 46, 50, 53, 56] com­
pared to studies reporting no effectiveness were: goals and 
planning; social support; shaping knowledge; natural conse­
quences; comparison of behaviour; comparison of outcomes; reg­
ulation; antecedents; and identity (see Figure 3). 
2722 Br I Clin Pharmacol (2018) 84 2716-2728 
Intervention effectiveness 
(a) Druguse
Overall, the mean number of drugs post-intervention was sig­
nificantly lower among intervention participants compared 
to the control participants in the presence of moderate 
between-study heterogeneity (mean difference -0.96, 95% 
242
Behaviour change techniques in deprescribing interventions 
Random sequence generafion (selection bias} 
Allocation concearment (selection bias) 
Blinding of particiøants and personnel (performance bias) 
Blinding of outcome assessment (detedion bias) 
lncomplete outcome data (firsttime point offollow-up) 
lncomplete outcome data {last Urne pointfor follow-up) 
Selective reøorting (reporting bias) 
Olherbias 
L -
0% 25% 50% 75% 
I 
• Lowriskofbias D Uncrear risk or bias • High risk of bias 
Figure 2 
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30 
Frequency of behaviour change techniques (BCTs) coded for studies reporting intervention effectiveness on the key outcomes of this review 
compared to studies reporting no effectiveness of interventions. The frequencies are weighed values based on the number of studies in each 
group, i.e. effectiveness versus no effectiveness 
er -1.53, -0.38, heterogeneity J2 = 70% and P = 0.002, 
Figure Sl). Regarding the difference in change in the number 
of drugs taken per patient, deprescribing interventions 
lowered the number (-0.74, 95% Cl -1.26, -0.22), but 
effects varied greatly across studies (r2 = 92%, P < 0.001) 
(Figure 4). Stratified analyses by; (i) whether the intervention 
was patient-centred or targeting solely healthcare profes­
sionals (Figure S2), (ii) intervention setting (Figure 4) and 
(iii) study quality (Figure S3) showed no effect of these
factors on summary estimates. In addition, the unexplained
variation within subgroups remained large.
(b) Prescribing appropriateness
Deprescribing interventions demonstrated a relatively
small effect and a high level of heterogeneity on the number 
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Expenmen1al Control Mean Difference 
Stud or Subgroup Mean Difference SE Total Total Wejght IV. Random. 95'!', Cl 
Mean Difference 
IV, Random. 95� Cl 
RiskofBias 
ABCDEFGH 
2.2.1 outpauent se!ting 
c,ottv 2004 ·0.39 0-46 32 39 
Ga,cia-Gollarte 2014 ·1.2 0.58 185 200 
Hanlon 1996 ·0.4 0.59 86 83 
Lenaghan 2007 ·0.87 0.4 59 55 
Milos 2013 .Q.6 0.79 171 174 
Potter2D16 ·2 0.15 35 32 
Vinks2009 •0.41 0 .22 87 87 
Williams 2004 ·0.98 0.19 57 76 
zermansky 2001 -0.2 0.08 576 549 
Subtotal (95'!> Cl) 1288 1295 
Heterogeneify:Tau•: 0.67; Chi'" 118.45, øf: 8 (P < 0.00001); P: 93% 
Test ror overall efl"ect Z = 2.63 (P = 0.008) 
2.2.2 lfospital selting 
8.5% ·0.39 (-1.29,0.51] 
7.4% ·1.20 (-2.34.-0.06] 
7.3% -0.40 l·l.56, 0.76] 
9.1% -0.87 /-1.65, ·0.09] 
5.7% -0.601·2.15, 0,95] 
11.1% ·2.0D /-2.29,-1.71] 
10.7% -0.41 U-84, 0.02J 
10.9% -0.98 �1.35, ·0.61) 
11.4% -0.201-0.36, ·0.04) 







••• ? ?, ? •• 
,??·?···· 
•1•1•••• 
Pope 2011 -0.88 0.35 110 115 9.6% -0.88 j-1.57. ·0.19) •1ee1,1•• 
···?···· Salt.ed! 2005 0.01 0.49 119 110 8.4'-'> 0.01 1-0.93, 0.95) 
Subtotal (95'!'. Cl) 229 225 17.9" .o.50 (-1.36, O.J7] 
Heterogeneily:Tau"= 0.22;Chf'= 2.24, (lf= 1 (P= O.t3);r: 55% 
Test for OYerall effect Z= 1.12 (P = 0.26) 
Total (9511 Cl) 1517 1520 100.0t. -0.74 [-1.26. -0.22) • 
Heterogeneit,-: Tau•: O.Øl: Chi'" 120.74, df: 10 (P • 0.00001); I': 92% 
Teslfor O\ll!rall etrect z" 2.80 (P = 0.005) 
Testror subgroup dilferences: Chr'= 0.33, df" 1 (P" 0.57), I'" O'l!> 
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Mean difference in the change in number of drugs comparing experimental (intervention) gro up and contra! group. Subgroup anafysis on inter­
vention setting (outpatient setting versus hospital setting) 
of inappropriate drugs per participant comparing interven­
tion and control groups post-intervention (-0.19, 95% Cl 
-0.40, 0.02, heterogeneity I2 = 90% and P = 0.07, Figure S4).
The proportion of participants with at least one inappropriate
drug, as defined in the individual studies, were reduced when
a deprescribing intervention was applied, but confidence in­
tervals were wide, and a high level of heterogeneity was
present (Figure 5).
(c) Implementation of recommendations
Only four studies reported implementation rates of rec­
ommendations to discontinue a medication or change a med­
ication [36, 38, 43, 49]. Action was taken in 55. 1 % of 
recommendations given by a pharmacist compared to only 
19.8% of the nurse recommendations as part of usual phar­
maceutical care [36]. In the study by Vinks et al. [43], 27 .7% 
of pharmacists' recommendations were implemented, and 
action was taken in 56% of drug-related problems identified 
by a pharmacist in Milos et al. [38]. A lower recommendation 
implementation rate of 15.4% was shown in Fick et al. [49]. 
This result was based on self-reported action taken by the 
physicians; only 71 % of physicians reported this, which 
may explain the Iower frequency of action observed. 
(d) MAI score
Seven studies reported changes in MAI scores for partidpants
pre- and post-interventions [34, 36, 47, 48, 51, 53, 54]. Across
studies, deprescribing interventions demonstrated a si.gnificant
effect on reducing the MAI score comparing intervention and
control groups post-intervention (-5.04, 95% CI -7.40,
-2.68, heterogeneity J2 = 88% andP < 0.0001, Figure SS).
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Discussion 
Effectiveness of deprescribing interventions is determined by 
a combination of factors. Consistent with the tindings ofre­
cent reviews [6, 17], our meta-analysis showed that 
deprescribing interventions are effective in reducing the 
number of drugs and inappropriate prescribing (reduced 
MAI scores) in older people, although the evidence is 
heterogeneous. 
Based on the tindings of the BCT coding exercise, effec­
tive deprescribing interventions included: (i) a goal and an 
action plan to solve prescribing problems, (ii) monitoring 
of behaviour, (iii) social support and the use of a credible 
source, and (iv) clear instructions and guidance on imple­
mentation to the prescriber and information about health 
consequences of doing/not doing the behaviour. Support 
from colleagues and information about potential risks and 
benefits to the patients in the presence/absence of a 
behaviour change may also be effective techniques of 
deprescribing. 
Differences in the delivery of prescribing recommenda­
tions were seen in the studies reporting intervention 
effectiveness compared to studies reporting no effect on 
key outcomes of this review. Studies reporting effectiveness 
[34, 35, 37, 40, 41, 45, 46, SO, 53, 56] used oral and face­
to-face communication to discuss and implement 
deprescribing recommendations consistent with the princi­
ples of educational outreach to inform clinical decision mak­
ing as described by Soumerai and Avorn [58]. lnvestigation 
of the delivery of recommendations to deprescribe may pro­
vide useful information on the delivery of a successful 
deprescribing intervention in addition to the use of BCTs. 
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Pharmacist recommendations to reduce drug intake and 
inappropriate prescribing were frequently enacted on in 
some studies [36, 38), consistent with previous literature 
reporting benefits of phannacist-led interventions to 
optimize medication use in older people [21, 59]. Other 
studies [43, 49) reported a lower acceptance rate of phar­
macist recommendations, between 15% and 28% of recom­
mendations enacted on. Recent research has demonstrated 
a high level of agreement between prescribers and pharma­
cists in the assessment of potential target medications for 
deprescribing (60, 61). In contrast, other research studies 
indicate that acceptance rates for recommendations made 
by pharmacists are lower than those made by their physi­
cian colleagues [62). The Iower uptake of pharmacist 
recommendations despite a high level of agreement 
about deprescribing is noteworthy. It may indicate that 
challenges to deprescribing are in faet dependent on the 
particular ways deprescribing interventions are delivered, 
particularly when there is a question of behaviour change. 
Based on the tindings of this review, we suggest that future 
research should investigate the behaviours associated with 
the acceptance and rejection of deprescribing recommenda­
tions to gain a better understanding of a successful delivery 
of deprescribing interventions. 
This is the first review to identify BCTs in deprescri­
bing interventions necessary to achieve a change in 
behaviours towards deprescribing. Our findings comple­
ment previous reviews on deprescribing [17, 19] by offer­
ing a broader analysis of BCTs that are effective for 
deprescribing. 
Limitations and strengths 
Tue review findings are based on a comprehensive search 
of the Iiterature. Tue novel aspect of this review is in the 
use of a validated taxonomy to describe intervention con­
tent that facilitates behaviour change. Limitations of this 
review reside mostly in the limited data available. RCTs to 
date are of a relatively small size (often :-,:100 participants) 
and usually with short follow-up periods. Other !imitations 
relate to the high-risk blinding procedures; these were 
needed because the interventions in question required 
blinding of the personnel whose behaviour was targeted, 
and this was logistically difficult. Absence of blinding 
procedures for outcome assessors were not considered to 
introduce important bias because the study outcomes, 
e.g. number of drugs taken, was not a particularly subiec­
tive measure. Random sequence generation and allocation
concealment were considered high importance biases in 
this review because participant characteristics such as
multimorbidity, age and polyphannacy could have an
impact on the number of drugs taken and risk of inappro­
priate prescribing [1, 5-8].
The meta-analysis was reliant on published or reported 
data and, while some reported outcomes were adjusted for 
baseline patient characteristics, others were not, which 
makes the direct comparison of intervention effect on 
specific outcomes open to question. Similarly, and as 
described in a previous review [27], the BCT coding was lim­
ited to the intervention descriptions reported in the studies. 
Limited reporting on interventions used to encourage 
deprescribing could have resulted in BCTs being undercoded 
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and others overcoded due to assumptions made about the 
strategies used based on the information available. For 
example, we assumed that the reporting of prescribing 
recommendations given to the prescriber would involve 
BCT codes: instructions on how to perform a behaviour and 
feedback on behaviour. Prescribing recommendations were 
a commonly used intervention in the studies and this 
may have resulted in these two BCTs being overcoded. 
One study was also excluded from the BCT coding due 
to lack of information which could have potentially 
impacted the true tindings of this review. Furthermore, 
we were unable to code BCTs in the control groups due 
to limited reporting of the control conditions. The con­
trol conditions such as usual care in hospital settings or 
in outpatient settings could include BCTs with potential 
implications on the interpretation of the review findings. 
Reporting of future behaviour change interventions and 
control conditions will benefit from the use of compre­
hensive checklists, such as the TIDieR [63], and give 
reviewers the ability to adequately code BCTs and exten­
sively appraise the reporting quality of such interven­
tions. This will improve the identification of 
relationships between BCTs used and intervention 
effectiveness. 
The main !imitation of our pooled estimates is the 
presence of typically large between-study variation and, 
for some of the analyses, the wide confidence intervals 
including trivial effects. Some may argue that a meta­
analysis should not be done in the presence of impor­
tant heterogeneity. Meta-analytical methods, however, 
allow for the exploration of sources of heterogeneity 
and we fully acknowledge that the magnitude of the 
summary estimates should be interpreted with care. To 
minimize the level of heterogeneity due to different 
study designs, we also decided to limit the inclusion 
criteria to randomized controlled studies and cluster ran­
domized controlled studies only. Although the direction 
of effect was favouring deprescribing, the magnitude of 
effect was very variable. This inconsistency, together 
with the imprecision and risk of bias issues lower our 
con:fidence in the estimates of effect so that the magni­
tude of effect is very low. 
Conclusion 
Deprescribing interventions are effective in reducing the 
number of drugs taken by patients and improving pre­
scribing inappropriateness. Their success may be 
explained by a cornbination of BCTs spanning a range 
of different intervention functions, although we could 
not empirically show this. The use of BCTs and delivery 
of such behaviour change interventions should be consid­
ered of importance to facilitate successful implementation 
of deprescribing. This review contributes to the existing 
evidence by critically analysing the content of depres­
cribing interventions in terms of behaviour change, 
clearly demonstrating that the current evidence base is 
too small to derive strong conclusions on determinants 
of success. 
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of each BCT and BCT cluster 
Figure SI Mean number of drugs per patient post-interven­
tion comparing experimental (intervention) group and con­
trol group 
Figure S2 Subgroup analysis on target person (patient or 
healthcare professional) for mean difference in the change 
in number of drugs per patient 
Figure S3 Subgroup analysis on risk of bias assessment (ran­
dom sequence generation) for mean difference in the change 
in number of drugs per patient 
Figure S4 Mean difference in the number of inappropriate 
drugs per participant comparing experimental (intervention) 
group and control group 
Figure SS Mean difference in the change in MAI score per 
participant comparing experimental (intervent ion) group 
and control group 
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Data collection process 
Data items 
Risk af bias in individual 
studies 
Summary measures 
Synthesis of results 
1 I ldentify the report as a systematic review, meta-analysis, or both. 2716 
2 I Provide a structured summary including, as applicable: background; objectives; data sources; study I 2716-17
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
!imitations; conclusions and implications of key findings; systematic review registration number.
3 I Describe the rationale for the review in the context of what is already known. 
4 I Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS}. 
5 I lndicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number. 
6 I Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale. 
7 I Describe all information sources (e.g., databases with dates of coverage, contact with study authors 
to identify additional studies} in the search and date last searched. 
8 I Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated. 
9 I State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 
if applicable, included in the meta-analysis}. 
1 O I Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators. 
11 I List and define all variables for which data were sought (e.g., PICOS, funding sources} and any 
assumptions and simplifications made. 
12 I Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis. 
13 I State the principal summary measures (e.g., risk ratio, difference in means). 
14 I Describe the methods of handling data and combining results of studies, if done, including 
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PRISMA 2009 Checklist 





Risk of bias within studies 
Results of individual studies 
Synthesis of results 
Risk af bias across studies 
Additional analysis 
DISCUSSION 






15 I Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective I 2718
reporting within studies). 
16 I Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating I 2718
which were pre-specified. 
17 I Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram. 
18 I For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations. 
19 I Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 
20 I For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
21 I Present results of each meta-analysis done, including confidence intervals and measures of consistency. 
22 I Present results af any assessment of risk of bias across studies (see Item 15). 
23 I Give results of additional analyses, if done ( e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). 
24 I Summarize the main tindings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers). 
25 I Discuss !imitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias). 











27 I Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the I 2726
systematic review. 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PloS Med 6(7): e1000097. 
doi: 10.1371 /journal. pmed 1000097 
For more information, visit: www.prisma-statement.org. 
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PROSPERO National lnstitute for 
International prospective register of systematic reviews Health Research 
UNIVERSITY eftnlc.. 
Centre for Reviews and Dissemination 
Systematic review 
1 . * Review title. 
Give the working title of the review, for example the one used for obtaining fund ing. ldeally the title should 
state succinctly the interventions or exposures being reviewed and the associated health or social problems. 
Where appropriate, the title should use the Pl(E)COS structure to contain information on the Participants, 
Intervention (or Exposure) and Comparison groups, the Outcomes to be measured and Study designs to be 
included. 
Effectiveness of deprescribing interventions in alder people: a systematic review and meta-analysis 
2. Original language title.
For reviews in languages other than English, this field should be used to enter the title in the language of the 
review. This will be displayed together with the English language title. 
3. * Anticipated or actual start date.
Give the date when the systematic review commenced, or is expected to commence. 
03/05/2016 
4. * Anticipated completion date.
Give the date by which the review is expected to be completed. 
01/03/2018 
5. * Stage of review at time of this submission.
lndicate the stage of progress of the review by ticking the relevant Started and Completed boxes. Additional 
information may be added in the free text box provided. 
Please note: Reviews that have progressed beyond the point af completing data extraction at the time af 
initial registration are not eligible for inclusion in PROSPERO. Should evidence of incorrect status and/or 
completion date being supplied at the time of submission come to light, the content of the PROSPERO 
record will be removed leaving only the title and named contact details and a statement that inaccuracies in 
the stage of the review date had been identified. 
This field should be updated when any amendments are made to a published record and on completion and 
publication of the review. lf this field was pre-populated from the initial screening questions then you are not 
able to edit it until the record is published. 
The review has not yet started: No 
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PROSPERO National lnstitute for 
International prospective register of systematic reviews 
Review stage 
Preliminary searches 
Piloting of the study selection process 
Formal screening of search results against eligibility criteria 
Data extraction 

















Provide any other relevant information about the stage of the review here (e.g. Funded proposal, protocol not 
yet finalised). 
The review has been finalised and published. 
The review has been finalised and published. 
6. * Named contact.
The named contact acts as the guarantor for the accuracy of the information presented in the register record. 
Ms Christina Raae Hansen 
Email salutation (e.g. 11Dr Smith" or "Joanne") for correspondence: 
Ms Hansen 
7. * Named contact email.
Give the electronic mail address of the named contact. 
christina. raaehansen@ucc.ie 
8. Named contact address
Give the full postal address for the named contact. 
Pharmaceutical Care Research Group, 
School of Pharmacy, University College Cork 
Cavanagh Pharmacy Building, College Road 
Cork City 
lreland 
9. Named contact phone number.
Give the telephone number for the named contact, including international dialling code. 
+353214901690
10. * Organisational affiliation of the review.
Full title of the organisational affiliations for this review and website address if available. This field may be 
completed as 'None' if the review is not affiliated to any organisation. 
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National University of lreland, University College Cork 
Organisation web address: 
www.ucc.ie 
11. * Review team members and their organisational affiliations.
Give the title, first name, last name and the organisational affiliations of each member of the review team. 
Affiliation refers to groups or organisations to which review team members belong. 
Ms Christina R. Hansen. Pharmaceutical Care Researcg Group, School of Pharrnacy, University College 
Cork, Cork, lreland and Section for Social and Clinical Pharmacy, Department of Pharmacy, Faculty of 
Health and Medical Sciences, University of Copenhagen, Copenhagen, Den mark. 
Dr Shane Cullinan. School of Pharmacy, Royal College of Surgeons, Dublin, lreland 
Professor Patricia M. Kearney. Department of Epidemiology and Public Health, University College Cork, 
Cork, lreland 
Professor Denis O'Mahony. Departrnent of Medicine, University College Cork and Geriatric Medicine, Cork 
University Hospital and St. Finbarr's Hospital, Cork 
Dr Sven Streit. lnstitute of Primary Health Care BJHAM, University of Bern, Bern, Switzerland 
Dr Laura Jane Sahm. Pharmaceutical Care Research Group, School of Pharmacy, University College Cork 
and Mercy University Hospital, Grenville Place, Cork, lreland 
Professor Stephen Syrne. Pharmaceutical Care Research Group, School of Pharmacy, University College 
Cork, Cork, lreland 
Ms C.J.A. Huibers. Department of Geriatric Medicine and Expertise Centre Pharmacotherapy in Old 
Persons, University Medical Centre Utrecht, Utrecht, The Netherlands. 
Ms Stefanie Thevelin. Louvain Drug Research lnstitute, Universite Catholique de Louvain, Brussels, Belgium 
Ms Anne W. S. Rutjes. University of Chiete-Pescara, Chiete-Pescara, ltaly. 
Dr Wilma Knol. Department of Geriatric Medicine and Expertise Centre Pharmacotherapy in Old Persons, 
University Medical Centre Utrecht, Utrecht, The Netherlands 
12. * Funding sources/sponsors.
Give details of the individuals, organizations, groups or other legal entlties who take responsibility for 
initiating, managing, sponsoring and/or financing the review. lnclude any unique identification numbers 
assigned to the review by the individuals or bodies listed. 
The systematic review is being conducted as part of Christina Raae Hansen's PhD. This work is part of the 
project "OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly" 
supported by the European Commission (EC) HORIZON 2020, proposal 634238, and by the Swiss State 
Secretariat for Education, Research and Innovation (SERI) under contract number 15.0137. The opinions 
expressed and arguments employed herein are those of the authors and do not necessarily reflect the official 
views of the EC and the Swiss government. Dr Shane Cullinan and Ms Christina Raae Hansen are both 
funded by the OPERAM project. 
13. * Conflicts of interest.
List any conditions that could lead to actual or perceived undue influence on judgements concerning the 
main topic investigated in the review. 
None 
14. Collaborators.
Give the name and affiliation of any individuals ar organisations who are working on the review but who are 
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not listed as review team members. 
Mr Joe Murphy. Hospital Library, Mercy University Hospital, Grenville Place, Cork, lreland 
15. * Review question.
State the question(s) to be addressed by the review, clearly and precisely. Review questions may be specific 
or broad. It may be appropriate to break very broad questions down into a series of related more specific 
questions. Questions may be framed or refined using Pl(E)COS where relevant. 
To determine the effectiveness of deprescribing interventions in reducing prescribed medications in adults. 
To identify behaviour change components present in interventions and whether they are deemed to be 
effective or non-effective. 
16. * Searches.
Give details of the sources to be searched, search dates (from and to), and any restrictions (e.g. language or 
publication period). The full search strategy is not required, but may be supplied as a link or attachment. 
The following electronic bibliographic databases will be searched for relevant literature: MEDLINE, EM BASE, 
CINAHL, The Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and Academic 
Search Complete. Grey literature will be searched from relevant sources. The search strategy will include 
only terms relating to ar describing the intervention. 
There will be no language or time restrictions. 
17. URL to search strategy.
Give a link to a published pdf/word document detailing either the search strategy ar an example af a search 
strategy for a specific database if available (including the keywords that will be used in the search 
strategies), ar upload your search strategy.Do NOT provide links to your search results. 
Alternatively, upload your search strategy to CRD in pdf format. Please note that by doing so you are 
consenting to the file being made publicly accessible. 
Yes 1 give permission for this file to be made publicly available 
18. * Condition ar domain being studied.
Give a short description of the disease, condition or healthcare domain being studied. This could include 
health and wellbeing outcomes. 
Deprescribing 
19. * Participants/population.
Give summary criteria for the participants or populations being studied by the review. The preferred format 
includes details af both inclusion and exclusion criteria. 
Older people (aged = 65 years) prescribed medication. 
20. * lntervention(s), exposure(s).
Give full and clear descriptions or definitions of the nature of the interventions or the exposures to be 
reviewed. 
The interventions to be reviewed are interventions to discontinue existing drug prescriptions and reduce drug 
dosages; targeting deprescribing in adults (aged = 18 years); and involving a healthcare professional with 
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prescribing authority and/or adult patients. 
lnclusion criteria: Original primary research, full-text availability, controlled trials of interventions. 
Exclusion criteria: Interventions targeting appropriateness of prescribing and interventions focusing on Opioid 
withdrawal or Nicotine Replacement Therapy. 
21. * Comparator(s)/control.
Where relevant, give details of the alternatives against which the main subject/topic of the review will be 
compared (e.g. another intervention or a non-exposed control group). The preferred format includes details 
of both inclusion and exclusion criteria. 
No control group, a non-exposed control group or a control group receiving 'treatment as usual' or 
'standard care' at the time that the particular eligible study was done. 
22. * Types of study to be included.
Give details of the types of study (study designs) eligible for inclusion in the review. lf there are no 
restrictions on the types of study design eligible for inclusion, or certain study types are excluded, this should 
be stated. The preferred format includes details of both inclusion and exclusion criteria. 
Controlled trials of interventions to deprescribe medications in adults will be included (i.e. randomised 
controlled trials, non-randomised controlled trials and before-and-after studies). Studies in primary, 
secondary and tertiary care evaluating the effect of a deprescribing intervention to reduce number of 
prescriptions and dosages per patient will be included. Exclusion af studies that evaluates interventions to 
prevent inappropriate prescribing and evaluating withdrawal of Opioid and Nicotine Replacement therapies. 
23. Context.
Give summary details of the setting and other relevant characteristics which help define the inclusion or 
exclusion criteria. 
Studies in primary, secondary and tertiary care including ambulatory and inpatient settings. 
24. * Main outcome(s).
Give the pre-specified main {most important) outcomes of the review, including details of how the outcome is 
defined and measured and when these measurement are made, if these are part of the revlew inclusion 
criteria. 
Number of prescriptions per patient and/or change in dosages of prescriptions per patient 
Timing and effect measures 
25. * Additional outcome(s).
List the pre-specified additional outcomes of the review, with a similar level of detail to that required for main 
outcomes. Where there are no additional outcomes please state 'None' or 'Not applicable' as appropriate 
to the review 
Medication Appropriateness Index (MAI). 
Timing and effect measures 
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Give the procedure for selecting studies for the review and extracting data, including the number of 
researchers involved and haw discrepancies will be resolved. List the data to be extracted. 
Retrieved citations from the search strategy will be screened for eligibility based on citation titles, abstracts 
and full-texts. The titles of studies will be reviewed by the primary researcher. Subsequent abstract review of 
potentially eligible studies will be conducted independently by the primary researcher and another member af 
the review team. Full texts af potentially eligible studies will be retrieved and the articles will be reviewed by 
the two researchers. The reviewing process will be perfarmed according to the pre-specified inclusion 
criteria. Any disagreements between the two reviewers will be resolved by consensus and a third reviewer 
will be consulted if this cannot be obtained. A pre-agreed data extraction form will be used to collect the 
relevant data by the primary researcher. This will include information on study characteristics such as study 
design, methods, setting, participants, intervention and outcomes. Where applicable, intervention 
characteristics such as delivery, theory, target component, behaviour camponents and prescriber component 
wi li be extracted. 
27. * Risk of bias (quality) assessment.
State whether and how risk of bias will be assessed (including the number of researchers involved and how 
discrepancies will be resolved), how the quality af individual studies will be assessed, and whether and how 
this will influence the planned synthesis. 
Risk of bias (quality) assessment will be performed independently by two reviewers for each study included 
individually using an appropriate Cochrane risk of bias tool. Disagreements between the reviewers will be 
resolved by discussion, with involvement of a third reviewer where necessary. 
28. * Strategy for data synthesis.
Give the planned general approach to synthesis, e.g. whether aggregate or individual participant data will be 
used and whether a quantitative or narrative (descriptive) synthesis is plan ned. It is acceptable to state that a 
quantitative synthesis will be used if the included studies are sufficiently homogenous. 
The tindings of the individual studies will be combined in a meta-analysis to estimate the effectiveness of the 
interventions. The level of heterogeneity between the studies will be evaluated by two reviewers based on 
the data extraction. A sensitivity analysis will be conducted on study quality. lf a meta-analysis is not 
appropriate due to heterogeneity of the studies reviewed, the tindings will be combined thematically in a 
narrative synthesis. 
29. * Analysis of subgroups or subsets.
Give details of any plans for the separate presentation, exploration or analysis of different types of 
participants (e.g. by age, disease status, ethnicity, socioeconomic status, presence or absence or co­
morbidities); different types of intervention (e.g. drug dose, presence or absence of particular components of 
intervention); different settings (e.g. country, acute or primary care sector, professional or family care); or 
different types of study (e.g. randomised or non-randomised). 
Where applicable in the studies, a subgroup analysis will be conducted to identify the presence and 
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frequency of behaviour change components as per the Behaviour Change Technique Taxonomy v1 
described by Michie S, et al. (2013): "The Behaviour Change Technique Taxonomy {v1) of 93 Hierarchically 
Clustered Techniques: Building an International Consensus for the Reporting of Behaviour Change 
Interventions." 
30. * Type and method of review.
Select the type of review and the review method from the lists below. Select the health area(s) of interest for 
your review. 

























Prospective meta-analysis {PMA) 
No 














International prospective register of systematic reviews 
No 






























Health inequalities/health equity 
No 






















Pregnancy and childbirth 
No 
Public health (including social determinants of health) 




International prospective register of systematic reviews 



















Wounds, injuries and accidents 
No 
Violence and abuse 
No 
31. Language.
Select each language individually to add it to the list below, use the bin icon to remove any added in error. 
English 
There is an English language summa ry. 
32. Country.
Select the country in which the review is being carried out from the drop down list. For multi-national 
collaborations select all the countries involved. 
lreland 
33. Other registration details.
Give the name of any organisation where the systematic review title or protocol is registered (such as with 
The Campbell Collaboration, or The Joanna Briggs lnstitute) together with any unique identification number 
assigned. (N.B. Registration details for Cochrane protocols will be automatically entered). lf extracted data 
will be stored and made available through a repository such as the Systematic Review Data Repository 
(SRDR), details and a link should be included here. lf none, leave blank. 
34. Reference and/or URL for published protocol.
Give the citation and link for the published protocol, if there is ene 
Give the link to the published protocol. 
Alternatively, upload your published protocol to CRD in pdf format. Please note that by doing so you are 
consenting to the file being made publicly accessible. 
Yes I give permission for this file to be made publicly available 
Please note that the information required in the PROSPERO registration form must be completed in fulf even 
if access to a protocol is given. 
35. Dissemination plans.




International prospective register of systematic reviews 
National lnstitute for 
Health Research 
A paper will be submitted to a leading journal in this field. 
Do you intend to publish the review on completion? 
Yes 
36. Keywords.
Give words or phrases that best describe the review. Separate keywords with a semlcolon or new line. 
Keywords will help users find the review in the Register (the words do not appear in the public record but are 
included in searches). Be as specific and precise as possible. Avoid acronyms and abbreviations unless 
these are in wide use. 
Deprescribing 
Behaviour Change 
37. Details of any existing review of the same topic by the same authors.
Give details of earlier versions of the systematic review if an update of an existing review is being registered, 
including ful! bibliographic reference if possible. 
38. * Current review status.
Review status should be updated when the review is completed and when it is published. For 
newregistrations the review must be Ongoing. 
Please provide anticipated publication date 
Review_Completed_published 
39. Any additional information.
Provide any other information the review team feel is relevant to the registration of the review. 
The findings of this review will be used to inform further research to be conducted as part of the PhD of the 
primary researcher 
40. Details of final report/publication(s).
This field should be lefl empty until details of the completed review are available. 
Hansen CR, O'Mahony D, Kearney PM, Sahm LJ, Cullinan S, Huiber CJA, Thevelin S, Rutjes AWS, Knol W, 
Streit S, Syrne S. ldentification of behaviour change techniques in deprescribing interventions: a systematic 
review and meta-analysis. Br J Clin Pharmacol. 2018;84:2716-28. Doi: 10.1111/bcp.13742 
Give the link to the published review. 
https://doi.org/10.1111/bcp.13742 
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13742 
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Intervention type Intervention Control type (e.g. usual Who delivered the 
(e.g. medication description care, different intervention? 
reviews, electronic education/training) (researcher, pharmacists 
alerts, education etc.) 
etc.) 
Intervention target Follow-up Prima ry outcome Secondary outcomes 
person (i.e. whose duration 
behaviour was 
cha nged/ta rgeted?) 
Tool /Measure to Number of N (participants, total) Gender female (%) (both 
identify participants total, intervention group 
ta rget/ o utcome enrolled in total and control group) 
{only for and for individual 
prescribing arm 
appropriateness) 
Age of study Ave rage of Mean Ethical considerations The study conclusion 
population (specify (SD) (yes/no/cant' tell) (short!) 
mean or median) 
Trial design Where were How were participants Sample size 
pa rtici pants recruited? (database, calculation/consideration 
recruited from? telephone etc.) reported (yes/no) 
Data collection (i.e. Blinding (who Randomisation strategy Eligibility criteria of study 
source of was blinded or subject/patients (who 
information) what process was invited?) 
what blinded?) 
lndusion criteria Exclusion criteria Medication use/prescribing Number of participants 
(study (study rate at baseline experiencing reduction in 
subjects/patients) su bjects/ patients) number of prescriptions 
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Number of Number of Change in number of Change in MAI-score 
participants participants PI Ps/Rx/Drugs/Dosages 
experiencing experiencing 
reduction in reduction in 
numberof number of 
medication (in all PIPs/PIMs (in all 
control and control and 
intervention intervention 
groups) groups) 
Healthcare services ADRs/ADEs Medication costs Other comments on 
utilization (hospita I prevalence outcomes (if relevant to 
admission, GP visits the review) 
etc.) 
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Longitudinal patterns of potentially inappropriate prescribing 
in early old-aged people 
Christina Raae Hansen 1 , Stephen Byrne1 , Shane Cullinan2 , Denis O'Mahony3•4 , 
Laura J. Sahm 1•5 , Patricia M. Kearney6 
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Abstract 
Purpose It is contentious whether potentially inappropriate 
prescribing (PIP) is predominantly a phenomenon of late life 
or whether it has its origins in early old age. This study exam­
ined the pattem of PIP in an early old-aged population over 
5 years. 
Methods Secondary data analysis of a population-based pri­
mary care cohort, of patients aged 60-7 4 years. Medication 
data were extracted from electronic patient records in addition 
to information on comorbidities and demographics. Explicit 
START criteria (PPOs) and STOPP criteria (PIMs) were used 
to identify PIP. Generalised estimating equations were used to 
describe trends in PIP over time and adjusted for age, gender 
and number ofmedicines. 
Electronic supplementary material The online version ofthis article 
(https://doi.org/10.1007 /s00228-0l 7-2364-6) contains supplementary 
material, which is available to authorized users. 
� Christina Raae Hansen 
christina.raaehansen@ucc.ie 
2 
Pharmaceutical Care Research Group, School of Pharmacy, 
University Colleg e Cork, Cavanagh Pharmacy Building, College 
Road, Cork, Ireland 
School of Pharmacy, Royal College ofSurgeons ofireland, 123 St 
Stephen's Green, Dublin 2, Ireland 
Department ofMedicine, University College Cork, Brookfield 
Health Sciences Complex, College Road, Code, Ireland 
4 Department of Geriatric Medicine, Cork University Hospital, Wilton,
Cork, Ireland 
5 Phannacy Department, Mercy University Hospital, Greenville Place, 
Cork, Ireland 
6 Department ofEpidemiology and Public Health, University College
Cork, Western Gateway Building, Western Road, Cork, Ireland 
Results A total of978 participants (47.8%) aged 60-74 years 
were included from the cohort. At baseline, PPOs were detect­
ed in 31.2% of patients and PIMs were identified in 35.6% at 
baseline. Prevalence of PPOs and PIMs increased significant­
ly over time (OR 1.08, 95% CI 1.07; 1.09 and OR 1.04, 95% 
Cl 1.0; 1.06, respectively). A higher number of medicines and 
new diagnoses were associated with the increasing trend in 
both PPO and PIM prevalence observed over time, indepen­
dent of PPOs and PIMs triggered by drug combinations. 
Conclusions Potentially inappropriate prescribing is highly 
prevalent among early old-aged people in primary care and 
increases as they progress to more advanced old age, suggest­
ing that routine application of STOPP/START criteria in this 
population would significantly improve medication 
appropriateness. 
Keywords PIM · Polyphannacy · Longitudinal pattems 
lntroduction 
Optimisation of pharmacotherapy is a core part of the care of 
older people [1, 2]. Medical treatment in older people is aften 
challenged by age-related physiological changes affecting 
pharmacokinetic and pharmacodynamic responses to drugs, 
with increasing risk of adverse drug-disease and drug-drug 
interactions [2, 3]. For that reason, many drugs must be used 
with caution in older people [l, 2]. Tue use of five or more 
daily drugs (i.e. polypharmacy) is increasing in older people 
and is associated with a higher risk of potentially inappropriate 
prescribing (PIP) for this population [ 4, 5]. PIP includes both 
the omission of a medical treatment that is clinically indicated 
in the patient for irrational or ageist reasons, potential prescrib­
ing omissions (PPOs) or the use of a medical treatment in 
� Springer 
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which the risks outweigh the benefits through the use of po­
tentially inappropriate medications (PIMs) [3, 6, 7]. 
Recent work by Cooper et al. [8] indicates high PIP prev­
alence in middle-aged ( 4 5-64 years) people using Prescribing 
Optimally in Middle-aged People's Treatments (PROMPT) 
criteria. Using prescription databases PIP prevalence rates 
among middle-aged people were found to be 21.1 and 
42.9%, in Northem lreland and the Republic of Ireland, re­
spectively [9). The high level of PIP in middle age suggests 
that the well-recognised high prevalence of PIP in advanced 
old age (those aged:::: 75 years) arises in late rniddle age/early 
old age [8]. However, to date, limited data exist to explore 
when in the life course of PIP emerges. 
PIP is well described in the older population [l 0-13] and is 
shown to be associated with increasing age [3, 12]. The ac­
knowledged high prevalence of PIP in late life is thought to 
result directly from high levels of multi-morbidity and 
polypharmacy in this population (3, 11, 12, 14). More infor­
mation is needed on PIP in younger populations to assess 
potential benefits ofminimising PIP befare people enter older 
age. Given the lack ofpublished data on PIP in the latter age 
group, we aimed to deterrnine the longitudinal pattern of PIP 
in people aged between 60 and 74 years. 
The central aim of the present study, therefore, was to as­
sess the lev els of PIP in early old age and to follow the trend of 
PPO and PIM prevalence over a 5-year interval in order to 
determine the patterns of PPO and PIM prevalence 
longitudinally. 
Methods 
We undertook a secondary analysis of a previously described 
population-based cohort from a large primary care centre in 
lreland [15]. The cohort includes a total of 2047 men and 
women aged 50-69 years at recruitment in 2010, and provides 
information on demographics, general health, medication use 
and private health insurance status. Updated information on 
clinical status, diagnoses and medications were obtained by 
researchers from annual screenings of electronic patient re­
cords, and thus provided ongoing passive follow-up of partic­
ipants between waves of active data collection. The follow-up 
screenings were scheduled every year, the first one commenc­
ing in April 2010 until April 2011, and following the patients 
to the end ofthe 5-year follow-up in October 2015. Patients 
were lost for the active follow-up ofthe original cohort study 
[15] but this did not impact the passive follow-up data that
were used in this study. We obtained detailed information on
all prescribed medications from electronic patient records
from enrolment in 2010-2011 until the end of 2015 [15].
The original medication data from baseline and all annua!
screenings were coded by the WHO Anatomical Therapeutic
Chemical (ATC) classification system [16]. Management of
� Springer 
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the original clinical data at baseline was completed and linked 
at patient-level to the coded medication data. 
The Screening Tool to Alert doctors to Right Treatment 
(STA RT) and Screen ing Tool for Older Persons' 
Prescriptions (STOPP) version 2.0 criteria [17, 18] were ret­
rospectively applied to the medication data from baseline and 
annua! screening of the electronic patient records in order to 
determine the prevalence of PPOs (START) and PIMs 
(STOPP) at annua! time points over a prospective five-year 
period [ 17]. Participants were dichotomised according to pres­
ence or absence of any PPOs and PIMs at baseline. For a sub­
analysis, the START/STOPP criteria triggered by the presence 
of more than one drug were removed to explore the effect of 
polypharmacy independent ofthose PPOs and PIMs triggered 
by drug combinations. 
Statistics 
The study population was summarised using descriptive sta­
tistics including means and standard deviations or median and 
interquartile range as appropriate for continuous variables, 
and proportions and percentages for categorical variables. 
Participant groups were compared using Pearson's chi­
square test or Fisher's exact test for categorical variables, 
Mann-Whitney U test for nonparametric continuous variables, 
and paired t test for normal distributed continuous variables. 
The proportions of people with any PPOs or PIMs were com­
pared for two consecutive years and for baseline and end of 
follow-up (year 6) using McNemar's test for paired groups 
[19]. We used negative binomial regression models or 
Spearman's rank correlation model, where appropriate, to de­
scribe the correlation between the presence of any PPOs and 
any PIMs and the reported number of medicines and age for 
each year of follow-up. Generalised estimating equation 
(GEE) models with exchangeable correlations were fitted for 
overall PPO and PIM prevalence from baseline to follow-up, 
and followed by multivariate GEE analysis which adjusted for 
gender, age, numbers of medicines and number of new diag­
noses over the five-year time frame to detennine associations 
between these and PPO and PIM prevalence [20, 21]. The 
results are presented as both unadjusted and adjusted odds 
ratios (OR and aOR, respectively) with 95% confidence inter­
vals (95% Cl). Data analyses were performed using Stata soft­
ware version 13 (StataCorp. College Station, TX. 2013) with a 
significance level ofp < 0.05. 
Results 
Baseline characteristics 
From the total cohort of 2047 patients, 978 participants 
(47.8%) were aged 60 to 74 years at recruitment and were 
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eligible for inclusion in the current study. Due to incomplete 
data, four participants were not included in the analysis. 
Baseline participant characteristics are presented in Table 1. 
There were no significant differences in baseline characteris­
tics between participants with PPOs and without PPOs. Tue 
proportion of people with � 2 medications was higher for par­
ticipants with PIMs compared to participants without PIMs 
(28 versus 19%,p = 0.001); this is to be expected, given the 
known association between polyphannacy and PIM occur­
rence [3, 9-12]. Differences between participants with and 
without PIM were non-significant for all other characteristics 
(Table 1). 
STOPP/START 
Based on data availability, 27 of 34 (79.4%) START criteria 
and 64 of81 (79.0%) STOPP criteria were applied (additional 
data are given in Online Resource). PPOs were detected in 
304 participants (31.2%) and PIMs were identified in 347 
participants (35.6%) at baseline (Table 1). Anxiety and rheu­
matological disorders were most often associated with PPOs, 
whilst hypno-sedatives (benzodiazepines and Z-drug hyp­
notics) and angiotensin-converting-enzyme (ACE) inhibitors 
were the most common drug classes accounting for PIMs 
(additional data are given in Online Resource). Three 
START criteria and ten STOPP criteria that were triggered 
309 
by drug combinations were excluded from the sub-analysis 
(additional data are given in Online Resource). 
PPO prevalence 
Tue number of patients with at least one PPO increased sig­
nificantly between consecutive years from baseline to year 3 
offollow-up with a continuing increasing, but non-significant, 
trend until the end of follow-up. After 5 years, an additional 
I 1 % ofparticipants (n = 33)had aPPO (p < 0.001) (see Online 
Resource). However, the mean number of PPOs per partici­
pant did not significantly change from baseline to end of 
follow-up with a mean of0.45 (SD 0.82) PPOs per participant 
at baseline and 0.42 (SD 0.49) at year 6 (p ;;;; 0.259). 
Unadjusted odds ratio (OR) showed a significant increase in 
the PPO prevalence comparing 5-year follow-up to baseline 
(OR 1.08, 95% CI 1.07; 1.09. Table 2). Tue multivariate GEE 
model showed that nu.m.ber of medicines and number of new 
diagnoses were significantly associated with the change in 
PPO prevalence and the change in prevalence comparing 
follow-up to baseline was not significant after adjusting for 
these variables. The multivariate analysis showed no signifi­
cant association of age and gender with change in PPO prev­
alence (Table 2). A positive but non-significant correlation 
was found between the number of PPOs and older age for 
all years offollow-up (see O nline Resource). Tue number of 
Table 1 Baseline characteristics of the study sample (n = 978) excluding n = 4 participants with incomplete data 
Baseline Study Withno WithPPO Without PPOs p WithPIMs WithoutPil\,fs Pvalue 
characteristics population medications (n = 304, (n = 670, value (n = 347, (n = 531, 
(n = 978) (n = 96, 9.9%) 31.2%) 68.8%) 35.6%) 54.5%) 
Age, years Mean 64.8 (2.96) 64.3 (3.00} 64.7 (2.99} 64.8 (2.96) 64.9 (2.92) 64.8 (2.99) 
(SD) 
Age, years Median 64.2 (61.8---67.3) 64.2 (61.8----66.4) 64.2 (61.8--67.3) 64.2 (61.8---67.3) 0.896 65.1 (61.8--67.3) 64.2 (61.8----67.3) 0.850 
(IQR) 
60--64 ycars 499 (51.0) 53 (55.2) 153 (50.3) 343 (51.2) 169 (48.7) 274 (51.6) 
70+ years 15 (1.5) 1 (1.0) 3 (1.0) 12 (1.8) 7 (2.0) 7 (1.3) 
Gender, female N(%) 505 (51.6) 46 (47.9) 148 (48.7) 353 (52.7) 0.247 184 (53.0) 271 (51.0) 0.564 
Chronic conditions 
0 N(%) 225 (23.0) 22 (22.9) 80 (26.3) 142 (21.2) 0.200 79 (22.8) 121 (22.8) 0.931 
I 238 (24.4) 30 (31.3) 69 (22.7) 169 (25.2) 80 (23.0) 128 (24.1) 
2:2 515 (52.8) 44 (45.8) 155 (51.0) 359 (53.6) 188 (54.2) 282 (53.1) 
Numberof Mean 2.1 (3.1) 0 (0) 2.4 (3.6) 2.0 (2.9) 3.2 (4.3) 1.8 ( 1.9) 
medications (SD) 
0 N(%) 100 (10.2) 96 (100.0) 33 (10.9) 63 (9.4) 0.144 0 (0) 0 (0) <0.001* 
l 682 (69.7) 0 (0) 200 (65.8) 482 (71.9) 250 (72.0) 432 (81.4) 
2:2 196 (20.0) 0 (0) 71 (23.4) 125 (18.7) 97 (28.0) 99 (18.6) 
CW'rent smoker N(%) 108 (11.0) Il (11.5) 37 (12.2) 71 (10.6) 0.552 36 (10.4) 61 (11.5) 0.499 
Private health N(%) 582 (59.5) 58 (59.5) 186 (61.2) 393 (58.7) 0.457 213 (61.4) 308 (58.0) 0.319 
insurance 
Living situation 
Living alone N(%) 146 (14.9) 12 (12.5) 41 (13.5) 105 (15.7) 0.379 57 (16.4) 77 (14.5) 0.352 
Living with 638 (65.2) 67 (69.8) 203 (66.5) 435 (64.9) 218 (62.8) 353 (66.5) 
others 
Unspecified 194 (19.8) 17(17.7) 60 (19.7) 130 (19.4) 72 (20.7) 101 (19.0) 




Unadjusted odds ratio (95% CI) 
Follow-up vs. baseline 
Adjusted odds ratio (95% CI) 
Follow-up (vs. baseline) 
Age (per year older) 
Gender (female vs. male) 
Eur J Clin Pharrnacol (2018) 74:307-313 
AnyPPO AnyPIM 
1.082* (1.071; 1.093) 1.042* (1.029; 1.055) 
Table 2 Univariate and 
multivariate GEE models for PPO 
and PIM prevalence showing the 
changes in the proportion of 
patients with a PPO or PIM 
during the study period and the 
association with the potential 
covariates; gender, age and 
nurnber ofmedicines. Study 
population n = 974 for PPO and 
n = 878 for PIM, excluding n = 96 
with no medications at baseline 
Number ofmedicines (per higher number) 
Number of new diagnoses" (per highcr number) 
1.037 (0.995; 1.080) 
1.033 {0.992; 1.075) 
0.813 (0.639; 1.033) 
1.02* l (1.011; 1.030) 
1.054* (1.043; 1.065) 
1.005 (0.963; 1.047) 
1.023 (0.984; 1.065) 
0.909 (0.717; 1.151) 
1.103* (l.084; 1.123) 
1.016* (1.022; 1.030) 
*p < 0.05, i.e. statistically significant
• new diagnoses refer to the diagnosed conditions after baseline data collection
PPOs and munber of medicines were positively correlated for 
all years with 1he exceptions ofbaseline and year 4 offollow­
up (see Online Resource). 
When excluding the START criteria triggered by drug com­
binations, a higher number of medicines and new diagnoses 
were still significantly associated with the change in PPO 
prevalence in the multivariate GEE analysis (aOR 0.99, 95% 
Cl 0.98; 0.99 and aOR 1.06, 95% CI 1.05; 1.07, respectively). 
The number of PPOs was not positively correlated with num­
ber of medicines after excluding the criteria triggered by drug 
combinations (p > 0.05 for all individual years). Additional 
data are given in Online Resource. 
PIM prevalence 
Prevalence of PIMs increased significantly between consecu­
tive years from baseline to year 2 offollow-up and decreased 
slightly thereafter ending with a significant decrease between 
year 5 and year 6 (see Online Resource). Despite this, the 
overall PIM prevalence from baseline to end of follow-up 
increased significantly from 39. 7% of participants receiving 
a PIJvl at baseline to 45.6% at end offollow-up. Tue unadjust­
ed GEE model showed a significant increase in the PIM prev­
alence comparing follow-up to baseline (OR 1.04, 95% Cl 
1.03, 1.06, p < 0.001; Table 2). The mean number of PIJvls 
per participant did, however, decrease significantly from 0.82 
(SD 1.53) at baseline to 0.45 (SD 0.5) at end of follow-up 
(p < 0.001). Adjusted odds ratios showed that higher numbers 
of medicines and higher number of new diagnoses were pos­
itively and significantly associated with change in PIM prev­
alence (aOR 1.10; 95% Cl 1.08; 1.12 and aOR 1.02, 95% CI 
1.00; 1.03, respectively), consistent with the published litera­
ture. No significant association was found between PIM prev­
alence and age or gender (Table 2). A positive correlation 
between the number of PIMs and older was, however, seen 
for all years (see Online Resource). The regression models 
showed a significant positive correlation between the number 
of daily medications and the number of PIMs prescribed at 
baseline and all years offollow-up (see Online Resource). Tue 
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odds of receiving any PIM were affected by the number of 
new diagnoses but there was no significant correlation be­
tween 1he number of PIMs and number of diagnoses (see 
Online Resource). 
Excluding the STOPP criteria triggered by drug combina­
tions, both a higher number of medicines and new diagnoses 
were still significantly associated with the change in PIM 
prevalence in 1he multivariate GEE analysis (aOR I .07, 95% 
CI 1.06; 1.08 and aOR 1.02, 95% Cl I.Ol ; 1.03, respectively). 
A positive correlation between the munber of PIMs and num­
ber of medicines was still shown for all years of follow-up 
(p < 0.001 for all individual years). Additional data are given 
in Online Resource. 
Discussion 
This study illustrates that inappropriate prescribing is present 
even in early old-aged community-dwelling people. This pre­
scribing challenge comprises both prescribing omissions and 
use of inappropriate medications to similar degrees. It is also a 
persistent problem with a tendency to increase over time as 
people progress to more advanced old age. 
Our findings showed that over time the number of people 
with a PPO increases significantly, and 1hat the odds of a PPO 
increase with higher number of medicines and new diagnoses 
independent of PPOs triggered by drug combinations. These 
findings are similar to those ofMoriarty et al. [12] that showed 
an increasing trend in PPO prevalence in people aged � 
65 years signi:ficantly associated with age, higher number of 
medicines and chronic conditions. Tue associations between 
higher nurnber of medicines with PPO prevalence found in 
Moriarty et al. [12] and this current study may hypothesise 
that older people experience side effects from their medication 
resulting in new diagnoses and new treatments, both of these 
generating a higher number of PPOs. Similarly, a continuing 
prevalence ofunderuse (PPOs) and misuse (PIMs) in multi­
morbid older people results in poorer health outcomes. As per 
Wauter et al., [22] in those aged � 80 years, every additional 
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PPO increases the rate ofhospitalisation (26%) and mortality 
(36%). 
In early old-aged people, our findings showed that the 
odds of receiving a PIMs over time (OR 1.04, 95% Cl 
1.03, 1.06) were similar to that of an older population 
studied by Moriarty et al. [12] (1.08; 95% CI 1.03, 
1.13). Polypharmacy was found to be significantly asso­
ciated with a higher risk of PIMs in our study, a finding 
that is well documented in the literature [3, 9-12], and 
was also shown to be independent of PIMs triggered by 
drug combinations. In addition, our findings showed a 
significant impact of the number of new diagnoses on 
PIM prevalence. Although PIM prevalence increased, the 
mean number of PIMs per patients decreased over time. 
This tinding highlights that a subset of this cohort was 
accumulating more and more PIMs rather than an increase 
in mean number of PIMs across the board. A preliminary 
characterisation of this subset of participants showed a 
similar mean age compared to the entire study population 
(65.0 versus 64.8 years) and a similar gender distribution 
(48.3 versus 51.6%). The subset was taking a higher num­
ber of medicines at basel ine compared to the entire pop­
ulation (9.2 versus 2.1) and a third of the subset suffered 
from high blood pressure (33.3%), a fourth (26.7%) suf­
fered from low back pain and nearly a fifth (18.3%) had 
osteoarthritis at baseline. This is an area that needs to be 
explored further to identify causative factors and future 
studies may examine a more detailed clusterisation of pa­
tients based on their number of PIMs. 
Our data did not show a significant association between 
changes in either PPO or PI!Vf prevalence and age in this early 
old-aged population (mean age 64.8 years (SD 3.0). In con­
trast, Moriarty et al. [12] found that advancing age was signif­
icantly associated with both increasing PPO and PIM preva­
lence in people aged � 65 years (mean age 74.8 years, SD 
6.2 years). These contrasting fmdings suggest that in early 
old-aged patients, age may not have the same influence on 
PPO or PIM prevalence as it does in older patients after the 
age of70 years. It has also been observed that in the 'old old' 
population (i.e. those aged over 85 years), age alone may no 
longer have such a significant impact on PPO and PIM prev­
alence, as was found by Wahab et al. [3]. 
The present study findings indicate that PPOs and 
PIMs, which are recognised to be highly prevalent in the 
older population aged 75-84 years [23] and 'old old' 
population (85 years and older) [3, 9], are also present 
in early old age. Our data indicate that PPO prevalence 
and PIM prevalence gradually increases over a five-year 
period as people progress from early old age towards 
more advanced old age. Albeit a quite small effect of 
the increase in PPO and PIM prevalence (ORs of 1.08 
and 1.04 for PPOs and PIMs, respectively), the findings 
highlight an increase in the prevalence of inappropriate 
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prescribing that may reach a clinically significant level 
over time. Long-term follow-ups from prospective cohort 
studies are needed to examine this potential clinical rele­
vance of PPO and PIM prevalence. Already known is that 
a substantially high prevalence of potentially inappropri­
ate prescribing has a negative impact on medication man­
agement and adherence in older patients increasing the 
likelihood of adverse drug events (ADEs) and drug­
related hospital admissions caused by overuse, underuse 
or misuse of prescribed medication [2, 22]. Non­
adherence t o  pharmacotherapy is known to be associated 
with a higher number of daily medicines, such that there 
is an estimated increase of 16% non-adherence for each 
one-unit increase in the number of daily medicines taken 
[24]. Improving medication adherence by preventing po­
tentially inappropriate prescribing (PIP) could therefore 
play an important role in reducing the need for healthcare 
services among older adults and improve their medical 
therapy. The findings of this study make a strong argu­
ment for minimising PIP among early old aged people in 
primary care, using screening tools such as STOPP/ 
START criteria. In the elderly multi-morbid hospitalised 
population, STOPP/START criteria have been shown to 
significantly improve prescribing appropriateness [6] and 
to minimise adverse drug reactions (ADRs) [25]. It is 
likely (although not yet proven) that routine application 
of STOPP/START criteria in late middle-aged/early old 
aged patients in the primary care setting would signifi­
cantly improve the medication appropriateness and reduce 
the incidence of both ADRs and ADEs in this cohort also. 
Recent clinical trials demonstrate tangible clinical benefit 
of applying STOPP/START criteria, albeit in older patient 
populations in settings other than primary care [6, 14, 25, 
26]. There are two large scale multi-centre clinical trials cur­
rently in progress designed around software-assisted applica­
tion ofSTOPP/START criteria to the medication lists of older 
people in hospital [27, 28]. Computer-assisted prescribing 
systems may provide a useful way of implementing routine 
screening for PIP and these trials may approve to be highly 
relevant to prescribing surveillance if they show positive re­
sults. Tue first results ofthe SENATOR trial (software engine 
for the assessment and optimization of drug and non-drug 
therapy in older persons) will be known in 2018, and will 
possibly have direct relevance to PIP prevention in older 
community-dwelling people [28]. In addition, future studies 
should examine the effect of training primary care physicians 
in the use of STOPP/START criteria on the prevalence of PIP 
in primary care. 
The present study is the first, to our knowledge, to report 
the pattem of PIM and PPO prescribing over a five-year peri­
od in early old-aged people (60-74 years). Tue use oflongi­
tudinal data describing prescription medication in this study 




Our study was, however, limited in that some of the required 
information was not available when applying the STOPP/ 
START criteria, and as a consequence, not all STOPP/ 
START criteria were applied. Additionally, same cr iteria 
may have been over triggered due to a lack of detail for diag­
noses such as anxiety. A prolonged use of benzodiazepines 
(more than 4 weeks) may be appropriate among patients with 
severe mental illnesses or personality disorders. Equally, 
omission of medical treatment of mild forms of anxiety would 
not necessarily reflect an omission of treatment for anxiety but 
rather these may have been treated using non-phannacological 
approaches e.g. cognitive behavioural therapy, not recorded in 
this study. Despit e this, both under-diagnosis and under­
treatment of anxiety in old age is quite common and the study 
tindings may be a reflection of the suboptimal treatment of 
anxiety with benzodiazepines in this group. Another limita­
tion of the current dataset is that it lacks any information on 
medication adherence. Nevertheless, our data indicate that PIP 
in early old age very likely contributes significantly to the high 
prevalence of PIP in more advanced old age. Based on the 
similarities of our tindings with comparable studies [11, 12, 
22], we consider our findings to be relevant to other European 
countries. 
In conclusion. this is the first study to examine the longi­
tudinal pattern of PIP among people in early old age in the 
primary care setting. Our data show that approximately one in 
three persons aged 60 to 74 years has one or more PIMs or 
PPOs and that over a 5-year follow-up interval, PPO preva­
lence rises significantly to over 40% whilst PIM prevalence 
exceeds 45%. Polypharmacy and multi-morbidity have a sig­
nificant impact on the odds of receiving PPOs and PIJ\.1s in­
dependent of those triggered by drug combinations. These 
tindings alongside the data emerging from recent clinical trials 
[6, 25] that describe the positive impact of STOPP/START 
criteria as an intervention support the use of STOPP/START 
criteria in the routine review of medication lists of patients in 
early old age (60-74 years) in the prevention of PIP among 
older people in primary care. 
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Data on the STOPP/START criteria identified in the study population (n=974}. 
START criteria version 2.0 identified in the study population (n=974), described as the number of people with each individual criteria for each year of follow­
up. 
A3 - Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) 
with a documented history of coronary, cerebral or peripheral vascular 
disease 
A4 - Antihypertensive therapy where systolic blood pressure consistently 
>160 mmHg and/or diastolic blood pressure consistently >90mmHg; if
systolic blood pressure >140 mmHg and/or diastolic blood pressure
>90mmHg, if diabetic
A5 - Statin therapy with a documented history of coronary, cerebral or
peripheral vascular disease, unless the patient's status is end-of-life or
age is >85 years
A6 - Angiotension Converting Enzyme (ACE) inhibitor with systolic heart
failure and/or documented coronary artery disease
A7 - Beta-blocker with ischaemic heart disease
AB - Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or
carvediol) with stable systolic heart failure.
B1 - Regular inhaled Beta-2 agonist or antimuscarinic bronchodilator (e.g.
ipratropium, tiotropium) for mild to moderate asthma or COPD
C1 - L-DOPA or dopamine agonist in idiopathic Parkinson's disease with
functional impairment and resultant disability
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START Criteria Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
01 - PPI with severe gastro-oesophageal reflux disease or peptic stricture 
requiring dilatation 
- ,,ore supplements (e.g. bran, isphaghula, methylcellulose, sterculia)
for diverticulosis with a history of constipation 
E1 - Disease-modifying anti-rheumatic drug (DMARD) with active, 
disbling rheumatoid disease 
E2 - Bisphosphonates and vitamin D and calcium in patients taking long­
term systemic corticosteroid therapy 
E3 - Vitamin D and calcium supplement in patients with known 
osteoporosis and/or previous fragility fracture(s) and/ar (Bone Mineral 
Density T-scores more than -2.5 in multiple sites) 
E4 - Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, 
strontium ranelate, teriparatide, denosumab) in patients with documented 
osteoporosis, where no pharmacological or clinical status contraindication 
exists (Bone Mineral Density T-scores > -2.5 in multiple sites) 
E5 - Vitamin D supplement in alder people who are housebound or 
experiencing falls or with osteopenia (Bone Mineral Density T-score is >-
1.0 but< -2.5 in multiple sites) 
E6 - Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat) with a 
history of recurrent episodes of gout 
E7 - Folie acid supplement in patients taking methotrexate 
G1 -Alpha-1 receptor blockerwith symptomatic prostatism, where 
prostatectomy is not considered necessary 
G2 - 5-alpha reductase inhibitor with symptomatic prostatism, where 
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START Criteria Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
0 0 0 0 0 1 
18 28 33 32 35 30 27 
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STOPP criteria version 2.0 identified in the study population (n=974}, described as the number of people with each criteria for all five years of follow-up.
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STOPP Criteria 
risk, i.e. incontrolled severe hypertension, bleeding diathesis, recent non­
trivial spontaneous bleeding) (high risk of bleeding) 
C4 - Aspirin plus clopidogrel as secondary stroke prevention, unless the 
patient has a coronary stent(s) inserted in the previous 12 months or 
concurrent acute coronary syndrome or has a high grade symptomatic 
carotid arterial stenosis (no evidence of added benefit over clopidogrel 
monotherapy) 
C5 - Aspirin in combination with vitamin K antagonist, direct thrombin 
inhibitor or factor Xa inhibitors in patietns with chronic atrial fibrillation (no 
added benefit from aspirin) 
C7 - Ticlopidine in any circumstances (clopidogrel and prasugrel have 
similar efficacy, strenger evidence and fewer side-effects) 
- v1tam1n K antagonist, direct thrombin inhibitor or actor Xa inhibitors for
first deep venous thrombosis without continuing provoking risk factors (e.g. 
thrombophilia) for >6 months, (no proven added benefit) 
C9 - Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for 
first pulmonary embolus without continuing provoking risk factors (e,g. 
thrombophilia) for > 12 months (no proven added benefit) 
C10 - NSAID and vitamin K antagonist, di reet thrombin inhibitor or factors 
Xa inhibitors in combination (risk of major gastrointestinal bleeding) 
C11 - NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis 
(increased risk of peptic ulcer disease) 
01 - Tricyclic antidepressants (TCAs) with dementia, narrow angle 
glaucome, cardiac conduction abnormalities, prostatism, or prior history of 
urinary retention (risk of worsening these conditions). 
02 - Initiation of Tricyclic antidepressants (TCAs) as first-line antidepressant 
treatment (higher risk of adverse drug reactions with TCAs than with SSRls 
or SNRls) 
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STOPP Criteria Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
D4 - Selective serotonin re-uptake inhibitors (SSRls) with current or recent 
significant hyponatraemia i.e. serum Na+ <130 mmol/1 (risk of exacerbating 
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STOPP Criteria 
E2 - Direct thrombin inhibitors (e.g. dabigatran) if eGFR <30ml/min/1.73m2 
(risk of bleeding) 
E3 - Factor Xa inhibitors (e.g. rivaroxaban, apixaban) if eGFR <15 
ml/min/1.73m2 (risk of bleeding) 
E4 - NSAIDs if eGFR<50 ml/min/1.73m2 (risk of deterioration in renal 
function) 
ES -Colchicine if eGFR <10 ml/min/1. 73m2 (risk of colchicine taxicity) 
E6- Metformin if eGFR < 30ml/min/1.73m2 (risk of lactic acidosis) 
F1 -Prochlorperazine or metoclopramide with Parkinsonism (risk of 
exacerbating Parkisonian symptoms) 
F3 - Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic 
drugs, oral iron, opioids, verapamil, aluminium antacids) in patients with 
chronic constipation where non-constipating alternatives are available (risk 
of exacerbation of consti ation 
G1 -Theophylline as monotherapy for COPD (safer, more effective 
alternative; risk of adverse effects due to narrow therapeutic index) 
2 -Systemic corticosteroids instead of inhaled corticosteroids for 
maintenance therapy in moderate-severe COPD (unnecessary exposure to 
long-term side-effects of systemic corticosteroids and effective inhaled 
therapies are available) 
G3 -Antimuscarinic bronchodilators (e.g. ipratropium, tiotropium) with a 
history of narrow angle glaucoma (may exacerbate glaucoma) or bladder 
outflow obstruction (may cause urinary retention) 
G4 -Non-selective beta-blocker (whether oral or topical for glaucoma) with 
a history of asthma requiring treatment (risk of increased bronchospasm) 
G5 - Benzodiazepines with acute or chronic respiratory failure i.e. p02 <8.0 
kPa±pCO >6.5 kPa (risk of exacerbation of respiratory failure) 
H1 - Non-sterodial anti-inflammatory drug (NSAID) other than COX-2 
selective agents with history of peptic ulcer disease or gastrointestinal 
bleeding, unless with concurrent PPI or H2 antagonist (risk of peptic ulcer 
relapse) 
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STOPP Criteria 
H2 - NSAID with severe hypertensian (risk of exacerbation af hypertension) 
or severe heart failure (risk of exacerbatian of heart failure) 
H4 - Long-term corticosteroids (>3 months) as monotherapy for rheumatoid 
arthritis (risk of systemic corticasteroid side-effects) 
H5 - Corticosteroids (other than periodic intra-articular injections for mono­
articular pain) for osteoarthritis (risk of systemic corticosteroid side-effects) 
H6 - Long-term NSAID or colchicine (>3 months) for chronic treatment of 
gaut where there is no contraindication to a xanthine-oxidase inhibitor (e.g. 
allopurinol, febuxostat) (xanthine-oxidase inhibitors are first choice 
prophylactic drugs in gout) 
H7 - COX-2 selective NSAIDs with concurrent cardiovascular disease 
(increased risk of myocardial infarction and stroke) 
H8 - NSAID with concurrent corticosteroids without PPI prophylaxis 
(increased risk of peptic ulcer disease) 
H9 - Oral bisphophonates in patients with a current or recent history of 
upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, 
duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of 
relapse/exacerbation af oesophagiti, oesophageal ulcer, oesophageal 
stricture) 
11 - Antimuscarinic drugs with dementia, or chronic cognitive impairment 
(risk of increased confusian, agitation) or narrow-angle glaucoma (risk of 
acute exacerbation of glaucome), or chronic prostatism (risk of urinary 
retention) 
12 - Selective alpha-1 selective alpha blockers (prazosin, doxazosin, 
tamsulosin, terazosin) in those with symptomatic arthostatic hypotension or 
micturition syncope (risk of precipitating recurrent syncope) 
J1 - Sulphonylureas with a lang duration of action (e.g. glibenclamide, 
chlorpropamide, glimepiride) with type 2 diabetes mellitus (risk of prolonged 
hypoglycaemia) 
J2 - Thiazolidenediones (e.g. rosiglitazone, pioglitazone) in patientswith 
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STOPP Criteria Baseline Year 1 Year 2 Year 3 · Year 4 Year 5 Year 6 
J4 - Oestrogens with a history of breast cancer or venous thromboembolism 
(increased risk of recurrence) 
K1 - Benzodiazepines (sedative, may cause reduced sensorium, impair 
balance) 
K2 - Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism) 
K3 - Vasodilator drugs (e.g. alpha-1 receptor blockers, calcium channel 
blockers, long-acting nitrates, ACE inhibitors, angiotensin I receptor 
blockers) with persistent postural hypotension i.e. recurrent drop in systolic 
blood pressure �20mmHg (risk of syncope, falls) 
K4 - Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon (may cause 
protracted daytime sedation, ataxia) 
L 1 - Use af oral or transdermal strong opioids (morphine, oxycodone, 
fentanyl, buprenorphine, diamorphine, methadone, tramadol, pethidine: 
pentazocine) as first line therapy for mild pain (WHO analgesic ladder not 
observed) 
L2 - Use of regular (as distinct from PRN) opioids without concomitant 
laxative (risk of severe constipation) 
L3 - Long-acting opioids without short-acting opioids for break-through pain 
(risk of persistence of severe pain) 
N - Concomitant use of two or more drugs with 
antimuscarinic/anticholinergic properties (e.g. bladder antispasmodics, 
intestinal antispasmodics, tricyclic antidepressants, first generation 
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STOPP/START criteria not applied to the dataset. 
START criteria version 2.0 that were not applied to the dataset due to unavailable clinical
information.
START Criteria 
A2 -Aspiring (75 mg -160 mg once daily) in the presence of chronic atrial fibrillation, wherelVitamin K �nta.�onists ar 9ir!�t th�?�bin in_hibitors or factor Xa inhibitors are contraindicated.
82 -Regular inhaled corticosteroid for moderate-severe asthma or COPD, where FEV1 <50% of
predicted value and repeated exacerbations requiring treatment with oral corticosteroids. 
83 - Home continuous oxygen with documented chronic hypoxaemia (i.e. p02 < 8.0 kPa or 60
[ mmHg or Sa02 < 89%). __ __ __ 
F1 -ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with
evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (>30mg/24 hours) with or
without serum biochemical renal impairment.
1------ ·- --- . ·- --
H 1 - High-potency opioids in moderate-severe pain, where paracetamol, NSAIDs or low-potency
opioids are not appropriate to the pain severity or have been ineffective.
11: Seasonal trivalent influenza vaccine annua Ily.- -·· 
12: Pneumococcal vaccine at least once after age 65 according to national guidelines.
STOPP criteria version 2.0 that were not applied to the data set due to unavailable clinical
information.
STOPP Criteria 
A 1 -Any drug prescribed without an evidence-based clinical indication.
A2 -Any drug prescribed beyond the recommended duration, where treatment duration is well
defined.
B2 - Veraparl!il or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure).
85 -Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmia (higher
risk of side-effects than beta-blocker, digoxin, verapamil or diltiazem).
B7 - Loop diureticfor dependent ankle oedema without clinical, biochemical evidence or
J radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg
elevation and/ar compression hosiery usually more appropriate). __
B10 - Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine, rilmenidine,
guanfacine), unless clear intolerance of, or Jack of efficacy with, other classes of antihypertensives
(centrally-acting antyhypertensives are generally less well tolerated by alder people than younger
people).
812 -Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent potassium­
conserving drugs (e.g. ACEl's, ARB's, amiloride, triamterene) without monitoring of serum
potassium (risk of dangerous hyperkalaemia i.e. >6.0 mmol/1 - serum K should be monitored
regularly, i.e. at least every 6 months). 
-- ---
C1 - Long-term aspirin at dases greater than 160mg per day (increased risk of bleeding, no
evidence for increased efficacy).
D7 -Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic
medications {risk of anticholinergic taxicity).
C9 -Neuroleptic antipsychotic in- patients with behavioural and· psychological symptoms of
I dementia (8PSD) unless symptoms are severe and other non-pharmacological treatments have
failed (increased risk of stroke).
C10 - Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia (risk of
confusion�hypotension_._ extra-pyramidal side effects, falls).
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E1 - Digoxin at a lang-term dase greater than 125µg/day if eGFR < 30 ml/min/1.73m2 (risk af 
digoxin taxicity if plasma levels not measured). 
F2 - PPI for uncomplicated peptic ulcer disease or erosive peptic aesophagitis at full therapeutic 
dosa�e !or_� weeks (dase reduction or earlier disc?�!inuation indicated) ..
F4 - Oral elemental iran dases greater than 200 mg daily (e.g. ferrous fumarate > 600 mg/day, 
ferrous sulphate > 600 mg/day, ferrous gluconate > 1800 mg/day; no evidence of enhanced iron 
absorption above these dases. 
H3 - Lang-term use of NSAID (>3 months) for symptom relief af osteoarthritis pain where 
paracetamal has not been tried (simple analgesics preferable and usually as effective for pain 
relief). 
----- ·- -�----
J3 - Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of suppressing 
hypoglycaemic symptoms). --··-
J5 - Oral oestrogens without progestogen in patients with intact uterus (risk of endametrial 
cancer}. 
STOPP/START criteria triggered by drug combinations and excluded in the sub-analysis. 
START criteria version 2.0 triggered by drug combinations. 
START Criteria 
E2 - B1sphosphonates and vitamin D and calcium m patients takmg lang-term systemic 
corticosteroid therapy. 
E7 - Folie acid supplement in patients taking methotrexate. 
H2 - Laxatives in patients receiving opioids regularly. 
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STOPP criteria version 2.0 triggered by drug combinations. 
STOPP Criteria -. 
A3 -Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRls, loop diuretics, 
ACE inhibitors, anticoagulants (optimisation of monotherapy within a single drug class should be 
observed prior to considering a new agent). 
------------
83 - Beta-blocker in combination with verapamil or diltiazem (risk of heart block). 
C4 -Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary 
stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high 
grade symptomatic carotid arterial stenosis (no evidence of added benefit over clopidogrel 
monotherapy). 
j C5 -Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa 
inhibitors in patietns with chronic atrial fibrillation (no added benefit from aspirin). 
C6 - Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 
in patients with stable coronary, cerebrovascular or peripheral arterial disease (no added benefit 
from dual therapy). 
1 C10 -NSAlD and vitamin K antagonist, di reet thrombin inhibitor or factors Xa inhibitors in 
combination (risk of major gastrointestinal bleeding). 
C11 - -NSAID with concurrent antip-latelet agent(°s) without PPI prophylaxis (increased risk of 
1 peptic ulcer disease) 
' D11 -Acetylcholinesterase inhibitors with aknown history of persistent bradycardia (<60 
beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that 
reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction 
1 failure, syncope and injury). 
Ha-= NSA.lffwith concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer 
disease). 
N -Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (e.g. 
bladder antispasmodics, intestinal antispasmodics, tricyclic antidepressants, first generation 
antihistamines) (risk of increased antimuscarinic/anticholinergic taxicity). 
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Abstract 
Purpose Older people are at risk of potentially inappropriate prescribing (PIP} due to polypharmacy arising from multi-morbid­
ity. Despite available explicit criteria to reduce PIP, it is highly prevalent. Whilst community pharmacists have the required 
knowledge to help reduce PIP, they are not currently engaged with the problem. This study explores the views of community 
pharmacists on their potential involvement in reducing PIP and determines the challenges to its implementation. 
Methods Semi-structured interviews with phannacists working in community phannacies in Ireland. The theoretical domains 
framework (TDF) was used to develop the topic guide and to analyse the transcript'i. Domains of highest relevance for PIP 
reduction were identified based on their frequency or whether the participants emphasised the impact of constructs within a 
domain. Local ethical approval was obtained. 
Results Of 18 participants, 12 were female, median age was 30 years (IQR, 27-35) with a median of 6 years (IQR, 3-8) of 
experience. Seven TDF domains were identified as relevant to PIP reduction. Pharmacists were uncertain about their role in 
reducing PIP and reluctant to challenge physicians' prescribing decisions. Challenges pertained to the environment, knowledge, 
social influences, professional role and identity. 
Conclusions Pharmacists welcomed new responsibilities in reducing PIP as part of their daily practice but expressed a need for 
removal of social and environmental barriers as well as, provision ofrelevant guidelines and education about PIP. This study 
provides useful insights into the target domains for overcoming barriers of pharmacist involvement in reducing PIP. 
Keywords Pharmacist · Primary care · Older patients · Prescribing · Qualitative 
lntroduction 
Older multi-morbid people are at substantial risk of having 
potentially inappropriate prescribing (PIP} [l, 2]. The risk of 
PIP increases as people grow alder and is strongly associated 
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with the higher number of daily medicines, i.e. polypharmacy, 
used to treat multi-morbid illness [3-5]. Patient safety is at risk 
when older people are exposed to PIP because of the associ­
ated a dverse  d rug events (ADEs) and drug-rel ated 
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prevalence of PIP throughout the primary care setting in 
Ireland, with prevalence estimates of 21-57% [3, 5, 8, 9]. 
Similar prevalence estimates have been reported in the 
neighbouring country, Northern Ireland (34%) [10] and in 
other European countries, e.g. Spain (38-46%) [11] and the 
Netherlands (35-85%) [4]. No intervention has succeeded in 
reducing the substantial PIP prevalence in primary care de­
spite the existence of explicit criteria to identify PIP for over 
10 years, and the evidence that they are effective in reducing 
PIP in hospitalised, older patients [2, 4, 12]. Two ofthe most 
commonly cited sets of PIP criteria are Beers' criteria [13-17] 
and screening tool of older people's prescriptions (STOPP) 
and screening tool to alert to right treatment (START) criteria 
[I]. There are currently four randomised clinical trials show­
ing the clinical efficacy of applying STOPP/START criteria to 
reduce PIP [2, 18], falls incidence and overall medication cost 
[19], as well as incidence of ADRs [12] in the hospital and 
nursing home settings. 
Reviewing new and repeat prescriptions and completing 
medication reviews are recognised ways of identifying PIP. 
Medication review is a broad term covering several interven­
tions carried out by prescribers themselves or by other practi­
tioners providing advice to prescribers (e.g. phannacists) with 
the overall aim of improving the quality, safety and appropri­
ateness of use of medicines [20]. Studies in primary care set­
tings have demonstrated a significant positive effect of medi­
cation reviews on the reduction of PIP in older people 
[21-24], and also in community pharmacy settings [24]. 
Pharmacists are in a position to identify and help reduce PIP. 
However, prevalence data of PIP arnong community-dwelling 
alder people indicate that pharmacists are not undertaking this 
important role of identifiers of PIP with a further remit of PIP 
prevention [25-27]. 
When designing an intervention to change traditional 
working practice, it is fundamental to understand the pro­
cesses underlying the behaviour [28, 29]. In the case of 
pharmacists, it is essential to understand the barriers and 
facilitators for the involvement, or lack thereof, of commu­
nity pharmacists in reducing PIP. The theoretical domains 
framework (TDF) was originally developed by Michie 
et al. [30] and later updated by Cane et al. [31]. The TDF 
considers a wide range of possible theoretical explanations 
for the relevant behaviours [28, 32, 33]. The 12 domain 
TDF [30J has been widely used in health research to define 
behaviours and to identify barriers and facilitators to that 
behaviour [28, 33, 34]. The identification of such domains 
relevant for a specific behaviour change is an important 
step in the design of an intervention [31, 35]. In this study, 
the 14 domain TDF was employed to identify barriers and 
facilitators of pharmacist involvement in reducing PIP. Tue 
14 domain TDF has previously been used to explore a 
similar topic: the utilisation of a screening tool in medi­
cines usages reviews (MURs) by community pharmacists 
� Springer 
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[35] and was deemed appropriate to investigate their in­
volvement in reducing PIP.
Whilst large randomised controlled trials are examining 
various ways to assess the interventions targeted at prevention 
of PIP in hospital care settings [2, 36, 37], little research is 
being carried out in primary care. To date, the views of the 
community phannacists on reducing PIP have been given lit­
tle attention [35]. Therefore, this study aimed to explore the 
views of community pharmacists on their potential involve­
ment in reducing PIP, and to determine the perceived barriers 
and facilitators to the implementation of PIP reduction in com­
munity pharmacy practice. 
Methods 
Sampling 
Community phannacists working in community practice in 
Cork in Ireland were recruited using convenience sampling 
based on a sampling matrix. Tue convenience sampling method 
was chosen due to time constrictions of the study and to in­
crease the likelihood of respondents. Renee, a close geographic 
proxirnity allowed the researcher (CH) to conduct face-to-face 
interviews with participants at suitable location. Pharmacies 
located in Cork were identified and cont.acted by telephone. 
Tue study was introduced to the phannacist on call at that actual 
time, and the pharmacist was asked to take part in the study. An 
agreed interview date, time and location were then arranged. 
Currently working in community practice was the only inclu­
sion criterion, and there were no exclusion criteria. 
A sampling matrix was designed to ensure variation of 
irnportant participant characteristics in the study population 
(see Online Resource I). Tue design of the matrix was done 
by three researchers (CH, LS and SB) together with a panel of 
pharmacists with backgrounds in academia and community 
pharmacy practice. Tue final matrix design was approved by 
all authors. Matrix parameters chosen were (i) experience 
from working with nursing homes ( either from working in a 
nursing home or from working in a pharmacy serving nursing 
homes), (ii) years of experience working as a community 
pharmacist ( < 3 years,::::: 3 years and 2- 10 years) and (iii) num­
ber of phannacists working simultaneously in the phannacy. 
A cutoff of3 years of community experience was chosen as a 
matrix parameter because pharmacists in Ireland after a 3-year 
period can choose to take up employment subsequently as 
supervising/superintendent pharmacist. 1 Being a supporting 
or a supervising pharmacist was considered to influence the 
1 The supeIVising/superintendent pharmacists is the person responsible for the 
day-to-day management and operation of the pharrnacy and must have a min­
imum of 3 years post-registration experience (http://www.thepsi.ie/gns/ 
Pharmacy _Practice/practice-guidance/Guidance_for _phannacists/Guidance _ 
for_ SupeIVising_Phannacists.aspx). 
283
Eur J Clin Pharmacol (2019) 75:265-274 
level of confidence and knowledge. A threshold of 10 years or 
more experience was then agreed by the authors and the expert 
panel due to an expected seniority after 10 years which might 
have influenced their opinions and answers. Experience of 
working in a nursing home was considered to have an influ­
ence on the pharmacists' answers relating to medication re­
views and polyphannacy issues as these are commonly under­
taken by pharmacists in Irish nursing homes. The number of 
registered pharmacists on duty in the pharmacy at any one 
time was believed to have an impact on their perceived capa­
bility to perfonn medication reviews compared to those phar­
macies with a single pharmacist on duty. Although not matrix 
parameters, the areas in which the phannacists worked, i.e. 
urban or rural as well as associated a:ffiuence or disadvantage 
were considered when recmiting. Areas with social affluence 
and disadvantage were identified from the deprivation index 
viewer (available from www.pobal.ie) [38]. 
Interview topic guide 
An interview topic guide (see Online Resource II) was de­
signed to explore the 14 domains of the framework [30, 31] 
whilst also allowing the participants to freely share their opin­
ions. Using the TDF to design the topic guide is a helpful tool 
in formulating questions that will enable the identification of 
the behaviour and the barriers and facilitators to that behav­
iour. The use of a TDF-formulated topic guide has also been 
shown to effectively elicit responses from the interviewees 
that they would not otherwise report [29]. The topic guide 
was refmed by consensus among all authors and with an ex­
pert panel of phannacists with backgrounds in academia and 
community pharmacy practice. Tue topic guide was pilot test­
ed in two community pharmacists. During the study, it was 
refined on an iterative basis after each interview was tran­
scribed to allow for emerging themes to be explored in subse­
quent interviews. Interviews were conducted until the point of 
thematic saturation as described by Francis et al. [39]. The 
interviews were introduced with some general questions re­
garding their awareness and beliefs about PIP and medication 
reviews. Participants were shown the recently developed 
deprescribing algorithms and asked to give their opinion about 
the content, layout and usefulness in their daily practice 
[40-43]. Participant demographic details were also collected 
including gender, age and number of years of experience in 
community phannacy. 
Data collection 
Semi-structured interviews with pharmacists working in com­
munity pharmacies in Ireland conducted by one researcher 
(CH). This type of interviews was chosen as it encourages 
interviewees to share the views and opinions that are impor­
tant to him/her [44]. Interviews were conducted face-to-face 
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or over the telephone. At the time of the interviews, the par­
ticipant received an information letter and gave their written 
consent. Interviews were audio recorded and transcribed ver­
batim. Transcripts were returned to participants for review, but 
no one accepted this offer. 
Qualitative data analysis 
Transcripts were anonymised and transferred to the QSR 
NVivo® Version 11 software. In line with framework analy­
sis, a familiarisation process took place whereby the research­
er (CH) repeatedly listened to the interview audio recordings 
and read the interview transcripts. From the transcribing pro­
cess and familiarisation process, the researcher (CH) attained 
an overview of specific beliefs within the data [ 45]. Following 
this step, CH coded excerpts from the interview transcripts 
into one or more of the 14 TDF domains. Three randomly 
selected transcripts were coded by a second researcher (LS) 
to assure validity and reliability of the data analysis. 
Disagreement in coding between the two researchers was re­
solved through discussion and consensus. Domains for which 
transcript excerpts were coded into were summarised by CH. 
Supporting excerpts were attached to each domain summaty. 
The summaries were reviewed by LS. The two researchers 
determined the domains of relevance for PIP reduction using 
a similar approach to previous studies [28, 35]. A domain was 
deemed relevant if excerpts were coded frequently into this or 
if the participants emphasised the significant impact of bar­
riers and/or facilitators within a domain on their involvement 
in reducing PIP. 
Results 
A total of 21 pharmacists were approached of whom 18 
agreed to participate. One pharmacist refused to participate 
and the remaining two were unavailable at the time of the 
study. There were no dropouts in this study. Interviews were 
conducted in the period from June to end of August 2017. The 
interviews were a mean length of 19 min (SD 6.00) and took 
place at the pharmacy in which the participant worked. Data 
saturation was reached after 15 interviews with no new themes 
emerging from conducting an additional three interviews. 
Characteristics of the participants are described in Text box 1. 
Text box 1 Characteristics of interview participants (N = 
18) 
• Cornmunity pharmacists interviewed worked in pharmacies placed in
urban (n== 15) and rural (n == 3) areas, ofwhich 13 areas were
categorised as affiuent and 5 were deprived areas according to data
from www.pobal.ie.
• 12 female and 6 male pharmacists were interviewed and were a median




• The pharmacists had a median of 6 years of experience from working in
a conununity phannacy (IQR 3-8) and 8 pharmacists had experience
from working in or for a nursing home. Seven pharmacists had
graduated before 2010 and 11 pharmacists after 2010.
• Eight phannacists were working in a pham1acy with only one licenced
pharrnacist and 10 pharmacists worked in a phannacy with 2 or more
licenced pharmacists on duty. 16 phannacists had help from technician
staff in the phannacy whilst 2 did not have teclmician staff.
Phannacists were familiar with the tenn 'inappropriate pre­
scribing' and defined this as: (i) any medication prescribed 
that has the potential to cause harm, side effects or drug inter­
actions; (ii) overprescribing or prescribing without a docu­
mented indication; (iii) prescribing a medicine to relieve side 
effects of another medicine that the patient is taking; (iv) pre­
scribing any medication for longer than indicated and (v) pre­
scribing a medicine not suitable for older people. A few phar­
macists mentioned the explicit STOPP/START criteria [1, 46] 
to identify PIP but the majority referred to treatment guide­
lines such as the NICE guidelines [ 4 7] and no pharmacist used 
explicit set of criteria to identify PIP in their daily work. Tue 
pharmacists perceived the presented deprescribing algorithms 
[40-43] to give a good overview and to be user-friendly. 
However, some phannacists also believed that the information 
on the algorithms was well known among pharmacists, and 
did not believe algorithms to have significant influence on 
their involvement in reducing PIP. 
Pharmacists described medication reviews as the systemat­
ic process of reviewing patients' medications and identifying 
drug-related problems. No pharmacist had experience of do­
ing medication reviews in community pharmacy setting but 
some had experience from educational sessions or from work­
ing in hospitals or nursing homes. No phannacist interviewed 
was carrying out medication reviews as part of their current 
routine practice. 
Qualitative analysis themes 
Transcript excerpts were most frequently coded into five do­
mains: (i) beliefs aboutcapabilities, (ii) environmental context 
and resources, (iii) knowledge, (iv) social influences and (v) 
social professional role and identity. The two domains 
memory, attention and decision processes and reinforcement 
were less frequently coded. However, those participants who 
made comments coded into these domains attached significant 
impor tance to the factors identified. The interview data coded 
into these seven domains are summarised in Table I with 
illustrative quotations. 
Beliefs about capabilities 
Phannacists perceived themselves as appropriate healthcare 
providers to identify PIP. Competencies were attributed to: 
being trained to do it; being good at identifying PIP; having 
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a good relationship with patients due to the nature of patients 
visiting their pharmacy more often than their General 
Practitioner (GP) and looking at alder patients' prescription 
drugs with fresh eyes. 
Beliefs about capabilities were affected by a phannacist's 
level of confidence and this subsequently influenced the like­
lihood of the pharrnacist communicating any recommenda­
tions to the GP. One pharmacist's self-perceived duty as a 
pharmacist gave her the confidence to aet when an instance 
of PIP was identified (Tab le 1). Another, younger pharmacist 
( 1.5 years of experience) described how her lack of con:fidence 
restrained her from actively giving her input despite her be­
liefs about her role (Table 1). 
Environmental context and resources 
Being busy with serving many patients and doing ad­
ministrative work were believed to restrict time to do 
medication reviews and to have follow-up contact with 
prescribers to discuss potential changes. Pharmacists de­
scribed a need to prioritise their time and focus on more 
immediately unsafe issues, such as major drug-drug in­
teractions, rather than reviewing medication lists for PIP, 
which was felt to have more medium or long-tenn im­
plications for the patient (Table 1). Protected time to 
review medications facilitated by extra phannacist staff 
was a suggested solution. 
Another challenge was a lack of communication be­
tween healthcare providers, e.g. between pharrnacists 
and GPs, and was thought to lead to confusion about 
medication changes and to impede the implementation 
of these changes. Phannacists described being unsure 
where the r esponsibility for stopping PIP resides. 
Suggested improvements included more direct lines of 
communication and willingness to collaborate from all 
parties. Geographic proximity and face-to-face interaction 
were believed to be key facilitators of a good collabora­
tive relationship (Table 1). 
Other challenges pertained to a lack of patient information, 
e.g. diagnosis or indication for a drug. Receiving hospital
discharge !etters and gaining access to a centralised clinical
record system for sharing patient information between phar­
macists and GPs were suggested improvements.
Knowledge 
Pharmacists believed their pharmacology/therapeutics knowl­
edge to be sufficient to identify PIP but stressed the need for 
continuing professional education to bring their knowledge in 
line with new medications and most up-to-date guidelines. 
Interdisciplinary training was suggested as one way to meet 
these educational needs whilst simultaneously improving col­
laboration between pharmacists and GPs (Table 1). 
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Table 1 Interview quotations supporting the individual theoretical dornains identified as relevant for PIP prevention in primary care 
TDFdomain 
Beliefs about capabilities 




Social professional role and 
identity 
Supporting quotes 
"I would not go down the route and ring up a doctor and saying: 'You should not be on this'. The patient has been on 
this for longer than two weeks, you should not be giving this anymore'. I just do not. That is probably my role to 
some extent but I would not like going down that route of complaining to another healthcare professional about 
what they are doing, so." [Pharmacist 6, Code: Beliefs about capabilities]. "I' d be fair ly confident. I' d be kind of, 
just thinking in my own head: 'Look, I have a duty ofcare' and ifthe doctors are a little bit annoyed with me, I'll 
take that." [Phannacist 17, Code: Beliefs about capabilities]. "I would be happy enough to have a look through 
somebody's medicine, if you are given a bit af time to go through it beforehand. lnstead ofthe cuffkind of walking 
offthe street: 'Oh here's my 42 medicines in a brown paper bag'( ... ) But ifyou have time to go through stuff 
beforehand and had a bit of time to spend with the patient then definitely I think it would be both cost-effective and 
much, much more beneficial to the patient in the long term." [Pharmacist 18, Code: Beliefs about capabilities]. 
"I think comrnunication is a huge issue because ( ... ) if something [prescription] comes out from the hospital, the GP 
might not want to stop it. You know the hospital's intention might have been 'let us go on this for 6 weeks'. But 
then the GP puts it on the repeat and then it c01nes to the pharmacist and I arn looking at it and they have been on it 
for two months. I arn not going to ring the GP after two months and say 'oh, it's probably inappropriate for you to 
stop this now'. It's kind oflike who actually [should tackle instances ofPIP], and where does the buck stop. Who 
should say 'this is where it stops' or 'this is where it starts' or." [Phannacist 15, Code: Environment] "Well it's just, I 
guess, everybody's busy. Ehrn, things maybe are not reviewed as often as they should bet( .. . ). So, you know, it 
does not, it it just flies by and you know, you have got a number of other reasons, which are far more immediate in 
tenns of inappropriate prescribing, that you need to look out for. So, you know, those are the ones that you are 
gonna go for, the ones that are immediately unsafe, I guess." [Pharmacist 2, Code: Environment] "I suppose 
between the doctor and the pharmacist. It's a two-way thing. Toere needs to be betler relationship, I suppose, 
between tbe prescribing doctor and the pharmacist. Tuen again, I think it just depends on which doctor you talk to. 
Some ofthem arehappy about engaging with the pharmacist and some ofthem are not. Some do not want to, so. I 
suppose, so." [Phannacist 16, Code: Environment] 
"I think interdisciplinary training would be very good. Get all the GPs and all the pharmacists into the room. Get a 
little bit ofa talk, a lecture, have a dinner, and let them [GPs] understand how we [pharmacists] work and the 
position that we are in, because we [GPs and phannacists] aften do not understand our jobs and they can explain. I 
mean we [phannacists] go to visit the GP for our own thing. So, we kind of have a little bit more of an 
understanding [ of the GP's work]. But they [GPs] may ever come to a phannacy and they may not know how we 
operate." [Pharmacist 12, Code: Knowledge I "Maybe if there was some sort of training about how to review those 
[PIP] that would be good. ( ... )and some sort oftraining so then it makes us aware that 'right, we are going to look 
out for' you know" [Phannacist 9, Code: Knowledge and Memory, attention and decision] "It is useful 
[ deprescribing algorithrns] but like at the same time like I feel like it's something that we all already know ( ... ) I do 
not think it's the spotting is the big problem. It's the like what do you do when you do spot it? So, it's the training of 
what are we actually supposed to do. So, I suppose you do spot it but like I do not necessarily know like what you 
are supposed to do with it." [Pharmacist 15, Code: Knowledge] 
"I suppose forour part it'sjusttime and for the patient's part it'sjust the interest in it. ..... Toere are some patients who 
want to know everything that they are on and every reason. And then other patients who genuinely ..... have great 
belief in the doctor and pharmacist and they just think if they were ever prescribed [ any medication] they need to 
take it." [Phannacist 13, code: Social influences] "A lot ofit is: 'well, ifthe doctor said' or 'ifyou said' or you 
know, someone else said. They do not kind oflisten to themselves or do what they think they should do or what as I 
say, that maybe they are not informed enough." [Pharmacist 1 7, Code: Social influences] "I sometimes, depending 
on the doctor, encourage the patient to go back and ask. Ifyoujust sayto the doctor, eh to the patient: 'maybe say to 
the doctor ehm could you check your leve Is'. So, like you say it in a nice way so they do not go like 'well the 
pharmacist said'. But you know that they kind of think themselves and maybe they should be questioning it. You 
are kind of empowering them a bit." [Pharmacist 5, Code: Social influences] Sametimes it, it can be quite difficult 
as a pharmacist to deal with certain doctors or certain doctors in the hospitals. Not for the faet that they are 
authoritarian or anything like that but it's that they are busy too. They just do not want the hassle of it. They are the 
almighties sometimes ( ... ) Tue channels need to be a bit more open. Sometimes they are very closed and if they [the 
doctors] were a bit more open and a bit more receptive to what our [pharmacists] role as like a professional could be. 
Which I think some, some ofthem are not, then I think it would help a lot." [Pharrnacist 18, Code: Environment] 
"We sbould be doing more but we are doing Jess [to reduce PIP than we should]. Whether that 's business or whether 
that's some people are ... shying away from it because they are afraid that they are out oftouch, [such as some] older 
pharrnacists. I arn not sure, but definitely there's this un-realisation ofwhat our role should be in [reducing PIP] for 
sure." [Pharmacist 18, code: Social/Professional role] "I think it's, the overall responsibility I think is a two-way 
think. I think it's between the GP and phannacy, and I do not think either holds the overall responsibility ( ... ) I 
suppose we would not review. I would not see it as a role, no. As a primary role. It would only be ifthere was an 
issuc with the prescription or if there was an interaction [that the pharrnacist would contact the prescriber]. But other 
than that I would not, no." [Pharmacist 3, Code: Soc. Prof. role] "I take an active interest into the medication. I have 
no problems ringing a doctor about anything, any time. Even if it's something small lifl think it's gonna benefit the 
� Springer 
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Table 1 ( continued) 
IDFdomain Supporting quotes 
patient. Within reason. I am not going to be annoying them without reason over stuff either. You know. I always try 
to put patient benefit over profit first." [Pharmacist 5, Code: Soc. Prof. role] 
Memory, attention and decision "Well those IPU [Irish Pharmacy Union] and HSE [Health Services Executive] campaigns about generic medications 
processes for example, have been very successful. I tltlnk a sirnilar campaign along the lines of'do you need everything you 
are taking?'. Or encouraging patients to go to their doctor. I think to a certain extent; the prescription levy did this 
very well. Where people went to their doctor and asked 'do I really need to be taking all this?"' [Pharmacist 10, 
Code: Memory, attention & decision process] "Probably advertising it a bit more in so that, and even advertising it 
in doctor surgeries. Cause I did have someone ask me before about a person that could do, a certain doctor that 
would do a medication review, and I was pretty confused, and I said 'but you know that everyone doctors and 
phannacists can do it?'. But they' d heard from one person that there was this one doctor tbat does medication 
reviews and tbat was the answer. So, I suppose maybe it's not advertised as a service or advertised as something tbat 
people eau, phannacists and doctors can do." [Phannacist 6, code: Memory, attention & decision process J "Well 
definitely there was one GP, wben it all carne out [regu[ations on b=odiazepine prescribing in Ireland], kind of 
contacted us and said: 'how am I? Like, am I prescribing more benzodiazepines than any other G P?'. And like that's 
an interesting one. Just to be able to say like, on a scale you are prescribing more. It might kind of open their eyes up 
a little ( ... ) It would be hard, but jt would be a nice study for someone to do at some stage. To say: 'look, as a GP you 
are prescribing this amount as opposed to the national average of such and such'." [Pharmacist I I, code: Memory, 
attention & decision process] 
Reinforcement "I suppose it's [PIP] a bit under tbe radar in a lot of my daiJy work because you are not incentivised to look for it( ... ) 
Well it's really a case ofyour incentives. You know, you are not incentivised to do it. It does not really benefit you 
directly at all." [Pharmacist 2, Code: Reinforcement] "If it [ medication reviews] could be incorporated into your 
CPD [ continuing professional development], I know pharmacists who would be much more inclined to do it 
because we are all trying to clock up our CPD hours ( ... ) it should be a thing that if you do your certain medicine 
reviews you can log this as CPD. You know that the PSI [the Phannaceutical Society oflreland], or the IPU would 
support us in that way. Tue IPU [Irish Pharmacy Union], support us in that way and encourage us." [Pharmacist 5, 
Code: Reinforcement] "But I think if you try and force people to do it [ medication reviews] for even for like a 
financial tbing. Reimbursernent or anything like this, it's just going to come to like the same thing as we do with say 
the HSE claims or something. Say, you are doing it for the wrong reasons and even in that case you might not do it 
properly." [Phannacist 7, Code: Reinforcement] 
Guidelines were perceived to be valuable information 
sources partly because of their generally easy application to 
daily practice and partly for the evidence-base guidance to 
pharmacists' recommendations. However, some phannacists 
criticised guidelines for !imitations such as describing how to 
identify PIP without specific guidance on how to manage it 
(Table 1). 
Social influences 
Patient demands and their relative interest in medication were 
noted to strongly influence the changing or discontinuation of 
medication. Some patients were described as demanding treat­
ment and not being content to adjust their medication due to 
fear of change or loyalty to the doctors' prescription orders 
(Table 1). 
Pharmacists also noted however that their regular contact 
with patients put them in a position to influence the patients' 
behaviours. Phannacists described how negative interactions 
with GPs resulted in Ioss of confidence in their own recom­
mendations, conversely, being acknowledged by patients' 
GPs motivated pharmacists to discuss potential changes with 
those GPs (Table 1). 
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Social professional role and identity 
Pharmacists described their current role to include: (a) 
infonning patients about their medication, (b) maintaining pa­
tient safety perspective over financial benefits for the phanna­
cy and ( c) being familiar with patients' particular medication 
needs. Pharmacists agreed that they had a role in PIP preven­
tion but were divided regarding the extent to which they 
should intervene when PIP is detected. A clear description 
of the phannacist's role in reducing PIP and an acceptance 
of this role among healthcare professionals was suggested as 
a way in which to increase the involvement of phannacists 
(Table 1). 
Memory, attention and decision process 
Raising awareness of PIP to pharmacists, doctors and pa­
tients was thought to enhance PIP reduction. Suggested 
initiatives were campaigns from health authorities to pa­
tients and/or healthcare providers (Table 1). The purpose 
of these campaigns should be to inform patients or GP 
about particularly proble matic drug classes and raise 
awareness (Table 1). 
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Rei nforcement 
State reimbursement, or professional acknowledgement, for 
doing medication reviews was both considered to be motivat­
ing factors to do medication reviews. However, concems were 
raised about the quality of govemment mandatory medication 
reviews and how incentives may shift focus away from patient 
benefits to fmancial and personal benefits instead. 
Discussion 
This study used a theoretical approach to explore the views of 
community pharmacists on their involvement in reducing PIP 
in older people and their perceived baniers and facilitators to 
this. Despite beliefs about capability and responsibility for 
reducing PIP structured medication, reviews and recornmen­
dations about stopping medications do not form a routine part 
of daily practice for community phannacists in Ireland. It is 
clear from this study that for some pharmacists, there was a 
sense of conflict in what they knew to be the identifiable 
instances of PIP and what they actually did to reduce PIP. 
Pharmacists in expressed uncertainties about the extent of 
what their role in reducing PIP should be. They described a 
reluctance to work outside of their current role and to chal­
len ge  prescribing decisions taken by GPs, such as 
recommending drug discontinuation. The consequences of 
this uncertainty about the pharmacist's role in patient care, 
such as reducing PIP, have also been described in the literature 
[23, 26]. In the study by Patterson et al. [23], the inconsistent 
description of pharmacists' responsibilities in a primary care 
team was considered to hinder collaboration between phanna­
cists and other healthcare professionals. They described how 
same healthcare professionals felt that pharmacists do not ad­
equately handle their responsibilities and described a likely 
relationship between this belief and a general lack of aware­
ness of the role of the pharmacist [23]. Schindel et al. [26] 
described how a Iack of consistency in the pharmacy service 
influences patients' expectations in that they may be infonned 
variably about pharmacist services. 
When asked specifically about stopping medications, phar­
macists in our study described uncertainty of where final re­
sponsibility for PIP avoidance lies. In a recent review, this 
same theme caused confusion for GPs and also differing opin­
ions ofGPs regarding pharmacist support [48]. Extending the 
role of the pharmacist to include patient care may therefore 
require a clear description of the tasks and responsibilities 
expected to be undertak:en by pharmacists that this is clearly 
communicated to all stakeholders. 
Our findings suggest a need for a shared goal of medicines 
optimisation, and that by having more interdisciplinarity with­
in training in medication reviews; this may be achieved. 
Consistent with our findings, the study by Patterson et al. 
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[23] described that collaboration between phannacists and
GPs was challenged by (i) a lack of understanding of each
other's professional role in combination with (ii) the busy
professional practice environment and (iii) the absence of a
shared platfonn with patient information. To date, there is no
centralised system in which patient information is shared be­
tw een community pharmacies and OP practices in the
Republic of Ireland. It would be reasonable to suggest that
having access to diagnoses and comorbidities would increase
the clinical relevance of pharmacist recornmendations and im­
prove communications with other healthcare providers.
Sharing patient clinical data was suggested in our study as
one fundamentally important way to improve communication
and collabomtion between community pharmacists and GPs.
This was also suggested in the study by Bergman et al. [25] as
a mean of improving satisfaction among same GPs with phar­
macist recommendations, which were aften criticised for lack­
ing consideration of patient context. Keller et al. [27] also
showed how shared patient information enhanced the commu­
nication between pharmacists and physicians and increased
mutual professional trust between them.
Pharmacists in the present study welcomed more education 
and guidelines on reducing PIP. These guidelines should ide­
ally give instruerions an the steps following the identification 
of a PIP, be up-to-date and be used by all, including pre­
scribers. To date, guidelines on stopping inappropriate medi­
cations in alder people have been criticised for being too dis­
ease specific and not addressing the steps of stopping and/or 
changing a medication identified as inappropriate [48-50]. 
There is a need to design guidelines that meet the needs of 
healthcare professionals in busy medical and pharmacy clini­
cal practice in terms of content, instruerions and relevance. 
The existing Beers' criteria and the STOPP/START criteria 
as well as the recently developed deprescribing guidelines 
and algorithms by Farrell et al. [40, 43], Bjerre et al. [41] 
Pottie et al. [42], Reeve et al. [51] and the newly developed 
STOPP Frail criteria [52] may meet these criteria However, a 
recent study by Cardwell et al. [35] has highlighted a number 
of barriers to the utilisation of screening tools by com unity 
pharmacist in daily practice-those barriers being similar to 
those of this study. Future investigation on the application of 
these deprescribing guidelines in primary care setting is thus 
warranted and may provide useful insights into the implemen­
tation of more deprescribing to reduce PIP in primary care. 
Whilst some studies to date have shown a positive im­
pact of pharmacist involvement in reducing PIP in primary 
care [21 ], more research is needed into the effective imple­
mentation of such interventions. The majority of barriers 
and facilitators identified in this study fall under the TDF 
domains of environment, knowledge, social professional 
role and social injluences. The design of future interven­
tions should target these domains. Our tindings suggest 




guidelines that suit the primary care setting as well as in­
vestigating new strategies to improve the collaboration and 
communication between healthcare professionals both 
across and within care settings. Policy makers and the ed­
ucational sector, such as universities, could support the 
work of community pharmacists in preventing PIP by of­
fering continuous training and encouraging interprofes­
sional education, whilst also researching new ways of mak­
ing more patient-specific information available to the 
pharmacist. 
A strength of this study is its use of a robust theoretical 
framework to analyse the interview data. Using the TDF 
ensures that a large variety of factors on behaviour are 
considered compared to a more restricting set of factors 
being explored when using individual theories of behav­
iour change [35]. The use of TDF allows the mapping of 
tindings to theory and is a useful way ofidentifying medi­
ators of change. Although the use of a pre-specified frame­
work to develop the interview topic guide and to analyse 
the data can prevent the emergence of non-predefined 
themes of relevance; nevertheless, the TDF has been ap­
plied successfully in previous studies to describe topics 
similar to this study [28, 33-35]. This study was not with­
out !imitations. The sample size of 18, although acceptable 
for qualitative research, is small. The nature of qualitative 
analysis is subjective and despite the use of a sampling 
matrix to recruit participants, the tindings ofthis sh1dy, as 
with any qualitative research, are not generalisable to all 
community pharmacists. Additionally, the convenience 
sampling methods has its !imitations to the generalisability 
of the study population, and the self-selected study popu­
lation may have introduced self-selection biases. However, 
the tindings ofthis study may still be relevant to healthcare 
providers in other countries. 
In conclusion, pharmacists were generally aware of PIP in 
older people and its related problems. Pharmacists mostly 
welcomed responsibilities into their involvement of reducing 
PIP but described challenges of overcoming social and envi­
ronmental barriers, compounded by a lack of relevant guide­
lines for reducing PIP and education on the subject of PIP. 
This study identified barriers and facilitators of more phar­
macist involvement in reducing PIP in community practice. 
The tindings pointed to the need for greater collaboration 
between physicians and pharmacists in reducing PIP through 
clearer descriptions and mutual awareness of their individual 
roles and responsibilities in this process. This study provides 
useful insights into the tm-get domains for overcoming bar­
riers of phannacist involvement in reducing PIP in commu­
nity practice and may prove useful in the design of fumre 
pharmacist-led interventions to reduce PIP. Although exclu­
sive to Irish community pharmacists, the tindings may be of 
use in the expansion ofthe role ofthe community pharmacist 
in other countries. 
%1 Springer 
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Interview topic guide used for the qualitative interviews with community pharmacists in Chapter 5. 
Part 2 - Interview questions 
1) What do you understand by the term "inappropriate prescrib1ng''? (example, no indication, risk
of side-effects}
2) How signlficant a problem is inappropriate prescribing in the older people? (often/rare in
older, multiple meds)
3) What do you think contributes to inappropriate prescribing for alder people? (time, hospital
transition)
4) What do you understand by the term 'medication review'?
5) We are not expecting pharmacists to conduct medication reviews, but if you experience with it,
what kind of review have you then performed? (sources, discussion with pts/GP/carer}
6} Think back to a situation where you noticed inappropriate prescribing (wrong drug, side
effects, interaction) in one of your alder patients. What was your next step? (contact
GP/patient) What was the outcome?
7) How do you think medication reviews would benefit your alder costumers? (health, adherence,j
QoL)
8) How easy do you find it to perform medication reviews in your daily practice (community
pharmacy)? (time, information source, knowledge)
19) What are the challenges in conducting medication reviews as part of your daily practice? (time,
staff, GP, pts)
10) What changes could be made to make it easier for you to do medication reviews as part of a
routine practice? (education, information, collaboration)
11) How confident would you say you are to suggest to stop a medication to a patient/carer or
relative/GP? (very/not, reasons for that)
,12) How easy do you f ind the communication with the patient/carer or GP/hospital ahout stopping 
a medication? 
13} How would you describe your role as a pharmacist in ensuring appropriate patient care? (give
information, recommend changes to GP/patient/carer, adherence)
14) Where do you feel the overall responsibilityfor medicines management lies? (GP, hospital,
patient)
15) In what way could you support the person (based on question 16) in medicines management?
16) Do you think that the pharmacist is the appropriate individual to identify inappropriate
prescribing and suggest stopping medicattons?
9.11 Appendix XI - Chapter 6 Topic Guide
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17) How can we involve the community pharmacist more in suggesting changes to the G Ps such as
stopping medications that no longer beneficial to the patient? (communication, structured
process, education)
18) How can we involve the patient more in their medical treatment and to follow medication
changes such as stopping a medication?
19) What type of information or training (in terms of content) would you like to get about stopping
inappropriate rnedicines in alder people? (dosing, e.g. in renal impairment, age-related
changes, co�rnorbidities)
20) How would you like to receive the information to be used when reviewing older people's
medications and suggesting changes to their GPs? {apps/booklets/algorithms/online tutorial)
21) What do you know about prescribing guidelines and tools? (useful in your practice and how?)
22) Can you propose one or more essential things that you think would address inappropriate
prescribing in older people? (barriers and facilitators}
23) Is there anything else you would like to add?
Part 3 - Demographics 
• Gender:
• Can I ask you how old you are?
• How many years have you worked as a community pharmacist? Full- time and/or part time?
• Pharmacist grade (supervising, manager, intern, support):
• Have you previously worked in a hospital?
• When did you complete your undergraduate and/or postgraduate training?
• Is your pharmacy serving a nursing home?
• How many pharmacists work with you on a regular basis?
• Do you have pharmacy technician(s) working with you?
294
• 
COISTE EITICE UM THAIGHDE CLINICIUIL 
Clinical Research Ethics Committee 
Tel: + 353-21-490 1901 
Fax:+ 353-21-490 1919 
Colaiste na hOllscoile Corcaigh, Eire 
University College Cork, lreland 
lancaster Hall,
6 Little Hanover Street,
Cork,
lreland.
Our ref: ECM 4 (c) 09/05/17 & ECM 3 (rrrr) 03/07/18
6th July 2018
Professor Stephen Syrne 






Re: lnappropriate prescribing in the older person - the voice of the community 
pharmacist. 
Dear Professor Syrne
The Chairman approved the foliowing:
� Cover letter dated 6th June 2018 (received 18th June 2018)
� Application Form signed 6th June 2018 
� Participant Information letter for Pharmacists Version 2.0 dated 6th June 2018 
� Participant Information letter for General Practitioners Version 2.0 dated 6th June
2018 
� Consent Form Version 2.0 dated 6th June 2018 
� Focus Group Topic Guide Version 1.0 dated 6th June 2018
� Roles and Responsibilities Version 1.0 dated 6thJune 2018
� Study Protocol Version 3.0 dated 6th June 2018.
Yours sincerely
��V) fessorMichael G Mollo�
Chairman 
Clinical Research Ethics Committee
of the Cork Teaching Hospital
The Clinical Research Ethics Committee of the Corl< Teaching Hospitals, UCC, is a recognised Ethics 
Committee under Regulation 7 of the European Communities (Clinical Trials on Medicinal Produets for 
Human Use) Regulations 2004, and is authorised by the Department of Health and Children to carry out 
the ethical review of clinical trials of investigational medicinal produets. The Committee is ful/y compliant 
with the Regulations as they re/ate to Ethics Committees and the conditions and princip/es of Good
Clinical Practice. 
Ollscoil na hEireann. Corcaigh - National University of lreland. COf"k. 
9.12 Appendix XII - Chapter 7 Ethical approval
295
Tel: + 353-21-490 1901 
Fax:+ 353-21-490 1919 
Colaiste na hOllscoile Corcaigh, Eire 
University College Cork, lreland 
COISTE EITICE UM THAIGHDE CLINICIUIL-:= 
Clinical Research Ethics Committee = 
Lancaster Hall, -= 
6 Little Hanover Street, -
Cork,­
lreland. =
Our ref: ECM 4 (c) 09/05/17 & ECM 3 (uu) 04/09/18 
31st August 2018 
Professor Stephen Byrne 
Head of School of Pharmacy 





Re: lnappropriate prescribing in the older person - the voice of the community 
pharmacist. 
Dear Professor Byrne 
The Chairman approved the foliowing: 
> Cover letter dated received 8th August 2018
> Amendment Application Form signed 3rd August 2018
, Participant Information letter for General Practitioners Version 3.0 dated August
2018. 
Yours sincerely 
��Y?Proffilor Michael G M� 
Chairman 
Clinical Research Ethics Committee 
of the Cork Teaching Hospital 
The Clinical Research Ethics Committee of the Cork Teachmg Hospitals, UCC, is a recogn,sed Ethics 
Comm,ttee under Regulat,on 7 of the European Commun,ties (Clinical Trials on Medicinal Produets for 
Human Use) Regulat,ons 2004, and is authonsed by the Oepartment of Health and Ch1ldren to carry out 
the ethical rev,ew of clinical trials of investigational medicinal produets. The Committee ,s fully compliant 





































Topic guide - Interview study - version 4.0 
Studytitle: "Deprescribing in the older person - the views of community pharmacists and general prac­
titioners" 
Part 1 - Description of the study 
Thank you for agreeing to participate in this interview. Just before we start, I want to make sure that you are happy for 
this interview to be recorded? I also want to stress that everything you say in this interview is completely confidential, 
and I will anonymize all transcripts of this interview, and your name or the name of others will not appear on any docu­
ments or recordings. lf you want to withdraw from this study, you can stop this interview at any time. 
These interviews with pharmacists are part of my PhD which is looking at how we can prevent inappropriate prescribing 
in older people (65 years and older) and how we can involve the community pharmacists more in the process of depre­
scribing. We hope to use these interviews to get an insight into your views about the potential role of the community 
pharmacist in deprescribing inappropriate medications and what future changes that could be made to involve pharma­
cists more. 
There are no right or no wrong answers to these questions, we just want your views and opinions and maybe same of 
your experiences, so just give as much detail as you can and would like to. The interview will probably last about 15-20 
minutes. 
I will let you do most of the talking and only ask you questions. 
Does all that sound okay? Do you have any questions before we begin? 
Deprescribing 
We know from previous studies that a major difficulty for GPs is that many prescriptions are initiated by many different 
prescribers but repeat prescribing occurs mainly in the GP practice. Optimising drug regi mens is a key component of 
care, especially in the multimorbid older patients using many medications daily and to achieve this regular drug reviews 
are required. 
Deprescribing is the systematic process of identifying and reducing and/or discontinuing drugs in patients for which ex­
isting and potential harms outweigh the benefits in a safe and rational manner. The deprescribing process includes 
same or all of the foliowing elements: a review of current medications, identification of medications to be reduced or 
discontinued, a discontinuation regi men, involvement of patients, and a review with follow-up. 
Close collaboration between pharmacists and doctors seems to be the most sensible approach for this patient group 
and we wish to explore your views and opinions about how we can improve collaboration and encourage more depre­
scribing in prima ry care. 
To pie guide Version 4.0 Page 1 of 2 
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1) How beneficial do you think it is for older patients to have inappropriate medicines deprescribed?
2) What do you think are the potential benefits of deprescribing for multimorbid patients exposed to polypharmacy?
3) How would you describe your current role in deprescribing?
4) What are your current responsibilities in deprescribing?
5) How would you describe the current role of the community pharmacist/GP in deprescribing?
6) Can you describe the responsibilities of the GP /community pharmacist in deprescribing?
7) How well-defined do you think the roles are in deprescribing? Are there any overlaps?
8) How well-described you think it is of who does what and when in deprescribing?
9) How would more well-defined roles of the GP and of the pharmacist help you in your daily work?
10) How aften do you interact with a GP/pharmacist?
11) What is a typical interaction you have with the GP/pharmacist about?
12} How often do you interact with a GP/pharmacist about deprescribing?
13) Can you describe a situation where you suggested/decided to deprescribe and tel1 me what you did?
14} How would you describe your current interaction with community pharmacists/GPs about deprescribing?
15) How do you find your communication with the GP/pharmacist about deprescribing?
16) What are your expectations to the GP/pharmacist when you interact with them about deprescribing?
17) So, if you were to sit down with the GP/pharmacist to work on deprescribing for a patient, what do you think your
responsibilities would be in that collaboration?
18) In the collaboration about deprescribing what would you expect the GP/pharmacist to do?
19) What would you suggest to improve your collaboration with community pharmacists/GPs about deprescribing?
20) How would more collaboration with community pharmacists/GPs help you in your daily work?
21} What are the challenges to get more collaboration?
22} How important is it that we involve the patient in the deprescribing process?
23) What role do you think the patient has in deprescribing?
24) How do you find your contact with patients about deprescribing?
25) How can you as a GP/pharmacist involve the patient in deprescribing?
26) Say in an ideal world where we would all have time to review medicines iri what way do you think a pharmacist
cou[d best support you? /How could you as a pharmacist best support the GP?
27) What information would you like to get from the GP/pharmacists in arder for you to suggest deprescribing/depre­
scribe?
28} What do you think would be the best way for you to de liver {community pharmacist) or receive (GP) deprescribing
recommendations to the GP/from the community pharmacist?
29) In the years to come what role do you think the community pharmacist could have in deprescribing? What would
you like to see?
30} What are the challenges, as you see it, to get more pharmacist involvement in the deprescribing process?
31) What are the key factors that will facilitate more deprescribing in primary care?
32) What in your view is the ideal way of introducing more deprescribing?
33) What can we do to be more proactive about deprescribing and reducing inappropriate medicines?
34) How realistic do you think it is to involve pharmacists more in deprescribing in primary care?
35) Can you propose one or more essential things that you think would ad dress deprescribing medicines in older peo­
ple? (barriers and facilitators)
36) Is there anything else you would like to add or to expand further on?
• Gender:
• Can I ask you how old you are?
• How many years have you worked as a community pharmacist/GP?
Tha nk you for your time 
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